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ABSTRACT 
 
In alpha-1-antitrypsin deficiency (A1ATD) there is excess neutrophil elastase activity, 
resulting in proteolytic destruction of the lung parenchyma. I hypothesised that the peptide 
fragments of proteins present in the lung might be detectable in plasma by mass spectrometry 
and that they might be useful biomarkers of disease activity and treatment efficacy. 
 
Calcium ionophore, neutrophil elastase and proteinase 3 were added to plasma from patients 
with A1ATD to create an in vitro model of the destructive processes.  MALDI-based peptide 
profiling of plasma from patients pre and post treatment with intravenous A1AT was 
undertaken and MS/MS performed to identify differences. Plasma was also depleted of 
abundant plasma proteins, labelled with isobaric tags and analysed by shotgun proteomics. 
 
The readily detectible components of the plasma proteome remained unchanged with 
intravenous A1AT. Addition of ionophore, elastase and proteinase 3 to patient blood generated 
predominantly fragments of fibrinogen.  In patients treated with intravenous A1AT, fragments 
of A1AT increased significantly with treatment: – 2 of these were fragments of a short C-
terminal segment of the A1AT protein and were also present in healthy subjects. The shotgun 
experiments did not identify any robust biomarkers and illustrate the challenging nature of 
plasma proteomics.  
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CHAPTER 1   INTRODUCTION 
 
1.1     COPD Definition and Epidemiology  
 
Chronic obstructive pulmonary disease (COPD) is a multi-system inflammatory 
condition, characterised by airflow obstruction which is not fully reversible, according 
to the ATS/ERS joint COPD guideline in 2004 (Celli et al., 2004). It is a common 
condition, diagnosed in around 1 million people in the UK alone, although this may be 
a gross underestimation of the actual number of people with this disease, which may be 
closer to 3 million (National Clinical Guideline Centre 2010). It is not only a health 
issue in the UK; globally the prevalence of COPD is increasing, particularly in less 
developed countries, and it has become the third leading cause of death worldwide 
(Lozano et al., 2012). Globally, it is estimated that there are over 200 million people 
who have COPD (Lopez et al., 2006). In the UK, around 25,000 people per year die 
from COPD, and the estimated health care costs exceed £800 million per year (National 
Clinical Guideline Centre 2010). There is a need for newer therapies for this common, 
progressive and debilitating condition, yet there have been few new classes of therapies 
introduced into routine patient care in recent years, and no specific therapies have 
shown a reduction in mortality, other than long term oxygen therapy (Stuart-Harris et 
al., 1981 and the NOTT Trial Group, 1980) and smoking cessation (Godtfredson et al., 
2008).  
 
The definition of COPD is based on airflow obstruction, diagnosed with post 
bronchodilator lung function parameters, (according to the ATS/ERS guidelines) 
therefore patients have to undergo spirometry in order to have a correct diagnosis. In 
the past, COPD was regarded as a condition which affected only the lungs. It is now 
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widely regarded as a multi-system inflammatory condition with extra pulmonary 
manifestations. Patients with COPD have an increased risk of ischaemic heart disease 
(Sin et al, 2003), depression (Wagena et al, 2001), lung cancer (Noruma et al, 1991) 
and osteoporosis (Agusti 2005). In addition, COPD is a term which encompasses 
several phenotypes, with similar spirometry, which were traditionally separated into the 
2 phenotypes of chronic bronchitis and emphysema. More phenotypes are now 
recognised, and can differ on the parameter used in the definition, whether it is based 
on physiology, radiology or symptoms including sputum production and exacerbations. 
It is possible that future treatments for COPD may vary according to these different 
phenotypes, as was the case with roflumilast, a phosphodiesterase type 4 (PDE4) 
inhibitor, which is effective in patients with a chronic bronchitic phenotype, who 
experience recurrent exacerbations despite maximal other therapies (Rennard et al., 
2011). 
 
1.2   Causes of COPD 
 
The main cause of COPD globally is tobacco smoking. However, only around 20% of 
people who smoke go on to develop COPD. (Doll et al., 1991 and Tashkin et al., 1984) 
Clearly the relationship between smoking and COPD is far more complex than simple 
cause and effect, and it has been hypothesised that there is a genetic link between 
smoking, the development of COPD and the environment (Sandford et al., Silverman 
2002). Familial clustering of cases adds further evidence to support the genetic 
hypothesis link (Marciniak et al., 2008), and first degree relatives of COPD patients 
have a higher incidence of airflow obstruction when compared with the general 
population. (Larson et al., 1970)  A genome wide association study by Pillai and 
colleagues in 2009 identified 2 single nucleotide polymorphisms (SNPs) – of the α-
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nicotinic acetylcholine receptor (CHRNA 3/5) which were significantly associated with 
COPD, and a further SNP of the hedgehog interacting protein on chromosome 4 which 
was associated, but did not reach genome-wide significance, with the development of 
COPD (Pillai et al., 2009). 
 
Amongst the other recognised causes of COPD are occupational exposures, air 
pollution, both outdoor and indoor (for example burning of biomass fuels in poorly 
ventilated housing in less developed countries (Bruce et al., 2000)), passive smoking 
and the genetic condition of alpha-1-antitrypsin deficiency (A1ATD).   
 
1.3  Alpha-1-Antitrypsin 
 
Alpha-1-antitrypsin (A1AT) is one of the most abundant plasma proteins. It is a 
member of the serine proteinase inhibitor family, which also includes C1 esterase 
inhibitor, α-1 antichymotrypsin and antithrombin III. It is 52kDa glycoprotein, 
consisting of 394 amino acids and is produced predominantly in the liver by the 
hepatocytes, although it is made in much smaller amounts by monocytes and lung 
airway epithelial cells (Lomas 2000). It has a plasma half-life of 4 to 5 days (Fregonese 
et al, 2007). Its function is to inhibit the actions of a number of serine proteases, but its 
main target is an enzyme released from neutrophils – neutrophil elastase (NE), and to a 
lesser extent the enzymes cathepsin G and proteinase 3 (PR3).  In common with other 
members of the serpin family, A1AT is made of 3 β sheets and 9 α helices. The most 
important part of the A1AT molecule is the reactive site; this is a mobile loop, which 
presents a ‘pseudosubstrate’ for neutrophil elastase (although this could be one of the 
other proteases such as cathepsin G or PR3). Once the elastase has covalently bound, it 
becomes inactivated and this complex of A1AT and protease is taken up from the 
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plasma by the liver and cleared (Mast et al., 1991). 
 
A1AT binds to NE in an irreversible manner, at a molar ratio of 1:1, and thus once it 
has bound, complexes of A1AT/NE can be found in the bloodstream prior to their 
removal by the liver.  Free NE is not usually detectable in the bloodstream. NE is 
responsible for proteolytic damage to the lung alveoli, which may result in the 
development of emphysema, a finding which also has been found in animal models 
whereby the instillation of NE results in changes typical of emphysema (Fukada et al., 
1989). 
 
A1AT is an acute phase protein, which means that its production, and subsequent 
release into the bloodstream, is increased in response to stimuli such as IL6 during 
intercurrent infection or inflammation. This is a protective mechanism; neutrophils 
travel to sites of infection and inflammation, and increasing the production of A1AT 
can help to enhance the inhibition of destructive enzymes released from the neutrophils 
during degranulation once their physiological role is complete. The lung is the main 
site requiring the presence of A1AT, which enters the airways by passive diffusion. The 
normal plasma level of A1AT in a healthy adult is 1.1-1.9g/L (20-48M), but may rise 
up to four fold in the bloodstream in response to systemic infection/inflammation 
(Grimstein et al., 2011 and Brantly, 2002). 
 
In addition to its inhibitory effects on the proteases outlined above, A1AT has a number 
of other anti-inflammatory and immunomodulatory effects such as regulation of the 
expression of several cytokines, which include TNF , IL6 and IL8 IL 10 and 
interleukin 1beta (Janciauskiene et al., 2007). 
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1.3.1    Alpha-1-Antitrypsin Deficiency  
 
Alpha-1-antitrypsin deficiency (A1ATD) is one of the most common genetic 
deficiencies in the UK. Its clinical manifestations include emphysema, cirrhosis of the 
liver and panniculitis. In 1963 the association of a deficiency of A1AT and emphysema 
was first recognised by Laurell and Erikson, who noticed the lack of a serum protein in 
association with severe emphysema in patients in their 40s, and much has been learnt 
about this condition since this time. 
 
1.3.2          Genetics and Epidemiology of A1ATD 
 
A1ATD is an autosomal co-dominant condition; each of the 2 copies of the gene is 
responsible for production of 50% of the body’s production of A1AT, and does so 
independently of the other (Luisetti et al., 2004). The gene is located on chromosome 
14, (14.q32.1) (Luisetti et al., 2004) and is part of the Serpin supergene cluster (Luisetti 
et al., 2004).  There are over 100 mutations of the A1AT gene which have been 
identified to date (Fregonese at al., 2007). The most common of these are the Z and S 
mutations. The nomenclature of these deficiencies was originally classified by a system 
which named the proteins by their mobility during starch gel electrophoresis. Thus, the 
normal protein is denoted by the letter M, as the proteins had medium migratory 
velocity, S for slow, Z for very slow and F for fast moving (Luisetti et al., 2004). Thus 
a normal person is denoted as PiMM (protease inhibitor MM), and the most deficient 
patients PiZZ, although there are a small number of null genes, which produce no A1AT 
at all (Luisetti et al., 2004).  
 
The Z protein arises as a result of a change in the amino acid sequence from glutamic 
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acid to lysine, at position 342, which causes polymerisation of the protein. Around 3-
4% of northern Europeans carry this genetic mutation (Luisetti et al., 2004). The 
structure of the Z molecule is altered, allowing the reactive loop of one molecule of 
A1AT to lock into the β sheet of another, leading to lengthening chains of the 
molecules, which accumulate in the rough endoplasmic reticulum of the liver (Lomas 
et al., 2004). Large polymers cannot be released from the liver and thus only around 10 
– 15% of the A1AT made by each Z allele enters the systemic circulation. This (in ZZ 
individuals) results in a plasma level of about 10 – 15% of normal. Besides patients 
who have null genes, the PiZZ patients are the individuals who are most at risk of 
developing disease, both of the lung and liver, as a result of their deficiency. The 
polymerised chains of proteins accumulate in the liver and may, over time, result in 
cirrhosis of the liver.  
 
The S protein is due to a different point mutation; at position 264 valine is substituted 
for glutamic acid, which results in some mis-folding of the A1AT protein. Patients who 
are homozygous with the S gene have A1AT levels of around 60% of normal. The S 
mutation is found in around 6% of people of northern European descent and originated 
in the Mediterranean (Luisetti et al., 2004). This milder form of deficiency is not 
thought to predispose to emphysema, even in S homozygotes (Mulgrew et al., 2007). 
 
1.3.3   Clinical Manifestations of A1ATD 
The clinical manifestations of A1ATD are most strongly associated with the ZZ 
genotype, and include primarily lung disease, liver disease and rarer associations such 
as the skin condition panniculitis and systemic vasculitis. The lung manifestations may 
include emphysema, (which is predominantly basal), a degree of bronchodilator 
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reversibility, chronic bronchitis and bronchiectasis. Thus the condition is 
heterogeneous, as seen in usual COPD, and there may be asymptomatic individuals 
who are diagnosed only as a result of family screening, at one end of the spectrum, with 
patients with end-stage lung disease (some of whom will progress and may require lung 
transplantation) at the other.  Active smoking is the most significant risk factor for the 
development of emphysema and accelerates the decline in lung function (Needham et 
al., 2004). Recurrent exacerbations have also been shown to result in more rapid 
decline, due to the increased levels of inflammation at these times, but air pollution can 
also play a role (Wood et al., 2009).  
 
A proportion of PiZZ A1ATD patients develop chronic liver disease; the incidence of 
cirrhosis is higher in men than women and the risk of developing cirrhosis increases 
with age (Needham et al., 2004).  Panniculitis is another, rarer manifestation, in which 
patients develop necrotic and suppurating lesions of the skin, which can be present 
almost anywhere in the body, but occur particularly over the anterior tibial region, in 
the gluteal region or on the arms. These can be treated with dapsone, and in some 
instances intravenous replacement of A1AT can produce rapid resolution of necrotising 
lesions (O’Riordan et al., 1997). 
 
1.3.4              Treatment of A1ATD 
 
Patients with A1ATD who develop COPD are treated in the same way as patients with 
usual (non A1ATD) COPD, with inhaled therapies, smoking cessation strategies, 
pulmonary rehabilitation, oxygen therapy where appropriate and adequate treatment of 
exacerbations and co-morbidities. Furthermore, for patients with end stage disease who 
are deemed suitable, lung transplantation may be considered, especially as patients with 
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A1ATD at this end of the spectrum are usually younger than those with non A1ATD 
COPD. In addition to this conventional treatment, in some countries, such as the US 
(but not in others such as the UK), intravenous augmentation therapy is licensed for 
patients with A1ATD.  
 
1.3.5             Role of Intravenous Augmentation Therapy  
 
A1AT can be purified from human plasma from blood donors and given intravenously 
to augment the low levels in deficient patients. This has been available in the US since 
the early 1980s when Gadek et al undertook a study to determine the feasibility of 
replacing A1AT, and were able to demonstrate significantly elevated levels of A1AT 
in epithelial lining fluid of the lungs followed intravenous replacement (Gadek et al., 
1981). 
 
Wewers et al in 1987 continued the work which showed that using a regimen of 
60mg/kg bolus weekly is able to produce a trough level in the airways within the ‘safe’ 
level 6 days post infusion. This regimen is the currently licensed by the FDA, and thus 
accepted and utilised in countries where treatment with augmentation therapy is 
available (Wewers et al., 1987). Clearly, the need for a weekly infusion has a patient 
acceptance issue as well as significant cost and time implications, therefore Hubbard 
and co-workers have investigated the use of 2 weekly and monthly infusions, of much 
higher doses of A1AT, of up to 250mg/kg per month, and have been able to demonstrate 
that plasma levels greater than 11M can be generated for most of the time. This is 
important as the threshold of 11M has been termed the ‘protective threshold’ below 
which the lungs are vulnerable to damage from proteolytic enzymes normally 
controlled by A1AT (Hubbard et al., 1988). However, these alternative regimens are 
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not approved by the FDA. 
 
Dirksen et al (1999) performed a randomised study of 55 patients with the PiZZ 
genotype of A1ATD. Calculations from this data, using FEV11 decline as the primary 
study endpoint, indicated that 550 patients would need to be included in each arm of an 
interventional augmentation trial to see a significant reduction in the rate of decline in 
FEV1 if this was the end-point measured. The study also showed that CT densitometry 
measurements were more sensitive than lung function parameters, and thus offered the 
use of an alternative endpoint in monitoring emphysema progression in patients with 
A1ATD and any benefit from treatment (Dirksen et al., 1999). 
 
Augmentation therapy at 60mg/kg over a short term study by Stockley et al 
demonstrated a rise in serum and sputum A1AT levels, a reduction in sputum elastase 
and leukotriene B4 (LTB4) activity, both of which were significant, and a non-
significant reduction in IL8 and myeloperoxidase (MPO) (Stockley et al., 2002). This 
demonstrated that intravenous replacement therapy can reduce bronchial inflammation 
in A1ATD and hence potentially halt the destructive progression of the disease. 
 
The EXACTLE trial conducted between 2003 and 2005 was a randomised controlled 
trial of 77 patients receiving augmentation therapy or placebo for a follow up period of 
2 to 2.5 years. Its primary endpoint was a change in lung densitometry measured on CT 
scans. The study confirmed that CT densitometry was a more sensitive measure of 
emphysema progression than either health status or lung physiology, and an overall 
trend towards a reduction in the rate of progression of emphysema with augmentation 
therapy was found (Dirksen et al., 2009). Combining the raw data from this study and 
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from the previous Dutch-Danish Study (Dirksen et al., 1999) provided robust evidence 
that the progression of emphysema as measured by CT density, can be reduced by 
augmentation therapy at the dose of 60mk/kg weekly (Stockley et al., 2010). 
 
However, there still remains controversy regarding the efficacy of augmentation 
therapy, as a recent Cochrane review concluded that there was not sufficient evidence 
to support its use (Gotzsche et al, 2010). This review ignored the wealth of data from 
observational studies, which have shown a reduction in the number of exacerbations 
whilst on treatment and differences in the rate of decline in FEV1 (Stockley et al., 2010). 
 
In addition to the cost implication of augmentation therapy, there is the theoretical risk 
of transmission of infection. The protein given to patients is purified from human donor 
blood, and theoretically, although rigorously screened, still carries the potential risk of 
infection. However, to date, no cases of transmission of hepatitis A, B or C, or HIV 
have been reported as a result of augmentation therapy (Tirado-Conde et al., 2008). 
Overall, the administration of intravenous therapy has been shown to be safe and well 
tolerated by patients. The infusions of purified A1AT contain 70-80% A1AT protein, 
whilst the remainder is made of common plasma proteins, including alpha2-plasmin 
inhibitor, alpha1-antichymotrypsin, C1-esterase inhibitor, haptoglobin, antithrombin III, 
alpha1-lipoprotein, albumin and IgA. The A1AT protein once purified and infused 
remains around 75% active (Wewers et al., 1987). 
 
1.3.6  Role of Nebulised Replacement Therapy  
 
An alternative approach to intravenous infusions of A1AT is the use of nebulised 
A1AT. Patients with chronic lung diseases are used to receiving inhaled treatment, and 
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theoretically, by nebulising the A1AT, the protein is delivered to the site from which 
its absence is deemed most critical. In order for this to be beneficial, the protein which 
is nebulised needs to be able to diffuse into the lung interstitium, which is the opposite 
direction of movement than normal. Work by Hubbard in 1989 showed that intact 
A1AT of the normal M variant could be found in the plasma and hence the epithelial 
lining fluid of patients with the PiZZ genotype of A1ATD post-delivery via the 
aerosolised route (Hubbard et al., 1989). However, direct sampling of levels in A1AT 
in the lung interstitium is much more difficult without undertaking invasive procedures, 
which is prohibitive in large numbers of patients. In addition, using the nebulised route 
removes the need for intravenous access with its’ inherent complications, and allows 
patients to administer their own treatment. Currently, clinical trials are ongoing to 
investigate any benefit of nebulised therapy in this patient cohort. 
 
1.3.7  Liver Transplantation 
A proportion of patients with A1ATD develop clinical liver disease instead of or in 
addition to lung disease. In some patients, this progresses into end stage liver disease 
and hepatic failure. In this instance, it is possible for patients to undergo liver 
transplantation if organs are available and the patient does not have other co-morbidities 
which may make them unsuitable. This results in the normalisation of the circulating 
plasma A1AT level, as nearly always the donor has the MM genotype and hence the 
transplanted liver will produce and release normal A1AT. This is clearly only an option 
available to patients with severe end stage liver disease, and not a treatment that could 
be offered to all patients with A1ATD, due to the morbidity and mortality of the surgery 
and post-operative immunosuppression, with its inherent risks, but also due to a lack of 
available donor livers which are needed for other conditions besides A1ATD.  
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1.4  Clinical Trial End-Points in COPD 
Lung function parameters, especially the forced expiratory volume in 1 second (FEV1), 
have formed the basis of outcome of clinical trials of therapy in patients with COPD. 
The FEV1 is easy to measure and record but is effort dependant and hence can be a 
variable measurement, even for patients in the stable state. The measurement also 
shows variable progression with time and in some cases FEV1 may remain stable; 
(Agusti et al., 2013 on behalf of the ECLIPSE investigators) this means that clinical 
trials require large numbers of patients, with lengthy follow up periods, in order to 
detect a significant change in the decline of this measurement whereas short term 
improvement with bronchodilator therapy is easier to detect. 
 
 Furthermore, the measurement of an abnormal FEV1 alone does not make a diagnosis 
of COPD, is not specific to COPD, and does not always provide a measurable change 
with treatment – for example treatment with long term oxygen therapy (LTOT) which 
has been proven to improve survival (Stuart-Harris et al., 1981 and the NOTT Trial 
Group, 1980) has no effect on the FEV1 decline. In addition, FEV1 alone does not 
provide comprehensive information on the COPD phenotype, and composite measures 
are being used as alternatives to the FEV1, such as the BODE index which is described 
below (Celli et al., 2004). 
 
 There is, therefore, a need for other markers for both usual COPD and that caused by 
A1ATD, and its’ phenotypes to predict response to treatment, particularly in phase II 
and proof of concept studies, in order to reduce the numbers of patients needed to be 
recruited and the duration of follow up. 
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1.5  Biomarkers Studied to Date in Usual COPD and A1ATD COPD 
A number of different markers have been studied to date as potential biomarkers in 
COPD. A biomarker should fulfil one or more of a number of key roles, which include:-  
 Being central to the disease process (disease specific)  
 Varying with progression of disease  
 Predicting progression  
 Stratifying individual patient risk  
 Being sufficiently sensitive to detect changes resulting from effective 
interventions or treatments (Stockley, 2007)  
 
Any measurable parameter including physiological measures such as the FEV1 may 
fulfil some or all of these criteria; however the following review and the remainder of 
this thesis will be focused on proteins. Proteins carry out many essential physiological 
functions, including those within cell structural integrity, through actions as enzymes, 
hormones, transport and storage molecules, and antibodies. Therefore, many potential 
candidate markers studied to date in both usual COPD and COPD secondary to A1ATD 
have been proteins.  
 
A literature review was performed in 2010, before the start of the work presented in 
this thesis, using the Embase, Pubmed and Web of Science databases and using the 
search terms ‘alpha 1 antitrypsin deficiency, biomarkers and augmentation therapy’. 
This search did not identify any relevant published work. The search was repeated using 
the same search terms in 2017 and identified a number of recent studies of desmosine 
and isodesmosine in A1ATD (although there is a wealth of data describing its role in 
usual COPD eg Rabinovich et al., on behalf of the ECLIPSE investigators, 2016), data 
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on exhaled breath condensate analysed using mass spectrometry which is discussed in 
more detail in section 1.7.5 (Fumigalli et al., 2008 and 2012) and 2 studies on a 
fibrinogen fragment termed Aαval 360, that met these criteria.  
 
The first study measured desmosine and isodesmosine in the serum of patients receiving 
A1AT augmentation therapy for A1ATD as part of the RAPID study, and demonstrated 
a significant reduction in patients on active drug, and this was associated with a 
reduction in decline in CT densitometry (Ma et al., 2017). The second by Ma and 
colleagues (2013) measured desmosine and isodesmosine in plasma, BALF and urine 
in patients with A1ATD pre and post augmentation therapy. These were significantly 
reduced following active treatment but not placebo (Ma et al., 2013). This is in contrast 
to work by Gottlieb and co-workers in 2000 who measured urinary desmosine in 12 
patients with A1ATD at the start and end of 8 weeks of augmentation therapy, and 
found that there was no significant reduction (Gottlieb et al., 2000).  A further 
desmosine paper analysed desmosine in urine and plasma samples from patients with 
A1ATD over a 14 month period; the authors concluded that plasma samples were more 
robust than urine samples, and that higher levels were likely to be the result of continued 
elastin degradation (Fregonese et al., 2011). However, this paper did not include 
samples from patients following treatment with augmentation therapy.  
 
The study of desmosine and isodesmosine began before the studies discussed above. 
Initially comparisons were made between patients with A1ATD, healthy smokers and 
healthy controls and patients with usual COPD (Viglio et al., 1998). Patients with 
A1ATD had higher urinary desmosine levels than seen in the other groups, including 
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usual COPD groups with exacerbations.  In addition, techniques to quantify desmosine 
and isodesmosine have improved considerably, from ELISAs to radioimmunoassay to 
the widespread use of mass spectrometry to increase the sensitivity of detection (Viglio 
et al., 2007). However, there have been only a small number of recent studies, discussed 
here, which measure desmosine and isodesmosine before and after augmentation 
therapy in patients with A1ATD. Desmosine and isodesmosine show promise as 
possible future end-points in clinical trials, but need to be more rigorously tested, and 
validated against CT densitometry data, before they could be routinely utilised. 
 
Aα-val 360 is a marker of pre-inhibition activity of NE and has been studied as a 
potential biomarker in both usual COPD and in patients with A1ATD. It has been 
shown, by Carter et al, to be elevated in patients with A1ATD compared to healthy 
control subjects, to increase further during acute exacerbations, and to decrease 
following treatment with augmentation therapy. In patients in the EXACTLE trial 
(Dirksen et al., 2009) who received intravenous A1AT, there was a significant decrease 
in this signal, whereas in patients receiving placebo infusions rather than active drug, 
there was no change in this signal at the end of the 6 months (Carter et al., 2011). 
 
There were no other potential biomarkers in A1ATD identified through this literature 
search. Besides augmentation therapy, the evidence for treatment for patients with 
COPD secondary to A1ATD is extrapolated from that for usual COPD, and because the 
literature review of biomarkers in A1ATD is sparse, a review of biomarkers in usual 
COPD is presented below. 
 
There is no biomarker at present in usual COPD which meets all of the above listed 
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criteria for a biomarker. In COPD, potential biomarkers may be measured a variety of 
clinical samples, including, blood (plasma or serum), sputum, tissue, exhaled breath 
condensate (EBC) and broncho-alveolar lavage fluid (BALF).  The advantages and 
disadvantages of each of these sample types are shown in table 1.1.  
 
Sample 
 
Advantages 
 
Disadvantages 
Blood Hold great potential – every tissue in 
the body requires a blood supply  
 
Could be collected pre and post 
intervention 
 
Easy to create standard operating 
procedure for sample collection and 
handling 
 
 
All patients, irrespective of disease 
severity, can have samples taken. 
 
Wide dynamic range of protein 
concentrations 
 
No mass spectrometer can overcome this 
dynamic range 
 
Attempts to remove abundant proteins may 
remove other information (albumin acts as a 
co-transporter for other proteins which may 
also be removed) 
 
Information may relate to a co-morbidity 
rather than COPD 
BALF Samples epithelial lining fluid, 
giving information close to the site 
of the inflammatory process 
Samples conventionally taken from right 
middle/lower lobes, emphysema typically 
affects upper lobes 
 
Some patients cannot tolerate procedure 
 
Repeat sampling more difficult. 
 
Saline used to harvest samples interferes with 
mass spectrometry, therefore samples need 
more preparation steps. 
 
Dilutional factor present which is difficult to 
quantify – inter-operator variability occurs 
Tissue Information about architecture in 
addition to protein content 
Invasive – follow up data difficult to obtain 
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Samples taken from site of 
inflammatory process. 
 
If taken endobronchially, multiple samples 
from different sites needed as the 
inflammation may be patchy in COPD 
 
Patients with severe disease may not be able 
to provide samples. 
 
Spontaneous 
or Induced 
Sputum 
Minimally invasive 
 
 
Gives information from closer to the 
site of the inflammatory process. 
 
 
Could be repeated pre and post 
intervention (not on consecutive 
days if induced sputum used). 
Not all COPD patients produce spontaneous 
sputum – this selects a subset of COPD 
patients with the chronic bronchitis 
phenotype. 
 
Contamination of sample from oropharynx 
when expectorated. 
 
Unlikely to represent disease in small 
airways/alveoli 
 
 
Healthy control population difficult for 
comparison as healthy people do not produce 
sputum. 
 
Repeat sampling of induced sputum cannot 
occur on consecutive days 
 
Induced sputum sampling is pro-
inflammatory and may alter inflammatory 
burden of the lower airways 
 
Saline may interfere with mass spectrometry, 
and samples need more preparation steps.  
Table 1.1 Advantages and disadvantages of each of the different samples which may be utilised in 
biomarker investigation in COPD. 
 
Some of the most clinically relevant/studied potential markers studied to date in each 
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of these sample types in patients with usual COPD will be discussed below. 
 
1.5.1  Serum and Plasma Biomarkers 
Fibrinogen is one of the most widely investigated candidate markers in COPD and on 
the strength of the evidence in COPD, has been recommended for review by the Food 
and Drug Administration (FDA) in the United States as a prognostic marker. It is a 
positive acute phase protein which is increased in concentration in the plasma in 
response to production of IL6 by the liver (Gabay et al., 1999). It is associated with 
mortality in patients with COPD (both COPD related and unrelated), disease 
progression, and increased risk of exacerbations and is discussed in depth in chapter 5 
(Manino et al., 2012, and Danesh et al., 2005). 
 
C reactive protein (CRP) is a protein synthesised mainly in the liver, in response to IL6, 
which has been investigated in patients with COPD. It has been shown to predict 
mortality in patients with mild to moderate COPD (Man et al., 2006), although not in 
moderate to severe disease (de Torres et al., 2008). In addition, IL6 levels have also 
been demonstrated to be higher in the plasma of patients with COPD when compared 
to healthy control subjects (Yende et al., 2006). Neither CRP nor IL6 are specific 
markers for COPD, and can be raised in many other infectious and inflammatory states, 
which reduces the potential usefulness as biomarkers for COPD.   
 
Tumour necrosis factor  (TNF) is a cytokine which has a role in systemic 
inflammation. In COPD it has been shown that patients have an elevated level of both 
TNF and its soluble receptor detectable in the bloodstream (Takabatake et al., 2000). 
It has also been demonstrated that levels of TNF correlate with disease severity (von 
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Haehling et al., 2009), and that levels are elevated following exacerbations compared 
to the stable state (Kardag et al., 2008). 
 
Surfactant protein D (SP-D) is a protein that’s expression is almost unique to type II 
pneumocytes and Clara cells in the lungs, where it plays a role in surfactant homeostasis 
and immunity. Therefore, this has the potential to be a more ‘lung specific’ marker of 
disease. In COPD patients, serum levels are higher than those measured in healthy 
controls, yet lower in lavage fluid, and it has been hypothesised that this results from 
leakage of the protein from the lungs into the bloodstream as a result of inflammation, 
rather than a problem with its production or integrity. Furthermore, its concentration 
correlates with health status and over a 3-month period can predict risk of exacerbations 
(Sin et al., 2007 and Sin et al., 2008). Furthermore, it is sensitive to steroid therapy, 
although the mechanism has yet to be determined (Lomas et al., 2009). 
 
Club Cell Secretory Protein 16 (CC-16) is produced predominantly in the lungs, but 
detectable in serum, and it is thought to have anti-inflammatory effects within the 
airways and reducing the burden of oxidative stress (Broeckaert et al., 2000). It was 
decreased in the serum of 4724 patients in the Lung Health Study and related to decline 
in lung function (FEV1) over a 9 year period (Park et al., 2013). However although the 
relationship was statistically significant the variance related to CC16 levels was weak 
(Stockley, 2013).  In the ECLIPSE patient cohort, CC-16 was measured in the serum 
of 2083 COPD patients, and levels were lower than in either non-smoking subjects or 
smoking controls who did not have evidence of airflow obstruction (Lomas et al., 
2008). 
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The receptor for advanced glycation end-products (RAGE) is a member of the 
immunoglobulin superfamily, and is a transmembrane receptor, and interactions 
between RAGE and its ligands initiates a pro-inflammatory cascade (Smith et al., 
2011). The soluble receptor for advanced glycation end-products (sRAGE) binds to 
RAGE and it therefore protective against the inflammatory cascade (Smith et al., 2011). 
sRage was significantly lower in the plasma of the 61 COPD patients when compared 
to 42 healthy controls, and correlated with FEV1 percent predicted (Smith et al., 2011). 
Miniati and colleagues measured sRAGE in 200 COPD patients and 201 control 
subjects. They found that sRAGE concentrations were significantly lower in the group 
of patients with COPD compared to the healthy control group. When further analyses 
were performed on the COPD patient group, there were significant differences between 
patients with and without cor pulmonale (lower in the group with cor pulmonale) and 
amongst those with emphysema on CT scan (those with severe emphysema having 
lower levels than those with mild emphysema) (Miniati et al., 2011). 
 
Adiponectin is a 244 amino acid protein which is made almost entirely by adipocytes 
in humans and as body mass increases, the circulating levels of adiponectin decrease 
(Yoon et al., 2012). Levels of adiponectin were measured in patients participating in 
the Lung Health Study, and Yoon et al were able to demonstrate that in patients with 
higher plasma levels were less likely to be hospitalised or die from coronary artery 
disease (hazard ratios 0.73 and 0.83 respectively) (Yoon et al., 2012). They also showed 
that higher levels were associated with an increased risk of respiratory death from 
respiratory disease (hazard ratio 2.09), and decline in lung function (Yoon et al., 2012) 
Leptin, which is part of a common pathway with adiponectin, and has a role in energy 
regulation through its actions on the hypothalamus, was investigated by Creutzberg and 
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colleagues and they described an association between elevated leptin levels in patients 
with COPD during acute exacerbations and disturbances in energy regulation 
(Creutzberg et al., 1999). 
 
A number of the markers described so far were combined and analysed in 1755 patients 
from the ECLIPSE cohort. Markers included peripheral white blood cell count, CRP, 
IL6, IL8, fibrinogen and TNFα. Patients who had evidence of systemic inflammation 
at baseline (based on values for each of the 6 parameters) had significantly higher 
exacerbation rates per year and increased risk of mortality compared to those without 
and therefore the authors concluded that this may represent a further phenotype of 
patients with a systemic inflammatory response (Agusti et al., 2012). Investigators from 
the Copenhagen General Population Study and City Heart Study analysed 3 of these 
markers together (CRP, fibrinogen and peripheral blood leucocyte count) and 
demonstrated that in patients where all 3 were high, there was an increased likelihood 
of having an exacerbation of their airways disease, even amongst patients who were not 
previously frequent exacerbators (Thomsen et al., 2013).  
 
1.5.2  BALF Biomarkers 
Broncho-alveolar lavage fluid is collected at bronchoscopy by the instillation of saline 
and is conventionally sampled from the right middle and lower lobes. One potential 
problem with this technique is that emphysema in usual COPD is often present only in 
the upper lobes. In addition, there is operator dependent technique in sample collection. 
A study by Lofdahl and colleagues conducted in patients with COPD and compared 
BAL recovery rates to those from healthy control subjects and smokers who did not 
have COPD. They observed that in the patient group the BALF recovery was lower 
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than either of the other 2 groups and this related to the severity of the emphysema both 
radiographically (measured using CT) and physiologically (TLCO) (Lofdahl et al., 
2005). 
 
Matrix metalloproteinases (MMPs) are released by macrophages and play a part of the 
inflammatory response in COPD, as they are able to degrade constituent of the 
extracellular matrix (Russell et al., 2002). MMPs are inhibited by a group of 4 proteins 
known as tissue inhibitors of metalloproteinases (TIMPs). Russell at al analysed 
macrophages from BAL from patients with COPD, and compared them to healthy 
subjects and smokers who did not have COPD. They demonstrated that stimulated 
macrophages from COPD patients released more MMP9 than those from either healthy 
subjects or smokers without COPD. In addition, more TIMP-1 was released by the 
macrophages from non-smokers when compared with either of the other 2 groups 
(Russell et al., 2002). BAL of smokers and ex-smokers with COPD, healthy smokers 
and never smokers was analysed by Babuyste and colleagues, who demonstrated that 
matrix metalloproteinase-12 (MMP12) positive macrophages and total number of 
neutrophils were higher in both of the COPD groups (Babuyste et al., 2007). 
 
Betsuyaku and colleagues (1999) measured human neutrophil lipocalin (HNL) MMP 8 
and MMP 9 in BALF from 65 individuals who were categorised by the presence or 
absence of emphysema on CT and by smoking status. They found that levels of HNL, 
MMP 8 and 9 were significantly higher in patients who smoked and had emphysema 
on CT imaging when compared to smokers with no evidence of emphysema despite no 
statistically significant difference in the total neutrophil numbers. They subsequently 
cultured alveolar macrophages and measured MMP 9 levels and concluded that as there 
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were no significant differences in MMP 9 from macrophages between any of the 
groups, neutrophilic inflammation was central to the development of emphysema 
(Betsuyaku et al., 1999). Subramanian and colleagues (2012) demonstrated an 
increased uptake of 18-fluorodeoxyglucose, particularly in the upper zones, on CT PET 
scans of patients with usual COPD when compared to patients with COPD secondary 
to A1ATD or to healthy controls. This increased uptake corresponded with the presence 
of upper zone emphysema in the COPD patient group (n=10) and the authors concluded 
that CT PET analysis could be utilised as a marker of neutrophilic inflammation in 
patients with usual COPD (Subramanian et al., 2012). These findings support the 
central role of the neutrophil in the pathogenesis of COPD (Stanescu et al., 1996; Pesci 
et al., 1998; Hoenderos et al., 2012). 
 
1.5.3  Biopsy Biomarkers 
 A wealth of data has been produced in patients with COPD who have undergone 
endobronchial biopsy sampling during fibreoptic endoscopy. This approach is 
advantageous in that it provides information from within the lung itself, however 
multiple samples are required as there is heterogeneity to the inflammatory process. By 
convention, between 4 and 6 biopsies are recommended (Hattotuwa et al., 2002). 
 
Bruno and colleagues analysed endobronchial biopsies from healthy control subjects 
(n=14), smokers without COPD (n=15) and smokers with COPD (n=27). They 
measured leptin which together with its receptor levels correlated with physiology, 
assessed using GOLD staging – there were significantly higher leptin positive cells with 
increasing GOLD stage (Bruno et al., 2005). This is of importance as the leptin receptor 
maybe expressed by lung tissue (Fantuzzi et al., 2000) and leptin has been shown to 
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have a significant role within a number of inflammatory pathways, in addition to roles 
within innate and adaptive immunity (Fantuzzi et al., 2000). This concurs with previous 
observations by Creutzberg and colleagues described above (Creutzberg et al., 2000). 
 
In endobronchial biopsies of smokers with no evidence of COPD and patients with 
COPD, the nuclear transcription factor NF-κB was increased compared to healthy 
control subjects, and the p65 sub segment was 2 to 4 fold higher. Furthermore, the 
increase in NF-κB correlated inversely with FEV1 % predicted (Di Stefano et al., 2002). 
NF-κB is of likely importance as it has a regulatory role in a number of cytokines and 
chemokines implicated in the pathophysiology in COPD, including TNFα, IL1, IL6, 
and IL8 (Di Stefano et al., 2002). In a further study by Di Stefano and colleagues, NK 
lymphocytes and macrophage inhibitory protein 1α (MIP 1 α) were also elevated in the 
biopsy samples of patients with COPD compared with healthy non-smokers, and in 
addition, there was an inverse correlation of these markers with lung function – patients 
with higher markers of inflammation having worse FEV1 (Di Stefano et al., 1998). 
 
1.5.4   Sputum Biomarkers 
Daily spontaneous sputum is produced in a proportion of patients with COPD, which 
infers a chronic bronchitic phenotype amongst this patient subset, who have been shown 
to have a higher risk of respiratory tract infections and hospitalisation, (with an 
increased mortality rate) which contribute to a more rapid decline in FEV1 (Vestbo et 
al., 1996). As an alternative to spontaneous sputum, induced sputum could be collected 
following the inhalation of an inducing agent, (most commonly hypertonic saline), 
however this has a number of disadvantages in its collection including the risk of 
inducing an inflammatory response and a fall in FEV1 during the sampling procedure 
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and subsequent bronchospasm (Bhowmik et al., 1999). There is difficulty of collecting 
repeated samples as this pro-inflammatory effect may persist for some time afterwards. 
There is also inherent variability in the concentrations of sputum biomarkers in patients 
with both usual COPD and A1ATD. This can be overcome by performing repeated 
sampling and averaging the results, which is more problematic with sputum induction; 
3 days was optimum for feasibility and reproducibility (Sapey et al., 2008 and Stone et 
al., 2012). 
 
Some markers, such as sputum interleukin 8 (IL8) and neutrophil count, are elevated in 
the sputum of smokers with COPD, compared to asymptomatic smokers and healthy 
control subjects. In particular, sputum neutrophil count correlates negatively with FEV1 
(Stanescu et al., 1996).  Furthermore, these measures are able to differentiate between 
differing stages of COPD, based on the GOLD classification using FEV1 % predicted 
(Cazzola et al., 2010). Other inflammatory mediators studied in sputum in COPD 
include myeloperoxidase (MPO) and leukotriene B4 (LTB4).  Parr et al demonstrated 
that the LTB4 concentration in sputum correlated with FVC decline and TLCO decline 
as well as the progression of emphysema, and that MPO also correlated with decline in 
FEV1 (Parr et al., 2006). 
 
Other markers studied include matrix metalloproteinases (MMPs) in induced sputum 
of patients with mild to moderate COPD. MMPs 8 and 9 were found to be increased in 
induced sputum of COPD patients when compared to healthy control subjects (Vernooy 
et al., 2004). 
 
Despite this wealth of research and data, there still remains the need for robust 
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biomarkers that fulfil all of the parameters outlined above, in this complex, 
heterogeneous condition. 
 
 
1.6           Proteomics  
  
Proteomics is defined as the study of all of the proteins within an organism or genome 
at a point in time (Wasinger et al., 1995). It is a term which was introduced in the 1990s, 
although the study of proteins in relation to disease, for example using 2 dimensional 
electrophoresis, pre dates this term. Genes remain constant over the lifetime, whereas 
the translation of genes into their products (proteins) is dynamic and constantly in a 
state of flux, making the proteome far more complex to study than the genome. 
Additionally, there are more proteins than genes, (partly at least as a result of alternate 
splicing) and proteins can also undergo post translational modifications, including 
glycosylation, phosphorylation and ubiquitination (Westermeier et al., 2008).  
Therefore studying the end product of genes ie the proteins that are produced and 
influence or reflect the physiology and therefore pathophysiology in disease states, can 
potentially provide much more information than is gained by studying the genes in 
isolation. 
 
Proteomics utilises a range of methodologies to analyse many peptides and proteins in 
a sample at a given time, which may provide information about the underlying 
pathophysiology of disease, in addition to looking for potential biomarkers. Typically, 
mass spectrometry is a key part of this process. A further advantage of using proteomics 
is the ability to analyse any bodily fluid, including plasma, serum, saliva, CSF, broncho-
alveolar lavage fluid, urine and even tissue samples processed for analysis.  
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1.6.1          Mass Spectrometry in Proteomics  
 
Technological advances in mass spectrometry have made this an integral part of many 
proteomics experiments. A mass spectrometer requires 3 parts; an ion source to 
generate ionisation of proteins and peptides (for example MALDI or electrospray) a 
mass analyser (eg time of flight (TOF), ion trap, quadrupole) which separates peptides 
based on their m/z ratio, and an appropriate detector. These will now be discussed in 
more detail.  
 
 
1.6.2  Surface Enhanced Laser Desorption/Ionisation SELDI/MALDI 
 
SELDI is a derivative of matrix assisted laser desorption/ionisation (MALDI), and these 
techniques use the same underlying principle for sample analysis. In a MALDI 
experiment, samples are prepared (of which there are many ways and optimisation of 
methods for this analysis and forms the basis of part of this MD thesis), co-crystallised 
using a matrix, and placed inside the mass spectrometer. A laser is fired at the samples, 
which are protected from destruction by the laser by the matrix, which also assists with 
the process of desorption/ionisation. Proteins and peptides generally become singly 
positively charged, and then are accelerated by a pulsed electromagnetic field to a 
detector. In a SELDI experiment, it is the surface of chip to which the proteins bind, 
(different chips are available, and have different binding/chromatographic properties) 
washing away anything in the sample which does not bind, to which matrix is then 
applied. SELDI has now largely been superseded by MALDI. 
 
In MALDI experiments, samples are prepared, placed onto a metal plate and overlaid 
with matrix. In a MALDI-TOF instrument, samples can be analysed in 2 different 
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modes. In linear mode, the peptides, once ionised, travel in a straight path to a detector. 
This has the advantage of being able to detect peptides at higher masses, although 
provides MS data of lower resolution. In contrast, in reflectron mode, the peptides are 
accelerated, and then reaccelerated in the opposite direction to a detector. This process 
is shown diagrammatically in Figure 1.1. This gives data of higher resolution, but limits 
the mass range of detectable peptides to around 5000 Daltons. The distance to the 
detector is known, thus the speed and hence the mass of the peptides can be calculated. 
Data generated gives information expressed as the mass to charge (m/z) ratio, which in 
a MALDI experiment is usually a charge of +1, as peptides are usually singly positively 
charged. 
 
 
 
Figure 1.1 shows the inside of the Bruker Ultraflextreme MALDI mass spectrometer, depicting 
how the samples are accelerated in linear and reflectron modes.  
 
 
Using a SELDI/MALDI approach, hundreds of samples a day may be analysed, so the 
throughput is high, and many individual samples can be analysed, which are usually 
done, at least, in duplicate.  This approach is semi-quantitative in that the signal 
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intensities for these peaks can be compared between the groups of samples, and peaks 
can then be selected for identification using tandem mass spectrometry (MS/MS). In 
order for this to occur, the instrument needs to select ionised peptides of a known m/z 
and subject these ions to further fragmentation. In most mass spectrometers this is done 
using a technique known as collision induced dissociation (CID), however in the Bruker 
Ultraflextreme this is laser induced. The resulting peptide fragments are then 
accelerated to the detector, allowing the sequence of the peptide to be identified, as 
known peptides fragment in a predictable way (Westermeier et al., 2008). 
  
1.6.3  Electrospray Ionisation (ESI) 
This is an alternative approach to MALDI to generate ions. The sample containing 
peptides is dissolved in solvent and pumped through a narrow stainless steel 
capillary/needle and a high voltage is applied to create an aerosol, which is dispersed 
as highly charged droplets. Nitrogen is usually used to direct the sample emerging 
towards the detector. The solvent evaporates and the positively charged ions pass into 
the mass spectrometer. By using this approach, peptides may adopt multiple charges, 
in contrast to MALDI where they are usually singly charged. This has the advantage of 
extending the mass range of the analyser and is therefore of use in identifying 
macromolecules. ESI is often coupled with a triple quadruople or an ion trap mass 
analyser, interfacing with HPLC and again is useful to try to detect as many as hundreds 
of peptides in a sample. 
 
1.6.4   Shotgun Proteomics 
This is a term which describes a method of identifying proteins in complex mixtures, 
such as plasma, using a combination of high performance liquid chromatography 
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(HPLC) and mass spectrometry. It requires the digestion of proteins within the complex 
sample, to generate peptides, which are separated using HPLC. Identification of the 
peptides is performed using tandem mass spectrometry (MS/MS).  
 
Plasma samples can be made less complex using an abundant protein depletion step, 
for which there are many commercially available products. IgY14 (Sigma Aldrich) 
columns are columns which contain antibodies to the 14 most abundant plasma 
proteins. These can be coupled with Supermix columns, which remove the next most 
abundant layer of proteins, working with the flow through from the IgY14 columns.  
Filter assisted sample preparation (FASP), using 30 kDa filters, allows the retention of 
proteins within filters, post abundant protein depletion, within the filters, where proteins 
can be reduced, alkylated and digested, an trypsin is often used in this instance. They 
have the advantage that larger volumes of sample can be processed, (mLs) compared 
to the small volumes conventionally used in standard in solution digests (typically only 
µL) to maximise potential peptide and subsequent protein identification (Wisniewski 
et al., 2009). 
 
iTRAQ labelling (isobaric tag for relative and absolute quantitation, AB Sciex) is 
a labelling strategy enabling multiplex quantitation of proteins via peptide LC-MS/MS. 
There are currently 2 commonly used sets of labels; 4 plex and 8 plex. The label reacts 
with the N- termini and lysine side chains of tryptic peptides. Different samples are 
labelled with different isobaric tags, and samples are mixed prior to LC-MALDI.  The 
iTRAQ labels fragment during the MS/MS stage to yield reporter groups with differing 
m/z ratios. The relative peak intensities of these reporter groups enable the calculation 
of quantitative differences between the samples. This is one method of performing 
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quantificative proteomics; other approaches such as tandem mass tag (TMT) and stable 
isotope labelling with amino acids in cell culture (SILAC) are alternatives to iTRAQ 
and are also widely utilised. The SILAC method is only applicable to cell culture, and 
would not have been possible to use in the experiments presented in this thesis. TMT 
is an alternative isobaric tag technique to iTRAQ labelling. 
 
Post iTRAQ labelling, complex samples can be separated using a number of methods, 
to reduce their complexity, and increase the chances of protein identification. 
Separation in 2 dimensions, for example using a mixed mode column (eg Acclaim 
mixed mode WAX 1), which involves multimodal separation mechanisms, using both 
reverse phase and weak cation exchange properties, within a single column.  
 
MALDI profiling can provide high throughput data on hundreds of moderately complex 
samples (such as plasma), and this is the approach I have utilised for this thesis. MALDI 
mass spectrometry is also more robust in the presence of impurities within the samples. 
This has also been as a result of instrument availability, and because preliminary data 
suggested that using a SELDI approach, it was possible to detect changes in the plasma 
peptidome in patients with A1ATD post treatment with pooled A1AT. 
 
1.7          Proteomics in COPD  
 
Some work in proteomics has been carried out previously in COPD. There are a number 
of samples that could potentially be analysed, including blood, sputum, tissue, exhaled 
breath condensate and broncho-alveolar lavage fluid (BALF).  As COPD is a multi-
system disease, it is possible to take samples from additional sites, such as from 
peripheral muscles. Barreiro and colleagues (2008) have biopsied vastus lateralis and 
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quadriceps muscles and used the tissue for proteomic analysis; however this review of 
proteomics in COPD is limited to blood and lung tissue/fluid samples. The important 
published work conducted to date for each of these different sample choices will be 
reviewed below.  
 
1.7.1          Proteomic Analysis of Plasma/Serum 
Only a small number of studies, mostly with small sample sizes, have been performed 
on plasma/serum in COPD. One of the best studies used protein microarray platform 
technology to analyse 24 markers to represent different parts of the underlying 
inflammatory process in COPD, and try to distinguish patients with COPD from healthy 
controls (Pinto-Plata et al., 2007). Forty-eight patients with COPD and a group of 48 
non-smoking healthy control subjects were included in the analysis. The panel included 
markers of destruction and repair (eg matrix metalloproteinase 9 (MMP9)), chemo-
attractants (eg (IL8)) markers of inflammation (eg TNF). These were able to 
differentiate between healthy controls and COPD patients and showed a significant 
correlation with a number of clinical parameters including FEV1, BODE, diffusion 
capacity of carbon monoxide, exacerbation rate and 6-minute walk distance, although 
not with BMI. The BODE index is a composite marker which aims to characterise the 
impact of COPD, encompassing BMI, (B), degree of airway obstruction (O), MRC 
dyspnoea score (D) and exercise capacity (E) measured on a 6 minute walk distance 
(Celli et al., 2004). This is one of the only studies published to date to correlate results 
from proteomics data with clinical parameters (Pinto-Plata et al., 2007). 
 
Pinto-Plata and colleagues subsequently refined their panel of markers to include just 
IL6, IL6, IL16, TNFα, vascular endothelial growth factor (VEGF), MMP 9, pulmonary 
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and activation-related chemokine (PARC/CCL) and monocyte chemotactic protein 1 
(MCP-1/CCL2). They measured these by ELISA in 253 patients with COPD and 
demonstrated that patients with high levels of IL6 and TNFα were more likely to have 
severe disease assessed by GOLD staging, and those with lower VEGF and MMP 9 had 
increased mortality (Pinto-Plata et al., 2012). This work demonstrates an initial set of 
experiments using proteomics to measure large numbers of peptides, before selecting a 
smaller panel to measure using ELISA – this is a common approach in proteomics, 
when attempting to validate potential candidate biomarkers.  
 
Bowler et al used SELDI chips to analyse plasma from 30 patients with COPD and 30 
asymptomatic smokers (Bowler et al., 2006a). There were no statistically significant 
differences in the peak intensities between the groups, although when they used 
classification and regression tree analysis, they found that 5 peaks were able to 
discriminate between the groups. Although the m/z ratios of these peaks were known, 
the peptide/proteins of origin remained unknown. The between analysis Coefficient of 
Variance (CVs) of this work ranged from 36% to 68%, which are values above the 
manufacturer’s specified CV of 15-20% in SELDI spectra, and this, together with the 
lack of protein identification, makes it difficult to draw any meaningful or clinically 
useful conclusions  from this work. 
 
Rana et al (2010) analysed plasma from COPD patients who they categorised into rapid 
or slow decliners after analysis of their lung function decline over a 5-year follow up 
period (Rana et al., 2010). The rapid decliners had an average annual fall in FEV1 of 
1.52% predicted/year, whilst the slow decliners had an average annual increase of 
0.73% predicted/year. They depleted the samples of abundant proteins, digested with 
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trypsin before using reversed phase capillary liquid chromatography (LC) with an 
electrospray instrument and found 55 peptides from 33 proteins to differentiate these 
groups. Of these, 12 were part of the complement/clotting cascade, including 
fibrinogen, which has previously been suggested as a possible COPD biomarker (Rana 
et al., 2010). 
 
 Serum amyloid alpha (SAA) was identified by Bozinoski et al (2008) in the serum of 
patients hospitalised with an acute exacerbation of COPD. Their work demonstrated a 
number of peaks in SELDI spectra that differed between stable and exacerbation states. 
One of these peaks had an m/z of 11 695, and a p value of 0.023. In previous work in 
severe acute respiratory syndrome, this peak had been identified as SAA. An 
immunoassay to SAA was applied and confirmed its presence in the COPD samples. 
The authors concluded that SAA was more sensitive than using CRP as a marker of 
acute exacerbations (Bozinoski et al., 2008). SAA has biological plausibility as it is a 
positive acute phase protein, (as is CRP) but it is also increased in other diseases, such 
as inflammatory bowel disease, (Murch et al., 1993) and is therefore, as with CRP, not 
specific to COPD.  
 
1.7.2  Proteomic Analysis of Broncho-alveolar Lavage Fluid 
In 2005 Merkel et al analysed BALF from 8 healthy subjects, 8 asymptomatic smokers 
and 10 smokers with COPD, using a variety of techniques including SELDI, and nano-
spray chromatography with MS/MS (Merkel et al, 2005). They detected significant 
changes in a number of proteins between healthy controls and smokers (calgranulin A, 
salivary proline-rich peptide P-C, and lysozome C were up-regulated, whereas salivary 
proline-rich peptide P-D and Clara cell phospholipid-binding protein were down-
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regulated). When comparing smokers with COPD and asymptomatic smokers, there 
were elevated levels of neutrophil defensins 1, 2, and calgranulins A and B. Plymoth 
and colleagues (2007) analysed BALF samples from 47 asymptomatic men, some never 
smokers, others lifelong smokers, who underwent bronchoscopy at the age of 60, using 
2 dimensional electrophoresis (2DE) followed by principal component analysis. 
Patients underwent bronchoscopy, at which time samples were taken and stored, then 
were reviewed after 7 years to record outcome. During the timeframe, 7 of the smokers 
developed COPD, whereas none of the never smokers developed this condition. 
Prediction models were created and from this the authors concluded that there was a 
pattern of protein expression that was different between the men who developed COPD 
and those who did not, thus enabling them to differentiate smokers who would develop 
COPD from those who would not (Plymoth et al., 2007).  
 
1.7.3   Proteomic Analysis of Lung Tissue  
In 2009 Lee et al used 2 dimensional electrophoresis (2DE) followed by MALDI-TOF 
to look at lung tissue from patients with COPD, healthy smokers and never smokers. 
They found that 8 proteins were up regulated in patients with COPD compared to 
healthy controls. They went on to characterise 2 of these proteins, which were matrix 
metalloproteinase 13 (MMP 13) and thioredoxin like-2, by using western-blotting. 
They reported a rise of these 2 proteins in healthy smokers compared to controls, and a 
further rise in patients with COPD. However, this work was carried out on tissue from 
patients undergoing surgery for lung cancer resections, so all patients had early stage 
disease (Lee et al., 2009). Whether or not these findings are relevant in patients with 
more severe disease or in areas distant from the tumour is not known. 
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Ohlmeier and colleagues used 2DE on 4 patients with GOLD stage IV COPD, and 
found that there were differences on the gels between healthy subjects and patients with 
COPD. One of the proteins was identified as being surfactant protein A (SP-A). The 
authors then performed Western blots on samples from patients with COPD (stages II-
IV) and healthy control subjects and found again that in COPD patients, SP-A was 
elevated, although none of the other surfactant proteins changed, suggesting it was a 
specific mechanism (Ohlmeier et al., 2008).  
 
Kelsen and co-workers used 2DE on tissue from groups of patients with COPD, healthy 
smokers and non-smokers. They hypothesised that smoking could produce an effect in 
the endoplasmic reticulum of the lung known as the unfolded protein response, via the 
effects of reactive oxidant species. This response was believed to affect a number of 
gene expression functions including inflammation, protein synthesis and apoptosis.  
They were able to determine that 26 proteins within the lung tissue were differentially 
expressed (20 up regulated and 6 down regulated) in the samples from the smokers, 
when compared to the non-smokers, and the authors felt that this might be partially 
reversible with targeted therapy (Kelsen et al., 2007). 
 
 1.7.4  Proteomic Analysis of Sputum 
Both induced and spontaneous sputum samples have been used for proteomics 
experiments however certain properties of sputum make its’ analysis difficult. For 
example, sputum contains multiple mucins which may form crosslinks, which may 
impair the results of gel analyses (Pelaia et al., 2014). However, Casado et al (in 2007) 
used induced sputum sampling in 56 patients categorised into groups according to 
symptoms and CT appearances (never smokers, healthy smokers, chronic bronchitics 
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who had no airflow obstruction, COPD patients who had no emphysema on HRCT and 
COPD patients with emphysema). They used liquid chromatography ion trap 
quadrupole mass spectrometry and 2DE MALDI TOF approaches and found that mucin 
5A was increased in all groups of smokers, compared to healthy controls (they 
hypothesised that this could be due to mucus gland hyper-secretion in smokers). A 
number of other proteins, such as Clara cell protein,  actin and proline rich 4 (PRR4) 
were reduced in the smoking group (Cassado et al., 2007). 
 
Ohlmeier and colleagues (2011) analysed induced sputum from 7 patients with COPD, 
7 smokers with normal spirometry and 7 healthy control subjects. They performed 2D 
DIGE on sputum samples and discovered 15 differentially expressed proteins between 
these groups. One of these was the polymeric immunoglobulin receptor (PIGR) which 
was subsequently measured in the plasma using an ELISA. Results from 36 non-
smokers, 52 smokers and 42 patients with COPD demonstrated that PIGR was 
significantly elevated in the patients with COPD when compared with the group of 
current smokers, and both of these groups were significantly higher than the non-
smokers. Furthermore, there was a correlation between plasma concentration of PIGR 
and airflow obstruction (Ohlmeier et al., 2011). 
 
Gray et al obtained induced sputum from patients with CF, bronchiectasis, asthma, 
stable COPD patients and healthy controls and analysed the samples using SELDI-
TOF. Patients with CF and bronchiectasis had the most differences from healthy 
subjects, thought to be a reflection of the extent of the underlying inflammatory 
processes. Some of these proteins, for example calgranulins A, B and C (proteins 
derived from neutrophils) were up-regulated in inflammatory airway disease, whilst 
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others such as Clara cell secretory protein were down-regulated (Gray et al., 2008). 
 
Nicholas and colleagues analysed induced sputum from patients with COPD and 
healthy controls, and used 2DE followed by mass spectrometry to identify potential 
differences. Some of their results were validated in a larger patient group using 
immunoassays, and results showed that 2 potential markers, apolipoprotein A1 and 
lipocalcin-1 were significantly reduced in patients with COPD compared to healthy 
smokers (Nicholas et al., 2006), and correlated with disease severity measured using 
the FEV1, FVC and FEV1/FVC ratio. 
 
Induced sputum samples were analysed from 6 patients with COPD, 8 patients with 
asthma and 5 healthy control subjects. The samples were prepared using mesoporous 
silica beads followed by MALDI-TOF TOF. When the spectra were analysed, there 
were 6 proteins which were able to distinguish these groups of patients – 3 remained 
unidentified and the other 3 were α defensins ( human neutrophil peptides 1, 2 and 3), 
which were elevated in the COPD patients (Terracciano et al., 2011). From this work 
the authors concluded that the analysis of induced sputum was possible, that the mucins 
did not preclude sputum analysis and that differences could be found between patients 
with inflammatory lung conditions such as asthma and COPD, and healthy control 
subjects (Terracciano et al., 2011). 
 
1.7.5  Proteomic Analysis of Exhaled Breath Condensate 
Exhaled breath condensate (EBC) was analysed by Fumagalli and colleagues in 20 
patients with emphysema secondary to A1ATD and 25 healthy control subjects. They 
used 2DE, HPLC and MS and found that the EBC of patients contained higher levels 
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of IL2, IL 15 as well as a number of cytokeratins including cytokeratins 1, 9, and 10 
than that of the healthy control subjects (Fumagalli et al., 2008). A further study of EBC 
analysed samples from 4 groups - never smokers (n = 25), healthy smokers (n = 20), 
patients with COPD (n=15) and patients with A1ATD (n=23). They used LC MS/MS 
and found that a number of proteins including calgranulins A and B, 2 separate isoforms 
of SP-A, IL 1α and β, IL 2 and 12 were differentially expressed between the patient 
groups (Fumagalli et al., 2012). Both of these studies demonstrate that it is possible to 
generate proteome profiles of EBC in patients with COPD. Stolk and colleagues (2015) 
analysed conductivity of EBC from patients with A1ATD with evidence of emphysema 
and their spouses (n=7) and 18 patients with usual COPD and 6 patients with 
sarcoidosis Stolk et al., 2015). They were able to demonstrate that conductivity was 
lower in patients with A1ATD than in their healthy spouses, and that this was stable 
over a follow up period of 14 months. They concluded that measuring conductivity may 
help to overcome the dilutional variation when analysing EBC (Stolk et al., 2015).   
 
To date, none of the potential biomarkers from these preliminary studies have been 
studied beyond the discovery phase and are a long way from transfer into clinical 
practice in COPD. This may be partly due to the complexity and heterogeneity of the 
condition, difficulties with each sample choice, small numbers of patients included in 
each analysis with little attempt to phenotype patients, cost or a lack of collaboration 
between clinicians, statisticians, bioinformatists and scientists from the outset of work. 
 
 
1.8              Proteomics in Alpha-1-Antitrypsin Deficiency 
 
A1ATD provides a good model for the study of proteomics in COPD. In this condition, 
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there is an excess of neutrophil elastase in the lung, due to a lack of its natural inhibitor, 
resulting in a protease/antiprotease imbalance, and proteolytic destruction of the lung 
parenchyma. This may result in the early onset of emphysema described above. At the 
point of release from the azurophil granule, where the NE is stored, the concentration 
of NE is 5mM, although the concentration falls exponentially with increasing distance 
from the point of release.  This results in a concept known as the ‘obligate area of 
damage’, (Liou et al., 1996) which is greater in patients with A1ATD when compared 
to healthy control subjects. Even in healthy individuals, where the concentration of 
A1AT in the plasma is around 30µM, the concentration of NE at the point of release is 
several orders of magnitude greater than its inhibitor, A1AT. This means that NE 
remains active until its concentration has fallen (at a point a distance away from the 
neutrophil) to that the surrounding of A1AT, its natural plasma inhibitor.  In patients 
with A1ATD, this is a greater problem, as the average plasma, and therefore lung 
interstitial concentration of A1AT is around 5µM (Liou et al., 1996), rather than the 
normal value of about 30µM, so the area of obligate proteolysis is exponentially greater 
as calculated by mathematical modelling.  
 
As the lungs, like every other tissue and organ in the body, have a blood supply, changes 
within the lung parenchyma should theoretically be detectable in the blood stream due 
to recirculation of lung interstitial lymph.  Therefore it seems likely that there will be 
products of the inflammation and proteolytic activity occurring in the lungs in the 
plasma of patients with A1ATD, and that this could be detectable by profiling the low 
molecular weight plasma proteome which will contain peptide fragments of degraded 
proteins. 
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Additionally, in A1ATD, there is an intervention (augmentation therapy), which can 
restore the serum and sputum levels of A1AT (Stockley et al., 2002). Since it is likely 
that augmentation is beneficial in preventing disease progression, studying samples 
before and during augmentation would provide data to explore potential markers of the 
destructive process.  
  
After tissue sampling, which is difficult to repeat, hence has limited use as an outcome 
in clinical trials, blood analysis has the greatest potential to offer in the field of 
biomarker discovery. Blood samples are routinely taken and stored, and are minimally 
invasive to collect, therefore these were the samples chosen for analysis and the results 
are presented in this thesis. 
 
1.9  Hypothesis 
The experiments described in this thesis test the hypothesis that proteolytic degradation 
of lung parenchyma will be reflected by changes in the low molecular weight plasma 
proteome and will be useful for predicting disease progression and monitoring response 
to treatment with augmentation therapy. The data will therefore fulfil one or more of 
the roles described in section 1.5 of a clinically relevant biomarker in patients with 
A1ATD.  
 
1.10            Aims of my MD 
 
The aims of my MD thesis were to use and assess different optimised proteomic 
techniques, with mass spectrometry at the centre, to identify potentially useful proteins 
and peptides in the plasma of groups of patients with A1AT including:- 
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a).The analysis of plasma from blood samples from A1ATD patients that have been 
treated with calcium ionophore. This stimulator of neutrophils releases various 
inflammatory mediators including neutrophil proteinases, which have immediate 
proteolytic effects prior to inhibition. The data will be compared to control samples 
from the same patient prior to treatment. This will act as an in vitro model for the actions 
of neutrophil proteinases and help to provide possible candidate markers for this 
condition, which are likely to be present in the clinical samples. 
 
b). To compare the plasma of patients with A1ATD deficiency during the stable state 
and during exacerbations when neutrophil activation and degranulation increases. 
Previous work has confirmed that during exacerbations, the inflammatory response in 
patients with usual COPD and those with A1ATD, is amplified returning to lower levels 
in the stable state (Hill et al., 1999 and Gompertz et al., 2001). 
 
c). Analysis of samples pre and post treatment with replacement therapy as part of the 
EXACTLE study (a double blind, randomised controlled trial of intravenous alpha 1 
antitrypsin over a two and a half year period). This will determine whether any of the 
peptide signals change reflecting the increase of antiprotease activity and hence a 
reduction in protein/tissue damage with treatment. Data will be compared to that in a 
group of patients receiving placebo infusions. 
 
 
d). The methods will be used to compare to patients with A1ATD, usual COPD and 
healthy controls. This will determine whether the patterns in the A1ATD group are 
reflected in patients with usual COPD, or unique to A1ATD. Data will also be 
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compared in a second study of patients receiving A1AT augmentation as part of an 
interventional study assessing FDG uptake from CT PET measurement. 
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CHAPTER 2 METHODS 
 
2.1 Patient Selection 
 
The ADAPT Project (Antitrypsin Deficiency Assessment and Programme for 
Treatment) in Birmingham hosts the UK registry for patients with A1ATD and lung 
disease. Patients are referred from all over the UK from either primary or secondary 
care for assessment and advice. On enrolment, patients have their alpha-1 antitrypsin 
status reassessed for level, phenotype by isoelectric focusing and genotype by DNA 
sequencing in a single laboratory (Heredilab, Salt Lake City, Utah). Those who attend 
for review have a variety of phenotypes, although the majority are of the PiZZ 
genotype. Patients enrolled into interventional trials all had the PiZZ genotype, with 
plasma A1AT concentrations below 8μM. 
 
The ADAPT register serves several purposes. Firstly, it acts as a centralised register for 
patients in the UK with this condition. Secondly, it provides data on demographics and 
progression of disease. Patients undergo annual review by a member of the research 
team, which includes accurate and detailed lung function testing, performed to the 
ATS/ERS and ARTP (American Thoracic Society, European Respiratory Society and 
the Association of Respiratory Technicians and Physiologists) guidelines, completion 
of quality of life questionnaires and Medical Research Council (MRC) dyspnoea score, 
and the collection of demographic data. Blood samples (stable state) are taken for 
routine biochemical and haematological testing, and aliquots of plasma and serum are 
stored for future biomarker and cell pellets generated for genetic studies. 
 
From the registry, it is possible to identify suitable patients for clinical trials. Two such 
trials of A1AT augmentation have been the double blind EXACTLE trial, funded by 
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Talecris (now Grifols) (Birmingham was 1 of 3 participating centres) and the open 
ECLIPSE A1ATD study, which was a single centre study carried out in Birmingham. 
Samples from these 2 studies were used in the research presented in this thesis. 
 
There were 77 patients enrolled into the EXACTLE trial (a randomised controlled trial 
of purified human A1AT therapy (Prolastin) versus placebo, consisting of 23 patients 
from the UK, 16 from Sweden and 38 from Denmark). Of these, there were 72 pairs of 
plasma samples (72 patients with samples pre and post treatment at 6 months) that were 
available and non-haemolysed and thus suitable for proteomic analysis. The aim of the 
trial was to investigate efficacy and safety of augmentation therapy and to explore the 
use of CT densitometry as the primary endpoint. Secondary endpoints included quality 
of life status pre and post treatment (measured using the St George’s Respiratory 
Questionnaire), and the measurement of lung function parameters. The baseline and 6 
month samples were used for the studies presented in this thesis. 
 
In the ECLIPSE A1ATD trial, there were 10 patients with A1ATD, 9 healthy control 
subjects and 9 patients with usual COPD with plasma samples available for analysis. 
Patients with A1ATD had plasma samples taken at baseline and during the last of 12 
weeks of weekly intravenous replacement therapy.  COPD patients and healthy control 
subjects had plasma samples taken on the day of their screening visit alone. The aim of 
the ECLIPSE A1ATD trial was to compare neutrophilic inflammation in the airways, 
as seen on CT PET scanning, in the patients with A1ATD before and at the end of 3 
months of augmentation therapy, and to compare results to patients with usual COPD 
and the healthy control subjects. The patients also had a urine sample taken to be 
analysed for cotinine concentrations, which is a metabolite of nicotine to confirm the 
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lack of smoking over the preceding week. The inclusion criteria for the study stipulated 
that the patients in the ECLIPSE A1ATD study were non- or ex-smokers, and the 
measurement of cotinine was to confirm this status, and thus eligibility for study 
enrolment.  Samples analysed within this thesis from patients with A1ATD were those 
provided at the screening visit and prior to the final Prolastin infusion, and samples 
from healthy control subjects and COPD patients were those taken at the screening visit.  
 
In both of these studies, the dose of A1ATD augmentation therapy used was 60mg/kg 
of body weight, and the A1AT used was Prolastin (provided by Talecris 
Biotherapeutics).  
 
 
2.1.1 Blood Collection 
 
All of the plasma samples were taken and processed in the same way, irrespective of 
the trial for which they were taken. Plasma was obtained from peripheral blood samples 
(using Greiner Bio-one Vacuettes (456089 + 454021) containing EDTA) and following 
centrifugation (Heraeus Rotina 46R) for 15 minutes at 1800 g at 21°C samples were 
stored at −80°C in cryovials until analysis. 
 
 
2.1.2   Urine Collections 
 
Patients provided a mid-stream urine sample which was collected in a sterile universal 
container and frozen at –800C until subsequent analysis.  
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2.2   SELDI Analysis 
Preliminary work was undertaken to determine the feasibility of this proteomic 
approach using samples from the 23 UK patients with A1ATD from the EXACTLE 
study pre and post 6 months’ of augmentation therapy.  The proteinchip arrays were 
loaded with Cu2+ as per the manufacturer’s instructions: 50µL of 0.1M copper sulphate 
was added to each spot and incubated for 5 min at room temperature with shaking 
followed by washing three times with 200µL of MiliQ water. 
  
The plasma samples were prepared by initially diluting fivefold with a solution of 8M 
urea in binding buffer at pH 7.0 (0.1M sodium phosphate, 0.5M NaCl and 1% by weight 
of CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1)  They were subsequently 
diluted a further 10 fold with binding buffer. One hundred µL of the diluted plasma 
sample was added to each spot on the chip, and left to bind for 1 hour at room 
temperature with shaking. After this time, the liquid was discarded and 4 washes were 
carried out using 200µL of buffer solution (0.1M sodium phosphate, 0.5M NaCl and 
1% by weight of CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1). Samples 
were placed on a plate shaker at 600 rpm for 5 minutes in between each cycle.  
  
Two further washes were performed, using 200µL of MiliQ water, allowing 2 minutes 
in between each wash cycle with shaking at 600 rpm. The chips were then allowed to 
dry, sinapinic acid (SPA) matrix applied (1µL of a 50% saturated solution made in 50% 
ACN, 0.5% TFA) allowed to dry completely, before a second µL of matrix  was applied 
and again allowed to dry completely prior to reading on the PBS IIc. 
 
Mass spectra were acquired over the low mass range (0-20 kDa) and the high mass 
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range (0-150 kDa), using 600 laser shots and laser intensities of 175/225 for the low 
and high ranges respectively. Peaks were detected using the Ciphergen proteinchip 
software.  
 
Samples were analysed in duplicate, and the peak intensities measured. Data was log 
transformed to achieve normality and then the mean of the 2 replicates analysed using 
the repeated measures test and the Huynh Feldt analysis to determine differences 
between the groups and between the 2 time points. A p value of <0.05 was taken as 
significant.  
 
2.3   MALDI Profiling  
 
Pooled samples from the 3 patient groups from the ECLIPSE A1ATD study were 
created, (using an equal volume of each individual sample) and used to optimise 
conditions for MALDI profiling.  From these data, it was possible to assess the quality 
of the spectra by visual inspection, to calculate an average coefficient of variance (CV) 
of peak intensities and to determine how many peaks were present within the spectra. 
The most informative and reproducible methods were then used to analyse individual 
samples – initially from the ECLIPSE A1ATD study, then from the EXACTLE trial. 
This follows conventional proteomics experiments with the ECLIPSE A1ATD samples 
used for a discovery phase, whilst the EXACTLE samples provided validation of any 
differences found.  A full description for each of the methods used is described below. 
 
In each experiment, samples were analysed in number order of the patients’ study 
enrolment number. For the patients with A1ATD in the ECLIPSE A1ATD and 
EXACTLE studies, pre and post intervention study samples were analysed 
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consecutively, in order to minimise intra-experiment variation for subsequent paired 
analyses. 
 
2.3.1    Creation of Quality Control sample  
 
In order to test reproducibility of the methods utilised, a quality control sample was 
created to process in parallel with individual samples. This consisted of a pool of plasma 
was made by pooling plasma from 4 different individual patients and healthy control 
subjects, each contributing an equal volume to the pooled sample. This allowed a 
Coefficient of Variance (CV) of the method to be calculated for each experiment 
throughout the series of experiments detailed in this thesis. The QC sample was 
analysed in triplicate alongside the clinical samples during each experiment to ensure 
reproducible results were obtained, and an inter-experiment CV was calculated for each 
experiment.  
 
2.3.2  Supel Tip Profiling  
 
Supel tips (Sigma Aldrich) are pipette tips packed with C18 reverse phase resin to allow 
protein/peptide binding. The tips were prepared by wetting them 3 times with 20µL of 
100% acetonitrile, (ACN) before washing 3 times with 20µL of 0.1% trifluoroacetic 
acid (TFA). Ten µL of plasma was mixed with 40µL of 0.1% TFA in a clean tube and 
centrifuged at 13,000 g for 5 minutes. The proteins and peptides were then bound to the 
adsorbent material in the pipette tips by pipetting up and down in the diluted plasma 
sample 20 times with the pipette set to 20µL. The tip was then washed 5 times with 
20µL of 0.1% TFA. Samples were eluted by drawing up 10µL of elution solution (50% 
ACN, 0.5% TFA) through the pipette tip and placing the eluant in a clean tube, prior to 
spotting 1.5µL of the sample on to a MALDI plate.  
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2.3.3  Weak Cation Exchange Beads Profiling (MB WCX)  
 
Samples were processed according to the manufacturer’s instructions. Briefly, 10µL of 
magnetic beads (Bruker Daltonics) were placed into a flat-bottomed 96 well plate with 
10µL of binding buffer. Plasma (5µL) was added to the beads, and incubated on a plate 
shaker at 600 rpm at room temperature for 5 minutes. 
 
The 96 well plate was placed on a magnetic separator for 1 minute and the liquid 
removed and discarded. Wash buffer (100µL) was added, and the plate left on the plate 
shaker for 2 minutes. The plate was then placed on a magnetic separator and the liquid 
removed. This wash step was repeated 3 times. 
 
Elution buffer (5µL) and 5µL of stabilisation buffer were added to the beads. The 96 
well plate was then placed on the plate shaker for 2 minutes. The beads were again held 
over the magnetic separator and 1.5µL of the eluant spotted on to a clean MALDI plate, 
and allowed to dry, prior to matrix addition. 
 
2.3.4   MB Immobilised Metal Affinity (IMAC) Cu Bead Profiling 
 
The manufacturer’s (Bruker Daltonics) instructions were followed in detail. Briefly, 
10µL of magnetic beads were placed into a flat-bottomed 96 well plate, and 10µL of 
binding buffer was added to activate the beads. The plate was transferred to the plate 
shaker at 600 rpm for 2 minutes and then held over a magnetic separator and the 
supernatant removed. This was repeated until 3 separate activation steps had been 
performed. The beads were re-suspended in 50µL of binding buffer and 10µL of plasma 
was added, and mixed by pipetting up and down 5 times. The 96 well plate was placed 
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on to the plate shaker, at 600 rpm, for 5 minutes. 
 
The beads were then washed 3 times using 100µL of wash buffer, leaving for 2 minutes 
on the plate shaker after the wash buffer was added, holding the plate over a magnetic 
separator and the liquid discarded. The proteins/peptides were eluted from the beads 
using 10µL of elution solution, mixed with the beads by pipetting, and then placed over 
the magnetic separator for 2 minutes, to draw the beads to the bottom of each well. The 
eluted sample (1.5µL) was spotted onto the MALDI plate. 
 
 
2.3.5    C8 and C18 Beads Profiling  
 
The same method was used for both of these bead types. The beads (6µL) (Bruker 
Daltonics) were placed into the wells of a flat-bottomed 96 well plate, with 100µL of 
0.1% TFA and 5µL of plasma. These were left on the plate shaker at 600 rpm at room 
temperature for 20 minutes to allow sufficient time for protein binding. The plate was 
then placed over a magnetic separator to draw the beads to the bottom and the liquid 
containing unbound material removed and discarded. 
 
The beads were washed 3 times with 100µL of 0.1% TFA. Following each wash, the 
samples were held over the magnetic separator and liquid discarded. Proteins and 
peptides were eluted from the beads using 50% ACN 0.5%TFA, prior to spotting 1.5µL 
on to a MALDI plate. 
            
2.3.6   SPE C8 Cartridge Profiling (Solid Phase Extraction C8 Cartridges) 
 
Twenty µL of plasma was diluted in 500µL of 0.1%TFA, and centrifuged at 13,000 g 
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for 1 minute. The 100mg 1mL SPE C8 cartridges (Sigma Aldrich) were prepared by 
adding three aliquots of 500µL of 100% ACN, and the solvent was allowed to flow 
through the cartridges under gravity, and discarded. The cartridges were then washed 
using 3 aliquots of 500µL of 0.1% TFA. Once the TFA had passed through the 
cartridge, the diluted plasma sample was added to the cartridge and allowed to pass 
through to enable protein and peptide binding.   The cartridge was again washed with 
500µL of 0.1%TFA, and the peptides eluted from the cartridge using 400µL of 60% 
ACN 0.1% TFA. One and a half µL of eluant was spotted onto a MALDI plate.  
 
2.3.7               Matrix Application 
 
Once the samples had dried on the MALDI plate, they were overlaid with 1.5µL of 
10mM ammonium phosphate, which was allowed to dry before application of 1.5µL of 
α-cyano-4-hydroxy-cinnaminic acid matrix (CHCA). The CHCA was made at a 
concentration of 5mg/mL in 50% ACN and water, which was vortexed for 1 minute, 
sonicated for 10 minutes and centrifuged for 10 minutes at 13,000 g prior to use. 
 
2.4               MALDI Mass Spectrometry 
Once the prepared samples had dried on the MALDI plate, the plate was inserted into 
a Bruker Ultraflextreme MALDI TOF/TOF mass spectrometer. The same instrument 
settings were used throughout each series of experiments. Samples were read in 2 
different modes; linear and reflectron. For the linear read the settings were; detection 
1000 – 20,000 m/z, detector gain 50%, 20, 000 laser shots per sample, laser offset 78% 
and laser power 50-55% (this was optimised for each individual experiment). For reflect 
mode the settings were 1000-5,600 Da, 15% detector gain, 20,000 laser shots per 
sample, laser offset 78%, laser power 40-45% (again this was optimised for each 
53 
 
experiment).  
 
2.5  Analysis of MS Data from Profiling 
 
Two different types of spectra were generated – linear and reflectron spectra. Linear 
spectra give information over a larger mass range and the higher resolution reflectron 
spectra provide information on accurate mass and charge state. The data were sorted 
into groups; for the ECLIPSE A1ATD samples this was A1AT pre and post treatment, 
COPD and healthy controls, and for the EXACTLE samples, placebo baseline and after 
6 months of placebo infusions and active treatment at baseline and after 6 months of 
augmentation therapy. The spectra were loaded into ClinProTools version 2.2 (Bruker 
software), and peak lists and intensities compiled. The settings used in this package 
were peptides and proteins from 1000 to 10,000 m/z in the linear spectra with no data 
point reduction, following baseline subtraction and total ion current normalisation with 
signal to noise set to 3. The same settings were used for the reflect spectra over a more 
limited range of m/z 1000 to 5000.  The peak picking element of the software package 
is designed to work on linear spectra and all linear data were used for the subsequent 
data analysis.  
 
 
2.6    LC-MALDI Optimisation for Identification of Endogenous Plasma                                                                            
Peptides 
 
The high performance liquid chromatography (HPLC) system used for this study was 
a Dionex HPLC UltiMate 3000, with a 15cm x 75µM C18 reverse phase column 
(Dionex). Two buffers were used; buffer A which was 98% HPLC grade water, 2% 
ACN and 0.05% TFA, and buffer B was 80% ACN 20% water and 0.04% TFA. One 
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hundred μL of each sample in 0.1% TFA was loaded on to the column and eluted with 
linear gradients of 0 – 60% buffer B. The column eluent was mixed 1:10 with matrix 
solution, and spotted on to a 384 spot 600μM anchorchip target plate. Three gradients 
were used to separate the sample over 96, 192 or 384 spots, dependent on whether 
throughput of samples or depth of coverage was the priority.  These required different 
times; (a) a 96 spot gradient which runs over 65 minutes (b) a 192 spot gradient which 
runs over 89 minutes, which is half of a standard plate, and (c) a 384 spot gradient 
which runs over 105 minutes. The matrix was made of 888µL of 100% ACN, 47µL of 
HPLC grade water, 45µL of CHCA (saturated in 90% ACN and 10% water, vortexed 
for 1 minute, sonicated for 15 minutes, and centrifuged for 5 minutes at 13,00rpm) 
10µL of 100mM ammonium phosphate and 10µL of 10% TFA. 
 
MS spectra were acquired with 3500 laser shots. For calibration, a mixture of peptides 
and matrix was added to a pre-determined spot in between each set of 4 samples. This 
was made up from Pepmix calibrants (Bruker) (containing bradykinin, angiotensin, 
substance P, bombesin, rennin, ACTH and insulin b chain) and 300µL of HPLC matrix. 
Calibrant (0.2µL) was manually added to each calibrant spot once the sample was 
spotted out on to the plate. During the reading of the plate, the calibrant spot was read 
first, followed by the 4 spots around it, and this cycle continued throughout the entire 
plate, to calibrate each set of 4 spots accurately. 
 
Peaks within the MS spectra with a signal to noise (S/N) of >10 were automatically 
selected for MS/MS and fragmented by laser induced dissociation, using 4000 laser 
shots, and analysed by TOF/TOF. 
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2.6.1               Sample Preparation for LC-MALDI 
   
 
Thirty kDa and a 50 kDa molecular weight cut off filters (Sartorius Stedi, Biotech, 30kDa 
Vivaspin 500) were washed 5 times with 200 µL water.  After the water was added, the 
column was centrifuged at 13,000 g and the water discarded. Plasma was mixed 1:2 with 
an 8M urea solution (120µL of 8M urea solution and 60µL of plasma). This was added 
to the filters and centrifuged at 13,000 for 60 minutes. The filtrate was acidified with 
1% TFA and analysed by LC-MALDI. 
 
2.6.2               Data Analysis LC-MALDI 
 
The MS/MS data from the LC-MALDI runs was analysed via ProteinScape software 
version 2.1 (Bruker Daltonics) with MASCOT server version 2.3 (Matrix Science) and 
both the SwissProt Human Database and a randomised database. The search settings 
were as follows:- the peptide had to be first ranked, with a molecular weight search 
(MOWSE) score of > 40 at the protein level, > 30 for an individual peptide, and mass 
tolerances of the precursor ion of +/- 20ppm and of the fragment ion +/- 0.7 Da and 
enzyme – ‘no enzyme’.  The data on individual peptides and proteins was exported to 
Microsoft Excel 2007 for further analysis. 
 
2.7   Urine Analyses  
2.7.1    Urine Protein Content Calculation Using Bradford Assay 
Each individual urine sample (20L) was aliquoted in duplicate into a 96 well plate and 
150L of Bradford reagent (Bio Rad) were added to each sample. Bovine serum 
albumin (BSA) calibration standards were made using MiliQ water to concentrations 
of 0, 60, 120, 180, 240 and 300µg/mL, and  20L of each was aliquoted in duplicate 
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into the same plate with 150L of Bradford reagent. The absorbance was measured at 
595nm. The protein content of each of the individual urine samples was calculated from 
the standard curve. 
 
2.7.2    Preparation of Urine for MALDI Profiling  
 
Urine samples were diluted to a final protein concentration of 30g/mL and 50L of 
each diluted sample was placed in a 96 well plate and acidified with10L of 5% TFA. 
The samples were then Supel tipped using 20L of 100% ACN for each ‘wetting’ step, 
20L of 0.1% TFA for each wash step, pipetting up and down in the samples 20 times 
and eluting with 10L of 50% ACN and 0.5% TFA. Each sample (1.5L) was spotted 
on to a MALDI plate in duplicate and 1.5L of 10mM ammonium phosphate and 1.5L 
of 5mg/mL CHCA added. Samples were read in both linear and reflectron modes as 
described in section 2.4. 
 
2.7.3   Urine Sample Preparation for HPLC 
Pooled urine samples were created, and diluted using 0.1% TFA to a final concentration 
of 30g/mL, and 10L of 5% TFA added. Samples were supel tipped as described in 
2.6.2, eluted with 10L of 50% ACN and 0.5% TFA, and 90L of 0.1% TFA was 
added. Each sample was analysed in triplicate by LC-MALDI, using the 192 spot 
gradient described above in section 2.5.  
 
2.8  In Vitro Manipulation of Samples                   
 
The purpose of this series of experiments was to activate neutrophils in whole blood 
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using calcium ionophore, which is a potent stimulator of neutrophils, in order to 
generate peptides which could act as an in vitro model of the actions of NE. This was 
done in patient with A1ATD, and in healthy control subjects, and comparisons between 
these groups were performed.  
 
 
2.8.1  Calcium Ionophore  
 
Freshly collected whole blood (1 mL taken in lithium heparin tubes) from 5 patients 
with A1ATD and 5 age matched healthy control subjects was incubated for one hour at 
370C with 1.5L 150µM calcium ionophore A23187, (Sigma, St Louis) dissolved in 
DMSO. The samples were then centrifuged at 500g for 5 minutes and the plasma 
harvested. For each patient and control, 1mL of blood was incubated alongside the 
ionophore sample and treated in the same way, but without the addition of ionophore. 
As soon as the samples had been centrifuged, the plasma samples were frozen at -80 
0C. The time taken from the blood sample collection to being frozen was less than 90 
minutes. 
 
The calcium ionophore samples and their controls were processed using the WCX 
beads and the SPE C8 cartridges (as outlined above in 2.2.3 and 2.2.6) and read in linear 
and reflectron modes as described in 2.4. A pool was created using 20 µL of eluant 
from each individual post SPE C8 clean up, and analysed in triplicate using LC-MALDI 
(as outlined in section 2.6.3.). These experiments provided data with and without PMN 
activation in order to allow a comparison between the in vitro actions of proteases 
released from the activated neutrophils in patients with A1TAD and healthy control 
subjects.  
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2.8.1   Effects of Neutrophil Elastase (NE) on the Plasma Proteome 
NE is one of the proteases released by activated neutrophils and inhibited by A1AT. 
Therefore the next series of experiments were performed to determine which of the 
peptides generated following the addition of calcium Ionophore to plasma were 
generated by the actions of NE. Pooled plasma from A1ATD patients at baseline and 
healthy control individuals from the ECLIPSE A1ATD study were used. NE (5μl of 3.4 
μM NE Athens Research and Technology, made up in PBS) was added to 44μL of 
phosphate buffered saline (PBS) and 1μl of plasma. This was incubated at 370C for 1 
hour. Following this time, the sample was supel tipped and then eluted with 10μL of 
50% ACN 0.1% TFA. Of the eluted material, 1.5μL was spotted on to a MALDI and 
MS spectra generated. The remainder was analysed in triplicate by LC-MALDI using 
a 384 spot gradient.  
 
2.8.2   Effects of Proteinase 3 (PR 3) on the Plasma Proteome 
PR3 is another of the major serine proteases released by activated neutrophils and 
inhibited by A1AT. The following series of experiments was to determine which of the 
peptides generated following the addition of calcium Ionophore to blood were 
generated by the actions of PR3. Proteinase 3 was added to plasma as described above 
with NE. PR3 (3.4 μM Calbiochem, in PBS) was added to 44μL of PBS and 1μL of 
plasma and incubated for 1 hour at 370C. Following incubation, the samples were supel 
tipped and 1.5 μL of the eluted material was spotted on to a MALDI plate and spectra 
generated. LC-MALDI was carried out in triplicate using a 384 spot gradient. 
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2.9   Statistical Analysis 
Peak intensity data was exported from ClinProTools (Bruker Daltonics) using the 
parameters outlined above. The data was entered into SPSS for Windows (Chicago Ill, 
version 17) and a Shapiro-Wilk test performed to determine whether or not the data was 
normally distributed. If the data was normally distributed, a paired or unpaired t test (as 
appropriate) was performed in Microsoft Excel (2007) to assess any differences in the 
data. If the data was not normally distributed, it was log transformed to achieve 
normality, and a repeat Shapiro-Wilk performed to verify a normal distribution of the 
data. For the log transformed  ECLIPSE A1ATD data, ANOVA was performed on all 
of the peaks intensities, to determine if any changed significantly between the groups, 
and where this occurred, a post hoc analysis using a Tukey test was performed. Separate 
analyses were performed between A1ATD baseline and COPD and healthy controls, 
and between A1ATD post treatment and COPD, and healthy controls. Log transformed 
A1ATD baseline and post treatment samples of the ECLIPSE A1ATD study were 
compared by a paired t test and treatment end to baseline ratios of peak intensities were 
calculated.  
 
The log transformed EXACTLE data was confirmed to be normally distributed using a 
Shapiro-Wilk test. A repeated measures test was performed to determine any 
differences between the groups and differences between the 2 time points, i.e. baseline 
and end of treatment samples, and the Huynh Feldt within patient factor test was used 
to determine the p value. 
 
With the ionophore data, a Shapiro Wilk test confirmed that the data was not normally 
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distributed, and thus it was log transformed to achieve normality. A repeated measures 
test was again performed on the data, in order to determine differences between the 
groups (A1ATD patients versus controls) and between the 2 conditions – with and 
without the addition of calcium ionophore. 
 
2.10  Shotgun Proteomics 
Plasma samples were depleted of the most abundant proteins, digested with trypsin, 
labelled with isobaric tag for relative and absolute quantification (iTRAQ) and analysed 
by LC-MALDI as described below.  
 
2.10.1  IgY14 Abundant Plasma Protein Depletion 
Pooled samples from both ECLIPSE A1ATD and EXACTLE were used. All samples 
were depleted of the 14 most abundant plasma proteins (albumin, A1AT, IgM, 
haptoglobin, fibrinogen, 1-acid glycoprotein, HDL, LDL, IgG, IgA, transferrin, α2 
macroglobulin and complement C3) using IgY14 columns (Sigma Aldrich), performed 
according to the manufacturer’s instructions. In brief, plasma (15 µL per column) was 
diluted in dilution buffer (Tris-HCl 100mM with 0.15MNaCl pH 7.4), centrifuged 
through spin columns to remove particulates from the sample, loaded on to the IgY14 
columns and incubated at room temperature for 15 minutes with mixing. The columns 
were centrifuged at 2000 rpm for 30 seconds and the flow through (now depleted of the 
14 most abundant proteins) was collected, and used in further analysis. Bound proteins 
were stripped using 500 L of, 0.1M glycine at pH 2.5 mixing for 2 minutes after each 
addition and centrifuging for 30 seconds at 2000 rpm. This was repeated for 4 cycles 
and the columns were then neutralised using 600L of 0.1M Tris-HCl at pH 8.0 mixed 
and left for 5 minutes. The columns were then centrifuged for 30 seconds at 2000 rpm, 
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and a further 500L of dilution buffer added. The plasma samples were either singly 
depleted (as above) or the flow through collected and passed back through the columns 
in a further cycle as described above, in order to maximise abundant protein depletion.   
 
2.10.2  Supermix Column Protein Depletion 
This was performed according to the manufacturer’s instructions (Sigma Aldrich). In 
brief, 100L of plasma was depleted using the IgY 14 columns, described in 2.10.1. 
The next layer of most abundant proteins (including complement C4, C4A, C4B, C5, 
factor B, C7, C8 α chain, hemopexin, fibrinogen α, β and γ chains, vitreonectin, 
ceruloplasmin, properdin, vitamin K dependent protein S, inter-α-trypsin inhibitors 
heavy chains H1 and 2, plasma protease C1 inhibitor, plasma retinol binding protein, 
histidine rich glycoprotein, apolipoprotein a and serum amyloid P component)  was 
depleted from the flow through material from the IgY14 columns, using the same buffer 
solutions. Each sample was loaded onto Supermix LC2 column (Sigma Aldrich) and 
the flow through collected. The column was regenerated using 0.1M glycine at pH 2.5 
to remove the bound proteins and neutralised using 0.1M Tris-HCl at pH 8.0. 
 
The flow through material from the Supermix column was collected directly into 15mL 
30,00kDa filters for filter assisted sample preparation (FASP) as described below in 
2.10.3. 
 
2.10.3  Filter Assisted Sample Preparation (FASP)  
Millipore 30 kDa 50mL filters (Millipore) were washed three times with 5mL of 50mM 
ammonium bicarbonate (ABC) solution, centrifuged at 3500 rpm. Urea (8M) and 
30mM final concentration DTT were added to the flow through material from the 
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supermix column.  The samples were left for 1 hour at room temperature, and then 
loaded on to the filters and centrifuged at 3500 rpm for 10 minutes, and the flow through 
the filters discarded, whilst retaining the unfolded proteins within the filters. 
 
Iodoacetemide (50mM final concentration), made up in 50mM ABC and 8M urea to a 
total volume of 3mL was added to each of the filters, and placed in the dark for 15 
minutes. The filters were then centrifuged at 3500 for 15 minutes, and the flow through 
discarded, retaining the unfolded, reduced and alkylated proteins within the filters. Four 
filter washes with 500 µL of 50mM ABC were performed, with centrifuging after each 
wash at 3500 rpm.  A further 2mL of 50mM ABC was then added to cover each of the 
filters, with 2µg trypsin and left to digest the proteins at 370C overnight. 
 
Following digestion, the filters were centrifuged at 3500 rpm for 15 minutes, and the 
flow through, containing tryptic peptides, collected. A salt wash was performed using 
3mL of 0.5M NaCl and 50mM ABC, and the flow through combined with the flow 
through from the previous step. 
 
The flow through from the 30kDa filters was processed using SPE C18 cartridges, as 
described previously in section 2.3.6. The peptides were eluted from the cartridges 
using 600uL of 50% ACN made with 0.1% TFA. Following elution of peptides from 
the cartridges, the samples were completely dried. 
 
2.10.4  Protein Assay Using BCA Reagent 
Ten μL of BSA standards ranging from 0 to 300 µg/mL were spotted in to a 96 well 
plate in duplicate as described in 2.7.1. Ten μL of each sample (prior to C18 clean up) 
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were also spotted in duplicate into separate wells. BCA (bicinochoninic acid) reagent 
was made by adding a ratio of 50:1 of reagent B to reagent A (Thermo Scientific), and 
150 μL were added to each of the samples and standards, and left to incubate over night 
at 370C. The plate was then read at 595nm wavelength. The absorbance data was used 
to create a calibration curve, and calculate the peptide concentration of each of the 
depleted plasma samples.  
 
2.10.5   iTRAQ Labelling of Peptides 
The samples were labelled using iTRAQ 4 plex reagents (AB Sciex) as per the 
manufacturer’s protocol. In brief, the peptides were suspended in 40µL of dissolution 
buffer (0.5M triethylammonium bicarbonate (TEAB)), vortexed for 1 minute and 
sonicated for 10 minutes. The labelling reagents were allowed to warm to room 
temperature from frozen, and then 70μL of 100% ethanol were added to each vial of 
label. These were vortexed and sonicated, then the labelling reagents were added to the 
peptides, centrifuged at 13,000 rpm for 2 minutes, and left at room temperature for 1 
hour.  
 
 
The samples were labelled as follows: 
Label   ECLIPSE A1ATD Study  EXACTLE Study 
114   A1ATD Baseline   Placebo Baseline 
115   A1ATD Treatment   Placebo 6 Months 
116   COPD     Treatment Baseline 
117   Healthy Control   Treatment Months 
After 1 hour, the 4 samples were mixed for further analysis. 
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2.10.6   Mixed Mode Separation 
The labelled samples were mixed and the peptides fragmented using a mixed mode 
column (Acclaim Mixed Mode WAX 1 Dionex).  The iTRAQ labelled mixture was 
loaded on to the Mixed Mode column. A gradient of 0 - 60% buffer B, (80% ACN, 
20mM ammonium formate at pH 3.0) was run over 40 minutes at 250μL per minute 
and 1 minute fractions collected. For the last 8 minutes, the gradient was increased from 
80 to 100% buffer B. One and a half µL of each fraction was spotted on to a MALDI 
plate, and spectra were acquired to determine which contained peptides, and which to 
combine for analysis by LC-MALDI.  
 
2.10.7   LC-MALDI 
The mixed mode fractions were dried down using a speedivac and dissolved in 100μL 
of 0.1% TFA. These were combined to make 8 to 12 fractions to analyse by LC-MALDI 
as described previously. 
 
 
2.10.8  Data Analysis of Shotgun Experiments 
The data from each of the individual LC-MALDI runs were combined and transferred 
to Proteinscape software (Bruker Daltonics) as described in section 2.6.6. The settings 
used in the search were a MOWSE score of >30 on peptides, mass tolerance of +/- 0.7 
Da on the MS/MS spectra, 30ppm on the precursor ion, enzyme = trypsin, a fixed 
modification of carbidomethylation and a variable modification of iTRAQ at the N 
terminus or lysine residues. Ratios of the intensities of the reporter group peaks were 
exported into Microsoft Excel 2013 for further analysis. 
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2.10.9  Pigment Epithelium Derived Factor (PEDF) 
This was measured in individual patient’s plasma using a commercially available 
sandwich ELISA kit (Chemicon International CYT 420), performed according to the 
manufacturer’s protocol. This included a sample preparation step of a 1 hour incubation 
of the plasma samples (10µL) in 40µL of an 8M urea solution to prevent protein-protein 
interactions. From the standard curve produced, plasma concentrations of PEDF in the 
plasma samples were calculated. 
 
2.11   Ethical Approval 
 
The work included in this thesis focuses upon samples from 2 separate clinical trials 
(EXACTLE  (Exacerbations and Computed Tomography Scan as Lung End Points 
Trial) and ECLIPSE A1ATD Trial (Evaluation and Control of Lung Inflammation 
assessed with PET Scanning in Emphysema and Alpha 1-AntiTrypsin Deficiency)) and 
an ongoing research project (Anti Trypsin Deficiency Assessment and Programme for 
Treatment (ADAPT)). Other samples utilised were from routine reviews of patients 
attending the ADAPT programme. The Local research Ethics Committees have 
supported the all of trials undertaken, with LREC numbers 2003/226 and 08/H0707/46, 
for the interventional studies respectively and 3396 for the overall ADAPT Project. All 
patients enrolled into these studies have provided written, informed consent in 
accordance with the Declaration of Helsinki, and were free to withdraw their consent 
at any time. 
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CHAPTER 3  SELDI PROFILING PRELIMINARY DATA 
 
3.1    Patient Demographics 
 
Baseline and 6 month plasma samples from the 23 patients from the UK arm of the 
EXACTLE study were analysed by SELDI-TOF-MS. On entry into the study, patients 
were randomly assigned to intravenous A1AT or placebo. The 6 months samples were 
taken pre infusion with either purified, human pooled A1AT (at least 75%, and 
containing small amounts (<5%) of other plasma proteins, including alpha2-plasmin 
inhibitor, alpha1-antichymotrypsin, C1-esterase inhibitor, haptoglobin, antithrombin III, 
alpha1-lipoprotein, albumin and IgA) or placebo, which was dextrose and 2% albumin. 
The demographic data of these patients at baseline is shown in table 3.1.  Of these 
patients, 10 were on active drug, and 13 were receiving placebo infusions. There were 
no statistically significant differences in the demography of patients on the 2 arms of 
the study. There was a tendency for patients in the placebo group to be younger and for 
the placebo group to contain more female patients, although neither of these achieved 
the conventional statistical significance of p<0.05. 
 Active Drug Placebo p Value 
N 10 13  
Age 56.8 (1.6) 49.9 (3.0) 0.054 
M:F 9:1 7:6 0.066 
FEV1 1.10 (0.1) 1.1 (0.3) 0.420 
FEV1 %  35.8 (4.9) 36.1 (3.0) 0.620 
FVC 4.3 (0.3) 4.1 (0.3) 0.710 
FVC%  109.6 (6.8) 108.6 (4.4) 0.840 
Ratio 26.2 (2.8) 28.4 (2.3) 0.420 
TLCO 4.3 (0.6) 5.8 (0.5) 0.072 
TLCO%  47.4 (5.2) 59.8 (4.1) 0.082 
KCO 0.8 (0.08) 0.90 (0.06) 0.100 
KCO %  53.6 (5.2) 62.0 (4.4) 0.385 
 
Table 3.1 Baseline characteristics of patients included in this work.  
Mean age is presented in years, (SEM) Forced expiratory volume in 1 second, (FEV1) and forced 
vital capacity (FVC) are mean data expressed in litres (SEM). Transfer factor of the lung to carbon 
monoxide (TLCO) is measured in mmol/min/kPa – the mean value is shown (SEM). KCO is 
measured in mmol/min/kPa/L – the mean value is shown (SEM). The FEV1, FVC, TLCO and KCO 
(% predicted) are average values corrected for age height and sex with (SEM).  
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3.2   SELDI Profiling Results 
 
 
Individual plasma samples were profiled on IMAC Proteinchip arrays as described in 
the methods section (section 2.2), analysed in duplicate and the peak intensities of the 
duplicates summed. The data were not normally distributed (using the Shapiro-Wilk 
test) and were therefore log transformed to achieve normality, which was confirmed by 
a repeat Shapiro-Wilk test. The repeated measures test was used to identify differences 
between the groups and between the time points, with the within factor Huynh Feldt 
test. A p value of <0.05 was taken as significant. 
 
Peak intensity lists in the low mass range (1 – 20 kDa) and the high mass range (20 – 
200 kDa) were combined prior to the statistical analysis. In total, there were 83 peaks 
within the spectra. The mean within experiment CV for this experiment was 20%, 
which was calculated using the peak intensities of all of the peaks from a single sample 
which was processed and analysed in quadruplicate during the experiment.  
A typical low mass range SELDI spectrum is shown in Figure 3.1. 
 
 
 
 
 
 
 
Figure 3.1 shows a typical plasma spectrum from a patient pre-treatment. The horizontal axis is 
the mass to charge (m/z) ratio and the vertical axis is signal intensity measured in arbitrary units.  
 
4000 6000 8000 10000
4000 6000 8000 10000
23
0
5
10
15
20
4000 6000 8000 10000
68 
 
Peaks with significantly different intensities between baseline and treatment and 
between the 2 groups of patients are shown below in table 3.2. There were 5 peaks 
within the spectra which changed in response to augmentation therapy with Prolastin, 
with a p value of <0.01. These were distributed throughout the mass ranges - from the 
smallest, which has an m/z of 3480 up to proteins with m/z ratios greater than 100,000. 
 
 
Table 3.2 shows the statistically significant peaks which change in response to treatment. The 
median peak intensities in arbitrary units for each of the 4 groups is shown. The fold change is the 
end of treatment value divided by the baseline value for each of the groups, and the arrows 
demonstrate either an increase (↑) or a decrease (↓) after 6 months of treatment. 
 
 
Of the peaks which change significantly, the one with the highest fold-change in 
intensities between the end of treatment and the start of treatment (> 2 fold and a p 
value of < 0.001) was at m/z of 50,337 Da, and likely corresponds to the A1AT in 
Prolastin. This increased in the patients receiving drug, whilst remaining unchanged in 
the patients receiving placebo therapy (placebo fold change 1.13). The intensities in 
this peak in individual patients are shown in figure 3.2, showing that the increase in the 
patients receiving active drug is seen all individual patients, whilst the results for those 
receiving placebo infusions demonstrate that the peak remains largely unchanged. 
Again, this lack of change is demonstrated in each individual patient.  
p 
Value m/z 
Treatment 
Baseline 
Treatment 
6 Months 
Fold 
Change  
Placebo 
Baseline 
Placebo 6 
Months  
Fold 
Change  
0.001 6004 4.68 2.61 0.6 ↓ 4.64 4.73 1.1 ↑ 
0.002 8940 1.79 2.16 1.2 ↑  1.82 1.53 0.8 ↓ 
<0.001 50337 0.03 0.07 2.2 ↑ 0.03 0.03 1.1 ↑ 
0.009 101597 0.010 0.01 1.4 ↑ 0.01 0.006 0.8↓ 
0.004 116650 0.004 0.01 2.2 ↑ 0.003 0.004 1.2↑ 
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Figure 3.2 shows the individual patient values, in arbitrary units, of the patients at baseline and 
after 6 months, in both treatment groups, for the peak at 50, 337 Da.  
 
  
Another peak which changed significantly following treatment was at m/z 6004 peak, 
which had a p value of <0.001 and decreased in the treated group compared to the 
placebo group. The ratios of peak intensities pre and post treatment were 1.02 in the 
placebo group, and 0.558 in the active drug group, which represents a 46% reduction 
in the intensity of this peak post treatment with Prolastin. The results for each of the 
individuals in both patient groups is represented graphically below in figure 3.3. It 
indicates that the change in intensities of this peak occurred, as demonstrated 
previously, in every treated individual, whilst again there was little change in the signal 
intensity in patients in the placebo group. The peak at m/z of 6004, which decreased 
significantly with treatment with Prolastin, is shown below in figure 3.4, which shows 
a pair of spectra from a single patient receiving the active drug at baseline and after 6 
months of treatment.  
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Figure 3.3 shows the individual patient values, in arbitrary units, for a peak at an m/z of 6004Da, 
for patients at baseline and after 6 months, in both treatment groups. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 shows a pair of spectra pre (23) and post (24) treatment with Prolastin. There is a 
decrease in the peak intensity of the peak at 6004Da post treatment.  
 
A further peak which demonstrated a reduction (a change in all active drug treated 
patients, whilst remaining relatively unchanged in the placebo treated patients) was the 
peak at 116554Da, which is represented graphically in figure 3.5.  
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Figure 3.5 shows the individual patient values, in arbitrary units, at baseline and after 6 months, 
in both treatment groups, for the peak at m/z 116654 Da. 
 
Of the other peaks which changed significantly with treatment, it is possible that the 
peak with an m/z of 8940Da is a fragment of complement C3a (data taken from other 
published work, for example work by Albrethsen in 2011). The other peaks which 
changed significantly with treatment remain unidentified. 
 
3.3   Conclusions 
 
The SELDI experiments indicated that it is possible to detect changes in the plasma 
proteome of patients with A1ATD when comparing pre and post augmentation therapy. 
From the 83 peaks present in the spectra, 5 of them changed significantly following 
treatment with intravenous A1AT (Prolastin).  
 
The next step in this procedure would be to identify the proteins underlying the 
significant peaks, which can be very time consuming and is probably only justified for 
72 
 
peaks with real potential as biomarkers. The identification process requires purification 
of the protein followed by a digestion with trypsin, and analysis of the peptides with a 
mass spectrometer with tandem capability (which the PBS IIc does not have). Because 
this purification/digestion process is technically difficult, and the changes in peak 
intensities and the changes in peak intensities detected here are moderate, it made sense 
to perform further discovery experiments before finalising a panel of candidate 
biomarkers to identify.  
 
In addition, the mass accuracy of the PBS IIc is around only 0.1. Newer instruments, 
with a greater mass accuracy, would be potentially more informative and provide more 
accurate data, therefore as the proof of principle had been established, further work was 
continued on a MALDI-TOF/TOF mass spectrometer, the Bruker Ultraflextreme. This 
instrument has a greater mass accuracy of <10 parts per million and the capability to 
perform tandem mass spectrometry to identify the peptides and protein fragments of 
interest, which change significantly in response to treatment. 
 
In this part of the work, although the p values suggest statistically significant changes 
in peak intensities with Prolastin therapy, the fold changes are small. I hypothesised, 
therefore, that a more in depth investigation, with a more sensitive mass spectrometer 
with tandem capabilities should reveal more clinically useful changes in the plasma 
peptidome which could act as treatment (and hence pathophysiologically important) 
biomarkers in A1ATD. 
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CHAPTER 4 OPTIMISATION OF METHODS FOR MALDI         
PROFILING    
4.1  Validation of Methods for MALDI Profiling 
 
In SELDI experiments, there are a number of different surfaces that can be utilised to 
profile plasma, and they all work on the principle that proteins and peptides with 
different physicochemical properties bind to the surface of the chips, whilst non-
binding material can be washed away. Different chip varieties have different 
chromatographic properties for protein and peptide binding.  However, many other 
approaches can also be used to fractionate and de-salt plasma prior to MALDI analysis. 
Figure 4.1 shows the different methods assessed in this thesis to obtain MALDI spectra 
from the ECLIPSE A1ATD pooled plasma samples, with the number of peaks and CVs 
of the peak intensities for each method which was carried out in triplicate. Each is 
discussed in more detail below.  
 
Figure 4.1 shows the profiling methods used to optimise plasma sample analysis   
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4.2        Matrix Optimisation 
The matrix is a key component of MALDI-MS. The matrix absorbs the laser energy 
and assists with the desorption/ionisation process, whilst protecting the sample from 
destruction. A number of different matrices can be used; α-Cyano-4-hydroxy-cinnamic 
acid (CHCA) is widely used for tryptic digests and is well suited for the detection of 
peptides. Sinapinic acid (SPA) is used to analyse larger polypeptides and proteins and 
is also widely used in SELDI/MALDI profiling studies.  
 
To optimise matrix addition, pooled samples from the ECLIPSE A1ATD study were 
spotted out on to a MALDI plate, allowed to dry and different matrices overlaid. CHCA 
was initially made as a saturated solution in 50%ACN/0.5%TFA, and 1.5μL was 
overlaid on to 1.5 μL of dried sample. For comparison, 2 x 1.5 μL of SPA was added, 
made as a 50% saturated solution using 50% ACN 0.5% TFA. Figure 4.2 below shows 
the difference in the spectra when CHCA and SPA were used in the peptide mass region 
(<4 kDa).  There were more peaks in the CHCA spectra, with greater peak intensities. 
Despite its usual use in the detection of larger polypeptides, in our hands, SPA did not 
produce sufficiently high quality spectra of plasma peptides or proteins to be useful in 
profiling experiments.  Therefore, CHCA was used as the matrix throughout all of the 
subsequent experiments. 
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Figure 4.2 above shows the application of 2 different matrices to the same sample. A is SPA and B 
is CHCA. CHCA spectra contained a greater number and greater intensity of peaks, therefore this 
method was optimised further.  
 
To optimise matrix addition further, we followed the method of Zhu et al., (2003) which 
included the addition of ammonium phosphate, which suppresses the formation of 
metal ion adducts. In this method, 1.5 μL of sample is allowed to air dry and then 
overlaid with 1.5 μL of 10mM ammonium phosphate and allowed to dry. CHCA is then 
made at 5mg/mL with 50% ACN and 50% H20. Finally, 1.5 μL of 5mg/mL CHCA is 
added to the sample prior to MALDI analysis.  
 
Figure 4.3 shows a single sample eluted onto the MADLI plate six times, with either 
1.5μL of saturated CHCA or 1.5 μL of 10mM ammonium phosphate and 5mg/mL 
CHCA. The peak intensities using ammonium phosphate and 5mg/mL CHCA were 
much greater than using the saturated CHCA matrix. Zhu et al reported an increase 
using the ammonium phosphate method of around 20%, which was thought to arise as 
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a result of reduction in contamination of adducts and salts (Zhu X et al., 2003). The 
increase in peak intensities demonstrated below exceeded this expected 20%.  
 
This improvement in peak intensities was seen using all sample preparation methods 
on the pooled samples, therefore this matrix method was used subsequently on all of 
the individual samples. 
 
Figure 4.3 shows the difference in triplicate peak intensities between the use of CHCA 5mg/mL 
with 1.5μL of 10mM ammonium phosphate (A) and 1.5μL saturated CHCA (B). 
 
4.3.1   IMAC Beads and SELDI Chips 
Once the matrix had been optimised, further experiments were performed to optimise 
conditions for plasma profiling and MALDI TOF MS. Figure 4.1 shows that the spectra 
obtained with the IMAC beads and analysed using the Ultraflextreme contained the 
fewest peaks of any of the profiling methods. The IMAC chips, however, contained 
more peaks than in the SELDI experiments (102 peaks versus 83), despite the mass 
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range being limited to below 10kDa using the Ultraflextreme, as it is a more accurate 
mass spectrometer. The IMAC beads and IMAC proteinchip experiments were repeated 
on 2 further occasions, with similar results achieved. It was not clear why the IMAC 
bead spectra contained so few peaks. However, it is possible that there was something 
inherent in the samples which prevented peptide/protein binding, although IMAC 
SELDI chips (which have similar properties to IMAC beads), have been previously 
used successfully on serum samples. Ward et al., 2006, used SELDI chips to analyse 
serum from patients with colorectal cancer, and identified several peaks that were able 
to differentiate healthy control subjects from patients with cancer.  However, in the 
current studies, plasma has been used and should be regarded as different from serum 
which is obtained after coagulation, and thus the profiles would not be directly 
comparable or represent the in vivo circulating state. 
 
As the results were poor on 3 separate occasions with pooled samples, the IMAC beads 
sample preparation methodology was not performed on individual samples. Although 
the results of the SELDI chips read on the Ultraflextreme contained more peaks than in 
the preliminary work, read on the Ciphergen PBS IIc, there were other profiling 
methods which were better, so this technique was also abandoned for individual 
samples. 
 
4.3.2  Reverse Phase Methods 
The C8 and C18 beads both use a reverse phase approach, and as shown in Figure 4.1, 
C18 beads provided more information with a greater numbers of peaks within the 
spectra. Therefore, the C8 bead approach was also abandoned for individual sample 
analysis. Typical spectra for each of these sample preparation techniques are shown in 
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figure 4.4. The C18 approach was further optimised using different concentrations of 
ACN and TFA to elute the peptides/proteins from the beads. Concentrations used 
ranged from 30% to 60% ACN, and 50% ACN with 0.5% TFA was deemed to be the 
optimum, as it gave the greatest number of peaks, over the widest mass range, with the 
greatest peak intensities. This technique was therefore used on the ECLIPSE A1ATD 
pooled samples in triplicate, and the intra-experiment CV for all peaks using this 
method was 18% on average. 
Figure 4.4 shows the MALDI spectra generated using C8 or C18 beads. A and B are replicates of 
spectra of plasma processed with C8 beads, and C and D are replicates of plasma processed 
withnC18 beads. 
 
4.3.3  Supel Tip and SPE C8 Cartridges  
 
Supel tipping plasma is an alternative C18 reverse phase approach to the C18 beads. 
This method was optimised by initially using different volumes of plasma diluted in 
0.1% TFA. Volumes used were 2.5, 5 and 10μL of plasma diluted in 40μL of 0.1% 
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TFA. From the spectra generated, 10μL of plasma gave better spectra than 5μL or 2.5μL 
therefore 10 μL of plasma was used for all subsequent experiments. Typical spectra for 
each plasma volume are shown in figure 4.5. The supel tip spectra are particularly 
enriched for peaks with m/z of below 3000. 
 
 
Figure 4.5 shows the results of different volumes of plasma diluted in 0.1%TFA – 2.5 μL (A), 5μL 
(B) and 10μL (C) and processed with supel tips.  
 
Once the volume of plasma had been optimised, the concentration of ACN in the elution 
solution was assessed by eluting from the supel tips using 30% - 60% ACN with 0.5% 
TFA. The concentration of ACN which gave the greatest number of peaks within the 
spectra over the widest mass range was 50%, and therefore this was used on the 
subsequent samples. The optimised supel tip method was then performed in triplicate 
on the pooled samples from the ECLIPSE A1ATD study. The mean intra-experiment 
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CV of the peak intensities for each group in the pools was 25%.  
 
C8 SPE cartridges were used as a final reverse phase approach. The data generated from 
the samples prepared using this technique contained a greater number of peaks with 
improved intra-experiment CVs when compared to supel tips. To optimise conditions 
for profiling, the volume of plasma was initially varied – volumes of 5, 10 and 20μL of 
plasma were diluted in 500μL of 0.1% TFA, centrifuged, loaded and eluted from the 
cartridges to obtain MALDI spectra. The volume of plasma which gave the greatest 
number and most intense peaks was 20μL, which was used in subsequent analyses. 
 
The concentration of ACN used to elute the proteins/peptides from the column was 
optimised using different concentrations of ACN, from 40% - 60% made up with 
0.1%TFA. Figure 4.6 below shows the spectra generated with each of these 
concentrations of ACN, and 60% was best, based on the quality of the spectra 
generated, and the number and intensity of the peaks present.  Linear data was used to 
calculate the intra-experiment CV of the triplicates, which was 18%. 
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Figure 4.6 shows the results of the different concentrations of ACN used to elute from the SPE C8 
cartridges – 40% (A), 50% (B) and 60% (C) ACN. The spectra with 60% ACN had more peaks, 
with greater peak intensities.  
 
4.3.4   Weak Cation Exchange (WCX) Beads  
The WCX bead spectra contained the greatest number of peaks of all of the methods 
(as shown in figure 4.1). The method was carried out in 2 ways: – according to the 
manufacturer’s protocol, and also using half the volume of beads, solutions and plasma. 
The spectra generated from half of the volume contained fewer peaks than using the 
recommended amount, as shown in the spectra below in Figure 4.7, therefore the 
experiment was performed in triplicate according to the manufacturer’s recommended 
volumes. The mean intra-experiment CV of the peak intensities in the triplicate 
experiment was 23% 
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Figure 4.7 shows the difference between the use of beads and plasma according to the 
recommendations from the manufacturer (A) versus of half of the volume of beads and plasma (B) 
 
4.3.5   Methods for Individual Samples 
One reverse phase and one non-reverse phase method was chosen to analyse all of the 
individual patient samples, as the different binding properties of these approaches were 
likely to give complimentary information. Therefore, the methods used to analyse all 
of the individual samples, both from the ECLIPSE A1ATD and EXACTLE trials, and 
experiments on the samples following stimulation of neutrophils with a calcium 
ionophore, were the SPE C8 cartridges and the WCX beads, as they gave the most 
information (greatest number of peaks within the spectra) with the greatest peak 
intensities and best reproducibility which was within acceptable limits (<25%). 
 
4.4                Plasma Peptidome Analysis by LC-MALDI 
 
LC-MALDI was used to identify the peptides which changed significantly in the plasma 
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profiling experiments. For this it was necessary to enrich the peptidome and remove 
large proteins which take up binding capacity in the HPLC column and potentially bind 
irreversibly to, or precipitate in, the HPLC system, preventing it from working 
effectively.  
 
4.4.1  Method Optimisation 
The optimum method for preparing the samples was investigated using supel tips and 
30 and 50 kDa molecular weight cut-off spin filters (Viva spin, Sartorius). Each of these 
methods was used and 50μL of sample (equivalent to 2µL of plasma) loaded on to the 
HPLC column and eluted using a 96 spot gradient. Figure 4.8 shows the initial ‘survey 
view’ of the results. Both of the filter approaches appeared to produce the greatest 
number of peaks present, but there was also a significant degree of sample 
contamination with polymer (the arrows show this as a repeating pattern of peaks in 
Figure 4.9). Despite further attempts using the filter methods, both 30kDa and 50kDa, 
including more wash steps with buffer solutions, water and 0.1% TFA, the polymer 
contamination problem persisted. Therefore this method was abandoned. The supel tip 
method appeared to be as good as the filter approaches but without the drawback of 
polymer contamination.  
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Figure 4.8 shows the survey view result of the methods used to prepare plasma prior to LC-
MALDI. The horizontal axis shows the m/z ratio of peptides, the right vertical axis is signal 
intensity, measured in arbitrary units, and the left hand vertical axis shows the spectrum number. 
A was generated using the supel tip approach, B the 30kDa filter and C the 50kDa filter. The 
arrows show the polymer contamination seen with the 2 filter approaches.  
 
However, as with the MALDI profiling experiments, the SPE C8 reverse phase 
cartridges gave more informative spectra for LC-MALDI than supel tips. Figure 4.9 
shows a comparison of a supel tipped plasma sample and one prepared using the C8 
SPE cartridge, with a 192 spot HPLC gradient. There was an increase in the number of 
peaks, and an increase in the peak intensities in the spectra when the SPE C8 approach 
was used rather than supel tipping, therefore the SPE C8 method was used for analysis 
of the ECLIPSE A1ATD and the EXACTLE pooled plasma samples. 
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Figure 4.9 shows the survey view of 2 methods tested in preparation for LC-MALDI. A shows a 
sample from an SPE C8 cartridge, and B shows the same sample prepared using a supel tip. There 
was a greater number and intensity of peaks, across a higher mass range, when the SPE C8 
cartridge was used. 
 
 
4.4.2   Reproducibility 
To ensure that this method was reproducible, a QC sample was processed using the 
cartridge approach described previously in 2.5.4. The initial plasma volume was 20μL, 
which was eluted using 400μL of 60% ACN with 0.1%TFA. This was completed in 
triplicate using a 192 fraction protocol. MS and MS/MS were performed on these 
samples to determine reproducibility of the technique. Table 4.1 summarises the 
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number of peaks contained within each spectrum and the number of MS/MS 
measurements performed on the samples. 
 
Sample 
Peaks in Spectra MS/MS Measurements 
QC 1 1869 398 
QC 2 1782 375 
QC 3 1926 509 
Table 4.1 shows the number of peaks in the LC-MALDI run, and the number of MS/MS 
measurements performed on the QC sample when performed in triplicate 
 
The peptides identified in each of the runs were compared. The top 10 proteins from 
each run were consistent between the different LC-MALDI runs, and were identified to 
be fragments of abundant plasma proteins including albumin, transthyretin, transferrin, 
complement C3, apolipoprotein CIII, A1AT and fibrinogen.  
 
4.4.3   Optimisation of Loading Volume 
Figure 4.10 shows the result of loading 4μL, 10μL, 20μL or 40μL of the 400μL of 
sample eluted from the SPE C8 cartridge, equivalent to 0.2μL, 0.5μL, 1μL and 2μL of 
plasma respectively. The number and intensities of the peaks present increased with 
sample loading, so 40μL was used in all subsequent work. This is important as the 
greater the intensity of the peaks, the greater the chance of identifying peaks of interest 
that reflect disease activity and or its abrogation with therapy. 
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Figure 4.10 shows the results of LC-MALDI runs of the QC sample with increasing volumes of 
eluted sample. A is 40μL, B is 20μL, C is 10μL and D is 4μL. There are visibly more peaks of 
greater intensity following increasing volume loading. 
 
 
4.5  Conclusions 
 
Methods for MALDI profiling of plasma, and LC-MALDI were optimised using the 
different approaches described above. The 2 best methods were SPE C8 cartridges with 
20μL of plasma diluted in 500 μL of 0.1% TFA and eluted with 400 μL of 50% ACN 
and 0.1% TFA, and the WCX beads according to the manufacturer’s protocol. These 
methods were therefore used to profile plasma from the ECLIPSE A1ATD and 
EXACTLE studies, and plasma from whole blood from patients and healthy control 
subjects post stimulation with calcium ionophore. The results are presented in the 
subsequent chapters. In addition, conditions were established for the subsequent LC-
MALDI MS/MS identification of endogenous plasma peptides. 
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CHAPTER 5         ENZYME EXPERIMENTS 
 
Calcium ionophore is a divalent cation, highly selective for calcium and magnesium, 
allowing these ions to pass through cell plasma membranes into the cytosol. Through 
these actions, ionophore stimulates the release of proteolytic enzymes from within the 
neutrophils, including NE, and PR3. This chapter describes a series of experiments 
designed to investigate which plasma proteins are susceptible to proteolytic cleavage in 
A1ATD patients and the proteases responsible for the cleavages. 
 
5.1  Patient and Healthy Control Subject Demography 
 
Five patients with the PiZZ genotype of A1ATD attending the ADAPT project for 
annual follow up, and 5 healthy control subjects were included in the calcium ionophore 
work. Four of the healthy controls were the spouse of an A1ATD patient attending the 
ADAPT centre for review, evenly matching the 2 groups for age. The plasma from 3 
male patients and 2 female A1ATD patients were analysed, together with the plasma 
from 2 male and 3 female healthy control subjects. The demographic data for the 
patients and healthy control subjects are shown below in table 5.1.  
 
There were significant differences in lung function and A1AT levels between the 
normal subjects and the A1ATD patients; the patients had lower levels of circulating 
plasma A1AT and worse lung function parameters, with significantly lower FEV1 
measurements, and obstructive ratios, consistent with the diagnosis of COPD secondary 
to their known A1ATD. The healthy control subjects all had normal spirometry with 
no evidence of airflow obstruction or COPD.   
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 A1AT Patients Control Subjects 
Number of Subjects 5 5 
M:F 3:2 2:3 
Age (Years) 60.0 (4.1) 57.8 (3.8) 
A1AT Level (µM) 3.1 (0.5) 30.4 (0.8) * 
FEV1 (L) 1.70 (0.3) 3.1 (0.5) * 
FEV1 % Predicted 59.4 (11.4) 104.5 (5.2) * 
FVC (L) 4.3 (0.7) 3.9 (0.7) 
FVC % Predicted 118.4 (13.8) 106.3 (3.2) 
Ratio (FEV1/FVC) 40.6 (8.9) 79.0 (4.7) * 
Table 5.1 shows the demographic data for patients with A1ATD and healthy control subjects.  
Data is presented as mean values with SEM in parentheses. 
* indicates a significant difference between the 2 groups with a p value < 0.01. 
FEV1 = forced expiratory volume in 1 second measured in litres 
FVC = forced vital capacity measured in litres 
A1AT level = plasma level of alpha-1-antitrypsin measured in micromoles 
 
5.2  Plasma Profiling Post Treatment with Calcium Ionophore 
The plasma samples were profiled using 2 separate approaches - WCX beads and SPE 
C8 cartridges as previously described (Chapter 2.2.3 and 2.3.6 respectively). Below in 
Figure 5.1 are spectra from plasma from an A1ATD patient plasma sample pre (A) and 
post (B) neutrophil stimulation with calcium ionophore and from plasma from a healthy 
control subject pre (C) and post (D) neutrophil stimulation with calcium ionophore. The 
spectra in Figure 5.1 were generated after the samples had been prepared using the 
WCX bead sample clean up technique. When all patients/control subjects were 
compared, and also when SPE C8 cartridges were used for sample preparation prior to 
obtaining MALDI spectra, consistent visually apparent differences were found in the 
spectra generated after addition of ionophore. 
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Figure 5.1 shows typical spectra of an A1ATD patient pre (A) and post (B) calcium ionophore, and 
a healthy control subject pre (C) and post (D) calcium ionophore. 
 
There are greater changes in the appearance of the spectrum, consisting of many more 
peaks and greater peak intensities, after the addition of calcium ionophore to the plasma 
of A1ATD patients when compared with that of healthy controls. This is indicative of 
greater changes in the plasma peptidome arising from uncontrolled protease activity, 
following neutrophil stimulation, of the 5 A1ATD patients than is seen in that of the 5 
healthy control subjects. 
 
The peak intensity data for individual samples, following total ion current normalisation 
and baseline subtraction, was exported into Microsoft Excel and log transformed to 
achieve a normal distribution, (confirmed using the Kruskall Wallis test). The repeated 
measures test was performed to determine differences between the peak intensities from 
peptides from patient and healthy control subjects, pre and post addition of calcium 
ionophore. The results are presented below in Tables 5.2 and 5.3 for the 2 different 
profiling methodologies used.  
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For the SPE C8 cartridge analyses of pre and post neutrophil stimulation with ionophore 
in A1ATD patients and healthy control subjects, there were 212 peaks within the 
spectra, and of these, 24 changed significantly post neutrophil stimulation with calcium 
ionophore. Of these 24, 8 peptides were identified, and all were fragments of fibrinogen. 
The 8 fibrinogen fragments all originated from the alpha chain and each increased in 
intensity post neutrophil stimulation. With the exception of the peak with an m/z of 
1872.6 Da, which increased more in healthy control subjects than in patients with 
A1ATD (fold changes 4.7 and 3.7 respectively), the intensities of these fragments of 
fibrinogen increased more in patients with A1ATD, with fold changes ranging from 1.1 
to 11.9.  
 
For the WCX beads experiments in A1ATD patient and healthy control samples, there 
were 172 peaks within the spectra, and of these, 16 changed significantly post 
neutrophil stimulation with calcium ionophore. Six of these 16 peptides were identified, 
and of these there were 3 fragments of fibrinogen (all originating from the alpha chain 
as was demonstrated in the SPE C8 reverse phase experiment). These increased in 
intensity in the A1ATD patients, whilst the intensities decreased in the healthy control 
subjects.  
 
Two fragments of A1AT (with m/z ratios of 2410 and 2505 respectively) increased in 
all patients and control subjects post stimulation with ionophore; the peak intensities 
increased more for the healthy control subjects than the patients with A1ATD, with fold 
changes of 1.6 and 0.9 in A1ATD patients and 2.5 and 2.6 in healthy subjects. This is 
likely to be a result of healthy control subjects having significantly higher baseline 
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plasma levels of A1AT (mean 30.8µM vs 3.5 µM in patients with A1ATD p = <0.01). 
The detected concentration of fragments identified would be a product of the 
concentration of substrate and enzyme activity – therefore as the concentration of 
A1AT is higher in healthy subjects, more fragments are generated following the 
addition of calcium ionophore, by an unknown protease not completely inhibited by 
A1AT.  
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m/z p Value Protein 
Median Patient 
Pre 
Median 
Patient Post 
Fold 
Change 
Median 
Control Pre 
Median 
Control Post 
Fold 
Change 
1487.7 0.004 Fibrinogen Alpha Chain 0.57 3.92 6.88 ↑ 0.27 0.66 2.44 ↑ 
1685.3 0.001 - 0.51 6.07 11.90 ↑ 0.47 1.13 2.40 ↑ 
1872.6 0.002 Fibrinogen Alpha Chain 1.29 4.77 3.70↑  0.41 1.93 4.71 ↑  
2031.6 0.001 Fibrinogen Alpha Chain 0.60 3.63 6.05 ↑ 0.37 0.93 2.51 ↑ 
2047.8 0.001 Fibrinogen Alpha Chain 1.98 10.57 5.34 ↑ 1.27 1.71 1.35 ↑ 
2133.6 0.003 Fibrinogen Alpha Chain 0.80 4.06 5.08 ↑ 0.37 1.03 2.78 ↑ 
2212.3 0.007 Fibrinogen Alpha Chain 2.08 2.12 1.02 ↑ 2.05 1.05 0.51 ↓ 
2219.8 0.001 Fibrinogen Alpha Chain 0.83 2.91 3.51 ↑ 0.72 1.15 1.60 ↑ 
2380.1 <0.001 - 3.55 1.48 0.42 ↓ 2.63 2.37 0.90 ↓ 
2732.7 0.005 Fibrinogen Alpha Chain 4.45 7.54 1.69 ↑ 4.19 3.18 0.76 ↓ 
3431.2 0.006 - 3.18 16.10 5.06 ↑ 1.24 5.87 4.73 ↑ 
3744.7 0.004 - 7.23 43.26 5.98 ↑ 13.16 34.81 2.65 ↑ 
3858.2 0.001 - 1.67 3.94 2.36 ↑  1.04 5.51 5.30 ↑ 
4148.6 0.004 - 0.48 1.75 3.65 ↑ 0.54 0.47 0.87 ↓ 
4615.6 <0.001 - 1.17 5.12 4.38 ↑ 0.52 0.99 1.90 ↑ 
4653.7 0.007 - 1.11 8.80 7.93 ↑  0.76 1.66 2.18 ↑ 
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4670.5 0.005 - 0.55 2.37 4.31 ↑  0.80 0.92 1.15 ↑ 
4678.9 0.008 - 0.86 1.69 1.97 ↑ 1.68 1.29 0.77 ↓ 
4891.5 0.002 - 0.35 3.60 10.29↑  0.18 0.26 1.44 ↑ 
4911.0 0.007 - 0.19 1.78 9.37 ↑  0.12 0.37 3.08 ↑ 
4929.5 0.001 - 0.25 7.72 30.88 ↑ 0.32 0.80 2.50 ↑ 
6177.7 0.001 - 0.28 1.00 3.57 ↑ 0.35 0.50 1.43 ↑ 
6813.0 0.001 - 0.81 2.06 2.54 ↑ 1.05 0.54 0.51 ↓ 
6949.5 0.009 - 0.09 0.33 3.67↑  0.35 0.23 0.66 ↓ 
Table 5.2 shows the significant results from the profiling using SPE C8 cartridges. The fold changes compare the end of treatment to the start of  
treatment median value for each group and the arrows denote the direction of the change. 
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m/z 
p 
Value Protein 
Median 
Patient Pre 
Median Patient 
Post Fold Change Median Control Pre 
Median 
Control Post 
Fold 
Change 
1349.6 0.01 Fibrinogen Alpha Chain 0.78 3.05 3.93↑ 3.35 2.02 0.60 ↓ 
1450.6 0.01 Fibrinogen Alpha Chain 0.87 2.61 3.02↑ 2.75 2.38 0.86↓ 
1703.1 0.004 Fibrinogen Alpha Chain 0.96 3.16 3.31 ↑ 2.51 1.46 0.58↓ 
1734.2 0.008 - 0.84 2.08 2.48 ↑ 2.62 1.99 0.760↓ 
2490.9 0.004 A1AT 2.13 3.43 1.61 ↑ 3.58 9.10 2.54 ↑ 
2505.0 0.006 A1AT 1.94 1.835 0.95 ↓ 1.61 4.10 2.55 ↑ 
2706.1 0.007 Apolipoprotein B1  2.30 2.38 1.04 ↑ 2.11 3.76 1.78 ↑ 
4304.3 0.003 - 0.64 1.74 2.73 ↑ 1.76 1.36 0.77 ↓ 
4487.9 0.003 - 1.62 1.21 0.75 ↓ 1.88 1.41 0.75 ↓ 
4714.8 0.007 - 3.89 1.83 0.469 ↓ 1.81 1.60 0.88 ↓ 
4981.9 0.003 - 5.83 7.18 1.23 ↑ 4.79 28.23 5.89 ↑ 
5003.2 0.001 - 2.00 1.96 0.98 ↓ 1.51 7.00 4.64 ↑ 
5019.8 <0.001 - 0.66 1.00 1.51 ↑ 0.83 3.15 3.80↑ 
5028.4 <0.001 - 1.07 1.15 1.08 ↑ 1.05 3.93 3.74 ↑ 
5043.4 0.001 - 0.58 0.82 1.41 ↑ 1.00 2.77 2.72 ↑ 
9681.3 0.003 - 0.79 0.40 0.51 ↓ 0.43 0.27 0.62 ↓ 
Table 5.3 shows the profiling results using WCX beads. The fold changes compare the end of treatment to the start of treatment median value for each group and the 
arrows denote the direction of the change. 
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A peak with an m/z of 2047 was identified from the SPE C8 experiments as a fragment 
of fibrinogen alpha chain, which increased in intensity in patients with A1ATD post 
neutrophil stimulation with ionophore. The m/z 2047 peak intensities are shown for the 
patients and healthy controls in Figure 5.2. There is a rise in signal intensity in all 
patients with A1ATD, whilst remaining largely unchanged in healthy control subjects. 
This rise amongst patients whilst not in healthy controls is also seen with other peaks, 
including the peak m/z 2219, which changed significantly only in patients with 
A1ATD, or with other peaks, such as those with m/z of 2031 and 2133, where the fold 
change was greater in patients than in healthy control subjects.  
  
 
Figure 5.2 Peak intensities for individuals (measured in arbitrary units) for the fragment of 
fibrinogen with an m/z of 2047. NHC - = healthy controls subjects pre neutrophil stimulation with 
calcium ionophore, NHC + = healthy control subjects post stimulation, A1ATD - = patients with 
alpha-1-antitrypsin deficiency pre stimulation, and A1ATD + = patients with alpha 1 antitrypsin 
deficiency post neutrophil stimulation. 
 
There were a number of peaks which were statistically significant between the patient 
and healthy control groups, shown in the tables above, which had an m/z above 4000Da. 
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This was more evident when the WCX bead approach was taken than the C8 SPE 
cartridges, as the WCX bead approach contained peaks within the spectra over a greater 
mass range (up to 10,000Da), when compared with the SPE approach in which the 
majority of peaks within the spectra were mainly below 4500Da. The identities of these 
larger peptides could not easily be obtained by MALDI-TOF-TOF MS/MS and 
currently remain unknown. 
 
5.3    LC-MALDI of Ionophore Samples 
Pooled samples, pre and post addition of calcium ionophore, in both the patient and 
control groups, were created post SPE C8 cartridge sample preparation and analysed in 
triplicate by LC-MALDI (as described in chapter 2.5 and 2.6.1).  Figure 5.3 shows an 
LC-MALDI survey-view of post treatment pooled samples in A1ATD patients (A) and 
healthy control subjects (B). 
 
Figure 5.3 shows the survey view and demonstrates differences between post ionophore treatment 
of samples from (A) A1ATD patients and (B) healthy control subjects. 
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There are many more peaks present in the survey view, shown above, in pooled patient 
plasma than in pooled healthy control subject plasma, in the same way that there were 
a greater number, and greater intensity of peaks seen in the MALDI spectra, when 
results for these 2 groups were compared. This again is indicative of a greater change 
post addition of calcium ionophore in the plasma peptidome of patients with A1ATD 
when compared with that of healthy individuals.  
  
LC-MALDI was performed in order to identify more of the peptides generated by the 
addition of calcium ionophore. In addition, following LC MALDI, lists of peptides 
identified were generated and a comparison made between those identified in healthy 
control subjects and patients with A1ATD.  In total, there were 439 unique peptides 
from 49 proteins identified in A1ATD patient plasma, and 88 unique peptides from 22 
proteins in the plasma of healthy control subjects. In patients with A1ATD, there were 
157 unique fragments of the alpha chain of fibrinogen identified in the plasma samples 
post stimulation with calcium ionophore. Some of these fragments were identified, 
using the profiling techniques outlined previously, as signals which changed 
significantly in intensity between healthy control subjects and patients with A1ATD 
and could act as potential footprints for the effects of neutrophil proteinases in the lungs. 
The data generated from the ionophore work was searched using the SwissProt Human 
Database to identify the protein origins of the peptides, but additionally against a 
random database, in order to calculate a false discovery rate (FDR). There were no 
matches identified in the random database, indicating a very low (<1%) FDR, and 
increasing the validity of the results generated.  
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The amino acid sequence of the alpha chain of fibrinogen and the peptides identified 
following the addition of calcium ionophore to the blood of patients with A1ATD is 
shown below in Figure 5.4. 
 
 
Figure 5.4 Amino acid sequence of the structure of fibrinogen. The amino acids in red are the 
amino acids in peptide sequences identified in patient plasma post neutrophil stimulation with 
calcium ionophore.  
 
In patients with A1ATD, the largest number of fragments identified were from 
fibrinogen, followed by haemoglobin subunits alpha and beta. In contrast, in healthy 
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control subjects, far fewer peptides from fibrinogen were identified; the largest number 
of fragments were from haemoglobin (subunits alpha and beta), albumin and 
transthyretin. Pie charts summarizing this data are presented below in Figure 5.5. The 
charts show the top 8 proteins identified in each group, together with the proportion of 
peptides for each protein.  
 
Figure 5.5 shows the origins of the most abundant peptides found in (A) plasma from patients with 
A1ATD and (B) healthy control subjects post addition of ionophore. 
 
The azurophil granules of neutrophils contain multiple enzymes. Two important 
enzymes implicated in the underlying pathophysiology of COPD are neutrophil elastase 
(NE) and proteinase 3 (PR3). Ionophore stimulates the release of these proteolytic 
enzymes from the neutrophils. Further work therefore was undertaken to determine 
whether adding NE or PR3 to the plasma of patients with A1ATD could generate the 
fragments of fibrinogen identified in the ionophore experiments. 
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5.4  Neutrophil Elastase and Plasma 
The following spectra were generated following the addition of NE to pooled plasma 
from patients with A1ATD pre augmentation and healthy control subjects. (Figure 5.6). 
As was seen with the addition of calcium ionophore, there were visual differences 
between the spectra of healthy subjects and those of patients with A1ATD, with a 
greater numbers of peaks with greater peak intensities in the patient plasma when 
compared to that of the healthy control subjects. The spectra below were generated 
following the SPE C8 cartridge sample preparation method; similar differences were 
obtained when the WCX bead method was used.  
Figure 5.6 Spectra generated post addition of neutrophils elastase to pooled plasma from patients 
with A1ATD (A) and pooled plasma from healthy control subjects (B), using SPE C8 cartridge 
sample preparation method. 
 
LC-MALDI was performed in triplicate and subsequent data analysis of the peptides 
generated by the addition of NE to plasma identified 632 unique peptides from 40 
proteins. The single protein contributing the largest number of peptides was fibrinogen, 
with 134 peptides identified (21.2% of the total). Of these, the majority were fragments 
from the alpha chain (93) with (28) from the gamma chain and a 13 from the beta chain. 
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Seventy four of the peptides generated by NE were also generated by ionophore and 41 
of these peptides (or 55%) were peptide fragments of fibrinogen. 
 
Figure 5.7 shows the total numbers and overlap between peptides generated following the addition 
of NE and ionophore to plasma and blood of patients with A1ATD 
 
 
The venn diagram above (Figure 5.7) shows the overlap between the peptides produced 
from plasma from patients with A1ATD treated with ionophore and those from the 
addition of elastase. It also suggests that other proteases contribute to the observed 
ionophore effect. 
 
5.5  Proteinase 3 and Plasma 
Following the addition of PR3 to plasma from patients with A1ATD and to healthy 
control subjects, the following spectra were generated (Figure 5.8). As was seen with 
the addition of calcium ionophore and NE experiments, there were clear differences 
between the spectra from patients and controls, in terms of the number and intensity of 
the peaks present. 
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Figure 5.8 Spectra generated post addition of proteinase 3 to pooled plasma from patients with 
A1ATD (A) and pooled plasma from healthy control subjects (B). 
 
LC-MALDI was performed in triplicate and subsequent data analysis identified 476 
unique peptides from 37 proteins following the addition of PR3 to pooled plasma from 
patients with A1ATD. The single protein contributing the largest number of peptides 
was apolipoprotein A1 (89 peptides, 18.7%). The second protein was fibrinogen with 
72 fragments (or 15.1%) identified.  Of these fragments of fibrinogen, 39 were from 
the alpha chain, 7 were from the beta chain and 26 were from the gamma chain.  
 
Figure 5.9 shows the total numbers and overlap between peptides generated following the addition 
of PR3 and ionophore to plasma and blood of patients with A1ATD 
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The venn diagram above (Figure 5.9) shows the number of peptides produced from 
blood treated with ionophore, following the addition of PR3 to plasma and the number 
generated by both. Of the 49 peptides produced by both ionophore and PR3, the 
majority (20 peptides, 40.8%) were fragments of fibrinogen.  
 
5.6   Comparison of Ionophore, NE and PR3 
The diagram below (Figure 5.10) demonstrates that 34 common peptides were 
generated following the addition of ionophore, NE and or PR3 to pooled plasma/whole 
blood from patients with A1ATD. A complete table of the m/z and peptide sequences 
from each of these experiments is shown in Appendix I. Of these 34 peptides, 16 
(47.1%) were fragments of fibrinogen, and 10 (31.3%) were fragments of 
apolipoprotein. 
 
Figure 5.10 Ion is ionophore, NE is neutrophil elastase and PR3 is proteinase 3. The numbers 
denote the numbers of peptides generated by the addition of each enzyme to pooled plasma/blood 
from patients with A1ATD.  
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Of the 115 peptides common to both NE and PR3, the majority of peptides were from 
apolipoprotein (46 peptides, 45.1%). The next most abundant protein/peptides common 
to both of these enzymes was fibrinogen (26 peptides, 22.6%). 
 
Table 5.4 shows the fragments of fibrinogen which were identified from the profiling 
experiments as changing significantly between the 2 groups studied (pre and post 
stimulation with ionophore), and which enzyme, identified from subsequent analyses, 
was responsible for generating them.   
 
m/z Sequence NE PR3 Ionophore 
1349.6 D.SGEGDFLAEGGGVR.G   Yes 
1450.6 R.GDSTFESKSYKMA.D   Yes 
1703.1 V.SETESRGSESGIFTNT.K  Yes Yes 
1487.7 V.SETESRGSESGIFT.N Yes Yes Yes 
1872.6 Y.KMADEAGSEADHEGTHST.K   Yes 
2031.6 T.LDGFRHRHPDEAAFFDT.A Yes  Yes 
2047.8 V.SETESRGSESGIFTNTKES.S Yes Yes Yes 
2133.6 V.SGNVSPGTRREYHTEKLVT.S Yes Yes Yes 
2212.3 T.KESSSHHPGIAEFPSRGKSSS.Y   Yes 
2219.8 V.SGNVSPGTRREYHTEKLVTS.K   Yes 
2732.7 G.SFRPDSPGSGNARPNNPDWGTFEEV.S Yes  Yes 
Table 5.4 shows the fibrinogen fragments which were identified as changing significantly in the 
profiling experiments following addition of ionophore, and which enzyme was responsible. 
 
 
NE and PR3 are both serine proteases which have similar 3 dimensional structures and 
similar functionality (Korkmaz B 2002). During LC-MALDI, 24.2% of peptides 
generated by the addition of PR3 to plasma were identical to those generated by the 
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addition of NE to plasma. In order to determine further information about the specific 
cleavage sites of each enzyme, the peptide sequences were uploaded in to the web based 
programme ‘WebLogo 3.4’ to generate sequence logos of the amino acids in the 
peptides generated by the addition of each of the enzymes. These are shown below for 
each of NE, PR3 and ionophore. A sequence logo is a way of graphically displaying 
amino acid sequences in peptides. At each position in the amino acid, a stack is 
generated; the amino acids are represented by the internationally accepted single letter, 
and the height of each letter within the stack denotes the relative frequency of the amino 
acid at that site in the peptide sequence.  
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Figure 5.11 Sequence Logos for the Addition of Neutrophil Elastase (NE), Proteinase 3 (PR3) and 
Ionophore (Ion) 
 
The sequence logos above demonstrate that the preferential amino acid cleavage sites 
for NE and PR3 are valine and alanine residues, and the top 7 preferred amino acids for 
each enzyme are the same. This is in agreement with published work which describe 
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the reportedly preferred cleavage sites for NE and PR3 as being valine and alanine 
residues. The ionophore logo suggests that neither NE nor PR3 are overwhelmingly 
responsible for the generation of peptides upon ionophore stimulation as the preferred 
cleavage site is at serine residues. This is likely to result from the large number of other 
enzymes which are found in the neutrophil azurophil granule, which include 
myeloperoxidase (Borregard N, 1997) in addition to NE, PR 3 and cathepsin G, and it 
is these other enzymes in combination which are responsible for the preferred cleavage 
site demonstrated in the web logo.  
 
 
5.7   Discussion 
This work uniquely describes the action of enzymes released from the azurophil 
granules of neutrophils as part of an in vitro model of the underlying pathophysiology 
of A1ATD. Calcium ionophore stimulates neutrophils, causing the release of 
proteolytic enzymes. Of these enzymes, NE is perceived to be one of the most crucial 
in the pathophysiology of disease in A1ATD. However, NE is not the only enzyme 
released from activated neutrophils. Upon stimulation with calcium ionophore, other 
enzymes such as proteinase 3 and cathepsin G are also released, and hence the rationale 
for undertaking further work on plasma from patients with A1ATD using PR3 and NE. 
 
The work has highlighted the effects of proteases released by calcium ionophore in the 
plasma of patients with A1ATD, when compared to that of healthy control subjects. 
Fibrinogen is the source of the most commonly identified peptides in patients with 
A1ATD, whereas in healthy control subjects, the protein with the most identified 
peptides was haemoglobin. This suggests that A1AT inhibits some proteases released 
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from neutrophils but not others. The reasons for this observation are not clear; it may 
be due to the actions of calcium ionophore being different in the relative absence of a 
major protease inhibitor (namely A1AT) as is the case in patients with A1ATD, as it is 
possible that A1AT prevents fibrinogen degradation, or potentially due to higher 
baseline levels of fibrinogen in patients with A1ATD (although this was not measured 
directly).  
 
The addition of calcium ionophore has identified several fragments of fibrinogen 
(although there were also peptides which remain unidentified due to either their size 
being greater than 4000 Da and their lower abundance in plasma) which could be 
potential markers of the actions of NE. It has also been possible to show the peptides 
generated following the addition of NE and PR3 to plasma, and show which fragments 
from the ionophore data were likely to have arisen as a result of the actions of each of 
these enzymes. A few peptides (3) were common to both of these enzymes.  
 
Fibrinogen is of interest for several reasons; firstly, as is the case with A1AT, it is a 
positive acute phase protein. It is a precursor of fibrin and an essential component of 
the plasma coagulation cascade (Kamath et al., 2003). In acute inflammatory states, its 
concentration in plasma may rise up to three-fold when compared with the normal 
steady state.   
 
Fibrinogen has previously been extensively investigated as a potential biomarker in 
usual COPD (Dahl et al., 2001; Groenewegen et al., 2008; Mannino et al., 2012). As is 
true for A1AT, it is released from the liver in response to IL6 production (Gabay et al., 
1999). Fibrinogen has been shown to be elevated in COPD patients when compared to 
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healthy control subjects, though not related to smoking status (Dahl et al., 2001). 
Groenewegen et al analysed plasma fibrinogen levels in patients with COPD, and 
reported that higher levels of fibrinogen were measured in patients during exacerbations 
of their COPD, and demonstrated a subsequent fall on resolution of the exacerbation 
(Groenewegen et al., 2008). In small studies, this elevation of fibrinogen was more 
evident amongst patients with infective exacerbations, with a greater rise in plasma 
fibrinogen when a viral pathogen was isolated (Seemungal et al., 2001). 
 
In the stable state, higher levels of fibrinogen were associated with a lower FEV1 and 
more moderate to severe exacerbations in patients with usual COPD. These are 
independent factors for a more rapid decline in lung function and therefore patient 
performance status, symptoms and subsequent worsening disease trajectory. It has also 
been suggested as a marker to predict hospitalisation as a result of COPD exacerbations 
(Groenewegen et al., 2008).  
 
In a 2005 meta-analysis which included 154 211 patients, Danesh et al identified during 
that an increased fibrinogen level was associated with an increased risk of death, from 
both vascular disease and COPD. In addition, Mannino et al in 2012 demonstrated that 
amongst 8507 patients from the Third National Health and Nutrition Examination 
Survey (NHANES III), overall, elevated plasma fibrinogen levels were a risk for 
increased all-cause mortality, including for patients with COPD. In addition, patients 
with COPD in GOLD stages 3 or 4 had higher levels of fibrinogen than people with 
normal lung function. 
 
Furthermore, an elevated plasma fibrinogen level was demonstrated by Papaioannou et 
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al in a small group of patients with emphysema demonstrated on CT scan when 
compared to a group of patients without emphysema present on the scan (Papaioannou 
et al., 2010).  
 
An integrated analysis of 5 separate studies (6376 patients were included) was 
performed in order to gain recognition of the use of fibrinogen as a biomarker in COPD 
(Mannino et al., 2015). The authors looked specifically at fibrinogen levels, and 
stratified patients into 2 groups – those with high fibrinogen levels (defined as 
concentrations greater than 350mg/dL) and those with low levels (below 350mg/dL). 
Those patients with higher plasma fibrinogen levels, had a higher rate of severe 
exacerbations, within 12 months, of their COPD requiring admission to hospital, and a 
greater mortality rate within the next 36 months due to all causes, supporting previous 
reports (Mannino et al., 2015). Both of these outcomes are clinically relevant in patients 
with COPD in clinical practice and when considering endpoints in clinical trials.  
 
In summary therefore, in usual COPD, fibrinogen shows promise as a biomarker in 
COPD. An elevation in plasma fibrinogen levels of COPD patients is associated with a 
higher risk of both exacerbation and all-cause mortality. However, it is not specific for 
COPD, as it may be elevated in other diseases such as cardiovascular disease (Pearson 
et al., 2003) and the metabolic syndrome (Ford, 2003), both of which are common co-
morbidities in patients with COPD, and inflammatory states. There have been no 
studies to date to explore this relationship in patients with A1ATD.  
 
However, each of these studies have measured total fibrinogen concentrations, rather 
than peptides or fragments of fibrinogen. In patients with COPD and A1ATD related 
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COPD, a specific cleavage product of fibrinogen termed Aα-val 360, which is a marker 
of pre-inhibition activity of NE, has been studied as a potential biomarker. It has been 
shown, by Carter et al, to be elevated in patients with A1ATD when compared to 
healthy control subjects, to increase further during acute exacerbations, and to decrease 
following treatment with augmentation therapy. In patients in the EXACTLE study who 
received placebo infusions rather than active drug, there was a statistically non-
significant rise in this signal at the end of the 6 months’ of treatment, and a significant 
decrease in patients who were given Prolastin (intravenous A1AT) (Carter et al., 2011). 
 
This is of particular interest as the enzyme experiments performed initially with calcium 
ionophore demonstrated a clear difference in the detected actions on the plasma 
peptidome of patients with A1ATD when compared to the healthy control patients; the 
major peptides detected in patient plasma were fragments of fibrinogen, whereas this 
was haemoglobin and other abundant plasma proteins in the healthy control group. 
Fibrinogen degradation is likely to be dysregulated in A1ATD patients due to the low 
level of this major serine protease inhibitor. Disappointingly, the fragment of Aα-val 
360 was not detected in this series of experiments.  
 
5.8   Conclusions 
 
Potential markers of NE and PR3 activity in plasma have been identified using this 
approach, and therefore the same profiling methods were undertaken in subsequent 
work on clinical samples in patients with A1ATD pre and post treatment with A1AT 
augmentation to determine whether or not the fibrinogen peptides identified could act 
as biomarkers and be measured by targeted tandem mass spectrometry. 
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CHAPTER 6  ENDOGENOUS PLASMA PEPTIDE PROFILING 
The experiments in the previous chapter identified several fragments of fibrinogen 
which may act as markers of NE activity in an in vitro environment. The following 
series of experiments were conducted on samples from clinical trials of augmentation 
therapy in patients with A1ATD to determine whether the previous experiments had 
identified clinically relevant markers of NE activity. 
 
6.1   Patient Demographics ECLIPSE A1ATD 
The demographic data of the patients enrolled into the ECLIPSE A1ATD study are 
shown in table 6.1. Patients with usual COPD and A1ATD were well matched in terms 
of lung function parameters, but patients with A1ATD were significantly younger (57.2 
years vs 66.6 years, p= 0.03). This is consistent with the observation that patients with 
A1ATD typically develop symptoms at an earlier age (in their 40s) than patients with 
usual COPD. There was no significant age difference between healthy control subjects 
and patients with usual COPD.  Healthy control subjects had normal lung function 
parameters, whereas patients with A1ATD or usual COPD had evidence of airflow 
obstruction, with an FEV1/FVC ratio < 70%, consistent with the diagnosis of COPD. 
There was evidence of reduced gas transfer parameters, (TLCO and KCO), consistent 
with the presence of emphysema, which is associated with both the diagnosis of COPD 
and COPD secondary to A1ATD. The groups were all predominantly male. Patients 
with usual COPD and healthy control subjects had normal serum A1AT levels and 
normal A1AT genotypes, excluding a concomitant diagnosis of A1ATD, whereas those 
with A1ATD had low levels (below the putative protective threshold of 11µM) and the 
PiZZ genotype, consistent with the diagnosis of A1ATD. All patients/control subjects 
were ex or never smokers, which was one of the main inclusion criteria for entry into 
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this particular study. However, there were more ex-smokers in the A1ATD group and 
usual COPD group, whereas the majority of the healthy control subjects (6 out of 9 or 
66.7%) had never smoked. 
 
 A1ATD COPD NHC 
N 10 9 9 
Male: Female 9:1 8:1 7:2 
Age in Years 57.2 (2.9) 66.6 (2.0) * 61.0 (2.4) 
FEV1  (L) 1.7 (0.2) 1.8 (0.3) 3.4 (0.2) **  ## 
FEV1 % Predicted 51.5 (5.7) 59.7 (6.1) 112.3 (3.3) ** ## 
FVC (L) 4.7 (0.3) 4.0 (0.3) 4.5 (0.3) 
FVC % Predicted 114.5 (5.2) 106.8 (2.2) 118.5 (4.3) 
FEV1/FVC  33.9 (3.4) 42.5 (4.3) 75.5 (2.3) ** ## 
TLCO 5.6 (0.7) 4.6 (0.9) 9.1 (0.6) * # 
TLCO % Predicted 58.8 (7.3) 54.7 (9.0) 101.1 (5.1) ** # 
KCO % Predicted 60.5 (6.8) 63.8 (7.9) 105.7 (5.9) ** ## 
A1AT Level (µM) 4.04 (0.5) 28.4 (2.6) 26.5 (0.9) **  
Ex-smokers  9 (90%) 9 (100%) 3 (33.3%) ** ## 
Never smokers  1 (10%) 0 (0%) 6 (66.7%) ** ## 
Table 6.1 shows the demographic data for patients in the ECLIPSE A1ATD study.   
A1ATD denotes patients with alpha-1-antitrypsin deficiency, COPD refers to patients with chronic 
obstructive pulmonary disease, and NHC is the normal healthy control group.  
Mean age is presented (SEM). Forced expiratory volume in 1 second, (FEV1) and forced vital 
capacity (FVC) are mean data expressed in litres (SEM). Transfer factor of the lung to carbon 
monoxide (TLCO) is measured in mmol/min/kPa – the mean value is shown (SEM). KCO is 
transfer of carbon monoxide corrected for alveolar volume - the mean values are shown (SEM). 
The FEV1 % predicted, FVC % predicted, TLCO % Predicted and KCO (transfer of carbon 
monoxide corrected for alveolar volume) are the mean data for FEV1, FVC, TLCO and KCO 
expressed as a percentage. A1AT is the mean level (with SEM in parentheses). 
 
* is a p value of < 0.05 when comparing either healthy control subjects or COPD patients with 
A1ATD patients, ** is a p value of < 0.01 for the same group comparisons. 
# is a p value of < 0.05 when comparing COPD patients to healthy controls, ## is a p value of < 0.01 
for the same group comparisons 
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6.2   Patient Demographics EXACTLE 
The demographic data for the patients enrolled in to the EXACTLE trial, whose plasma 
samples were analysed in this work are shown in table 6.2. The patients in the Prolastin 
(intravenous A1AT) and placebo groups were well matched with the exception of the 
A1AT level at 6 months, which was elevated to above the putative protective level of 
11μM in the patients who received the active drug, whilst remaining constant and well 
below this level in patients receiving placebo infusions. This is consistent with previous 
work, which has demonstrated that the trough levels, following weekly infusions, 
remain above this protective level (Wewers et al., 1987). There was no significant 
difference in the A1AT levels between the groups at baseline. The mean FEV1 in both 
groups was 46.4%, which is classified as moderate disease according to the GOLD 
criteria for the diagnosis of COPD, and the mean FEV1/FVC ratios were 41% in both 
groups, again consistent with this diagnosis. All patients had reduced gas transfer 
measurements, consistent with the presence of emphysema, with mean KCO % 
predicted values of 53.7% and 55.8% for the active drug and placebo groups 
respectively.  
 
Overall, there were almost equal numbers of male and female patients recruited into the 
EXACTLE study (37 v 35). However, there was a trend towards more men in the group 
receiving Prolastin (intravenous A1AT), and more females in the placebo group, 
although this was due to the randomisation process and did not reach conventional 
statistical significance (p = 0.055). The smoking history in both patient groups was 
similar; the majority of patients had previously smoked. As was the case with the 
ECLIPSE A1ATD study, none of the patients were current active smokers in 
accordance with the study protocol. 
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 Prolastin Group 
(A1AT) 
Placebo Group Overall 
UK Patients 13 10 23 
Swedish Patients 8 8 16 
Danish Patients 15 18 33 
Age  in years 55.6 (1.3) 55.1 (1.6) 55.3  (1.7) 
Male : Female 22 : 12 15 : 23 37 : 35 
FEV1 (L) 1.4 (0.1) 1.3 (0.1) 1.4 (0.1) 
FEV1 % Predicted 46.4 (3.2) 46.4 (3.4) 46.4 (2.4) 
FVC (L) 3.7 (0.2) 3.5 (0.1) 3.6 (0.1) 
FVC % Predicted 95.6 (3.7) 97.1 (3.9) 96.4 (2.7) 
FEV1/FVC Ratio 41.0 (2.9) 41.0 (2.8) 41.0 (2.0) 
TLCO (mmol/min/kPa) 4.5 (0.4) 4.7 (0.3) 4.6 (0.2) 
TLCO % Predicted 49.3 (3.3) 52.2 (2.5) 50.9 (2.0) 
KCO % Predicted 53.7 (3.5) 55.8 (2.5) 54.8 (2.1) 
Baseline A1AT  Level 
(µM) 
7.47 (0.6) 6.87 (0.4) 7.2 (0.4) 
A1AT  Level at 6 
Months (µM) 
15.2 (0.9) ** 8.31 (0.8) NA 
Never smokers 3 (9%) 2 (6%) 5 (8%) 
Ex-smokers 33 (91 %) 34 (94%) 67 (92%) 
Table 6.2 shows the demographic data of the patients in the EXACTLE trial. 
Age is expressed in years (SEM in parentheses). Forced expiratory volume in 1 second, (FEV1) and forced vital 
capacity (FVC) mean data expressed in litres, (SEM in parentheses). Transfer factor of the lung to carbon 
monoxide (TLCO) mean data are shown (SEM in parentheses). KCO is transfer of carbon monoxide corrected 
for alveolar volume mean data is shown (SEM in parentheses). FEV1 % predicted, FVC % predicted, TLCO 
% predicted and KCO% predicted are the mean data for FEV1, FVC, TLCO and KCO expressed as a 
percentage. Mean A1AT levels (SEM in parentheses) are presented 
 
** denotes significant difference between Prolastin group and placebo groups with a p value  
< 0.01 
 
A comparison of demographic data between the ECLIPSE A1ATD group of patients 
and all of the patients in the EXACTLE study is shown in table 6.3. There were no 
significant differences between patients enrolled in to either study in terms of age or 
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lung function. There was a higher proportion of male patients in the ECLIPSE A1ATD 
study, (9 patients (90%) versus 36 (50%) respectively), and the ECLIPSE A1ATD 
patients had lower levels of A1AT at baseline). However, this may be due to differences 
in the assay used to measure the A1AT levels. The EXACTLE study patients had their 
A1AT levels measures in mg/dL, and these values were subsequently converted to µM, 
whereas patients in the ECLIPSE A1ATD study has levels measured in µM. However, 
all patients had the most severe deficiency of A1ATD (the PiZZ genotype), and had 
A1AT levels below the putative protective threshold of 11μM (mean 4.02 and 6.2 μM 
respectively for the ECLIPSE A1ATD and EXACTLE patients). The post treatment 
values were measured in the EXACTLE study but not in the ECLIPSE A1ATD due to 
differences in the study protocols (post treatment A1AT levels were not a requirement 
of the ECLIPSE A1ATD study).  However, previous work has clearly demonstrated 
that a weekly infusion at the dose given to both of these patient groups, leaves a trough 
level above 11 μM, thus making the measurement of A1AT unnecessary after 3 months 
of treatment in the ECLIPSE A1ATD study (Wewers et al., 1987). 
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 ECLIPSE A1ATD EXACTLE 
Age 57.2 (2.9) 55.3 (1.7) 
FEV1 (L) 1.7 (0.2) 1.4 (0.1) 
FEV1 % Predicted 51.5 (5.7) 46.4 (2.4) 
FVC (L) 4.7 (0.3) 3.6 (0.1) ** 
FVC % Predicted 114.5 (5.2) 96.4 (2.7) * 
FEV1/FVC 33.9 (3.4) 41.0 (2.0) 
TLCO 5.6 (0.7) 4.6 (0.2) 
TLCO % Predicted 58.8 (7.3) 50.9 (2.0) 
KCO % Predicted 60.5 (6.8) 54.8 (2.1) 
Male 9 (90%) 36 (50%) ** 
Never smokers 1 (10%) 5 (8%) 
Ex-smokers  9 (90%) 67 (92%) 
A1AT Baseline Level (μM) 4.0 (0.4) 6.2 (0.4) * 
Table 6.3 shows the comparison between the demographics of the patients in the ECLIPSE A1ATD 
study and the EXACTLE study.   
 
Mean age is presented, (SEM in parentheses). Forced expiratory volume in 1 second, (FEV1) and 
forced vital capacity (FVC) mean data expressed in litres, (SEM in parentheses). Transfer factor 
(TLCO) mean values for the groups are shown (SEM in parentheses). KCO mean values for the 
groups are shown (SEM parentheses). The FEV1 % predicted, FVC % predicted, TLCO % 
predicted and KCO% predicted are the mean data for FEV1, FVC, TLCO and KCO expressed as 
a percentage. A1AT levels were measured in μM, and the mean values shown (with SEM in 
parentheses). 
 
* denotes a significant difference between the groups with a p value < 0.05 
**denotes a significant difference between the groups with a p value <0.01 
 
 
6.3  ECLIPSE A1ATD Plasma Sample Inclusion 
 
During the initial MALDI profiling of the ECLIPSE A1ATD plasma samples, it was 
evident that 2 of the A1ATD patients had baseline samples which were different from 
the remainder of the samples; the spectra generated using these samples contained a 
dominant peak with an m/z ratio of 5900kDa. This peak (from previous published data 
119 
 
from Ward et al., 2010) was likely to be a fragment of fibrinogen, which is commonly 
seen as an intense peak in serum samples, whilst being virtually absent from plasma. It 
was likely that the presence of this peak represented a degree of haemolysis and clotting 
within the samples at the time of the sample collection. These samples (both pre and 
post augmentation) were therefore removed from further analysis, leaving total 
numbers of patients in each group of 8 patients with A1ATD pre and post augmentation 
therapy, 9 COPD patients and 9 healthy control subjects. The haemolysed samples were 
also not included in the pooled sample analysis during the more in depth shotgun work 
(chapter 7). 
 
6.4  ECLIPSE A1ATD Urine Collection 
Urine samples were collected in sterile sample pots from the patients and control 
subjects recruited to the ECLIPSE A1ATD trial. For healthy control subjects and 
patients with usual COPD, the samples were taken at the screening visit. For patients 
with A1ATD, samples were collected at the screening visit and at immediately before 
the final infusion of Prolastin. 
  
6.4.1  Urinary Protein Concentration Determination 
The urinary protein content of the ELCIPSE A1ATD samples was measured as per the 
method described in chapter 2.7.1.  There was a wide variation in the urine protein 
concentration of the samples from 30 to 80 µg/mL. This did not vary according to the 
treatment group to which the individual patients belonged. The protein concentration 
therefore was standardised to 30 µg/mL prior to sample preparation, by dilution with 
de-ionised water. All of the patients and healthy control subjects had both normal renal 
function parameters and plasma albumin levels, and did not have any other medical 
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history of conditions affecting the renal tract or evidence of significant proteinuria, 
which could potentially influence the results of this experiment. 
 
6.4.2  Urine Supel Tip Results 
 
The diluted urine samples were prepared in duplicate using the supel tip method 
described in chapter 2.7.2. Data from duplicate experiments were analysed 
independently, following log transformation to normalise the distribution of the data, 
then the mean value for each of the peak intensities for each study subject was 
calculated and the data re-analysed. There were 171 peaks in the MALDI spectra, and 
the intra-experiment CV for the QC sample was 14%.  Using ANOVA, there were only 
8 peaks which differed between the 3 patient groups (A1AT, COPD and healthy control 
subjects) with a p value of < 0.05. Using paired analysis, there was only 1 peak which 
differed between A1ATD samples at baseline and at the end of 3 months of treatment, 
(m/z ratio 5555.8 Da and a p value of 0.004). The m/z of this peptide was >4000 Da, 
and therefore not possible to identify the protein origin of the peptide using MS/MS 
with the Ultraflextreme. The remainder of the results are shown below in tables 6.4 and 
6.5. 
 
Table 6.4 shows the results of the ECLIPSE A1ATD ANOVA analysis of urine, between A1ATD 
at baseline, COPD and normal healthy control subjects (NHC)  
 
 
 
 
 
 
m/z p Value Baseline  v COPD Baseline v NHC COPD v NHC 
1520.8 0.0034 0.071 0.0053 0.953 
3842.1 0.0016 0.0012 0.268 0.376 
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m/z p Value Post Treatment  v COPD Post Treatment v NHC 
3842.1 0.001 0.001 0.531 
4026.6 0.013 0.01 0.19 
4930.9 0.005 < 0.001 0.852 
5530.4 0.006 0.004 0.135 
5555.8 0.002 0.002 0.625 
6655.8 0.008 0.006 0.118 
8241.9 0.002 0.001 0.097 
Table 6.5 shows the results of the ECLIPSE A1ATD ANOVA analysis of urine data,  
between A1ATD post 3 months of treatment and COPD and normal healthy control  
subjects (NHC) 
 
There were few differences in the urinary peptidome between these groups of patients, 
and of those peaks which were significantly different, the majority (7) were above 
4000Da, making them above the threshold to identify using MS/MS with this mass 
spectrometer. There were more changes post treatment (7 v 2), and these were 
differences between patients with A1ATD and COPD patients.  
 
Following LC-MALDI of the pooled urine samples, it was also possible to use 
comparative analysis software (Profile Analysis Software (Bruker Daltronics)) to 
analyse the peak intensities from the LC-MALDI data, and this did not reveal any 
further additional differences to those listed above. It was therefore felt that there were 
too few changes present between patients pre and post augmentation therapy, and 
between patients with A1AT pre-treatment compared to COPD or healthy control 
subjects,  to warrant further in depth urine investigation in these patient groups. In 
addition, there were no urine samples collected during the EXACTLE study, as this was 
not part of the study protocol, to use as a validation of potential findings from the 
ECLIPSE A1ATD samples. Therefore, we concluded that the MALDI analyses of the 
urinary peptidome did not reveal any disease associated changes worthy of further 
investigation. 
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6.5 Plasma Reverse Phase SPE C8 Cartridge Data 
Plasma from both the ECLIPSE A1ATD study and EXACTLE study were profiled 
using SPE C8 cartridges and the data for each series of experiments is presented below.
  
 
6.5.1  ECLIPSE A1ATD Results 
Typical spectra from the ECLIPSE A1ATD study processed and analysed using SPE 
C8 cartridges are shown in Figure 6.1. Individual ECLPISE A1ATD samples were 
processed singly using the SPE C8 cartridges, but spotted on to the MALDI plate in 
triplicate and the mean peak intensities used. The data presented below is the average 
of the linear MALDI TOF MS data.  
 
There were a total of 247 peaks within the spectra.  A QC sample was analysed and the 
intra-experiment CV of the QC sample was 15%. The data was analysed in 2 ways after 
log transformation to achieve normal distribution of data; firstly a paired analysis was 
performed on the pre-treatment and post treatment samples (Table 6.6), followed by 
ANOVA between the A1ATD baseline samples with COPD data and healthy control 
sample data (Table 6.7), and ANOVA between the post treatment data compared to 
healthy controls and COPD samples (Table 6.8). 
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Figure 6.1 Spectra from a patient with A1ATD pre (A) and post treatment (B) from the ECLIPSE 
A1ATD study post sample preparation with SPE C8 cartridges.   
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Table 6.6.  Significant changes pre and post augmentation therapy in patients with A1ATD in the ECLIPSE A1ATD study. 
m/z is the mass to charge ratio of peaks which change significantly with treatment. Sequence is the amino acid sequence of the peptide, and protein is the protein 
from which the peptide originated. The fold change is the end of treatment peak intensity, measured in arbitrary units, divided by the baseline value, and the arrows 
denote the direction of change. 
m/z p Value Protein Sequence Median Base Median End Fold Change 
1099.4 0.0033 Complement C3 I.HWESASLLR.S 10.60 6.37 0.60 ↓ 
1564.4 0.0019 Albumin R.DAHKSEVAHRFKDL.G 0.79 0.62 0.79 ↓ 
1607.4 0.0028   1.73 1.2 0.69 ↓ 
1738.2 0.0094 Complement C4 R.NGFKSHALQLNNRQI.R 1.46 1.17 0.80 ↓ 
1935.9 0.00040 Complement C3 S.SKITHRIHWESASLLR.S 2.86 1.81 0.63 ↓ 
2022.9 0.0069 Complement C3 R.SSKITHRIHWESASLLR.S 30.29 23.94 0.79 ↓ 
2038.6 0.0048 Transthyretin A.ALLSPYSYSTTAVVTNPKE.- 1.45 1.19 0.82 ↓ 
2392.2 0.0016 A1AT L.MIEQNTKSPLFMGKVVNPTQK.- 0.81 2.27 2.27 ↑ 
2491.1 0.0023   0.52 1.72 3.34 ↑ 
2505.6 0.00040 A1AT 
F.LMIEQNTKSPLFMGKVVNPTQK.
- 1.51 6.68 4.42 ↑ 
2521.5 0.00079   1.27 4.60 3.63 ↑ 
2537.3 0.0024 Complement C3 G.SPMYSIITPNILRLESEETMVL.E 1.07 1.56 1.45 ↑ 
4679.7 0.00039   0.85 1.56 1.85 ↑ 
4781.3 0.00096   0.40 0.68 1.69 ↑ 
4791.9 0.00034   0.56 1.18 2.11 ↑ 
4812.7 0.0083   1.00 1.29 1.30 ↑ 
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m/z 
p 
Value 
Baseline v 
COPD 
Baseline v 
Healthy Control 
COPD v Healthy 
Control Protein Sequence 
2392.2 0.05 0.004 0.008 0.359 A1AT L.MIEQNTKSPLFMGKVVNPTQK.- 
2483.8 0.005 0.004 0.205 0.156   
2505.6 <0.001 <0.001 <0.001 0.534 A1AT F.LMIEQNTKSPLFMGKVVNPTQK.- 
2521.5 <0.001 <0.001 <0.001 0.74   
4679.7 0.005 0.017 0.007 0.927   
4781.3 <0.001 <0.001 0.003 0.494   
4791.9 <0.001 <0.001 <0.001 0.196   
4812.7 0.002 0.001 0.219 0.061   
6487.3 0.006 0.007 0.029 0.807   
6767.7 0.007 0.006 0.046 0.629   
6784.4 0.01 0.014 0.027 0.958   
Table 6.7 shows the results of ANOVA analysis between A1ATD patients at baseline, and COPD and healthy control subjects. m/z is the mass to charge ratio. Sequence 
is the amino acid sequence of the peptide. 
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Table 6.8. Results of the ANOVA analysis of the SPE C8 cartridge data between patients with A1ATD after 3 months of treatment and COPD patients and healthy 
control subjects.  
 
 
m/z p Value Treated v COPD Treated v Healthy Control  Protein ID Sequence 
2392.2 0.386 0.628 0.913 A1AT L.MIEQNTKSPLFMGKVVNPTQK.- 
2483.8 0.151 0.25 0.988   
2505.6 0.42 0.409 0.914 A1AT F.LMIEQNTKSPLFMGKVVNPTQK.- 
2521.5 0.8 0.924 0.961   
4679.7 0.819 0.809 0.973   
4781.3 0.316 0.351 0.979   
4791.9 0.269 0.727 0.676   
4812.7 0.079 0.425 0.563   
6487.3 0.057 0.054 0.173   
6767.7 0.098 0.083 0.362   
6784.4 0.131 0.144 0.23   
127 
 
There were 16 peaks in the MALDI spectra which changed significantly pre and post 
treatment with intravenous A1AT. Of these peaks, the one with the most significant 
fold change (4.42 increase) is a fragment of A1AT, with an m/z of 2505. This is elevated 
in the post treatment samples when compared to the baseline. The values for individuals 
are presented in Figure 6.2, and shows that this effect is seen in each individual patient. 
Other peaks which also behave in this way are the peaks with m/z ratios of 1607, which 
decreased in all patients receiving treatment, (a fragment of an unidentified protein) and 
2392 which increased in all patients (a further fragment of A1AT); these are also shown 
in the histograms below. 
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Figure 6.2 Signal intensities for individual patients in the ECLIPSE A1ATD study pre and post 
treatment with Prolastin for the peaks with the most significant p values and greatest fold change. 
(A) is a fragment of A1ATD with an m/z of 2392 Da, and (B) is a fragment of A1AT with an m/z of 
2505 Da and (C) is a fragment with an m/z of 1607 Da. In A and B, in every patient post treatment, 
there is an increase in signal intensity post treatment. In C, there is a reduction in signal intensity 
in each patient post treatment.  
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In total there were 2 fragments of the A1AT protein identified as changing significantly 
in response to treatment with intravenous A1AT. The ANOVA data shows that the peak 
intensities were lower in patients than in all other groups pre-treatment but normalizes 
with treatment. The results for each individual demonstrating this relationship are 
shown in figure 6.3. 
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Figure 6.3. Individual peak intensities (in arbitrary units) for the fragment of A1AT with an m/z 
of 2505. Group 1 are the patients with A1ATD at baseline, group 2 are the patients with A1ATD 
following 3 months of augmentation therapy, group 3 are the patients with usual COPD, and group 
4 are the healthy control subjects. 
 
In total, there were 11 peaks in the MALDI spectra which were significantly different 
between the 3 groups (patients with A1ATD at baseline, and patients with COPD and 
healthy control subjects). Post treatment, there are no significant differences between 
these groups, and there were no new differences identified. 
 
6.5.2   EXACTLE Plasma Peptide Profiling 
 
The EXACTLE samples were prepared and analysed using the same methodology as 
the ECLIPSE A1ATD samples. There were 215 peaks within the spectra of these 
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samples, and the intra-experiment CV calculated, on the QC sample was 17%. The 
samples were spotted onto the MALDI plate and analysed in triplicate, the data log 
transformed, and the mean of the duplicates calculated and used in further data analyses.  
 
The peaks which changed significantly following treatment with Prolastin are presented 
below in table 6.9. In total, there were 7 peaks which changed significantly, and in each 
if these cases, there was an increase in the intensity of the peak post treatment with 
Prolastin, whilst there was no change post treatment amongst the patients receiving 
placebo infusions. 
 
The peak intensities for individual patients for the peak with an m/z of 2505, which is 
one of the peaks with the most significant p value (<0.001) and is a fragment of A1AT, 
are shown below in figure 6.3. This demonstrates a rise in the intensity of this fragment 
in patients who receive Prolastin, and remains unchanged in patients in the placebo arm 
of the trial. The same relationship was seen in the ECLIPSE A1ATD samples, and the 
fold changes were 4.42 in the ECLIPSE A1ATD samples and 2.20 in the EXACTLE 
samples.  
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Figure 6.4 shows the individual 2505 peak intensities for all of the patients in the EXACTLE study. 
Group 1 is patients in the Prolastin at baseline, group 2 is patients on Prolastin after 6 month’s 
treatment, group 3 is patients who received placebo at baseline and group 4 is patients receiving 
placebo after 6 months of treatment. The median value for each group is shown by the horizontal 
line. There was a significant difference between the groups between the baseline and 6 month 
samples (p <0.001). 
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p Value m/z Protein 
Median 
Baseline 
Placebo 
Median End 
Placebo 
 
 
Fold Change 
Median Baseline 
Drug 
Median End 
Drug 
 
Fold Change 
0.001 2392.2 A1AT 0.92 0.98 1.06 ↔ 0.90 1.87  2.10  ↑ 
<0.001 2505.6 A1AT 1.14 1.20 1.05 ↔ 1.17 3.16  2.70 ↑ 
0.001 2521.5  1.16 1.190 
1.03 ↔ 1.10 2.41  2.20 ↑ 
<0.001 2537.3 
Complement 
C3 1.07 1.15 
0.93 ↔ 
1.09 1.85  
1.69 ↑ 
0.001 4679.7  0.82 0.89 
1.08 ↔ 1.00 1.21  1.21 ↑ 
0.001 4791.9  0.59 0.61 
1.03 ↔ 0.64 0.96  1.50 ↑ 
0.005 4812.7  0.84 0.80 
1.03 ↔ 0.77 0.99  1.29 ↑ 
Table 6.9 shows the significant peaks from the EXACTLE trial samples following 6 months of treatment with either Prolastin or placebo. The median values of peak 
intensities for each group, measured in arbitrary units, are displayed, together with the fold change of the end of treatment to baseline values. The arrows demonstrate 
the direction of change. 
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Each of the peaks with a p value < 0.01 which change demonstrates a fold change of 
1.21 to 2.70 in the patients receiving active drug, whilst in the placebo group, the fold 
changes of range from 0.96 to 1.08, indicating little change in the peptidome in the 
placebo group, as would be anticipated. 
 
6.5.3  Comparison of Results from ECLIPSE A1ATD and EXACTLE  
Table 6.10 shows a comparison of results using the same sample preparation technique 
from both independent sets of samples (ECLIPSE A1ATD and EXACTLE). There 
were 7 peaks which were significantly different pre and post treatment with 
augmentation therapy that were present in both experiments. There were 3 fragments 
of A1ATD that increased in both sets of patient samples post augmentation therapy, 
whilst remaining unchanged in patients receiving placebo (demonstrated in the 
EXACTLE samples only as there was no placebo arm in ECLIPSE A1ATD). Of the 
remaining peaks, the fold changes were in agreement across the 2 experiments; 
increasing in both sets of samples. There were more peaks which changed significantly 
following augmentation therapy in the ECLIPSE A1ATD samples, although this may 
reflect false positive results due to smaller patient numbers included in the analysis (8 
samples pre and post compared to 72 pairs of samples in EXACTLE). As previously 
described, there were a number of peaks with m/z ratios above 4000Da which were 
significantly different between the baseline and post treatment samples, which 
remained unidentified. 
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m/z Protein 
p Value 
ECLIPSE  
Fold Change 
ECLIPSE 
A1ATD  
p Value 
EXACTLE 
Fold Change 
EXACTLE 
2392.2 A1AT 0.0023 3.34 ↑ 0.001 2.10  ↑ 
2505.6 A1AT 0.00040 4.42 ↑ <0.001 2.70 ↑ 
2521.5  0.00079 3.63 ↑ 0.001 2.20 ↑ 
2537.3 Complement C3 0.0024 1.45 ↑ <0.001 1.69 ↑ 
4679.7  0.00039 1.85 ↑ 0.001 1.21 ↑ 
4791.9  0.00034 2.11 ↑ 0.001 1.50 ↑ 
4812.7  0.0083 1.30 ↑ 0.005 1.29 ↑ 
Table 6.10.  Comparison of the significant peaks, p values and fold changes between patients in the  
ECLIPSE A1ATD Study and the active drug group of the EXACTLE Study.  
 
 
6.6   WCX Bead Data Plasma Analysis 
The results for the WCX bead analyses, performed as per the methodology in chapter 
2.3.3, for both the ECLIPSE A1ATD and EXACTLE studies are presented in the tables 
and figures below.  
 
6.6.1   ECLIPSE A1ATD Results 
There were 197 peaks within the WCX bead spectra when samples from the ECLIPSE 
A1ATD study were analysed. The intra-experiment CV calculated from the QC sample 
was 16%. Typical spectra generated using WCX beads as the preparation method and 
linear MS are shown below in Figure 6.5 
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Figure 6.5 Typical spectra from patients with A1ATD pre (A) and post treatment (B) with 
augmentation therapy as part of the ECLIPSE A1ATD study. 
 
The samples were processed in triplicate and spotted on to the MALDI plate in 
triplicate. The data was log transformed and a mean calculated and used for further 
analysis. The peaks which changed significantly between baseline and post 3 months 
of treatment with intravenous A1AT are shown in table 6.11. There were only 6 peaks 
which differed between the start and end of 3 months of treatment, and of these, there 
were only 2 which were in the mass range where it was possible to identify them using 
LC-MALDI MS/MS. It was only possible to identify 1 of these and this was a fragment 
of albumin which increased following 3 months of treatment with intravenous A1AT, 
with a fold change of 1.73. 
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Table 6.11 Significant changes pre and post augmentation therapy in patients with A1ATD in the 
ECLIPSE A1ATD study 
 
m/z is the mass to charge ratio of peaks which change significantly with treatment. Sequence is the 
amino acid sequence of the peptide and protein is the protein from which the peptide originated. 
The fold change is the end of treatment peak intensity, measured in arbitrary units, divided by the 
baseline value and the arrow denotes the direction of change.  
 
The results from the ANOVA analysis, initially between A1ATD patients at baseline 
and COPD and healthy control subjects are presented in table 6.12. The ANOVA results 
for the analysis between A1ATD patients after augmentation therapy and COPD and 
healthy control subjects are shown in table 6.13. There were 18 changes identified 
between the A1ATD patients at baseline and the usual COPD patients and healthy 
control subjects. Of these, 4 were identified, and 3 were fragments of albumin and 1 
was a fragment of IgG2. The majority of these were significant differences between 
patients with A1ATD and healthy control subjects.  
 
Post treatment there were 18 changes between the patient groups when ANOVA was 
performed, again the majority of these were between A1AT patients and the healthy 
control subjects. However, it was not possible to identify most of these changes using 
LC-MALDI MS/MS, therefore limiting the utility of the data generated. 
m/z 
p 
value 
Protein Sequence 
Median 
Baseline 
Median 
3 
Months 
Fold 
Change 
2660.9 0.004   14.76 17.87 1.21 ↑ 
2741.01 0.009 Albumin R.DAHKSEVAHRFKDLGEENFKALVL.I 2.85 4.95 1.73 ↑ 
5068.01 0.009 
 
 0.51 0.40 0.78 ↓ 
6879.8 0.005   0.44 0.26 0.59 ↓ 
8872.1 0.003   1.01 0.81 0.81 ↓ 
9290.6 0.021   3.21 3.98 1.24 ↑ 
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m/z 
 
p Value Baseline v COPD 
Baseline  v 
Healthy Control 
COPD  v 
Healthy 
Control 
Protein Sequence 
1296.8 0.01 0.011 0.039 0.839 Ig G2 D.PEVQFNWYVD.G 
1607.0 0.01 0.766 0.012 0.048   
1720.2 0.008 0.228 0.006 0.18   
2429.0 0.009 0.009 0.049 0.714 Albumin R.DAHKSEVAHRFKDLGEENFKA.L 
2741.1 0.005 0.031 0.005 0.677 Albumin R.DAHKSEVAHRFKDLGEENFKALVL.I 
2754.4 0.007 0.021 0.01 0.94 Albumin R.DAHKSEVAHRFKDLGEENFKALVLA.I 
2790.1 0.004 0.038 0.003 0.536   
3883.9 0.01 0.11 0.008 0.427   
3903.9 0.004 0.053 0.003 0.405   
3911.2 0.001 0.017 0.001 0.348   
3919.9 0.001 0.035 0.001 0.165   
3955.6 0.005 0.42 0.004 0.064   
4715.7 0.001 0.204 0.001 0.048   
5133.7 0.001 0.104 0.001 0.067   
6882.2 0.006 0.009 0.018 0.957   
7349.9 0.007 0.462 0.006 0.078   
7567.3 0.001 0.052 0.001 0.043   
9292.4 0.009 0.1 0.007 0.435   
Table 6.12. Results of the ANOVA analysis between patients with A1ATD at baseline with usual COPD and healthy control subjects 
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Table 6.13 Results of the ANOVA analysis between patients with A1ATD after 3 months of 
treatment, and patients with usual COPD and healthy control subjects.  
 
6.6.2  EXACTLE WCX Bead Results 
The sample preparation was carried out in triplicate, and spotted on to the MALDI plate 
in triplicate. Post log transformation, a mean was calculated and used in further 
analyses. The spectra from the WCX bead preparation of the EXACTLE samples 
contained 185 peaks. The intra-experiment CV for this experiment was 19%. 
 
The significant peaks between the active drug (Prolastin) and the placebo groups 
between the baseline and post 6 months of treatment are demonstrated below in table 
m/z p Value 
Treated  
v COPD 
Treated 
v NHC Protein Sequence 
1296.8 0.004 0.006 0.017 Ig G2 D.PEVQFNWYVD.G 
1607.0 0.022 0.926 0.031   
1720.2 0.053 0.576 0.045   
2229.5 0.008 0.008 0.042   
2429.0 0.138 0.119 0.416   
2741.1 0.009 0.05 0.008 Albumin R.DAHKSEVAHRFKDLGEENFKALVL.L 
2754.4 0.097 0.194 0.105 Albumin R.DAHKSEVAHRFKDLGEENFKALVLA.I 
2790.1 0.015 0.145 0.012   
3883.9 0.054 0.313 0.043   
3903.0 0.016 0.189 0.012   
3911.2 0.003 0.079 0.002   
3919.9 0.003 0.136 0.002   
3955.5 0.095 0.99 0.173   
4072.0 0.004 0.389 0.003   
4715.7 0.002 0.319 0.001   
5133.7 0.008 0.403 0.006   
6882.2 0.487 0.473 0.669   
7349.9 0.031 1 0.059   
7567.3 0.004 0.376 0.003   
7641.1 0.006 0.521 0.006   
8144.1 0.006 0.313 0.005   
9292.4 0.064 0.353 0.051   
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6.14. There were 8 peaks with a p value of < 0.01. The protein identification of these 
peptides are demonstrated within the table. Of the 3 possible identifications, there was 
a fragment of albumin which increased in the group of patients in the placebo arm of 
the trial, whilst remaining unchanged in the group on active treatment, and a fragment 
of complement C3 which decreased in patients receiving active drug whilst remaining 
unchanged in the placebo group.   
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p Value m/z Protein 
Median 
Baseline 
Placebo 
Median 6 
Months 
Placebo 
Fold 
Change 
Median 
Baseline 
Drug 
Median 6 
Months 
Drug 
Fold 
Change 
0.002 1136.9 Complement C3 1.53 1.69 1.105 ↔ 1.545 1.175 0.76 ↓  
0.001 2429.1 Albumin 1.165 1.565 1.343 ↑ 1.26 1.265 1.00 ↔  
<0.001 2741.1 Albumin 1.475 1.54 1.044 ↔  1.355 3.115 2.29  ↑ 
0.0065 2862.3  7.9 7.13 0.903 ↔  9.445 20.705 2.19  ↑ 
0.01 3818.1  0.465 0.655 1.409 ↑  0.525 0.5 0.952 ↔ 
0.001 4614.9  1.07 1.405 1.313 ↑  1.23 0.955 0.77 ↓ 
6.82317E-
06 5000.3  0.42 0.79 1.881 ↑ 0.34 0.915 2.69 ↑ 
0.004 6882.2  0.32 0.395 1.234 ↑ 0.3 0.24 0.80 ↓ 
Table 6.14. Significant peaks post WCX sample preparation of the EXACTLE samples.  The median values for each group are shown, measured in  
arbitrary units. The fold changes are presented and the arrows denote the direction of change. 
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6.6.3 Comparison of ECLIPSE A1ATD and EXACTLE WCX 
Bead Data 
 
There was much less agreement between the data generated from the WCX bead 
analyses between the ECLIPSE A1ATD and EXCATLE analyses than was seen with 
the SPE C8 data for the same analyses. Pre and post treatment there was only 1 peak in 
the MALDI spectra which was significant in both WCX bead datasets – this was a peak 
with an m/z of 2741.1 and was identified as a fragment of albumin. This increased in 
both experiments – with a fold change of 1.73 in the ECLIPSE A1ATD samples and 
2.29 in the EXACTLE samples. None of the other peaks behaved consistently across 
the 2 separate sets of experiments. 
 
The spectra generated from the WCX beads was across a greater mass range than was 
seen using the SPE C8 cartridges, where the majority of the peptides were in the mass 
range below 4000Da. Sixty-one percent of the peaks in the WCX bead spectra were 
above 4000Da, compared to 49% in the SPE C8 cartridge experiments. However, as 
demonstrated previously, it was not possible to identify these peptides and therefore 
proteins. In order to prepare samples for LC-MALDI to increase peptide identification, 
the SPE C8 cartridge methodology was used. This was to ensure that none of the WCX 
beads caused damage to the HPLC column. This may, in part at least, explain the lack 
of identifications following profiling with WCX beads. 
 
6.7 Responder Analysis  
 
CT scans were performed at baseline and at 12 and 24 months on patients in the 
EXACTLE Study. CT densitometry was measured and overall there was a trend 
towards a reduction in progression of emphysema (as reflected in a reduced loss of lung 
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density) in the patients who received active drug compared to patients who had received 
placebo. However, the number of patients in each arm of the study was small (38 on 
active drug 39 receiving placebo).  Responder analysis based on individual data has yet 
to be validated as it has an inherent patient variability even on placebo and with data 
from the larger, more recent RAPID Study (Chapman et al, 2015) which included 93 
patients in the active treatment arm and 87 in the placebo arm. Responder analysis using 
CT densitometry is being assessed as part of a phase 4 study of 400 patients requested 
by the FDA. Individual patient data from the EXACTLE study is owned by Grifols, and 
has not been released using the “end-point” CT densitometry analysis and hence was 
not possible with the current limited dataset even though mean data has been published. 
To partially address the question of a responder analysis, this was achieved 
biochemically as an alternative using the Aα-val360 assay data which is both 
reproducible and reflects proteinase control by treatment.  
 
 Aα-Val360 is an NE specific cleavage of fibrinogen that has been measured in patients 
with A1ATD, healthy control subjects and patients with usual COPD who were 
recruited into the ECLIPSE A1ATD trial. Carter et al demonstrated that this was 
elevated in patients with A1ATD compared to healthy control subjects, it related to 
severity of lung disease measured using CT densitometry and lung physiology, and, 
importantly, levels decreased following treatment with A1AT replacement 
intravenously (Carter et al., 2011; Carter et al., 2013). 
 
Aα-Val360 was measured in the baseline and 6 month samples of the EXACTLE study 
by Carter et al, according to their published methodology (Carter et al., 2011). A median 
value for Aα-Val360 for each of the following 4 groups (placebo baseline and post 6 
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months’ treatment and Prolastin baseline and post 6 months’ treatment) was calculated 
for the patients included in this study, together with a median reduction between the 
start and end of treatment in the active drug and placebo groups. The data from the 
WCX bead and SPE C8 MALDI profiling analyses in the EXACTLE study from this 
series of experiments were re-analysed using patients in the active treatment group who 
had a reduction in this signal which was greater than the median for the group. The data 
are presented below in tables 6.15 and 6.16. This subgroup analysis was only performed 
on the EXACTLE dataset, even though Aα-Val360 had been measured in the ECLIPSE 
A1ATD study. In addition there were only 8 patients with samples analysed in the 
A1ATD group in the ELCIPSE A1ATD study, and reducing this number further would 
have made interpretation of further statistical analysis less valid.  
 
The SPE C8 cartridge data did not show any further peaks that emerged to become 
significant when this sub-group data analysis was undertaken; the fold changes for 6 of 
the 7 significantly different peaks were higher in this sub-group data analysis. The 
signals with the most significant change were the fragments of A1AT, which increased 
post treatment suggesting it reflected the overall plasma replenishment with A1AT 
alone and hence (potentially) better NE control in vivo. 
 
From the WCX bead data, it is possible to see that there are 4 further peaks which 
demonstrate a significant difference, in addition to the 9 previously highlighted. The 
majority of these are in the higher mass range, (> 4000Da) and, as previously noted, it 
was not possible to identify the proteins from which the peptides originated. Therefore, 
this re-analysis of data did not identify any further markers to indicate a response to 
treatment in patients with A1ATD who receive intravenous replacement therapy.  
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m/z 
p 
Value 
Median 
Placebo Base Median Placebo End 
Fold 
Change 
Median Prolastin 
Baseline 
Median 
Prolastin End Fold Change 
2392.2 < 0.001 0.945 1.005 1.06 ↔ 0.715 1.61 2.25 ↑ 
2505.6 < 0.001 1.24 1.295 1.04 ↔ 1.27 3.095 2.44 ↑ 
2521.5 < 0.001 1.185 1.22 1.03 ↔ 1.185 2.655 2.24 ↑ 
2537.3 < 0.001 1.09 1.07 0.98 ↔ 1.07 1.905 1.78 ↑ 
4679.7 0.008 0.9 0.85 0.94 ↔ 0.865 1.17 1.35 ↑ 
4792.0 < 0.001 0.57 0.545 0.96 ↔ 0.535 0.985 1.84 ↑ 
4812.7 0.006 0.805 0.708 0.88 ↓ 0.685 1.01 1.47 ↑ 
Table 6.15 The SPE C8 cartridge data re-analysed using the data from those patients on active drug with a greater than mean reduction in Aα val 360.  
The fold change is the end of treatment value divided by the baseline value, and the arrow denotes the direction of change. 
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m/z p Value 
Median 
Placebo 
Baseline Median Placebo End 
Fold 
Change 
Median Prolastin 
Baseline 
Median 
Prolastin End 
Fold 
Change 
1136.9 0.001 1.53 1.69 1.10 ↑ 1.59 0.965 0.61 ↓ 
1378.0 0.005 1.985 2.01 1.01 ↔ 2.125 1.33 0.63 ↓  
1466.6 < 0.001 2.47 2.605 1.05 ↔ 2.685 1.47 0.55 ↓ 
1552.6 0.002 1.515 1.715 1.13 ↑ 2.15 0.79 0.37 ↓ 
2429.0 0.005 1.165 1.565 1.34 ↑ 1.285 1.275 0.99 ↔  
2741.1 < 0.001 1.355 1.54 1.14 ↑ 1.4 3.625 2.59 ↑ 
2862.3 0.008 9.445 7.13 0.75 ↓ 7.175 21.96 3.06 ↑ 
3086.1 0.004 0.785 0.76 0.97 ↔ 0.865 0.57 0.66 ↓ 
3968.9 0.01 0.52 0.625 1.20 ↑ 0.58 0.475 0.82 ↓ 
4614.9 0.003 1.07 1.405 1.31 ↑ 1.145 0.935 0.82 ↓ 
6551.5 0.008 0.5 0.47 0.94 ↔  0.52 0.375 0.72 ↓ 
6882.2 0.004 0.3 0.395 1.32 ↑ 0.355 0.24 0.68 ↓ 
9521.9 0.009 0.27 0.29 1.07 ↔ 0.32 0.17 0.53 ↓ 
Table 6.16 shows the results of the WCX bead data including only those with a greater than the mean fall in Aα val 360 levels. The median  
value, measured in arbitrary units, is shown for each group.  The fold change is the ratio of the end of treatment value to the start of treatment  
value for each group and the arrow denotes the direction of change. 
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6.8  Discussion 
The SPE C8 cartridge data and WCX bead approaches allowed reproducible profiling 
to be performed in plasma and urine of patients with A1ATD. The 2 separate 
approaches allowed differential properties to be utilized to complement one another. 
On the whole, they identified few changes in the plasma and urinary peptidomes in 
response to treatment with intravenous A1AT in patients with A1ATD. The average 
intra-experiment CV for each of these experiments was below 20%, which was the 
previously quoted value using other sample preparation techniques (such as SELDI 
profiling), indicating that this approach is at least as good as the other technique in 
terms of reproducibility, whilst providing more potentially clinically useful 
information. 
 
6.8.1  Urine Data Analysis 
Urine is analysed in a number of different diseases, both of the renal and urinary tracts, 
and of non-related diseases. Small peptides and proteins may be filtered by the kidney. 
Therefore, it was hypothesised that small, proteolytic fragments, originating during 
proteolysis in the lungs, would be cleared from the plasma by the kidney, and thus 
amenable to detection following the analysis of urine samples. 
 
Previous published work has been carried following analysis of urine samples in 
patients with usual COPD. For example, hydroxydeoxyguanosine, which is a marker 
of oxidative stress, was compared in the urine of 19 COPD patients and compared to 
that of 13 healthy control subjects; levels were significantly elevated in the COPD 
patients when compared with the healthy control group, from which the authors 
concluded that this was indicative of increased oxidative stress in the COPD group 
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(Igishi, 2003). Other possible markers have included the analysis of urinary desmosine 
as a marker of elastin and collagen breakdown. Results from studies of desmosine 
differ; some have reported that this is increased where lung function decline is rapid; 
(Stone et al., 1995) whilst others have reported that there is no association between 
urinary desmosine and FEV1. In addition, it has been suggested that desmosine may be 
affected by other variables including diet (Stone et al., 1994) and renal function, 
(Davies et al., 1983) and elastin degradation outside the lung which limit its widespread 
use.  
 
Huang et al measured desmosine in the plasma and urine of patients with COPD, both 
in the stable state and during exacerbations, in patients with asthma and in healthy 
control subjects - both smokers and non-smokers. Using mass spectrometry they 
demonstrated that during COPD exacerbations, the urinary concentrations of desmosine 
were elevated and that in plasma, there was an association between patients with 
elevated levels of desmosine and a low transfer factor (Huang et al., 2012). Despite this 
positive observation, desmosine has still not been validated sufficiently for routine use 
in clinical practice.  
 
Urine has a lower total protein concentration than that of plasma, and is thus 
theoretically easier to analyse using mass spectrometry. It is routinely collected and 
relatively operator independent in its collection, and also minimally invasive to collect 
which means repeated collections, such as pre and post an intervention, are possible. 
This means, therefore, that collection and analysis of urine has many potential 
advantages over other biological and tissue samples, such as blood, lung tissue/BALF. 
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Patients enrolled in to the ECLIPSE A1ATD study had urine samples collected pre and 
post treatment. This was primarily to test for urinary cotinine to ensure that none of the 
patients recruited into the study were current smokers, as this was an exclusion criterion 
from the study protocol. Unfortunately, there were only 9 differences detected between 
the 4 groups when the data was analysed using ANOVA, and only 1 difference between 
the baseline and post treatment samples. In addition, the protocol for the EXACTLE 
study did not include urine sample collection, and therefore there was not a larger 
dataset for comparison/validation of the results. Therefore, LC-MS/MS was not 
performed on these samples, as any data generated would be limited to a small number 
of individuals, and would not be able to replicate on a larger dataset to test any 
hypotheses that were generated.  
 
6.9.2  Clinical Significance of A1AT Fragments  
 
This work has demonstrated an increase, post treatment, of fragments of A1AT in 
patients who received active drug, but remained unchanged in patients receiving 
placebo infusions. This occurred irrespective of the duration of treatment (in ECLIPSE 
A1ATD study, the samples were taken at 3 months post treatment initiation, in the 
EXACTLE study the second time point was 6 months). These same fragments were 
also detected in the plasma of healthy control subjects, and patients with usual COPD, 
and post augmentation there were no statistically significant differences between 
patients with A1ATD and either of the other 2 groups. The fragments are all from the 
C terminus of the A1AT protein.   
 
It has been well demonstrated that patients on intravenous A1AT therapy have a rise in 
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the total plasma concentration of A1AT, and therefore it is biologically plausible that 
fragments of this protein are detectable in the plasma of patients with A1ATD after they 
have received treatment with augmentation therapy as such fragments are likely to be 
present in purified A1AT from healthy subjects.  
 
Previous work by Niemann et al (1997) investigated a 44 residue peptide of the C 
terminus of the A1AT protein (termed SPAAT – short peptide of A1AT) and found that 
this fragment of the A1AT protein, which was first isolated from human placental cells, 
was an inhibitor of a number of serine proteases, including NE, pancreatic elastase and 
chymotrypsin. Unlike the complete A1AT protein, it binds reversibly to the enzymes.  
They concluded that, in vivo, SPAAT may have a role in the protection of extracellular 
proteins from the proteolytic actions of proteases, as a further protective mechanism 
(Niemann et al., 1997). 
 
The amino acid sequence of the SPAAT peptide, published by Niemann and colleagues, 
is as follows:- 
 MFLEAIPMSIPPEVKFNKPFVFLMIEQNTKSPLMGKVVNPTQK (Niemann et al., 
1997) 
 
Two of the fragments of A1AT which were significantly different pre and post 
treatment with intravenous A1AT from the profiling experiments were sections of this 
previously described C-terminal peptide. Of these, 
LMIEQNTKSPLFMGKVVNPTQK and MIEQNTKSPLFMGKVVNPTQK (2506 and 
2392 respectively) are the same fragment but with 1 less amino acid in the peak at 2392.  
The underlined section of SPAAT demonstrates the fragments identified in the profiling 
work.   
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Figure 6.6 shows the 3-dimensional structure of A1AT determined by x-ray 
crystallography.   The blue area denotes the fragment that Niemann and colleagues 
named SPAAT. The red sections demonstrate the terminal sequence identified in the 
profiling experiments which was a segment of the C terminus of SPAAT. 
 
Figure 6.6 shows the 3 dimensional structure of A1AT 
 
6.9.4   Complement C3 
Complement C3 is a further abundant plasma protein (9th most abundant; Tirumalai et 
al (2003), and an integral part of the classical complement pathway (Marc et al., 2004). 
Type II pneumoncytes in the lungs are able to make C3 and C3 fragments, and animal 
models have suggested that some of these, including C3a and C5a (which are generated 
following proteolysis is C3 and C5 respectively) may produce some of the features seen 
in COPD, including contraction of smooth muscle (Marc et al., 2004). The SPE C8 
cartridge analyses demonstrated an increase signal intensity in a peptide of complement 
C3 in both the ECLIPSE A1ATD samples and those from the EXACTLE study 
following treatment with intravenous A1AT. Marc et al, however, demonstrated that 
151 
 
levels of C3a were increased in induced sputum samples in patients with COPD when 
compared to healthy controls. The WCX bead data demonstrated that a separate 
fragment of complement C3 (m/z 1136.9) decreased in intensity post treatment with 
augmentation therapy in the patients in the EXACTLE study, whilst remaining 
unchanged in patients who were receiving placebo infusions (fold changes of 0.76 and 
1.1 respectively). This may be related to the observation by Marc and colleague, 
however, the fold changes demonstrated are small. 
 
6.9.5   WCX Bead Analyses 
 
The WCX bead data provided fewer peptide identifications than the SPE C8 approach. 
This was in part due to the size of the peptides – there were a greater proportion of 
peptides which had m/z ratios above 4000Da with the WCX bead approach. Of the 
proteins which were shown to change significantly with treatment, 3 of the proteins 
identified as changing significantly in patients receiving placebo infusions were 
fragments of albumin. The data generated from the WCX bead analyses from these 
clinical samples was less consistent than that produced when the samples were prepared 
using the SPE C8 cartridges. The data only identified 1 peptide which changed in the 
same way in both independent datasets – and this was a fragment of albumin and 
therefore of limited clinical value, as previously panels of markers together have been 
required to detect differences between patient groups in COPD (Rana et al., 2010) and 
in malignant diseases (Useland et al., 2011).  When the WCX beads were used to 
analyse the ionophore samples, there were easily identifiable differences. The intra-
experiment CVs for both the EXACTLE and ECLIPSE A1ATD studies were below 
20% and therefore the lack of consistent findings across the 2 separate experiments was 
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not due to the way the experiments were conducted. At the method optimization stage, 
it was the number of peaks and the peak intensities which were used to determine the 
best techniques for profiling, rather than through identification of peptides using LC-
MALDI MS/MS. 
 
As would have been anticipated, the remainder of the low molecular weight plasma 
proteome remained unchanged post augmentation therapy, and this was a finding across 
both of the profiling techniques utilized in this work. All of the proteins which were 
identified as changing significantly in response to augmentation therapy were in the 
group of high abundance plasma proteins. This approach did not identify a new 
candidate protein worthy of further study in the attempt to find biomarkers to predict a 
response to treatment in patients with A1ATD. It did correctly identify a change in 
fragments of A1AT, however, total A1AT levels are easily measurable and therefore 
this alone did not generate new clinically relevant information. 
 
 
6.9.6  Comparison of in vitro and Clinical Sample Results 
Following neutrophil stimulation with calcium ionophore, differences were seen in the 
plasma profiles of patients with A1ATD compared to healthy control subjects; the 
majority of these differences were fragments of fibrinogen, particularly the fragments 
of fibrinogen α chain. These could represent potential candidate markers of the actions 
of NE. During the profiling experiments, there were no peaks within the MALDI 
spectra to correspond to the fragments of fibrinogen identified as potential markers 
during the ionophore experiments. This does not imply that the fragments were not 
present – the signals may have been masked by the presence of more highly abundant 
153 
 
peptides. 
 
Furthermore, when LC-MALDI was performed in order to maximize peptide 
identification, only 2 of the 11 fibrinogen fragments from the ionophore data were 
identified in the clinical samples from ECLIPSE A1ATD and EXACTLE studies 
(namely W.YSMRKMSMKIRPFFPQ.Q and D.SGEGDFLAEGGGVR.G). This again 
does not mean that the potential candidate biomarkers were not present in the clinical 
samples or that they do not change significantly in response to treatment. These signals 
may have been present but the mass spectrometer was not able to overcome the diverse 
concentration range (fibrinogen typically has a concentration of 1.5 to 4.5g/L in human 
plasma in contrast to albumin, which has a concentration of 60-80g/L) in the presence 
of more abundant proteins, in particular albumin.  
 
6.9.7  Complexity of the Plasma Proteome 
 
Plasma is one of the most difficult clinical samples to analyse using mass spectrometry, 
yet one of the most potentially informative, as every tissue and organ in the body 
requires a blood supply. It is, therefore, theoretically possible to detect changes within 
any tissue or organ by analysing plasma or serum. Plasma and serum have the 
advantages that such samples are routinely collected, and minimally invasive in doing 
so, and research samples may be taken alongside samples taken for routine clinical care. 
In addition, samples may be easily taken for analysis pre and post an intervention. 
 
However, the utility of plasma is limited by the dynamic range of the concentrations of 
proteins present within it. The total protein content of plasma is around 70mg/ml 
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(Tirumalai et al., 2003). The most abundant plasma protein is albumin, which accounts 
for almost half of this, and the top 22 proteins make up 99% of the total plasma protein 
content (Tirumalai et al., 2003). It is therefore, the remaining 1% of plasma proteins 
which are of particular interest when attempting to characterise the plasma proteome, 
certainly in the application of proteomics in other branches of medicine such as in 
cancer studies, and to detect differences or changes within this which have the potential 
to act as a marker of disease. This dynamic range of plasma protein concentrations 
means therefore that the plasma proteome is the most complex proteome, and thus the 
most difficult to interrogate for biomarker discovery. 
 
Plasma does however give the opportunity for repeated sampling, for example, if a 
marker was detected and used as an endpoint in a clinical trial, samples could easily be 
taken pre and post intervention, as was the case with both of the studies in this thesis 
whereby samples pre and post treatment with intravenous A1AT were analysed.  Using 
other modalities, such as tissue from biopsy specimens or BALF are not so easily suited 
to this purpose, especially not on a large scale, without subjecting patients to invasive 
procedures.  
 
Many proteomics experiments to date have been carried out in patients with malignant 
diseases. In this scenario, a tumour may be small (in the order of cms), and plasma has 
been analysed to identify changes which may be related to the presence of this small 
tumour. The surface area of the alveoli is several orders of magnitude higher than that 
of a small tumour, in order to promote efficient gas exchange, and the volume of blood 
in contact with this significantly higher, theoretically than would be expected in the 
presence of a small neoplasm. Hence, in theory at least, the rationale for the application 
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of proteomic technology to the plasma in patients with A1ATD, where there is an 
imbalance between neutrophil elastase in the lung and its natural inhibitor A1AT, and 
therefore, in theory at least, fragments of proteolytic destruction in the lung could be 
detectable in plasma. 
 
MALDI profiling has allowed the measurement of fragments of the most abundant 
plasma proteins in these patient cohorts. There were some differences identified, 
namely fragments of A1AT and other abundant proteins, such as albumin, which 
changed significantly in patients receiving augmentation therapy. However, no robust 
biomarker has been identified from this work so far. By performing profiling 
experiments, only the surface of the plasma peptidome has been analysed, thus it is not 
surprising that the proteins which changed significantly arise from the most abundant 
plasma proteins. Other markers of inflammation which have been implicated in COPD, 
such as interleukins and matrix metalloproteinases are cytokines and chemokines and 
these are of much lower concentrations in the plasma than the proteins and peptides 
detected in the profiling experiments. Furthermore, the concentrations of these 
cytokines are several orders of magnitude lower in concentration than that of the 
abundant plasma proteins identified in these experiments – the concentrations of plasma 
proteins spans more than 10 orders of magnitude (Tirumalai et al) from albumin at 60-
80g/L to interleukin 6 at picograms per mL, and currently there is no mass spectrometer 
which has the ability to detect proteins across this complete and diverse concentration 
range. 
 
The results generated in the profiling work were unlikely to have been due to inter-
current disease states. Each of the individuals that were enrolled into the ECLIPSE 
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A1ATD were rigorously screened for the presence of comorbid conditions. 
Furthermore, each patient or control subject had undergone a CT PET scan to exclude 
underlying inflammatory and neoplastic conditions. One healthy control subject was 
excluded from further participation in the study when a possible renal abnormality was 
detected on his scan, although this was subsequently determined to be a false positive 
result. This is essential in proteomics experiments to ensure that patients are adequately 
phenotyped at the outset to ensure that any observed differences between patient groups 
reflects underlying pathophysiology of disease to be studied.  
  
6.10   Conclusions 
The profiling experiments identified fragments of A1AT which increase in intensity in 
the MALDI spectra following treatment with augmentation therapy. These 2 fragments 
are of a previously identified short segment of A1AT known as SPAAT. This is 
biologically plausible and proves the validity of the data generated by these 
experiments. However, this does not add any new information in the search for 
biomarkers in response to treatment with intravenous A1AT. The complexity of plasma 
and the presence of abundant plasma proteins may mask lower intensity signals within 
the spectra, thus making them difficult to detect, and therefore a more in depth approach 
using shotgun proteomics with abundant plasma protein depletion was may be needed 
to unmask clinically useful biomarkers.   
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CHAPTER 7  SHOTGUN PROTEOMICS 
 
 
Shotgun proteomics is a term given to the process of identifying proteins in complex 
mixtures, such as plasma, using a combination of high performance liquid 
chromatography (HPLC) and mass spectrometry. It requires the digestion of proteins 
within the complex sample, to generate peptides, which are separated using HPLC. 
Identification of the peptides generated is performed using tandem mass spectrometry 
(MS/MS). Plasma is the most complex clinical sample to analyse due to the wide range 
of protein concentrations that are contained within it, and separating and simplifying 
this with abundant protein depletion is central this process. 
 
Figure 7.1 Steps involved in the workflow of the shotgun experiments. Step 2 was not performed 
in all experiments. iTRAQ allows quantification of peptides identified with LC-MS/MS 
 
The workflow used for these experiments is demonstrated in Figure 7.1. Labelling the 
N terminus of peptides with iTRAQ allowed relative quantification of peptides in the 
samples. This experimental workflow was conducted initially on pooled samples from 
the ECLIPSE A1ATD study, with and without step 2 (the Supermix depletion step) 
followed by the EXACTLE pools, performed with step 2, and the results from 
individual experiments are presented below.  
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7.1   ECLIPSE A1ATD Post IgY14 Depletion  
This experiment was firstly performed on 40µL of pooled plasma from the ECLIPSE 
A1ATD study, processed without step 2, as shown in figure 7.1. Following iTRAQ 
labelling, the peptides were separated using mixed mode separation, which separated 
the peptides into 48 fractions based on hydrophobic properties and charge states. Mixed 
mode separation is a multimodal separation technique, based on reverse phase and 
anion exchange within a single column. Figure 7.2 shows that this was an effective 
separation technique. A similar effective separation was seen in both of the subsequent 
shotgun experiments (data not shown).  The majority of the peptides were distributed 
amongst the middle of the gradient, and these peptide containing fractions were 
combined and analysed by LC-MALDI. 
 
Figure 7.2. Survey view of the mixed mode fractions post abundant protein depletion. 
m/z is along the horizontal axis, with the spectrum number and signal intensity, measured in 
arbitrary units on the vertical axes. The majority of the peptides are distributed across the middle 
of the gradients (fractions 10-40)  
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In total there were 144 proteins identified and quantified. Peptides which were not 
labelled with iTRAQ markers, and therefore not quantifiable, were removed from 
further analysis. In addition, there were 2 peptides of keratin identified within the 
samples; these are usually contaminants within proteomics experiments and were 
therefore also removed from further data analysis. This was the case in all of the shotgun 
data analyses. 
 
In the ECLIPSE A1ATD samples, multiple comparisons between the relative iTRAQ 
reporter ion peak intensities were performed as previously described in chapter 6; 
between A1ATD at baseline compared to A1ATD post treatment, COPD and healthy 
control subjects, and between COPD and healthy control subjects. However – the most 
clinically relevant analyses to determine a response to treatment with intravenous 
A1AT were those between patients with A1ATD pre and post treatment and compared 
to healthy control subjects, and these will be presented in the remainder of this series 
of results. 
 
The most abundant proteins were albumin (135 peptides), transferrin (84 peptides), 
A1AT (53 peptides) and fibrinogen (21 peptides). Post treatment with augmentation 
therapy, the iTRAQ data show that levels of A1AT increase, with a median ratio of 
baseline to the end of 3 months of treatment of 2.7, proving the validity of subsequent 
results generated as it has been well documented that total A1AT levels rise with 
treatment with intravenous A1AT (Wewers et al., 1987). 
 
However, as the abundant protein depletion step was not complete, as shown by the 
presence, identification and quantification of abundant plasma proteins such as 
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albumin, A1AT and fibrinogen, the proteome coverage of this series of experiments 
was limited. The experiment was repeated with the extra level of abundant protein 
depletion using a Supermix column as demonstrated by step 2 in Figure 7.1, and this 
was then replicated with the EXACTLE pooled samples. 
 
7.2  ECLIPSE A1ATD Post Supermix Depletion 
 
The experiment was performed using 100µL of plasma which was depleted using the 
IgY14 method described in chapter 2.10.1, followed by the second level of depletion 
using the Supermix column (step 2, 2.10.2), to increase abundant protein depletion. 
 
In total, there were 362 peptides from 77 unique proteins identified and quantified, and 
these are presented in Appendix II. Peptides which were not labelled with iTRAQ 
reagent (2) were removed from further analysis. Of the labelled and identified peptides, 
there were 120 peptides from albumin, 58 peptides from transferrin and 28 from alpha-
2 macroglobulin. These are again abundant plasma proteins, which should theoretically 
have been removed during the IgY14 depletion step; the depletion is only up to 95% 
efficient, according to the manufacturer’s specifications – and hence some peptides 
from these highly abundant proteins may still be present. The same patient group 
comparisons were made as described in 7.1. These are demonstrated in the waterfall 
plots below (Figures 7.3-7.5) 
 
Post treatment with augmentation therapy, A1AT increases, and the ratio of pre to post 
treatment is 2.38↑. When comparisons are made between healthy control subjects and 
patients with A1ATD, A1AT levels are 2.1 times higher in the healthy controls. 
Following treatment with intravenous A1AT, this difference between patients with 
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A1ATD is removed and the ratios between the groups is 0.87 (levels higher in healthy 
control subjects). 
 
Two further potentially interesting proteins changed with augmentation therapy; these 
were pigment epithelial derived factor (PEDF) and corticosteroid binding globulin 
(CBG). PEDF was elevated in the A1ATD baseline samples compared to healthy 
control subjects (9.29), and reduced but remained elevated post treatment (3.38), and 
in patients post treatment with intravenous A1AT, decreased (2.74). CBG was elevated 
in patients with A1ATD at the start of treatment compared to healthy control subjects 
(5.54 ↑), and reduced following treatment with augmentation therapy when compared 
to baseline in patients with A1ATD (2.43↓). 
 
 
Figure 7.3. Waterfall plot demonstrating the pre-treatment compared to the post treatment ratios 
of identified peptides from the ECLIPSE A1ATD study 
The number in brackets denotes the number of peptides identified and quantified from 
each protein. The labelled proteins are proteins which changed significantly either in 
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this or in the subsequent analyses. The ratios of peak intensities were log transformed 
to base 2; an increase of 1 indicates a doubling of the intensity, and -1 denoted a halving. 
Figure 7.4. Waterfall plot demonstrating the median ratios between the ECLIPSE A1ATD patients 
pre-treatment and healthy control subjects 
 
 
Figure 7.5 Waterfall plot demonstrating the median ratios between the ECLIPSE A1ATD patients 
post treatment and healthy control subjects. 
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7.3  EXACTLE Post Supermix Depletion 
There were 161 peptides from 57 proteins identified and quantified in this experiment 
and these are presented in Appendix II. As there were still abundant plasma proteins, 
including A1AT and albumin, in the ECLIPSE A1ATD following a single IgY14 
depletion strategy, the plasma from the EXACTLE study were doubly depleted using 
the IgY14 columns prior to the second depletion step using the Supermix column. 
 
There were 2 analyses performed on the data generated; a comparison of pre and post 
treatment in the active drug treated group of patients, and pre and post in the placebo 
treated patient group. The results are presented in the 2 waterfall plots below, in Figures 
7.6 and 7.7. 
 
Figure 7.6 Waterfall plot demonstrating the ratios of post to pre-treatment in the EXACTLE 
pooled plasma samples in the group of patients on Prolastin (Intravenous A1AT).  
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Figure 7.7 Waterfall plot demonstrating the ratios of post to pre-treatment in the EXACTLE 
pooled plasma samples in the group of patients on placebo infusions.  
 
 
A1AT again demonstrates a rise post treatment with Prolastin, with a ratio of post 
treatment to pre-treatment of 3.5. There were 2 peptides of A1AT identified and 
quantified and these should in theory have been removed by the preceding depletion 
steps. However, these demonstrated a rise in the patients who received active drug and 
again confirmed the validity of the results generated. There was no significant change 
in A1AT in the patients who received placebo infusions, as demonstrated in Figure 7.7 
above. There was little change in the plasma proteome post augmentation therapy as 
was demonstrated with the profiling experiments– most of the proteins on the waterfall 
plots fall within a narrow range implying no significant change with treatment. 
 
CBG behaved differently in the EXACTLE experiments to those from the ECLIPSE 
A1ATD; instead of a reduction post augmentation therapy as was demonstrated in the 
ECLIPSE A1ATD experiments, it increased in the EXACTLE samples, with a fold 
change of 1.5. In the EXACTLE group of patients who received placebo infusions, 
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there was no significant change when the baseline and 6 month analyses were 
performed (fold change 0.91). 
 
PEDF, however, demonstrated the same effect in the EXACTLE samples, as in the 
ECLIPSE A1ATD -  decreasing with treatment when the baseline and either 3 or 6 
month samples were analysed, whist remaining unchanged in the patients who received 
placebo infusions (fold changes 2.45 in the active drug group versus 0.89 in the placebo 
treated group). Therefore, as 2 independent experiments on independently collected 
pools of samples indicated the same change in this protein, PEDF was studied in greater 
detail as a possible marker of response to treatment in patients with A1ATD, and 
measured using a sandwich ELISA (Chemicon International CYT 420) on individual 
plasma samples from both studies (see below). 
 
Other potential candidates included angiotensinogen and tetranectin (both increased in 
EXACTLE samples in patients receiving placebo, whilst remaining unchanged in 
patients on intravenous A1AT), cystatin A (which decreased in patients receiving 
placebo infusions in the EXACTLE samples, whilst not changing significantly in 
patients on intravenous A1AT but was not detected at all in the ECLIPSE A1ATD 
samples) and complement C2 (in the EXCATLE samples patients in the placebo group 
did not demonstrate any significant change after 6 months of treatment, whilst in 
patients receiving intravenous A1AT the levels were higher). 
 
7.4   Pigment Epithelium Derived Factor (PEDF) 
The MS/MS spectrum for the PEDF peptide identified in the ECLIPSE A1ATD pooled 
samples is shown below in Figure 7.8. It shows both the peptide fragmentation and the 
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iTRAQ reporter ions indicating that PEDF was higher in patients with A1ATD pre-
treatment and decreased with treatment. 
 
Figure 7.8 PEDF fragment m/z 1932 from the pooled ECLIPSE A1ATD samples. 
114 = A1ATD patients at baseline 
115 = A1ATD patients after 3 months of treatment 
116 = COPD 
117 =Normal healthy control subjects 
 
The reduction in PEDF post treatment looked promising as a biomarker and this was 
confirmed by the EXACTLE samples. Therefore PEDF concentrations were measured 
in the UK samples from the EXACTLE study and all of the patients in the ECLIPSE 
A1ATD study as described in chapter 2.10.9. The results are shown in Tables 7.1 and 
7.2 for the ECLIPSE A1ATD and EXACTLE samples respectively. There was no 
significant difference between PEDF in healthy control subjects compared to patients 
with A1ATD, and there was no significant reduction post treatment, in either the 
samples from the ECLIPSE A1ATD study or the EXACTLE study, as was suggested 
by the data from the shotgun experiments. In addition, there was no significant 
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difference in the values measured from the patients with A1ATD from the 2 separate 
clinical trials.  
 
ECLIPSE A1TATD Median 
 
IQR 
A1AT Baseline 14.6 9.6 18.6 
A1AT 3 months  15.1 12.8 18.0 
COPD 15.9 13.7 16.9 
NHC 14.4 11.7 15.7 
 
Table 7.1 Median values and interquartile ranges for PEDF concentrations, measured in 
micrograms per mL, for patient groups in the ECLIPSE A1ATD study. A1AT Baseline is the 
median value for A1ATD patients pre-treatment, A1AT 3 months is the median value for A1ATD 
patients after 3 months of augmentation therapy, COPD is the median value for the group of 
patients with COPD and NHC is the median value for healthy control subjects. 
 
 
 
EXACTLE Median IQR 
Placebo Baseline 12.7 9.5 15.4 
Placebo 6 months 14.4 11.0 17.5 
Treatment Baseline 12.3 10.8 19.0 
Treatment 6 months 15.5 11.1 20.6 
 
Table 7.2 Median values and interquartile ranges for PEDF concentrations, measured in 
micrograms per mL, for patients in the EXACTLE study. Placebo baseline and end of treatment 
are the median values for the placebo treated patients at baseline and after 6 months of placebo 
infusions. Treatment base and end are the median values for the patients receiving active drug at 
baseline and after 6 months of treatment.  
 
 
7.5   Discussion 
 
The shotgun proteomic experiments were intended to provide an in depth analysis of 
the plasma proteome to be undertaken in order to determine whether there were any 
significant effects with intravenous replacement therapy in patients with A1ATD. As 
was demonstrated during the profiling series of experiments, the majority of the 
detectable plasma proteins remained unchanged following treatment with augmentation 
therapy. However, despite abundant protein depletion strategies, it was not possible to 
interrogate deeper into the plasma proteome.   
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7.5.1  Use of Pooled Samples 
 
Shotgun proteomics investigates further into the plasma proteome, and analyses the 
digested peptides (in this instance tryptic digests) rather than endogenous plasma 
peptides. Such experiments require several steps, and are very time consuming and 
therefore it becomes difficult to perform these on individual plasma samples (72 pairs 
of samples were utilised from the EXACTLE study). Pools were therefore used for 
further analysis. In this series of experiments, 2 separate groups of pools were created 
– samples from the ECLIPSE A1ATD study and in addition pools from the EXACTLE 
study. Equivalent volumes of individual samples were added to create the pools. The 
aim of the shotgun experiments was to uncover potential candidate biomarkers which 
change in response to a treatment or intervention (in this instance to intravenous 
A1AT), which could then be validated using an alternative method, carried out on 
individual samples, such as by ELISA.  
 
The use of pooled samples for in depth analysis is not universally accepted. Some 
groups feel that pooled samples should be avoided entirely, and that only individual 
samples should be analysed. This allows full characterisation of the studied proteome 
and allows biological and methodological differences to be studied. (Westermeier et 
al., 2008). Conversely, others, such as Diz et al (2009), have studied the effects of 
undertaking proteomics experiments on pooled samples, and they concluded that this 
is a valid approach to take (Diz AP et al., 2009). With the complexity of the shotgun 
experiments, and the amount of time taken to doubly deplete plasma, the quantity of 
plasma required and the instrument time needed to perform LC MALI MS/MS, it was 
not feasible to perform this on each individual sample. If single samples from each 
group had been randomly selected for analysis, they may not have been representative 
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of the group to which they belonged, and thus comparisons may have been inaccurate 
and the results invalid. Therefore, pooling samples was the approach taken. 
Furthermore, Diz and colleagues proved during their analyses that this approach could 
make differences and similarities between groups easier to detect as the effects of 
biological variation will be removed (Diz et al., 2009). 
 
In this series of experiments, using 2 separate pools of samples – ECLIPSE A1ATD 
and EXACTLE, allowed confirmation of changes identified on an independent set of 
samples, adding further evidence to any changes discovered. Examples of this from this 
work include the decrease in PEDF with augmentation therapy, which was elevated in 
patients in the ECLIPSE A1ATD study with A1ATD at baseline when compared to 
healthy control subjects, and deceased with treatment. The duration of treatment did 
not affect the results of the experiments as a decrease was also seen in patients in the 
EXACTLE study who received active drug, whereas no change was seen in patients 
who received placebo.  
 
Despite its many advantages, the use of pooled samples, however, has disadvantages, 
and one such example is the problem that one individual may be an outlier, and 
subsequently affect the results from the entire pooled sample. This may have been the 
reason for the conflicting results found with CBG, which decreased with augmentation 
therapy in the ECLIPSE A1ATD study, but behaved in the opposite way and increased 
in the EXACTLE study. It is not clear why this protein behaved differently in these 
separate pools of samples, however, one patient who was enrolled in to the ECLIPSE 
A1ATD study died 18 months after the end of the study of a malignancy, which was 
either a neoplasm of the head of the pancreas or bile duct, and this was complicated by 
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an episode of decompensated liver failure. As this pool was made of only a small 
number of patients (n=8), the data in the pooled sample created could have been skewed 
by anomalous results in this individual. This individual had undergone 2 separate CT 
PET scans according to the study protocol (at baseline and following 3 months’ of 
treatment) which had not identified any abnormality, and his liver function tests during 
the study had been within the normal range. To answer this question specifically, further 
work could be undertaken to measure the levels of CBG in this individual at screening 
and after treatment to determine whether or not this individual was responsible for the 
effect seen. An alternative explanation could be that the results demonstrated may have 
been false positive results and that CBG remains unchanged following augmentation 
therapy. 
 
7.5.2   PEDF 
PEDF is a member of the serpin supergene family, although unlike other members of 
this family of proteins, such as A1AT, it does not have protease inhibitory activity 
(Filleur et al., 2009).  It has a number of properties including being anti-angiogenic, 
anti-tumourogenic and is neurotrophic. It was first discovered in foetal retinal pigment 
cells, but has since been identified in a number of other different tissue varieties 
including liver, skeletal muscle, heart, ovary and lung (Li et al., 2015). 
 
In the field of respiratory disease, PEDF has been implicated in the pathogenesis of a 
number of conditions including idiopathic pulmonary fibrosis (IPF), non-small cell 
lung cancer and more recently in COPD. Cosgrove et al in 2004 discovered PEDF 
concentrations to be elevated in the fibroblastic foci of patients with idiopathic 
pulmonary fibrosis when measured using a microarray, and in BALF fluid of IPF 
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patients when compared to control subjects when this was measured using an ELISA 
(Cosgrove et al., 2004). This was felt to be due to the antiangiogenic actions of PEDF. 
 
In tumours, the antiangiogenic properties demonstrated by PEDF may have a protective 
effect. Furthermore, in cancers where PEDF expression is reduced, there is a greater 
propensity to tumour progression to metastatic disease and therefore a worse prognosis, 
making treatments targeting PEDF an exciting avenue of research. In non-small cell 
lung cancer (NSCLC), where PEDF levels were reduced, this was of prognostic 
importance, and patients had an increased rate of mortality (Zhang et al., 2006). These 
authors studied the levels of PEDF and PEDF mRNA in 91 patients with non-small cell 
lung cancer who had undergone surgical resections of their tumours. They found lower 
total levels of PEDF in 57% of patients, and PCR analysis of mRNA showed a 
significantly lower concentration in cancer tissue when compared to healthy tissue 
taken at the same time as the surgical resection. Furthermore, there was a significantly 
lower survival in the patients with lower levels of PEDF (Zhang et al., 2006). 
 
In 2009, Chen et al used 77 NSCLC tissue samples to measure PEDF using quantitative 
PCR. They compared results from the cancer tissue to those obtained from biopsy 
samples collected at the same time from normal sections of lung. They demonstrated 
that there was a significant reduction in PEDF in patients who had evidence of lymph 
node involvement (p = 0.007) and that there was a significantly reduced survival in the 
group with lower PEDF levels (p = 0.0459) (Chen et al., 2009). The authors concluded 
that this observation was due to the ability of PEDF to perform an antiangiogenic role, 
and this is lacking when levels of PEDF are low, thus promoting tumour growth and 
subsequent spread. 
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In COPD, Li et al (2015) explored the relationship between PEDF and rat pulmonary 
epithelial cells exposed to cigarette smoke, and found that there was a significant rise 
in the levels of PEDF in the cells compared to those of control samples which had not 
been exposed to cigarette smoke. The authors subsequently measured PEDF levels in 
the plasma of 80 subjects – 10 smokers with normal spirometry, 50 stable state patients 
with COPD and 20 healthy control subjects. This was performed using a multiplex 
enzyme-linked immunosorbent assay, which also included measurements of CRP, IL6, 
IL8 and TNF alpha. They demonstrated that PEDF levels were increased in the plasma 
of patients with COPD compared to healthy control subjects and healthy non-smokers 
(551 +/-23.6 ng/mL in the COPD patients, versus 378 +/- 27.9 ng/mL in the non-
smokers and 439ng/mL in the healthy smokers). PEDF levels correlated with CRP, Il6, 
IL8 and TNF although not with disease severity (Li et al., 2015). This was felt to merit 
further investigation as to the potential role of PEDF in the pathophysiology of COPD. 
To date, however, there has been no published data looking specifically at PEDF in 
patients with COPD secondary to A1ATD.   
 
It was hypothesised from the shotgun data that in patients with A1ATD, the deficiency 
in a member of the serpin gene superfamily results in a compensatory rise in other 
members of this supergene family, namely PEDF. Therefore, PEDF was measured in 
individual samples from ECLIPSE A1ATD and in the UK arm of the EXACTLE trial 
using an ELISA which failed to confirm the findings from the shotgun proteomics 
experiments; there were no significant differences pre and post treatment (14.6 (IQR 
9.6 -18.6) vs 15.1 (IQR 12.8-18.0 µg/mL) and there were no significant differences 
between patients with A1ATD and healthy control subjects (14.4 vs 14.6 µg/mL). There 
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are a number of potential reasons for this observation. Firstly, the results could have 
been false positive results, although as the protein was elevated in both the ECLIPSE 
A1ATD and EXACTLE samples at baseline, and decreased with treatment, this would 
be less likely.  It could be due to fact that the peptides from PEDF from the mass 
spectrometry were only fragments of the entire protein, and therefore the peptides 
which changed significantly in the shotgun data were surrogate markers for the entire 
protein. The ELISA kit used (Chemicon International CYT 420) contains mouse 
monoclonal antibody and measures the levels of the entire protein within a sample. In 
the shotgun experiments, there was only 1 peptide from PEDF that was detected in the 
ECLIPSE A1ATD samples and there were 4 from the EXACTLE samples – these were 
found towards the C terminus of the PEDF protein. The amino acid sequence of the 
PEDF protein and the fragments identified form the EXACTLE samples is shown 
below in Figure 7.9. 
 
Figure 7.9. Amino acid sequence of PEDF. The sequences in red were identified in the EXACTLE 
pooled samples.  
 
The single peptide identified from the ECLIPSE A1ATD samples was not one of the 4 
peptides detected in the EXACTLE experiments. The protein scores were 106.2 for the 
ECLIPSE A1ATD and 197.0 for the EXACTLE pooled samples, which are both well 
above the pre-determined cut off score, hence the rationale for performing the ELISA. 
However, the data was normalised to generate the waterfall plots above, and within the 
EXACTLE samples, this may have enhanced the reduction post treatment, and be a 
reason that the ELISA results did not support the results from the shotgun data. 
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7.5.3   Corticosteroid Binding Globulin 
Corticosteroid binding globulin is a further member of the serine protease inhibitor 
family (serpin) although unlike A1AT, it does not have protease inhibitory effects, but 
has important functions with regards to the transport of glucocorticoids (van Gent et 
al., 2003). From the shotgun experiments it looked like a promising candidate for 
further work in patients with A1ATD. However, in the 2 sets of samples analysed, it 
behaved in the opposite way – there was a fall in the ratio measured in the ECLIPSE 
A1ATD study and a rise in the EXACTLE study samples. There were 3 peptides from 
CBG in the ECLIPSE A1ATD study and 2 peptides from CBG from the EXACLTE 
study – the peptides were identified were not the same from both series of experiments. 
It was hypothesised after the ECLIPSE A1ATD samples were analysed that there could 
be a compensatory rise in this member of the serpin gene super family in patients with 
A1ATD, and that this was normalised when patients received augmentation therapy. 
However, this was not supported by the EXACTLE samples, and the hypothesis was 
limited due to the lack of protease inhibition actions of CBG. 
 
7.5.4  Other Potential Candidate Proteins 
There were a number of other proteins that could have been analysed in further detail 
and these include cystatin A, angiotensinogen, tetranectin, and complement C2. As 
these proteins were not detected in 2 independent experiments, they were not prioritised 
for further study within my research project. However, of these, angiotensinogen, which 
is also a further member of the serpin gene family, and complement c2, are described 
below. 
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Angiotensinogen is produced almost entirely by the liver, and like PEDF, it has no 
protease inhibiting activity (Shrikrishna et al., 2012). However, it is an integral part of 
the renin angiotensin system. Once it is cleaved by renin, angiotensinogen produces 
angiotensin I which is converted to angiotensin II by angiotensin converting enzyme 
(Shrikrishna et al., 2012). During this process, other products such as kinins are 
generated which may have localised effects within the lungs as well as within skeletal 
muscle, and these may produce some of the extra-thoracic manifestations of COPD 
such as skeletal muscle dysfunction. In the ECLIPSE A1ATD samples, 
angiotensinogen was lower in patients both pre and post treatment when compared to 
healthy control subjects, and did not change significantly when patients were compared 
pre and post treatment. Within the EXACTLE samples, angiotensinogen remained 
unchanged in the patients who received the active drug, whilst increased at the end of 
the placebo infusions. Due to these inconsistencies, and due to time and sample 
availability, angiotensinogen was not studied in any further detail, although could 
represent a possible target for future analysis. 
  
The complement system is a complex system which is an integral part of the immune 
system. Complement C2 forms part of the classical and lectin pathways, and may be 
made by type II pneumocytes within the lungs (Pandaya et al., 2014). A number of 
inflammatory cytokines, including IL6 and TNF α may initiate complement factor 
synthesis within the lung micro-environment. However, unlike other parts of the 
complement system, including C3, C3a and C5, there have been no studies 
demonstrating the role of complement C2 in the pathogenesis of COPD (Pandaya et al., 
2014). In the shotgun experiments, complement C2 was lower in patients with A1ATD 
at baseline compared to post treatment levels, and was higher in healthy control subjects 
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compared to A1ATD patients. In the EXACTLE samples, patients in the placebo group 
did not demonstrate any significant change after 6 months of treatment, whilst in 
patients receiving intravenous A1AT the levels were higher.  
 
7.5.5  Protein Depletion 
In the first shotgun experiment performed on the ECLIPSE A1ATD, 40μL of plasma 
in each pool were depleted of the 14 most abundant proteins using the IgY14 columns, 
and there was no further depletion using the supermix column. The LC-MALDI results 
revealed that the depletion step was not adequate as there were fragments of the 14 
highly abundant proteins detected despite attempts at its removal. 
 
The shotgun experiment was repeated on 100μL of plasma from the ECLIPSE A1ATD 
samples with the extra depletion step using the supermix column. Again, the most 
fragments detected were from common plasma proteins, namely albumin, A1AT, 
haptoglobin and fibrinogen. 
 
In the EXACTLE shotgun experiment, the 100μL of pooled plasma was doubly 
depleted (same methodology used twice on the samples to ensure abundant depletion) 
using the IgY14 method, as recommended by the manufacturer. In this instance, the 
protein depletion was effective, but the amount of protein remaining after the supermix 
step was low at 18µg, which is lower than reported by Quian et al (2008) who used the 
IgY12 columns rather than IgY14, and recovered 55 µg of plasma from 225µL (Quian 
et al., 2008). This could mean that valuable information was lost through more 
depletion of proteins bound to the abundant proteins, and this may account for the lower 
number of labelled peptides and proteins studied in the EXACTLE samples compared 
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to the ECLIPSE A1ATD samples. This resulted in too little material left for the 
sensitivity of the mass spectrometer to identify sufficient numbers of peptides to 
uncover clinically significant differences.  
 
Plasma protein concentration ranges from 60-80g/L. Albumin is the most abundant 
plasma protein at a concentration of 35-50g/L, and the lowest concentrations include 
cytokines and chemokines whose concentrations are up to 10 orders of magnitude lower 
than this. Therefore, it is difficult for any mass spectrometer to analyse these proteins, 
which are at much lower concentrations in the plasma, in the presence of more abundant 
plasma proteins. This is the rationale for using commercially available products in order 
to facilitate abundant protein depletion  – ranging from simple resins which bind only 
to albumin, to more complex columns with polyclonal antibodies to some of the 
abundant plasma proteins (such as the IgY14 columns used here). Whilst these methods 
have good results, there is always the theoretical risk that because albumin acts as a co-
transporter of other, smaller proteins, valuable information may potentially be lost from 
the sample. With each additional step in a complex experiment, such as here with a dual 
depletion strategy, there is a risk of non-specific protein binding and subsequent loss of 
information or of contamination. Ideally, a sample preparation with the fewest possible 
steps involved whilst still providing effective abundant protein depletion would 
constitute the best possible scenario. In addition, there is no series of experiments that 
can provide information and coverage of an entire proteome – in COPD that could 
involve tissue – from lung or skeletal muscle, in addition to plasma, sputum, exhaled 
breath condensate and urine proteomes. 
Overall, in this series of experiments, peptides from 23 proteins were identified and 
quantified in both the ECLIPSE A1ATD and EXACTLE pooled samples, and overall, 
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the abundant plasma protein depletion was effective and allowed identification and 
quantification of proteins that were not identified during the profiling experiments due 
to their signal potentially being masked by abundant plasma proteins. The pie charts in 
Figure 7.10 demonstrate that most of the proteins originate from the extracellular 
compartment and that the nuclear and cytoplasmic proteins which are of more interest 
as potential markers of tissue leakage only make up a small proportion of this.  This 
implies that very few peptides from tissue leakage were identified during these 
experiments. 
 
Figure 7.10 Pie charts showing the proportions of peptides and their cellular 
compartmentalisation.  
 
 
 
7.6   Conclusions 
The shotgun experiments were undertaken in order to analyse the plasma proteome in 
greater detail than was possible during the profiling work. Experiments of this sort, with 
multiple complex steps, would take months to optimise further, due to the increased 
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level of complexity and number of stages involved, and would require further analyses 
that were beyond the time frame of this thesis. An experiment of this length could take 
months to optimise each step, and additionally have a resource implication in terms of 
plasma and instrument time. This series of experiments did, however, in agreement with 
the profiling work, demonstrate that the majority of the most abundant layer of the 
plasma proteome remained unchanged following treatment with intravenous A1AT in 
patients with A1ATD. Whilst PEDF initially looked promising as a potential candidate 
worthy of further investigation, this was not confirmed by the ELISA analysis. Overall, 
no clinically relevant marker of response to treatment was identified during the shotgun 
experiments. It has previously been demonstrated that despite abundant protein 
depletion, it is not possible to identify and quantify other markers – such as cytokines, 
which have previously been studied in the pathophysiology of COPD. 
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CHAPTER 8  DISCUSSION 
 
 
The ADAPT project in Birmingham holds the UK registry and is the UK national centre 
for patients with A1ATD and respiratory disease. Patients with liver related 
complications of their A1ATD are not routinely referred to and followed up at this 
centre. The ADAPT project however allows the collection and analysis of unique data 
into the respiratory complications of this genetic condition, and allows patients to be 
enrolled in clinical trials of therapy. Such studies have included the ECLIPSE A1ATD 
and EXACTLE commercially funded clinical trials, in addition to smaller independent 
studies and research, such as the in vitro ionophore and protease work presented within 
this thesis. 
 
The patients who attend this centre for annual review are very well characterised in 
terms of demographic data, health status (measured using the SGRQ, CAT and SF36) 
and lung physiology, which is crucial when undertaking biomarker research, and when 
aiming to determine and interpret meaningful outcomes. This is because COPD 
secondary to A1ATD, like that seen in usual COPD, is a heterogeneous condition, with 
different rates of decline and different phenotypes, despite having a common 
underlying genetic basis (Dawkins et al., 2009). 
 
Proteomic technologies have evolved and been widely utilised over the last few 
decades, since the term proteomics was first introduced in the 1990s, despite the study 
of proteins pre dating the introduction of this term. This widespread use is clearly 
demonstrated through the rapid increase throughout the last 2 decades in the number of 
publications accessible through Pubmed and other on line search engines using this 
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technology. These approaches have been used in a vast range of different disease 
processes including COPD, although their greatest use has been in the field of oncology 
in the hunt for biomarkers of disease which could be used clinically to monitor and treat 
the disease. 
 
A1ATD introduced the protease/antiprotease hypothesis in to the pathogenesis of 
COPD. In this condition, individuals with the PiZZ genotype have a genetically 
determined low plasma levels of an important protease inhibitor, A1AT, which can 
predispose to the unopposed action of proteases, including NE, in the lung, leading to 
the early onset of emphysema. The rationale and hypotheses therefore for the series of 
experiments conducted within this thesis were to try to detect the effects of this putative 
protease/antiprotease imbalance by analysing plasma from patients with A1ATD pre 
and post treatment with the aim to detect fragments of proteins by plasma profiling. 
 
8.1 Plasma Profiling 
 
The 2 clinical trials of augmentation therapy presented in this thesis were the ECLIPSE 
A1ATD study and the EXACTLE study. Patients in the ECLIPSE A1ATD study 
received infusions for a total of 12 weeks, whereas in the EXACTLE study, patient 
samples were obtained from a 2 year study of therapy with A1AT or placebo, using 
samples taken at an interim point of 6 months. In a previous short-term study, only 6 
weeks of therapy was required to show a reduction in sputum inflammatory signals, 
such as IL8 and LTB4 concentrations (Stockley et al., 2002). Both the EXACTLE and 
ECLIPSE A1ATD samples were taken after a longer treatment time period than this 
short study. Analysing the 2 sets of independent samples allowed a discovery phase to 
be undertaken, followed by a validation phase, in independent experiments, to gain 
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further confidence in the subsequent data generated.  It was also the rationale behind 
analysing the 6 month samples from the EXACTLE study, as this was the nearest time 
point at which samples were available to the 3 month duration of the ECLIPSE A1ATD 
study. 
 
It was possible to optimise plasma profiling techniques to study the samples from these 
clinical trials, and to obtain reproducible sample preparation and analysis methods with 
low intra-experimental CVs. The plasma and urinary peptidomes of patients with 
A1ATD pre and post augmentation therapy have been analysed and studied in this 
work. Mass spectra were generated using MALDI profiling techniques, following on 
from preliminary work undertaken using SELDI profiling. Significant differences were 
identified using LC-MALDI. However, the majority of the differences identified were 
fragments of the most abundant plasma proteins, namely A1AT, albumin and the 
complement system, and further work was required in order to attempt to reveal 
potential biomarkers of neutrophil elastase activity in the tissues.  
 
An acceptable CV for any proteomics experiment is ~20%, (Bowler et al., 2006b) and 
each of the techniques I have used has had a similar CV when the QC sample has been 
analysed, during each separate experiment. This figure is also the accepted CV quoted 
by most manufacturers of SELDI proteinchips. Some of the published work carried out 
so far in COPD, for example by Bowler et al (2006 a) who used SELDI proteinchips 
on the plasma of 30 patients with COPD and 30 healthy control subjects, obtained CVs 
of almost 70% (Bowler et al., 2006 a). This highlights the difficulty to perform such 
experiments reproducibly, and optimisation of methods at the outset, to ensure 
reproducibility, is a crucial initial step. This is necessary as these techniques are 
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extremely sensitive to very small intra experimental changes, which would make 
interpretation of results difficult with high variability. 
 
Furthermore, attention to detail at every step in the process is crucial – from sample 
collection, to sample processing and storage, to the number of freeze thaw cycles the 
samples have been exposed to. Mitchell et al (2005) undertook a study to determine the 
effects of repeated freeze after thaw cycles had on the quality of data subsequently 
generated using plasma samples. Following ACN precipitation of peptides, they were 
able to demonstrate that following 2 or more freeze thaw cycles, there was a trend 
towards a difference in peak intensities in the MALDI spectra generated, with samples 
that had more than 2 freeze thaw cycles having lower peak intensities in the spectra, 
whereas the duration of time spent with the samples stored below -700C had little effect 
on the subsequent analysis. It was felt that the repeated freezing and thawing of samples 
led to degradation of proteins and peptides contained within them, and hence the 
differences in terms of lower peak intensities they identified in the subsequent MALDI 
spectra (Mitchell et al., 2005).   The samples utilised in this thesis analysis had been 
taken and stored in the same way, and stored in cryovials at -800C, and the number of 
freeze thaw samples minimised to maintain the quality of the samples. During the 
method optimisation phase, pooled samples were created and these used to perform 
experiments, to maintain the integrity and quality of the peptides and proteins in the 
remaining individual clinical samples. In addition, the number of freeze thaw cycles 
each sample underwent was minimised and no clinical sample was subjected to this on 
more than 2 occasions. 
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Two methods were selected to profile individual patient samples – WCX beads and 
SPE C8 cartridges, as they gave the most information and were the most reproducible.  
The supel tip, SPE C8 cartridges, C8 and C18 bead methods utilise the same underlying 
principle – namely reverse phase. The SPE C8 cartridges were the optimum reverse 
phase approach to use, as the spectra contained the most peaks and the lowest CVs of 
the reverse phase techniques. 
 
The WCX beads gave more information above 4,000 Da, whereas information using 
the reverse phase approach with the C8 cartridges was limited to a lower mass range, 
so the approaches were complementary, although there was also a significant degree of 
overlap with the data produced. However, differences at higher mass ranges are more 
difficult to identify using MS/MS, as the proteins/peptides are too large to generate 
interpretable fragment patterns and therefore identify using this approach. The LC-
MALDI data generated from these samples, unfortunately, did not give any 
identifications above 4000Da.  
 
This has demonstrated the difficulties of undertaking work on biomarker discovery on 
plasma samples. Plasma is the most complex proteome to study, despite being 
potentially the most informative. An alternative approach would be to undertake 
proteomic analysis of lung tissue. This could be undertaken from samples obtained 
when patients undergo lung transplantation (proteomic analyses to date have largely 
been done on patients with concurrent malignancy with tissue samples taken from areas 
away from the tumour) as this would provide information at the site of lung tissue 
damage and potential biomarkers would not be hidden by abundant plasma proteins. 
This is potentially more applicable to patients with A1ATD rather than those with usual 
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COPD as patients with A1ATD tend to be younger when they develop symptoms, 
which may result in patients having end stage disease at an earlier age and thus more 
likely to be considered for lung transplantation. Any changes detected at this time using 
tissue analysis could potentially be transformed into serological tests for future study. 
 
8.2  SELDI Compared to MALDI Profiling 
 
SELDI analysis techniques differ from MALDI techniques in that SELDI uses 
Proteinchips and samples are incubated directly on to the surface of the 
chromatographic chip before matrix addition and generation of mass spectra. In 
MALDI experiments, the samples are prepared prior to being transferred to a plate 
where they are overlaid with matrix prior to analysis. The initial SELDI sample 
analyses presented in this thesis generated data across a wide mass range – from 1000 
to 120000 Da. It was possible to detect peaks within the SELDI spectra with m/z ratios 
greater than 100,000Da. Within the MALDI spectra, the data generated was more 
limited; the majority of the peaks within these spectra were concentrated below 
5000Da, therefore limiting the search to the endogenous plasma peptidome, rather than 
the entire proteome. Although it would have been difficult to identify larger proteins, 
which would have required a purification followed by digestion step, there were few 
peaks in the MALDI spectra detectable above 10,000 Da. This was despite the use of 
different matrices; SPA in particular has previously been used in the detection of larger 
proteins, and was the matrix of choice for the proteinchips used in the previous SELDI 
experiments. This was therefore the matrix used with the proteinchips, both in the 
preliminary work and following the move to a more sensitive mass spectrometer during 
this series of experiments. In changing mass spectrometer, conducting the same 
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experiment on proteinchips yielded a similar number of peaks within the spectra as with 
the Ciphergen PBS IIc mass spectrometer, however the mass range became more 
limited with few peaks observed above 10,000Da. This was also the case when other 
sample preparation techniques besides proteinchips were utilised with SPA as the 
matrix. The change to the Bruker Ultraflextreme from the Ciphergen PBS IIc was 
thought to be important because of improved mass resolution, however the more 
sophisticated analyser did not seem to work as well at the higher mass range. At that 
point it was not possible to change back to the previous mass spectrometer as it had 
been decommissioned. This resulted in information from the higher mass range being 
lost, but the sample preparation techniques used allowed more data to be generated in 
the mass range where subsequent identifications were possible.  
 
8.3  Proteomics in Malignancy 
Using plasma profiling in the search for biomarkers in some malignant conditions has 
led to the transfer of investigations from the research arena to routine clinical practice. 
Initially, there was anticipation and high expectation that proteomics would offer great 
success in the field of biomarker discovery. However, despite this, there have been few 
clinically useful biomarkers identified this way. This is in part due to the volume of 
data produced during experiments and need for the development of bioinformatics 
platforms to interpret the data, in order to determine which of the hundreds of proteins 
and peptides measured are of clinical relevance. 
 
An example of the translation of clinical experimentation into clinical practice this is 
the use of the OVA 1 test in ovarian cancer. This is a combination of 5 proteins, namely 
CA 125 II, transthyretin, β2-microglobulin, apolipoprotein A1 and transferrin, which 
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have formed the basis of a serological test which can be used in patients with a 
suspected ovarian malignancy. Measurements of these 5 proteins are analysed using an 
algorithm to determine the likelihood of the patient having a malignancy (Useland et 
al., 2011). This test has been approved by the FDA for use in clinical practice, and is 
superior to the measurement of CA 125 alone, with an increase in sensitivity 60% to 
89% and an increase in negative predictive value from 90 to 94% (Abraham, 2010). 
 
Within the field of respiratory medicine, Veristrat is a serological test developed to be 
used in patients with non-small cell lung cancer. Taguchi et al used MALDI technology 
to generate algorithm based on 8 specific peaks in MALDI spectra, which may predict 
the outcome of treatment with epidermal growth factor (EGFR) tyrosine kinase 
inhibitors (TKIs) (Taguchi et al., 2007). They analysed serum and plasma taken pre-
treatment with either erlotinib or gefitinib in 2 separate patient cohorts and classified 
these patients into 2 groups: – those who demonstrated a good response to treatment 
(median survival 306/207days respectively) or a poor response to treatment (median 
survival 107/92 days respectively) with hazard ratios of 0.5 and 0.41 (CI 0.24 to 0.78 
and 0.17 to 0.63). This is of clinical benefit pre-treatment when determining optimal 
second line treatment strategies – i.e. whether or not to give conventional chemotherapy 
or to give one of the newer EGFR targeted therapies such as erlotinib and gefitinib, 
based on the likelihood of responding to treatment. 
 
Other work, such as that by Ward et al in 2006, used SELDI proteinchips and plasma 
from patients with and without colorectal cancer and discovered a number of peaks 
within the spectra, corresponding to transferrin, A1AT, compliment C3a des-arg and 
apolipoprotein A1, which when used in combination were able to distinguish between 
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patients with colorectal cancer and those without (Ward et al., 2006). The specificity 
and sensitivity of this combination of markers was 91% and 95% respectively, 
compared to that of CEA alone which has a sensitivity of between 30 and 40% for early 
stage disease.   
 
The work from the OVA I, Veristrat and the study of colorectal cancer have 
demonstrated that the search for a single biomarker is likely to be unrealistic, as in these 
examples only panels of markers have been shown to be informative.  COPD is a 
complex heterogeneous disease, even amongst patients with COPD secondary to 
A1ATD, and panels of markers together in well phenotyped groups of patients, may be 
more clinically relevant.   
 
To date, the majority of published work using plasma proteomics in the analysis of 
clinical samples has been studying patients with cancer. In malignant disease, without 
treatment, there is inevitably disease progression. This is also a heterogeneous process 
and may occur at different rates between different individuals, and affect different distal 
sites away from the primary source, (Sallam, 2015) however progression and 
subsequently death are usually the expected outcomes. COPD, however, is a far more 
heterogeneous condition; there are many different phenotypes, the pathophysiology is 
not clearly understood and the disease trajectory differs from patient to patient. The 
ECLIPSE investigators measured FEV1 in 2163 patients with COPD on 8 occasions 
over a 3 year period (Vestbo et al., 2011). They described a wide range in decline in 
FEV1 between groups they characterized into those with emphysema on CT, those with 
chronic bronchitis, presence of bronchodilator reversibility and patients with 
cardiovascular disease, proving the highly variable nature of this condition.  
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Additionally, it is not a disease confined to a single organ i.e. the lung – it is a multi-
system disease with well described comorbidities outside the lungs, including 
cardiovascular disease (Sin et al., 2003), osteoporosis (Agusti 2005), depression 
(Wagena et al., 2001) and an increased lifetime risk of lung cancer (Noruma et al., 
1991). This is further complicated by transient worsening in symptoms with recovery 
which may not return to the previous baseline when patients experience exacerbations 
of their COPD. Therefore the search for biomarkers in COPD is inherently more 
complex than in the case of malignancy, and may, at least in part, explain the lack of 
transfer of any of the potential candidates identified to date using proteomic techniques 
to routine clinical practice in COPD.   
 
This is complicated further by many of the observations that the proteomes of people 
who smoke but do not have COPD, may differ from those who have never smoked and 
those who do have COPD. Even in A1ATD, there is heterogeneity of the clinical 
presentation of symptoms amongst patients with the same genotype (PiZZ), highlighted 
by differences amongst siblings (Dawkins et al., 2009). Hence there is a critical need to 
phenotype patients accurately prior to embarking on proteomics experiments, and even 
that may not result in the discovery of useful biomarkers as in the current study. 
 
 
8.3  Ionophore and Protease Work 
The ionophore series of experiments demonstrated clear differences in the actions of 
calcium ionophore between healthy control subjects and patients with A1ATD, in 
particular the generation of peptides from fibrinogen in patients with A1ATD. Further 
work could be undertaken to determine whether or not the plasma peptide profile 
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following neutrophil stimulation with ionophore of patients with A1ATD is normalized 
when patients receive augmentation therapy. In the UK, this is not currently possible 
outside a research project, as augmentation therapy is not licensed for routine clinical 
use, apart from certain exceptional circumstances (for example panniculitis with 
ulceration of lesions). To be replicated, this experiment has to be carried out on fresh, 
whole blood samples, where neutrophils are present and still viable, hence to replicate 
this work, would require samples from a cohort of patients who were about to 
commence augmentation therapy. This would allow the pre and post treatment analyses 
within the same individuals in order to specifically answer this question, to discover 
whether or not fibrinogen fragments (for instance) is the predominant peptides which 
are detected post stimulation with ionophore, and remains an area for possible future 
study. 
 
The ionophore series of experiments was performed on whole blood.  Whole blood 
contains leucocytes other than neutrophils, including lymphocytes and eosinophils, 
although neutrophils make up the largest proportion at > 60% of the total (Palmer et al., 
2006). Future work could be undertaken on neutrophils (though less physiological) 
isolated using techniques described by Sapey et al (Mikami et al., 1998) to confirm that 
the results of the ionophore experiments are specifically due to release of proteases 
from neutrophils and not from other cell types. 
 
8.5  Exacerbation Samples 
Exacerbations of COPD are defined as ‘a worsening of a patient’s symptoms beyond 
the normal day to day variation’ (NICE 2010) and may manifest as an increase in cough, 
sputum production, change in colour or viscosity of sputum, or worsening dyspnea. 
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COPD exacerbations are a significant cause of morbidity and mortality amongst this 
patient group, and a wealth of evidence supports the finding that measures of 
inflammation increase during exacerbations of COPD and in COPD secondary to 
A1ATD (Gompertz et al., 2001 and Hill et al., 1999). I originally aimed to profile 
plasma from patients taken at baseline and during exacerbations of their airways 
disease. The samples I used were collected as part of a study published in 1999, which 
included sputum and serum samples from 11 patients with the PiZZ genotype of 
A1ATD who were experiencing well characterized exacerbations of their airways 
disease. This included assessment of sputum purulence in addition to measurement of 
markers of inflammation such as IL8 and LTB4, and serum markers including CRP and 
A1AT.  
 
However, the samples had been collected in the late 1990s, and had undergone multiple 
freeze thaw cycles for previous analyses of inflammatory markers, including those 
published in the paper (Hill et al., 1999), and the quality of the samples was therefore 
likely to be inappropriate for plasma peptide profiling. The total number of samples 
was limited (11 baseline and 10 on day 1 of exacerbation) due to the nature of the study, 
and the spectra generated contained very few peaks (65 compared to >170 for the 
ECLIPSE A1ATD and EXACTLE samples) which were of low signal intensity, despite 
the same sample preparation techniques used throughout the remainder of this thesis. 
Furthermore, the sample intra-experiment CV was 18% when performed on the QC 
sample which was analysed throughout all of the series of experiments, implying that 
it was the exacerbation samples themselves rather than technical error of the 
experiments which was responsible for the poor results generated.  It was likely due to 
the reduction in quality of the samples secondary to repeated freeze thaw cycles that 
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the samples had been subjected to, as previously described in 8.1. The data was not of 
sufficient quality therefore to analyse and generate clinically useful results, and there 
was insufficient time to gain further ethical approval to conduct a new clinical trial and 
hence collect new exacerbation samples to profile. Therefore this section of work was 
not completed as planned in the aims section of this thesis, but remains a potential future 
series of experiments to perform. However, the same difficulties experienced in 
profiling plasma would still be present and therefore unless there were changes in the 
abundant plasma proteome, clinically relevant changes may not be generated. 
 
8.6  Shotgun Experiments 
The identification of a rise in fragments of A1AT in the plasma of patients who had 
received A1AT replacement therapy whilst remaining unchanged in patients receiving 
placebo demonstrates the ability of the experiments to produce some positive results, 
and acted as an extra level of validation. However, it also demonstrates the difficulties 
in profiling plasma whereby potential biomarkers or lung tissue fragments are not 
detectable or identifiable in the vast excess and abundance of plasma proteins. The 
shotgun series of experiments was performed to analyse the plasma proteome in greater 
depth than in the profiling work, in order to use a complementary approach to the high 
throughput profiling work. The work demonstrated some success of the abundant 
protein depletion strategy used – the proteins which were subsequently identified and 
quantified were from lower abundance proteins including vitamin D binding protein, 
tetraspanin, vascular cell adhesion protein and thyroxine binding globulin. A full list of 
proteins is presented in Appendix II. The majority of proteins were from the 
extracellular space highlighting the difficulty of detecting peptides from tissue damage 
within the plasma amongst other more abundant proteins. There were a number of 
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proteins which changed post treatment with intravenous A1AT but it was not possible 
to analyse them all in more detail – these include, cystatin A and tetranectin. However 
as they were not identified in both sets of samples, PEDF (which was identified in both 
datasets), was prioritized to measure on individual samples.   
 
The shotgun experiments also demonstrated the potential difficulties when depleting 
samples of abundant proteins – namely that of loss of valuable material and hence 
potential future biomarkers. However, despite this, it was not possible to identify and 
quantify other markers, such as cytokines and chemokines, which have been 
investigated in the pathophysiology of COPD, as these are difficult to quantify due to 
their low plasma concentrations.  
 
8.7  Electrospray-Peptidome Analyses 
ESI ionization differs from MALDI in that the analysates are sprayed into the mass 
spectrometer which allows direct interfacing with separation technologies such as 
HPLC or capillary electrophoresis.  ESI has been utilized successfully in plasma and 
serum and data published in the literature. For example, in lung cancer, Ueda and 
colleagues performed size exclusion chromatography and were able to detect 3537 
peptides in the serum of patients and with lung adenocarcinoma and compare these to 
healthy control subjects (Ueda et al., 2011). They found that of these, 118 were 
statistically significant between the cancer patients and the control group, and went on 
to perform MS/MS on the samples and discovered that fragments of apolipoprotein A4, 
fibrinogen alpha chain and limbin were differentially expressed in patients with lung 
cancer and therefore could be investigated further in biomarker discovery (Ueda et al., 
2011).  
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Thus, ESI MS may allow more in depth peptidome analysis than MALDI profiling. ESI 
analysis of the pooled samples was attempted during the experimental phase of this 
thesis using a Bruker Maxis post ACN precipitation of peptides from plasma. Ten µL 
of plasma was diluted in 90 µL of ACN and centrifuged at 500g for 5 minutes. The 
supernatant was transferred to a clean tube, placed into the speedivac until dry, and 
peptides re-suspended in 10 µL of 0.1% formic acid for ESI analysis. One of the major 
advantages of this approach is the ability to use automation to analyse samples. This 
technique was not successful with the current set of samples (data not shown) as 
repeatedly the experiments stopped mid-processing due to problems with the HPLC 
column blocking with excess peptide and particulate material. 
 
Others have used ESI successfully coupled with tandem mass spectrometry to measure 
drug levels within plasma. Bazoti and colleagues used liquid chromatography with ESI 
to optimise conditions to measure the levels of the antibiotic daptomycin in human 
plasma. This was subsequently proven to be a sensitive enough test to perform on 
patient plasma (Bazoti et al., 2011).   This approach remains a possible area for future 
work in the attempt at biomarker discovery in A1ATD. However, measurement of small 
molecules is easier than measuring peptides and proteins. Geyer and colleagues 
published a methodology that analysed 1µL of plasma, and using a combination of steps 
starting with a reduction, alkylation and digestion of proteins (performed within an 
hour), followed by analysis of LC MS/MS and by optimizing the HPLC gradient were 
able to identify almost 1000 proteins. This methodology has taken many years to 
optimize to this workflow, but demonstrates that label free identification and 
quantification of plasma peptides is possible (Geyer et al., 2016).  
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8.8                   Future Work 
The observation that SPAAT increased on augmentation was unique and hence 
unexpected. The role of these A1AT peptides is currently unknown and may reflect 
peptides that remain inhibitors of NE are retain other biological properties of A1AT. 
To investigate SPAAT further a specific assay for the SPAAT peptide could be created 
using multiple reaction monitoring (MRM).  MRM is a targeted mass 
spectrometry approach where the SPAAT peptide would be pre-selected for isolation 
and fragmentation using a triple quadrupole mass analyser and coupled with a heavy 
isotope labelled version of SPAAT to allow absolute quantitation of SPAAT in clinical 
samples. 
  
An alternative approach would be to undertake mass spectrometry analysis of Prolastin 
directly. This would allow confident exclusion of the rise in the SPAAT signal 
following treatment being merely due to the presence of the SPAAT peptide in the 
replacement therapy. This should also be done by profiling plasma before and 
immediately after direct addition of Prolastin in case analytical sensitivity for SPAAT 
is strongly influenced by matrix effects.  
 
A final approach might be to develop a specific immune-assay for the SPAAT peptide/s 
which could be used not only to track its’ presence but also as a means to immune purify 
the peptide/s and enable in vitro studies of the properties. 
  
Further experiments could include the use of the approach described above by Geyer et 
al., and perform the same comparative analyses presented in the current thesis. The 
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authors of this methodology paper are able to identify up to 1000 proteins from 1µL of 
plasma, which may reveal potential candidate markers of response to augmentation 
therapy in A1ATD. This approach combined with the latest generation of mass 
spectrometers with higher mass accuracy, faster data acquisition and increased 
sensitivity would allow a deeper analysis of the plasma 
proteome/peptidome.   Additionally the increasing availability of highly multiplexed 
immunoassay platforms (e.g. olink proteomics) may circumvent the difficulty of 
detecting very low abundance species by mass spectrometry.  
 
8.9  Conclusions 
Using these proteomic techniques in the search for potential biomarkers in patients with 
the PiZZ genotype of A1ATD has revealed that post augmentation therapy, the majority 
of the plasma peptidome remains unchanged. The main differences post augmentation 
therapy were increases in signal intensity of fragments of A1AT previously described 
and termed SPAAT.  
 
On further, more in depth analysis of pooled samples, again the majority of the 
detectable plasma peptidome remained unchanged post augmentation therapy. There 
were no peptides or proteins identified using any of the approaches in the work in this 
thesis that could act as biomarkers in the use of augmentation therapy in patients with 
A1ATD. This lack of a clear signal could be a result of either there being no actual 
changes in the plasma proteome following treatment with augmentation therapy, 
changes present but too small to detect,  or changes present but the peptides at low 
concentrations below the limit of detection of the techniques and mass spectrometers 
utilized. Aα-Val 360 has been demonstrated to decrease with augmentation therapy in 
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the patient samples analysed within this thesis, which clearly negates the first option 
suggesting any signal is too small to detect without more specific or sensitive 
methodologies.  At the start of this thesis the use and sensitivity of proteomics was 
largely unknown and hence this became an exploratory study. Power calculations 
depend upon knowing the reproducibility of the method both within sample and 
between samples.  
 
There are other proteomic techniques that could be utilized, including ESI techniques, 
and these, in addition to the continual improvement in the technology of mass 
spectrometers, mean that plasma proteomics in COPD whilst challenging at present, 
may still offer potential biomarker discovery in the future. Clearly, however, careful 
validation will be an essential part of the development to enable sensible power 
calculations to be made before embarking on patient studies including any influence of 
patient phenotype. 
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Peptide/Protein Identifications from Neutrophil Elastase Experiments 
m/z  Scores Sequence Protein m/z  Scores Sequence Protein 
2530.15 188 C.HPNSPLDEENLTQENQDRGTHV.D Alpha-1-antichymotrypsin  907.37 60.1 T.SHNGMQFS.T Fibrinogen gamma chain  
2296.04 140.8 P.NSPLDEENLTQENQDRGTHV.D Alpha-1-antichymotrypsin  1363.65 58.5 I.QYKEGFGHLSPT.G Fibrinogen gamma chain  
2430.03 129.8 A.EDPQGDAAQKTDTSHHDQDHPT.F Alpha-1-antitrypsin  1982.92 51.7 L.RVELEDWNGRTSTADYA.M Fibrinogen gamma chain  
2932.32 69.9 A.EDPQGDAAQKTDTSHHDQDHPTFNKI.T Alpha-1-antitrypsin  1659.85 84.1 L.TIGEGQQHHLGGAKQV.R Fibrinogen gamma chain  
1948.08 72.4 A.KKQINDYVEKGTQGKIV.D Alpha-1-antitrypsin  1606.78 101.3 S.KASTPNGYDNGIIWA.T Fibrinogen gamma chain  
1569.82 42.4 I.FFKGKWERPFEV.K Alpha-1-antitrypsin  1394.69 79.5 T.GTTEFWLGNEKI.H Fibrinogen gamma chain  
2030.00 84.4 I.FFLPDEGKLQHLENELT.H Alpha-1-antitrypsin  1445.72 64.6 I.GEGQQHHLGGAKQV.R Fibrinogen gamma chain  
2508.27 127.6 I.FFLPDEGKLQHLENELTHDII.T Alpha-1-antitrypsin  1736.78 57.4 I.QLTYNPDESSKPNMI.D Fibrinogen gamma chain  
1465.75 46.1 I.TKFLENEDRRSA.S Alpha-1-antitrypsin  2285.90 68.3 G.DAGDAFDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  
1761.99 61.3 M.SIPPEVKFNKPFVFL.M Alpha-1-antitrypsin  1407.66 86 A.STPNGYDNGIIWA.T Fibrinogen gamma chain  
4133.30 84.6 M.SIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  2829.53 143.1 A.TWKTRWYSMKKTTMKIIPFNRL.T Fibrinogen gamma chain  
1504.82 70 S.EGLKLVDKFLEDV.K Alpha-1-antitrypsin  3043.65 47.5 A.TWKTRWYSMKKTTMKIIPFNRLTI.G Fibrinogen gamma chain  
1752.87 49.7 T.EIPEAQIHEGFQELL.R Alpha-1-antitrypsin  2781.09 185.2 A.YFAGGDAGDAFDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  
2010.03 121.2 T.EIPEAQIHEGFQELLRT.L Alpha-1-antitrypsin  1553.81 40.8 A.MFKVGPEADKYRL.T Fibrinogen gamma chain  
1447.81 54.5 T.TGNGLFLSEGLKLV.D Alpha-1-antitrypsin  1654.86 49.1 A.MFKVGPEADKYRLT.Y Fibrinogen gamma chain  
1847.92 47.4 V.FSNGADLSGVTEEAPLKL.S Alpha-1-antitrypsin  2399.95 144.5 A.GGDAGDAFDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  
1322.71 93.4 V.KKLYHSEAFTV.N Alpha-1-antitrypsin  2068.02 72.8 V.KAHYGGFTVQNEANKYQI.S Fibrinogen beta chain  
2811.41 134.1 V.NFGDTEEAKKQINDYVEKGTQGKIV.D Alpha-1-antitrypsin  2247.10 89.3 T.RMGPTELLIEMEDWKGDKV.K Fibrinogen beta chain  
1959.99 75.1 V.NYIFFKGKWERPFEV.K Alpha-1-antitrypsin  2446.24 60.4 T.RMGPTELLIEMEDWKGDKVKA.H Fibrinogen beta chain  
2242.09 102.3 I.LSDETLPAPEFSPEPESGRAL.R Alpha-1B-glycoprotein  1833.02 64.3 S.LRPAPPPISGGGYRARPA.K Fibrinogen beta chain  
1625.82 75.3 M.HHGESSQVLHPGNKV.T Alpha-1B-glycoprotein  1378.72 42.7 M.SMKIRPFFPQQ.- Fibrinogen beta chain  
1850.06 83.8 S.KLLELTGPKSLPAPWLS.M Alpha-1B-glycoprotein  1160.65 43 M.KIRPFFPQQ.- Fibrinogen beta chain  
2699.46 52.5 V.DFQLRRGEKELLVPRSSTSPDRI.F Alpha-1B-glycoprotein  2753.42 159.5 I.IRKGGETSEMYLIQPDSSVKPYRV.Y Fibrinogen beta chain  
2049.06 43.9 V.DLKPPFGGSAPSERLELHV.D Alpha-1B-glycoprotein  2970.43 53.5 I.QNRQDGSVDFGRKWDPYKQGFGNVAT.N Fibrinogen beta chain  
2597.30 95.3 V.ELILSDETLPAPEFSPEPESGRAL.R Alpha-1B-glycoprotein  2640.34 92 I.RKGGETSEMYLIQPDSSVKPYRV.Y Fibrinogen beta chain  
2866.48 94.6 V.ELILSDETLPAPEFSPEPESGRALRL.R Alpha-1B-glycoprotein  1572.78 76.3 I.RNSVDELNNNVEAV.S Fibrinogen beta chain  
3273.61 87 V.TFLLRREGDHEFLEVPEAQEDVEATFPV.H Alpha-1B-glycoprotein  1675.93 51.4 V.TSKGDKELRTGKEKV.T Fibrinogen alpha chain  
3489.83 105.4 L.KGFPRGDKLFGPDLKLVPPMEEDYPQFGSPK.- Alpha-2-antiplasmin  1776.98 41.7 V.TSKGDKELRTGKEKVT.S Fibrinogen alpha chain  
1162.64 47.5 A.AGPVVPPCPGRI.R Alpha-2-HS-glycoprotein  2149.92 61 A.ANPNGRYYWGGQYTWDMA.K Fibrinogen beta chain  
1083.59 83 A.APPGHQLHRA.H Alpha-2-HS-glycoprotein  1868.88 73.6 A.HYGGFTVQNEANKYQI.S Fibrinogen beta chain  
941.46 41.7 A.HYDLRHT.F Alpha-2-HS-glycoprotein  3589.98 65.7 A.RGHRPLDKKREEAPSLRPAPPPISGGGYRARPA.K Fibrinogen beta chain  
1474.72 71.1 A.HYDLRHTFMGVV.S Alpha-2-HS-glycoprotein  1937.06 92.2 V.TKTVIGPDGHKEVTKEVV.T Fibrinogen alpha chain  
1861.91 60.5 I.DYINQNLPWGYKHTL.N Alpha-2-HS-glycoprotein  2759.22 80.6 V.SGSTGQWHSESGSFRPDSPGSGNARPN.N Fibrinogen alpha chain  
2560.24 91.3 I.DYINQNLPWGYKHTLNQIDEV.K Alpha-2-HS-glycoprotein  2873.26 70.3 V.SGSTGQWHSESGSFRPDSPGSGNARPNN.P Fibrinogen alpha chain  
1357.65 61.3 I.NQNLPWGYKHT.L Alpha-2-HS-glycoprotein  3933.75 65.1 V.SGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEV.S Fibrinogen alpha chain  
2169.07 97.8 I.NQNLPWGYKHTLNQIDEV.K Alpha-2-HS-glycoprotein  2320.99 73 V.SGSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  
1527.84 75.7 I.SRAQLVPLPPSTYV.E Alpha-2-HS-glycoprotein  3687.03 82.6 V.SGNVSPGTRREYHTEKLVTSKGDKELRTGKEKV.T Fibrinogen alpha chain  
1666.66 40.4 I.YRQPNCDDPETEEA.A Alpha-2-HS-glycoprotein  3788.05 44.3 V.SGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVT.S Fibrinogen alpha chain  
1154.63 75.6 L.AAPPGHQLHRA.H Alpha-2-HS-glycoprotein  2131.09 71.8 V.SGNVSPGTRREYHTEKLVT.S Fibrinogen alpha chain  
893.50 44.1 L.KLDGKFSV.V Alpha-2-HS-glycoprotein  2030.05 61.6 V.SGNVSPGTRREYHTEKLV.T Fibrinogen alpha chain  
992.57 69.6 L.KLDGKFSVV.Y Alpha-2-HS-glycoprotein  3807.85 138.9 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
1267.70 74 L.LAAPPGHQLHRA.H Alpha-2-HS-glycoprotein  3720.80 123.5 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  
761.42 40.2 S.APHGPGLI.Y Alpha-2-HS-glycoprotein  3292.54 68.6 V.SETESRGSESGIFTNTKESSSHHPGIAEFPS.R Fibrinogen alpha chain  
2744.37 103 V.AIDYINQNLPWGYKHTLNQIDEV.K Alpha-2-HS-glycoprotein  3505.63 56.7 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  
1657.85 74.3 V.KVWPQQPSGELFEI.E Alpha-2-HS-glycoprotein  2045.95 53.4 V.SETESRGSESGIFTNTKES.S Fibrinogen alpha chain  
2459.22 139 V.KVWPQQPSGELFEIEIDTLET.T Alpha-2-HS-glycoprotein  1486.65 47.7 V.SETESRGSESGIFT.N Fibrinogen alpha chain  
2560.25 131.9 V.KVWPQQPSGELFEIEIDTLETT.C Alpha-2-HS-glycoprotein  1507.82 83.7 V.IGPDGHKEVTKEVV.T Fibrinogen alpha chain  
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1380.79 92.4 V.LLAAPPGHQLHRA.H Alpha-2-HS-glycoprotein  2117.91 71.8 T.WNPGSSERGSAGHWTSESSV.S Fibrinogen alpha chain  
2000.99 66.5 V.RQLKEHAVEGDCDFQLL.K Alpha-2-HS-glycoprotein  1878.88 67.1 V.DLKDYEDQQKQLEQV.I Fibrinogen alpha chain  
1309.65 51 V.SLGSPSGEVSHPR.K Alpha-2-HS-glycoprotein  4043.83 61.8 T.SYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
1538.80 101.5 V.SLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  3169.34 43.2 T.SYNRGDSTFESKSYKMADEAGSEADHEGT.H Fibrinogen alpha chain  
1637.87 71.5 V.VSLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  1568.69 96 T.SYGTGSETESPRNPS.S Fibrinogen alpha chain  
864.47 42.6 M.HGPEGLRV.G Alpha-2-macroglobulin  1477.66 75.4 T.SYNRGDSTFESKS.Y Fibrinogen alpha chain  
1210.65 61.1 S.DVMGRGHARLV.H Alpha-2-macroglobulin  1899.86 109.5 T.SYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
1425.61 98.3 V.GFYESDVMGRGHA.R Alpha-2-macroglobulin  1970.89 113.7 T.SYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
1793.87 83.4 V.GFYESDVMGRGHARLV.H Alpha-2-macroglobulin  2246.01 81.1 T.SSTSYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
2144.18 64.8 V.KKDNSVHWERPQKPKAPV.G Alpha-2-macroglobulin  2174.97 61.6 T.SSTSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
1171.65 41.5 A.ELQEGARQKL.H Apolipoprotein A-I  1675.94 50.8 T.SKGDKELRTGKEKVT.S Fibrinogen alpha chain  
2049.10 83.4 A.ELQEGARQKLHELQEKL.S Apolipoprotein A-I  1574.89 70.5 T.SKGDKELRTGKEKV.T Fibrinogen alpha chain  
2792.44 96 A.ELQEGARQKLHELQEKLSPLGEEM.R Apolipoprotein A-I  2026.92 129.6 T.RGGSTSYGTGSETESPRNPS.S Fibrinogen alpha chain  
3290.69 153 A.ELQEGARQKLHELQEKLSPLGEEMRDRA.R Apolipoprotein A-I  2340.14 126.3 T.NTKESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
3517.84 71.3 A.ELQEGARQKLHELQEKLSPLGEEMRDRARA.H Apolipoprotein A-I  3181.52 150 T.NTKESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
3754.00 114.1 A.ELQEGARQKLHELQEKLSPLGEEMRDRARAHV.D Apolipoprotein A-I  3456.64 106.5 T.NTKESSSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
1198.60 52.6 A.EYHAKATEHL.S Apolipoprotein A-I  1824.86 75.6 T.NTKESSSHHPGIAEFPS.R Fibrinogen alpha chain  
1285.63 72.6 A.EYHAKATEHLS.T Apolipoprotein A-I  2253.11 127.6 T.NTKESSSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  
1386.66 76.8 A.EYHAKATEHLST.L Apolipoprotein A-I  1279.70 59.8 T.KTVIGPDGHKEV.T Fibrinogen alpha chain  
2211.14 154.8 A.EYHAKATEHLSTLSEKAKPA.L Apolipoprotein A-I  2966.46 78.8 T.KESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
3022.58 47.2 A.EYHAKATEHLSTLSEKAKPALEDLRQG.L Apolipoprotein A-I  1215.58 78.7 T.GKTFPGFFSPM.L Fibrinogen alpha chain  
3444.86 231.1 A.EYHAKATEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1760.86 88.5 T.GKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
2944.64 105.6 A.KATEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2275.98 86.5 T.GTWNPGSSERGSAGHWTSESSV.S Fibrinogen alpha chain  
1548.92 40.5 A.KPALEDLRQGLLPV.L Apolipoprotein A-I  2125.05 49.8 T.KESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
3128.59 48.6 A.KVQPYLDDFQKKWQEEMELYRQKV.E Apolipoprotein A-I  3702.63 41.6 S.TGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEV.S Fibrinogen alpha chain  
3467.79 87.8 A.KVQPYLDDFQKKWQEEMELYRQKVEPL.R Apolipoprotein A-I  2045.01 116.7 T.ADSGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
1252.72 51.7 A.LEDLRQGLLPV.L Apolipoprotein A-I  1474.71 41.1 T.ASTGKTFPGFFSPM.L Fibrinogen alpha chain  
1497.84 87.1 A.RLEALKENGGARLA.E Apolipoprotein A-I  2019.99 100.1 T.ASTGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
2165.13 97.1 A.RQKLHELQEKLSPLGEEM.R Apolipoprotein A-I  2897.35 50.8 S.SSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
2663.40 120.1 A.RQKLHELQEKLSPLGEEMRDRA.R Apolipoprotein A-I  2622.27 62.8 S.SSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
2890.54 55.5 A.RQKLHELQEKLSPLGEEMRDRARA.H Apolipoprotein A-I  1265.58 44 S.SSHHPGIAEFPS.R Fibrinogen alpha chain  
3126.67 83.8 A.RQKLHELQEKLSPLGEEMRDRARAHV.D Apolipoprotein A-I  1780.89 72.1 S.SSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
2745.51 78.6 A.TEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2535.24 92.1 S.SHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
1728.87 57 A.TVYVDVLKDSGRDYV.S Apolipoprotein A-I  2810.33 75.4 S.SHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
1639.91 78.6 L.AARLEALKENGGARLA.E Apolipoprotein A-I  3367.61 66.9 S.KSYKMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  
1426.70 42 L.GEEMRDRARAHV.D Apolipoprotein A-I  1375.69 74.4 S.RGKSSSYSKQFT.S Fibrinogen alpha chain  
2601.32 87.7 L.HELQEKLSPLGEEMRDRARAHV.D Apolipoprotein A-I  1650.82 57.2 S.RGKSSSYSKQFTSST.S Fibrinogen alpha chain  
1089.56 76.5 L.KLLDNWDSV.T Apolipoprotein A-I  1779.76 77 S.SAGSWNSGSSGPGSTGNRN.P Fibrinogen alpha chain  
1316.68 90.3 L.NLKLLDNWDSV.T Apolipoprotein A-I  1933.85 46.6 S.SAGSWNSGSSGPGSTGNRNPG.S Fibrinogen alpha chain  
1964.11 101.6 L.SEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2265.98 106.1 S.SAGSWNSGSSGPGSTGNRNPGSSGT.G Fibrinogen alpha chain  
1723.87 67.7 L.SPLGEEMRDRARAHV.D Apolipoprotein A-I  2552.11 102.3 S.SAGSWNSGSSGPGSTGNRNPGSSGTGGTA.T Fibrinogen alpha chain  
2265.29 148.6 L.STLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2653.14 101.6 S.SAGSWNSGSSGPGSTGNRNPGSSGTGGTAT.W Fibrinogen alpha chain  
1325.61 48.4 Q.DEPPQSPWDRV.K Apolipoprotein A-I  3121.38 43.9 S.SAGSWNSGSSGPGSTGNRNPGSSGTGGTATWKPG.S Fibrinogen alpha chain  
1752.85 51.4 Q.DEPPQSPWDRVKDLA.T Apolipoprotein A-I  1178.56 43.7 S.SHHPGIAEFPS.R Fibrinogen alpha chain  
1853.89 60.7 Q.DEPPQSPWDRVKDLAT.V Apolipoprotein A-I  1606.82 81 S.SHHPGIAEFPSRGKS.S Fibrinogen alpha chain  
2215.10 46.8 Q.DEPPQSPWDRVKDLATVYV.D Apolipoprotein A-I  3599.80 42.9 S.GIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
1927.05 141.6 S.ALGKQLNLKLLDNWDSV.T Apolipoprotein A-I  1777.88 50.5 S.GIGTLDGFRHRHPDEA.A Fibrinogen alpha chain  
2028.10 145.9 S.ALGKQLNLKLLDNWDSVT.S Apolipoprotein A-I  1848.89 41.1 S.GIGTLDGFRHRHPDEAA.F Fibrinogen alpha chain  
2216.16 54.1 S.ALGKQLNLKLLDNWDSVTST.F Apolipoprotein A-I  2430.18 43.9 S.GIGTLDGFRHRHPDEAAFFDTA.S Fibrinogen alpha chain  
1039.62 67.4 S.KLREQLGPV.T Apolipoprotein A-I  3222.51 42 M.ELERPGGNEITRGGSTSYGTGSETESPRNPS.S Fibrinogen alpha chain  
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2178.24 121.6 S.TLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2011.97 56.8 N.SLFEYQKNNKDSHSLTT.N Fibrinogen alpha chain  
2644.47 183.3 T.EHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2364.16 93.6 M.DLGTLSGIGTLDGFRHRHPDEA.A Fibrinogen alpha chain  
1273.73 61.4 T.FSKLREQLGPV.T Apolipoprotein A-I  2435.21 60.7 M.DLGTLSGIGTLDGFRHRHPDEAA.F Fibrinogen alpha chain  
1597.84 61.4 T.HLAPYSDELRQRL.A Apolipoprotein A-I  1864.90 52.8 L.SGIGTLDGFRHRHPDEA.A Fibrinogen alpha chain  
1739.92 70.4 T.HLAPYSDELRQRLAA.R Apolipoprotein A-I  1935.93 48 L.SGIGTLDGFRHRHPDEAA.F Fibrinogen alpha chain  
2077.21 117.6 T.LSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2260.05 50.2 I.GTLDGFRHRHPDEAAFFDTA.S Fibrinogen alpha chain  
1461.80 80 T.STFSKLREQLGPV.T Apolipoprotein A-I  2127.96 157.8 I.TRGGSTSYGTGSETESPRNPS.S Fibrinogen alpha chain  
1627.83 93.2 T.VYVDVLKDSGRDYV.S Apolipoprotein A-I  1336.62 50.8 L.DGFRHRHPDEA.A Fibrinogen alpha chain  
2263.09 59.8 T.VYVDVLKDSGRDYVSQFEGS.A Apolipoprotein A-I  1407.66 40.2 L.DGFRHRHPDEAA.F Fibrinogen alpha chain  
2296.20 84.3 V.DALRTHLAPYSDELRQRLAA.R Apolipoprotein A-I  1607.77 45.8 I.GTLDGFRHRHPDEA.A Fibrinogen alpha chain  
1266.63 49.5 V.DVLKDSGRDYV.S Apolipoprotein A-I  1678.80 52.1 I.GTLDGFRHRHPDEAA.F Fibrinogen alpha chain  
3327.73 145.7 V.KAKVQPYLDDFQKKWQEEMELYRQKV.E Apolipoprotein A-I  1858.93 78.8 D.SGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
3666.92 145.4 V.KAKVQPYLDDFQKKWQEEMELYRQKVEPL.R Apolipoprotein A-I  1173.56 64.3 G.FFSPMLGEFV.S Fibrinogen alpha chain  
1862.94 134.3 V.LESFKVSFLSALEEYT.K Apolipoprotein A-I  2733.21 70.2 G.SFRPDSPGSGNARPNNPDWGTFEEV.S Fibrinogen alpha chain  
2575.35 108.9 V.LESFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  2464.09 67.7 G.STGTWNPGSSERGSAGHWTSESSV.S Fibrinogen alpha chain  
3240.61 48.7 V.QPYLDDFQKKWQEEMELYRQKVEPL.R Apolipoprotein A-I  1849.87 41.2 A.STGKTFPGFFSPMLGEF.V Fibrinogen alpha chain  
1159.55 77.2 V.SFLSALEEYT.K Apolipoprotein A-I  1948.93 107.5 A.STGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
1743.91 96.8 V.SFLSALEEYTKKLNT.Q Apolipoprotein A-I  1403.66 84.6 A.STGKTFPGFFSPM.L Fibrinogen alpha chain  
1871.97 124.4 V.SFLSALEEYTKKLNTQ.- Apolipoprotein A-I  1375.63 67.7 A.FFDTASTGKTFPG.F Fibrinogen alpha chain  
1264.65 68.2 V.SQFEGSALGKQL.N Apolipoprotein A-I  1984.90 124.5 A.FFDTASTGKTFPGFFSPM.L Fibrinogen alpha chain  
1491.77 90.2 V.SQFEGSALGKQLNL.K Apolipoprotein A-I  1973.95 132.1 A.DSGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
2562.29 155.3 V.SQFEGSALGKQLNLKLLDNWDSV.T Apolipoprotein A-I  2049.99 95 I.EGVDAEDGHGPGEQQKRKI.V Complement factor B  
2663.35 56.2 V.SQFEGSALGKQLNLKLLDNWDSVT.S Apolipoprotein A-I  1694.87 56.6 I.GTRKVGSQYRLEDSV.T Complement factor B  
3085.53 49.4 V.SQFEGSALGKQLNLKLLDNWDSVTSTFS.K Apolipoprotein A-I  1583.76 74.7 I.ILMTDGLHNMGGDPI.T Complement factor B  
1539.70 62.4 V.TQEFWDNLEKET.E Apolipoprotein A-I  2146.13 67.3 I.NYEDHKLKSGTNTKKALQA.V Complement factor B  
1838.86 62.3 V.TQEFWDNLEKETEGL.R Apolipoprotein A-I  2245.18 158.5 I.NYEDHKLKSGTNTKKALQAV.Y Complement factor B  
2383.07 139 V.TQEFWDNLEKETEGLRQEM.S Apolipoprotein A-I  2478.30 63.6 I.RDLLYIGKDRKNPREDYLDV.Y Complement factor B  
2470.13 86.4 V.TQEFWDNLEKETEGLRQEMS.K Apolipoprotein A-I  2445.20 76.9 S.KKDNEQHVFKVKDMENLEDV.F Complement factor B  
3183.47 144 V.TQEFWDNLEKETEGLRQEMSKDLEEV.K Apolipoprotein A-I  2694.33 164.5 S.SLTETIEGVDAEDGHGPGEQQKRKI.V Complement factor B  
1562.86 83.1 V.TSTFSKLREQLGPV.T Apolipoprotein A-I  1309.72 57.7 V.ASYGVKPRYGLV.T Complement factor B  
1528.77 86 V.YVDVLKDSGRDYV.S Apolipoprotein A-I  1764.86 110 V.DAEDGHGPGEQQKRKI.V Complement factor B  
2164.00 78.6 V.YVDVLKDSGRDYVSQFEGS.A Apolipoprotein A-I  1863.94 68.4 V.DAEDGHGPGEQQKRKIV.L Complement factor B  
1897.98 70.6 A.EAKSYFEKSKEQLTPL.I Apolipoprotein A-II  2234.07 71.2 V.KVSEADSSNADWVTKQLNEI.N Complement factor B  
2837.56 87.2 A.EAKSYFEKSKEQLTPLIKKAGTELV.N Apolipoprotein A-II  2055.09 110.4 V.NINALASKKDNEQHVFKV.K Complement factor B  
1697.90 73.9 A.KSYFEKSKEQLTPL.I Apolipoprotein A-II  1241.65 55.9 V.TYATYPKIWV.K Complement factor B  
2637.46 165.2 A.KSYFEKSKEQLTPLIKKAGTELV.N Apolipoprotein A-II  1291.70 73.2 V.YVFGVGPLVNQV.N Complement factor B  
958.59 46.6 L.IKKAGTELV.N Apolipoprotein A-II  1823.78 83 V.SSAMEPDREYHFGQAV.R Complement factor H  
2048.05 125.6 V.LKPEEEAPAPEVGASKPEGI.D Vitronectin  1446.70 68.6 A.AFFDTASTGKTFPG.F Fibrinogen alpha chain  
1107.54 67.2 S.SLSAVFEHFA.M Vitronectin  2055.94 127.1 A.AFFDTASTGKTFPGFFSPM.L Fibrinogen alpha chain  
1698.82 97.4 T.SDLQAQSKGNPEQTPV.L Vitronectin  1582.77 124.6 T.HYSSSGSLGGLYELI.Y Complement component C9  
1476.90 84.4 T.EYKKKLAERLKA.K Vitamin D-binding protein  1155.66 43.7 V.KGEIHLGRFV.M Complement component C9  
1646.81 94.6 I.RDVWGIEGPIDAAFT.R Vitronectin  1335.68 44.8 L.MLHYEFLQRV.K Complement component C8 beta chain  
1394.69 55.6 V.RVVAEGFDFANGI.N Serum paraoxonase/arylesterase 1  2442.29 127.3 V.TLSSTGRNGFKSHALQLNNRQI.R Complement C4-A  
1653.95 46.6 V.LRIQNILTEEPKVT.Q Serum paraoxonase/arylesterase 1  1156.58 50.7 V.YELNPLDHR.G Complement C4-A  
1639.85 78.5 V.ELFKFQEEEKSLL.H Serum paraoxonase/arylesterase 1  1953.03 53.1 T.GRNGFKSHALQLNNRQI.R Complement C4-A  
2232.22 121.2 V.ELFKFQEEEKSLLHLKTI.R Serum paraoxonase/arylesterase 1  1739.93 84.4 R.NGFKSHALQLNNRQI.R Complement C4-A  
1294.75 46.1 T.RLNALREVQPV.E Serum paraoxonase/arylesterase 1  1896.04 57.4 R.NGFKSHALQLNNRQIR.G Complement C4-A  
2004.06 79.3 S.SGLKYPGIKSFNPNSPGKI.L Serum paraoxonase/arylesterase 1  2314.04 125.3 V.QKEDIPPADLSDQVPDTESET.R Complement C3  
2091.11 95.6 I.SSGLKYPGIKSFNPNSPGKI.L Serum paraoxonase/arylesterase 1  2583.24 142 V.QKEDIPPADLSDQVPDTESETRI.L Complement C3  
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1271.68 68 I.QNILTEEPKVT.Q Serum paraoxonase/arylesterase 1  2809.42 104 V.QKEDIPPADLSDQVPDTESETRILL.Q Complement C3  
1431.84 73.1 I.RHKLLPNLNDIV.A Serum paraoxonase/arylesterase 1  4062.10 40.6 V.RTLDPERLGREGVQKEDIPPADLSDQVPDTESETRI.L Complement C3  
1601.94 75.5 I.RHKLLPNLNDIVAV.G Serum paraoxonase/arylesterase 1  1246.67 114.7 V.TAEGKGQGTLSVV.T Complement C3  
1466.68 40.3 I.SNHQNSNRYLYA.R Serum amyloid A-4 protein  1705.94 96.4 I.RGLEEELQFSLGSKI.N Complement C4-A  
1745.86 72.4 A.RGNYDAAQRGPGGVWAA.K Serum amyloid A-4 protein  3016.38 97.2 L.DHRGRTLEIPGNSDPNMIPDGDFNSYV.R Complement C4-A  
1520.81 46.9 V.ARLSQRFPKAEFA.E Serum albumin  2340.25 137 V.KWLILEKQKPDGVFQEDAPV.I Complement C3  
1504.84 61.3 V.RYTKKVPQVSTPT.L Serum albumin  1939.98 51 V.AQMTEDAVDAERLKHLI.V Complement C3  
1945.11 62.1 V.RYTKKVPQVSTPTLVEV.S Serum albumin  2039.05 46.1 V.AQMTEDAVDAERLKHLIV.T Complement C3  
2100.14 79.9 V.AHRFKDLGEENFKALVLI.A Serum albumin  2932.49 114 V.HYLDETEQWEKFGLEKRQGALELI.K Complement C3  
1661.83 97 V.AHRFKDLGEENFKA.L Serum albumin  996.62 51.4 T.RILLQGTPV.A Complement C3  
1774.92 111.3 V.AHRFKDLGEENFKAL.V Serum albumin  1766.98 44.2 T.VAVRTLDPERLGREGV.Q Complement C3  
1873.98 119.8 V.AHRFKDLGEENFKALV.L Serum albumin  2362.18 67 T.AKDKNRWEDPGKQLYNVEAT.S Complement C3  
2203.04 91.6 S.ALEVDETYVPKEFNAETFT.F Serum albumin  1651.89 70.2 I.KKGYTQQLAFRQPS.S Complement C3  
2937.53 65.7 R.DAHKSEVAHRFKDLGEENFKALVLIA.F Serum albumin  1136.56 46.1 I.THRIHWESA.S Complement C3  
2157.06 57.4 A.KLHDRNTYEKYLGEEYV.K Serotransferrin  2868.37 65 R.EGVQKEDIPPADLSDQVPDTESETRI.L Complement C3  
1703.88 62.4 A.HRFKDLGEENFKAL.V Serum albumin  1241.68 63.1 L.NLDVSLQLPSR.S Complement C3  
1802.95 72.1 A.HRFKDLGEENFKALV.L Serum albumin  3102.58 43.9 I.AVHYLDETEQWEKFGLEKRQGALELI.K Complement C3  
1677.89 43.9 A.RLSQRFPKAEFAEV.S Serum albumin  1471.68 49.4 A.QYQKDAPDHQEL.N Complement C3  
1381.76 59.2 A.SLQKFGERAFKA.W Serum albumin  1912.91 72.8 A.QYQKDAPDHQELNLDV.S Complement C3  
1801.94 119.1 A.SAQAKALSKHQDFNSAV.Q Prothrombin  1838.91 124.8 A.SLLRSEETKENEGFTV.T Complement C3  
1191.67 95 A.SLLQAGYKGRV.T Prothrombin  1629.91 91.6 A.LLQLKDFDFVPPVV.R Complement C3  
2045.97 109.3 I.DGRIVEGSDAEIGMSPWQV.M Prothrombin  1388.67 60 A.NYMNLQRSYTV.A Complement C3  
2475.21 54.4 I.YIHPRYNWRENLDRDIALM.K Prothrombin  2024.01 107.9 I.LQDTKALHQVFEHMLDV.S Complement C2  
2357.23 63.6 L.FEKKSLEDKTERELLESYI.D Prothrombin  1619.76 46.7 V.IFKSDFSNEERFT.G Complement C1s subcomponent  
1581.97 54.1 T.HVFRLKKWIQKV.I Prothrombin  1506.68 44.9 I.FKSDFSNEERFT.G Complement C1s subcomponent  
1220.68 45.1 T.RYERNIEKI.S Prothrombin  1174.69 40.5 I.RLEKGFQVVV.T Complement C1s subcomponent  
1048.50 41.8 V.AFSDYIHPV.C Prothrombin  2241.96 52.2 V.SVHPDYRQDESYNFEGDIA.L Complement C1r subcomponent  
1345.84 40.3 V.FRLKKWIQKV.I Prothrombin  1985.95 117 V.DLLFFTDESGDSRGWKL.R Complement C1r subcomponent  
1036.62 52.4 V.NLPIVERPV.C Prothrombin  2094.06 127.6 T.LHLKFLEPFDIDDHQQV.H Complement C1r subcomponent  
1292.62 61 V.TGWGNLKETWT.A Prothrombin  2234.09 64.6 V.AGEHNIEETEHTEQKRNVI.R Coagulation factor IX  
2131.05 129.5 V.TGWGNLKETWTANVGKGQPS.V Prothrombin  2289.14 47.4 S.IPPWEAPKEHKYKAEEHTV.V Coagulation factor XII  
1176.66 62.6 V.ISKMLFVEPI.L Plasma protease C1 inhibitor  1980.98 91 L.HLKFLEPFDIDDHQQV.H Complement C1r subcomponent  
1517.85 91.9 V.ISKMLFVEPILEV.S Plasma protease C1 inhibitor  1336.71 62.5 V.SRKNPKFMETV.A Clusterin  
1885.86 65.4 V.RGEEDFSWFGYSLHGV.T Phosphatidylinositol-glycan-specific phospholipase D  1783.98 65.4 V.NKEIQNAVNGVKQIKT.L Clusterin  
1908.12 59.9 V.KDLLGIYEKLYGRKVI.T Phosphatidylinositol-glycan-specific phospholipase D  991.45 42.8 V.MQDHFSRA.S Clusterin  
1444.72 42 A.RHDVREGKEYGV.V N-acetylmuramoyl-L-alanine amidase  934.48 64.8 V.KLFDSDPI.T Clusterin  
1409.71 47.8 V.GAHTLGHNSRGFGV.A N-acetylmuramoyl-L-alanine amidase  1915.02 65.9 V.AEKALQEYRKKHREE.- Clusterin  
1337.65 64 V.QRIFENGYDPV.N Neutrophil elastase  1862.91 53 T.REPQDTYHYLPFSLP.H Clusterin  
2244.19 87.6 V.SAAFKGLKSLEYLDLSFNQI.A Lumican  1586.72 89.8 T.HMLDVMQDHFSRA.S Clusterin  
2315.21 119.3 V.SAAFKGLKSLEYLDLSFNQIA.R Lumican  1673.76 74.8 T.HMLDVMQDHFSRAS.S Clusterin  
1713.86 50.4 I.SNIPDEYFKRFNAL.Q Lumican  1360.76 45.3 T.LIEKTNEERKT.L Clusterin  
2069.01 73.8 V.DAALKKYNSQNQSNNQFV.L Kininogen-1  1270.60 58.5 T.QGEDQYYLRV.T Clusterin  
1882.97 113.8 V.TQNNFRLLFKGSEMVV.A Inter-alpha-trypsin inhibitor heavy chain H4  1630.81 73.6 S.SIIDELFQDRFFT.R Clusterin  
1900.91 85.5 V.QLLDSSNQEERLPEGSV.S Inter-alpha-trypsin inhibitor heavy chain H4  1280.63 66 R.SLMPFSPYEPL.N Clusterin  
1783.92 53.7 V.TQNNFRLLFKGSEMV.V Inter-alpha-trypsin inhibitor heavy chain H4  2157.03 61.9 I.IDELFQDRFFTREPQDT.Y Clusterin  
1605.76 51.2 V.HSGSTFFKYYLQGA.K Inter-alpha-trypsin inhibitor heavy chain H4  1624.77 75.7 L.NFHAMFQPFLEMI.H Clusterin  
1704.84 102.7 V.HYFAPEGLTTMPKNV.V Inter-alpha-trypsin inhibitor heavy chain H4  1318.63 61.8 I.DSLLENDRQQT.H Clusterin  
1053.57 41.1 T.QWRPSLVPA.S Inter-alpha-trypsin inhibitor heavy chain H4  1791.85 94.5 I.HFHSPAFQHPPTEFI.R Clusterin  
1440.77 88.9 V.AGKLQDRGPDVLTA.T Inter-alpha-trypsin inhibitor heavy chain H4  1430.69 62 I.IDELFQDRFFT.R Clusterin  
1640.90 61.1 V.AGKLQDRGPDVLTATV.S Inter-alpha-trypsin inhibitor heavy chain H4  1717.83 82.2 A.SSIIDELFQDRFFT.R Clusterin  
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1655.84 78.9 S.SRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2272.00 109.1 G.DQTVSDNELQEMSNQGSKYV.N Clusterin  
1568.82 62.9 S.RQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  1978.04 113.9 V.HLKNLASRPYTFHSHGI.T Ceruloplasmin  
2526.30 66 M.NFRPGVLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  1343.64 87.6 V.KWYLFGMGNEV.D Ceruloplasmin  
1742.88 42.5 L.SSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  1836.86 95.4 V.KWYLFGMGNEVDVHAA.F Ceruloplasmin  
1897.98 89.8 I.ILLTDGDPTVGETNPRSI.Q Inter-alpha-trypsin inhibitor heavy chain H4  1919.88 92.2 V.NKDDEEFIESNKMHAI.N Ceruloplasmin  
2808.43 86.8 I.ILLTDGDPTVGETNPRSIQNNVREAV.S Inter-alpha-trypsin inhibitor heavy chain H4  1115.55 40.8 A.FQHPPTEFI.R Clusterin  
1786.97 80 I.KILDDLSPRDQFNLI.V Inter-alpha-trypsin inhibitor heavy chain H4  1485.84 40.7 A.KLRRELDESLQV.A Clusterin  
1545.78 51.1 I.LDDLSPRDQFNLI.V Inter-alpha-trypsin inhibitor heavy chain H4  1736.86 62.3 V.HFHGHSFQYKHRGV.Y Ceruloplasmin  
2160.11 88.9 I.RFKPTLSQQQKSPEQQET.V Inter-alpha-trypsin inhibitor heavy chain H4  1976.83 86.4 V.DKDNEDFQESNRMYSV.N Ceruloplasmin  
2419.10 45.2 I.TFQTESSVAEQEAEFQSPKYI.F Inter-alpha-trypsin inhibitor heavy chain H4  2176.08 92.4 I.GIIETTWDYASDHGEKKLI.S Ceruloplasmin  
1155.66 43 L.ALDNGGLARRI.H Inter-alpha-trypsin inhibitor heavy chain H4  1440.76 52.8 I.IFKNMATRPYSI.H Ceruloplasmin  
3160.52 51 L.ALDNGGLARRIHEDSDSALQLQDFYQEV.A Inter-alpha-trypsin inhibitor heavy chain H4  2057.99 62.6 I.SVDTEHSNIYLQNGPDRI.G Ceruloplasmin  
2105.12 91.9 I.DKSGSMSGRKIQQTREALI.K Inter-alpha-trypsin inhibitor heavy chain H4  2092.00 56.2 I.YFSGNTYLWRGERRDTA.N Ceruloplasmin  
1319.68 47.5 I.GLLFWDGRGEGL.R Inter-alpha-trypsin inhibitor heavy chain H4  1892.05 57.1 I.YLQNGPDRIGRLYKKA.L Ceruloplasmin  
2023.88 133.6 I.HEDSDSALQLQDFYQEV.A Inter-alpha-trypsin inhibitor heavy chain H4  1635.86 44.1 T.RIYHSHIDAPKDIA.S Ceruloplasmin  
1955.03 78.4 G.VLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2912.23 109.2 T.YCSEPEKVDKDNEDFQESNRMYSV.N Ceruloplasmin  
1534.79 56.4 A.SAENVNKARSFAAGI.Q Inter-alpha-trypsin inhibitor heavy chain H4  1549.75 65.5 A.LYLQYTDETFRT.T Ceruloplasmin  
2092.04 66.5 V.KSMEDKGMTNINDGLLRGI.S Inter-alpha-trypsin inhibitor heavy chain H3  2203.04 69.7 V.TWPDESKAGGSWDLAVQERA.A Carboxypeptidase N subunit 2  
1766.83 51.5 V.AGRLVDEDMNSFKADV.K Inter-alpha-trypsin inhibitor heavy chain H3  1430.76 63.7 I.LYEPPAEKEQKV.L CD5 antigen-like  
1649.90 63.6 V.HFFAPQGLPVVPKNV.A Inter-alpha-trypsin inhibitor heavy chain H3  2038.02 51.8 A.FFHGQALTNKNYRIDTI.N Ceruloplasmin  
2446.14 47.8 A.RRIYEDSDADLQLQGFYEEV.A Inter-alpha-trypsin inhibitor heavy chain H3  2059.09 42.3 A.NLQSVPHASASRPRVTEPI.S Apolipoprotein L1  
1831.89 49.5 I.MLTDGDANVGESRPEKI.Q Inter-alpha-trypsin inhibitor heavy chain H3  1675.86 85.3 I.LNNNYKILQADQEL.- Apolipoprotein L1  
1333.75 42.6 V.VFDVQIPKGAFI.S Inter-alpha-trypsin inhibitor heavy chain H2  1709.05 43.7 T.RGIGKDIRALRRARA.N Apolipoprotein L1  
1726.77 108.3 V.TQNNFHNYFGGSEIV.V Inter-alpha-trypsin inhibitor heavy chain H2  2413.23 80.6 V.YESKHLHEGAKSETAEELKKV.A Apolipoprotein L1  
1825.84 109.9 V.TQNNFHNYFGGSEIVV.A Inter-alpha-trypsin inhibitor heavy chain H2  2788.45 60.8 V.YLVYESKHLHEGAKSETAEELKKV.A Apolipoprotein L1  
2893.33 122.2 V.LETLAQMDDLQDFLSKDKHADPDFT.R Inter-alpha-trypsin inhibitor heavy chain H2  1648.84 44.2 V.YQAGAREGAERGLSAI.R Apolipoprotein E  
1193.55 56.9 V.QFNYPHTSVT.D Inter-alpha-trypsin inhibitor heavy chain H2  1834.85 84.1 S.WFEPLVEDMQRQWA.G Apolipoprotein E  
1407.66 108 V.QFNYPHTSVTDV.T Inter-alpha-trypsin inhibitor heavy chain H2  1226.65 53.9 V.GSLAGQPLQERA.Q Apolipoprotein E  
2127.03 83.1 V.KENIQDNISLFSLGMGFDV.D Inter-alpha-trypsin inhibitor heavy chain H2  1313.73 70.7 V.RAKLEEQAQQI.R Apolipoprotein E  
2097.10 44 V.HFFAPDNLDPIPKNILFV.I Inter-alpha-trypsin inhibitor heavy chain H2  1508.86 50.1 I.RERLGPLVEQGRV.R Apolipoprotein E  
1737.91 106.9 V.HFFAPDNLDPIPKNI.L Inter-alpha-trypsin inhibitor heavy chain H2  1807.05 66 I.RERLGPLVEQGRVRAA.T Apolipoprotein E  
1518.83 53.9 V.ADAKRYIEKIQPS.G Inter-alpha-trypsin inhibitor heavy chain H2  1033.53 54.2 I.RLQAEAFQA.R Apolipoprotein E  
1341.75 71.1 S.GGTNINEALLRAI.F Inter-alpha-trypsin inhibitor heavy chain H2  1426.76 86 A.TVGSLAGQPLQERA.Q Apolipoprotein E  
1940.86 115.9 T.DVTQNNFHNYFGGSEIV.V Inter-alpha-trypsin inhibitor heavy chain H2  1086.57 41.7 A.QAWGERLRA.R Apolipoprotein E  
1642.85 83.4 T.ILDDLRAEDHFSVI.D Inter-alpha-trypsin inhibitor heavy chain H2  2109.02 100.5 V.KDKFSEFWDLDPEVRPT.S Apolipoprotein C-III  
1312.72 61.4 I.NQLLAERSLAPT.A Inter-alpha-trypsin inhibitor heavy chain H2  1759.86 129.7 T.AKDALSSVQESQVAQQA.R Apolipoprotein C-III  
2019.97 110 I.YGNQDTSSQLKKFYNQV.S Inter-alpha-trypsin inhibitor heavy chain H2  1504.69 98.2 T.DGFSSLKDYWSTV.K Apolipoprotein C-III  
2437.09 70.7 L.AQMDDLQDFLSKDKHADPDFT.R Inter-alpha-trypsin inhibitor heavy chain H2  1199.53 41.1 L.SFMQGYMKHA.T Apolipoprotein C-III  
1675.81 79 L.GMGFDVDYDFLKRL.S Inter-alpha-trypsin inhibitor heavy chain H2  1300.58 54.1 L.SFMQGYMKHAT.K Apolipoprotein C-III  
2427.13 82.1 L.GMGFDVDYDFLKRLSNENHGI.A Inter-alpha-trypsin inhibitor heavy chain H2  1529.71 63.8 L.SFMQGYMKHATKT.A Apolipoprotein C-III  
1804.91 79.9 I.DFNQNIRTWRNDLI.S Inter-alpha-trypsin inhibitor heavy chain H2  1842.91 94.2 A.SLLSFMQGYMKHATKT.A Apolipoprotein C-III  
1884.05 133.3 I.ILVSDGDPTVGELKLSKI.Q Inter-alpha-trypsin inhibitor heavy chain H2  1613.77 87.2 A.SLLSFMQGYMKHAT.K Apolipoprotein C-III  
2840.35 44.8 I.RGMADQDGLKPTIDKPSEDSPPLEML.G Inter-alpha-trypsin inhibitor heavy chain H1  1512.72 87.6 A.SLLSFMQGYMKHA.T Apolipoprotein C-III  
1746.92 44.4 I.RGRFPLYNLGFGHNV.D Inter-alpha-trypsin inhibitor heavy chain H1  2116.05 48.1 S.ELSAKMREWFSETFQKV.K Apolipoprotein C-I  
2384.22 80.7 T.IDKPSEDSPPLEMLGPRRTFV.L Inter-alpha-trypsin inhibitor heavy chain H1  2390.30 126.2 S.SALDKLKEFGNTLEDKARELI.S Apolipoprotein C-I  
2890.43 166.4 V.AGRIADNKQSSFKADVQAHGEGQEFSI.T Inter-alpha-trypsin inhibitor heavy chain H1  2889.52 225.9 G.TPDVSSALDKLKEFGNTLEDKARELI.S Apolipoprotein C-I  
2229.11 124.1 V.LALTQNHHKQYYEGSEIVV.A Inter-alpha-trypsin inhibitor heavy chain H1  2815.44 76.9 I.SRIKQSELSAKMREWFSETFQKV.K Apolipoprotein C-I  
1577.87 58.4 V.LFGTRVQSWKGSLV.Q Inter-alpha-trypsin inhibitor heavy chain H1  2691.42 181.2 P.DVSSALDKLKEFGNTLEDKARELI.S Apolipoprotein C-I  
1151.63 45.2 V.TAWKQYRKA.A Inter-alpha-trypsin inhibitor heavy chain H1  1989.94 47.9 S.SYWESAKTAAQNLYEKT.Y Apolipoprotein C-II  
1335.74 43.9 V.TAWKQYRKAAI.S Inter-alpha-trypsin inhibitor heavy chain H1  1634.84 58.1 T.GIFTDQVLSVLKGEE.- Apolipoprotein C-II  
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2989.47 87 V.VAGRIADNKQSSFKADVQAHGEGQEFSI.T Inter-alpha-trypsin inhibitor heavy chain H1  1998.05 53.4 T.YLPAVDEKLRDLYSKST.A Apolipoprotein C-II  
1447.80 46.8 A.DAKRYIEKIQPS.G Inter-alpha-trypsin inhibitor heavy chain H2  2069.09 75.3 T.YLPAVDEKLRDLYSKSTA.A Apolipoprotein C-II  
1944.06 44.5 L.GGPSVFLFPPKPKDTLMI.S Ig gamma-4 chain C region  2140.10 61.4 T.YLPAVDEKLRDLYSKSTAA.M Apolipoprotein C-II  
2409.04 118.9 V.TNDWIPEGEEDDDYLDLEKI.F Heparin cofactor 2  2114.94 104.4 A.SEAEDASLLSFMQGYMKHA.T Apolipoprotein C-III  
2177.00 72.8 I.FKYSHYNERDEIPHNDI.A Hyaluronan-binding protein 2  1024.49 44.1 A.RGWVTDGFS.S Apolipoprotein C-III  
2304.15 43.9 V.VLGDQDLKKEEFHEQSFRV.E Hyaluronan-binding protein 2  2104.01 157.8 A.RGWVTDGFSSLKDYWSTV.K Apolipoprotein C-III  
1497.79 47.6 V.WKSHKWDRELI.S Hemopexin  2146.12 125.6 V.SQFTLPKSVSDGIAALDLNAV.A Apolipoprotein B-100  
1574.80 71.6 V.DAAFRQGHNSVFLI.K Hemopexin  1814.96 63.3 V.SSKLRRNLQNNAEWV.Y Apolipoprotein B-100  
1346.68 52.2 I.SERWKNFPSPV.D Hemopexin  2285.21 49.3 V.STTKTEVIPPLIENRQSWSV.C Apolipoprotein B-100  
2040.10 78.4 I.RHYEGSTVPEKKTPKSPV.G Haptoglobin  1186.60 59 V.YDKSLWDFL.K Apolipoprotein B-100  
2449.19 74.7 A.LYSGNDVTDISDDRFPKPPEIA.N Haptoglobin-related protein  1213.56 51.4 A.KMREWFSET.F Apolipoprotein C-I  
1303.75 64.9 I.SLLLWGRQLFA.L Haptoglobin-related protein  1715.85 81.7 A.KMREWFSETFQKV.K Apolipoprotein C-I  
927.43 53.7 A.HGYVEHSV.R Haptoglobin  2260.10 102.6 V.RIHSGSFQSQVELSNDQEKA.H Apolipoprotein B-100  
2249.14 98.9 A.ATASRGASQAGAPQGRVPEARPN.S Gelsolin  1797.05 73.4 V.RVPSYTLILPSLELPV.L Apolipoprotein B-100  
1443.78 104.3 A.HLMSLFGGKPMII.Y Gelsolin  1114.51 49 V.NKYHWEHT.G Apolipoprotein B-100  
1511.73 60.4 A.YLWVGTGASEAEKT.G Gelsolin  2706.39 52.9 V.QFLEYELNVLGTHKIEDGTLASKT.K Apolipoprotein B-100  
2378.22 80.2 A.YLWVGTGASEAEKTGAQELLRV.L Gelsolin  1964.84 104.3 V.DHFGYTKDDKHEQDMV.N Apolipoprotein B-100  
2904.42 120.2 C.SNKIGRFVIEEVPGELMQEDLATDDV.M Gelsolin  2248.98 113.1 V.DHFGYTKDDKHEQDMVNGI.M Apolipoprotein B-100  
1188.60 53.5 I.ANVERVPFDAA.T Gelsolin  1514.77 44.9 V.GFHLPSREFQVPT.F Apolipoprotein B-100  
1862.99 40 I.FVWKGKQANTEERKAA.L Gelsolin  3346.43 54.6 V.GMDMDEDDDFSKWNFYYSPQSSPDKKLT.I Apolipoprotein B-100  
2462.16 113.6 I.GRFVIEEVPGELMQEDLATDDV.M Gelsolin  2461.14 129.4 V.LVDHFGYTKDDKHEQDMVNGI.M Apolipoprotein B-100  
1674.87 52.6 I.LYNYRHGGRQGQII.Y Gelsolin  1963.27 44.5 V.ALKAGKLKFIIPSPKRPV.K Apolipoprotein B-100  
1338.67 49.6 I.TKMDYPKQTQV.S Gelsolin  2416.29 66.9 T.SSFALNLPTLPEVKFPEVDVLT.K Apolipoprotein B-100  
1434.76 113 I.TVVKQGFEPPSFV.G Gelsolin  2937.51 67.4 T.LNLNDFQVPDLHIPEFQLPHISHTI.E Apolipoprotein B-100  
1567.83 42.3 I.WRIEGSNKVPVDPA.T Gelsolin  1812.90 103.1 T.KYSQPEDSLIPFFEI.T Apolipoprotein B-100  
1585.87 47.9 I.WRVEKFDLVPVPT.N Gelsolin  1098.60 56 S.AFGYVFPKAV.S Apolipoprotein B-100  
1667.81 48 I.YKGGTSREGGQTAPAST.R Gelsolin  1390.62 80.8 S.SFHDFPDLGQEV.A Apolipoprotein B-100  
1062.60 65.9 M.SLFGGKPMII.Y Gelsolin  1903.95 63.3 T.AFVYTKNPNGYSFSIPV.K Apolipoprotein B-100  
2520.31 48.2 S.AAYLWVGTGASEAEKTGAQELLRV.L Gelsolin  1806.00 52.7 T.ALTKKYRITENDIQI.A Apolipoprotein B-100  
1438.73 71.3 S.HIANVERVPFDAA.T Gelsolin  1613.92 48.4 T.DLHLRYQKDKKGI.S Apolipoprotein B-100  
1525.78 79.5 S.SHIANVERVPFDAA.T Gelsolin  1386.70 54 T.FHVPFTDLQVPS.C Apolipoprotein B-100  
2259.19 51.7 T.SAKRYIETDPANRDRRTPI.T Gelsolin  1185.62 61.8 M.SAFGYVFPKAV.S Apolipoprotein B-100  
2096.01 134.6 V.FVWVGKDSQEEEKTEALT.S Gelsolin  1445.71 89.4 I.EMSAFGYVFPKAV.S Apolipoprotein B-100  
2313.02 57.8 V.GWFLGWDDDYWSVDPLDRA.M Gelsolin  3193.67 126.3 I.KFDKYKAEKSHDELPRTFQIPGYTVPV.V Apolipoprotein B-100  
2534.33 139.6 V.LGPKPALPAGTEDTAKEDAANRKLA.K Gelsolin  1049.65 52.4 I.QIYKKLRT.S Apolipoprotein B-100  
3165.76 50.2 V.LGPKPALPAGTEDTAKEDAANRKLAKLYKV.S Gelsolin  1603.85 57.3 I.RQIDDIDVRFQKA.A Apolipoprotein B-100  
1198.66 45.5 V.QSRVVQGKEPA.H Gelsolin  1871.03 51.8 I.TLPDFRLPEIAIPEFI.I Apolipoprotein B-100  
1947.91 42.4 V.QVAEGSEPDGFWEALGGKA.A Gelsolin  2182.21 78.1 I.TLPDFRLPEIAIPEFIIPT.L Apolipoprotein B-100  
2699.43 42.1 V.RANSAGATRAVEVLPKAGALNSNDAFV.L Gelsolin  1662.86 58.4 I.TTPPLKDFSLWEKT.G Apolipoprotein B-100  
1700.92 68.2 V.SKGIRDNERSGRARV.H Gelsolin  1541.77 58.4 L.FGKQGFFPDSVNKA.L Apolipoprotein B-100  
2038.06 46.7 V.SVLPEGGETPLFKQFFKN.W Gelsolin  1911.04 92.7 L.NLPTLPEVKFPEVDVLT.K Apolipoprotein B-100  
2936.47 57.4 V.SVLPEGGETPLFKQFFKNWRDPDQT.D Gelsolin  2591.30 47.2 A.ALGKLPQQANDYLNSFNWERQV.S Apolipoprotein B-100  
1616.86 65.2 V.WKGKQANTEERKAA.L Gelsolin  2033.13 94.2 A.HLDIAGSLEGHLRFLKNI.I Apolipoprotein B-100  
1137.53 77 V.YYQGGTYSKA.S Fibrinogen gamma chain  2871.51 48.3 V.SQKIGDNLRELQQRLEPYADQLRT.Q Apolipoprotein A-IV  
1536.70 56.4 V.YYQGGTYSKASTPN.G Fibrinogen gamma chain  3098.63 52.5 V.SQKIGDNLRELQQRLEPYADQLRTQV.N Apolipoprotein A-IV  
2155.95 109.7 V.YYQGGTYSKASTPNGYDNGI.I Fibrinogen gamma chain  2588.34 87.5 V.NTQAEQLRRQLTPYAQRMERV.L Apolipoprotein A-IV  
2269.03 88 V.YYQGGTYSKASTPNGYDNGII.W Fibrinogen gamma chain  1529.80 48.4 V.RGNLRGNTEGLQKS.L Apolipoprotein A-IV  
2526.20 150.2 V.YYQGGTYSKASTPNGYDNGIIWA.T Fibrinogen gamma chain  1713.94 84.3 V.RGNLRGNTEGLQKSLA.E Apolipoprotein A-IV  
2627.17 43.8 V.YYQGGTYSKASTPNGYDNGIIWAT.W Fibrinogen gamma chain  1902.86 91.9 V.MWDYFSQLSNNAKEAV.E Apolipoprotein A-IV  
2016.93 84.6 T.TGQSYNQYSQRYHQRT.N Fibronectin  1922.91 86.8 V.NSFFSTFKEKESQDKT.L Apolipoprotein A-IV  
222 
 
2232.05 54.5 T.TGQSYNQYSQRYHQRTNT.N Fibronectin  1262.71 41.2 S.FLEKDLRDKV.N Apolipoprotein A-IV  
2445.14 42.9 T.TGQSYNQYSQRYHQRTNTNV.N Fibronectin  3092.65 95.8 T.ELHERLAKDSEKLKEEIGKELEELRA.R Apolipoprotein A-IV  
1782.74 76.6 V.SHYAVGDEWERMSES.G Fibronectin  1700.89 122.3 L.RQKLGPHAGDVEGHLS.F Apolipoprotein A-IV  
2036.07 71.6 V.TLPHPNLHGPEILDVPSTV.Q Fibronectin  2944.59 145.7 L.RQKLGPHAGDVEGHLSFLEKDLRDKV.N Apolipoprotein A-IV  
1661.86 68.6 A.TFRLLGEVDHYQLA.L Ficolin-3  1807.00 88.7 L.TFQMKKNAEELKARI.S Apolipoprotein A-IV  
1712.88 51.5 I.DWASGRGVGHPYRRV.R Ficolin-3  2419.25 119.5 L.GPHAGDVEGHLSFLEKDLRDKV.N Apolipoprotein A-IV  
2696.25 72.6 S.SYRAGFGNQESEFWLGNENLHQL.T Ficolin-3  2651.38 182.1 V.KSPELQAEAKSYFEKSKEQLTPL.I Apolipoprotein A-II  
2276.00 102.5 V.RPEHPAETEYDSLYPEDDL.- Fibrinogen gamma chain  3091.72 188 V.KSPELQAEAKSYFEKSKEQLTPLIKKA.G Apolipoprotein A-II  
1727.76 74.4 V.ELEDWNGRTSTADYA.M Fibrinogen gamma chain  3249.79 110.7 V.KSPELQAEAKSYFEKSKEQLTPLIKKAGT.E Apolipoprotein A-II  
1232.72 46.5 T.TMKIIPFNRL.T Fibrinogen gamma chain  3590.98 253.8 V.KSPELQAEAKSYFEKSKEQLTPLIKKAGTELV.N Apolipoprotein A-II  
1446.85 48.3 T.TMKIIPFNRLTI.G Fibrinogen gamma chain  889.46 52.9 V.NFLSYFV.E Apolipoprotein A-II  
3015.20 194.8 T.YAYFAGGDAGDAFDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  1298.63 82.8 V.TDYGKDLMEKV.K Apolipoprotein A-II  
2527.40 91.4 T.RWYSMKKTTMKIIPFNRLTI.G Fibrinogen gamma chain  2592.38 100.1 A.KIDQNVEELKGRLTPYADEFKV.K Apolipoprotein A-IV  
    2351.20 108.2 I.DQNVEELKGRLTPYADEFKV.K Apolipoprotein A-IV  
    1955.03 109.8 I.SASAEELRQRLAPLAEDV.R Apolipoprotein A-IV  
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Peptide/Protein Identifications from Proteinase 3 Experiments 
m/z Score Sequence Protein m/z  Score Sequence Protein 
3775.71 113.9 A.EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFA.F Alpha-1-antitrypsin  1749.84 111.5 R.SLMPFSPYEPLNFHA.M Clusterin  
2172.16 47.3 A.LVNYIFFKGKWERPFEV.K Alpha-1-antitrypsin  1543.78 64.7 S.IIDELFQDRFFT.R Clusterin  
1007.62 41.9 A.SLHLPKLSI.T Alpha-1-antitrypsin  1711.84 92.8 S.LLENDRQQTHMLDV.M Clusterin  
1569.81 53.9 I.FFKGKWERPFEV.K Alpha-1-antitrypsin  1662.80 70.7 S.LMPFSPYEPLNFHA.M Clusterin  
1578.79 49.6 I.ITKFLENEDRRSA.S Alpha-1-antitrypsin  1630.82 78.2 S.SIIDELFQDRFFT.R Clusterin  
2127.13 118.9 I.TGTYDLKSVLGQLGITKVFS.N Alpha-1-antitrypsin  2097.12 94.3 T.NNPSQAKLRRELDESLQV.A Clusterin  
1194.62 49.6 K.KLYHSEAFTV.N Alpha-1-antitrypsin  1371.66 78.5 T.QGEDQYYLRVT.T Clusterin  
2390.24 114.2 L.MIEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  1472.71 51.9 T.QGEDQYYLRVTT.V Clusterin  
1591.86 103.1 L.SEGLKLVDKFLEDV.K Alpha-1-antitrypsin  1967.95 116.6 T.QGEDQYYLRVTTVASHT.S Clusterin  
2259.21 108.5 M.IEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  3667.98 47.4 T.REPQDTYHYLPFSLPHRRPHFFFPKSRIV.R Clusterin  
1501.83 80.7 M.SIPPEVKFNKPFV.F Alpha-1-antitrypsin  2014.07 63.7 T.VAEKALQEYRKKHREE.- Clusterin  
1761.98 53.9 M.SIPPEVKFNKPFVFL.M Alpha-1-antitrypsin  1915.02 71 V.AEKALQEYRKKHREE.- Clusterin  
4133.31 121.4 M.SIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  1758.94 119.2 V.KLFDSDPITVTVPVEV.S Clusterin  
2579.31 96.4 T.AIFFLPDEGKLQHLENELTHDI.I Alpha-1-antitrypsin  3076.65 80.8 V.KLFDSDPITVTVPVEVSRKNPKFMETV.A Clusterin  
1545.83 54.6 T.KSPLFMGKVVNPTQ.K Alpha-1-antitrypsin  2690.29 94.6 V.MQDHFSRASSIIDELFQDRFFT.R Clusterin  
1673.94 110.9 T.KSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  1336.71 50.1 V.SRKNPKFMETV.A Clusterin  
2169.10 40.7 V.DKFLEDVKKLYHSEAFTV.N Alpha-1-antitrypsin  3232.71 89.6 V.SRKNPKFMETVAEKALQEYRKKHREE.- Clusterin  
1322.71 88.8 V.KKLYHSEAFTV.N Alpha-1-antitrypsin  1961.03 50.7 V.TVPVEVSRKNPKFMETV.A Clusterin  
3142.74 56.6 V.LGQLGITKVFSNGADLSGVTEEAPLKLSKAV.H Alpha-1-antitrypsin  3274.80 42.8 V.VVKLFDSDPITVTVPVEVSRKNPKFMETV.A Clusterin  
1960.02 86.6 V.NYIFFKGKWERPFEV.K Alpha-1-antitrypsin  1327.75 64.4 G.SIPIPQKLFGEV.T Complement C1r subcomponent  
2049.08 42.1 V.DLKPPFGGSAPSERLELHV.D Alpha-1B-glycoprotein  2022.06 93.4 R.IIGGQKAKMGNFPWQVFT.N Complement C1r subcomponent  
1964.97 77.7 I.KEDFLEQSEQLFGAKPV.S Alpha-2-antiplasmin  1240.72 82.6 S.IPIPQKLFGEV.T Complement C1r subcomponent  
1961.97 84.7 L.KLVPPMEEDYPQFGSPK.- Alpha-2-antiplasmin  1669.81 60.2 T.DESGDSRGWKLRYT.T Complement C1r subcomponent  
2216.13 93.1 A.ALVAIDYINQNLPWGYKHT.L Alpha-2-HS-glycoprotein  1906.03 54.3 T.NIHGRGGGALLGDRWILT.A Complement C1r subcomponent  
1861.92 93.6 A.IDYINQNLPWGYKHT.L Alpha-2-HS-glycoprotein  2460.32 67.3 V.FLGHTNVEELMKLGNHPIRRV.S Complement C1r subcomponent  
2673.33 80.9 A.IDYINQNLPWGYKHTLNQIDEV.K Alpha-2-HS-glycoprotein  1487.76 40.6 V.MEEKIAHDLRFV.R Complement C1r subcomponent  
1115.57 42.3 Q.NLPWGYKHT.L Alpha-2-HS-glycoprotein  1934.98 57.6 V.SGFGVMEEKIAHDLRFV.R Complement C1r subcomponent  
1451.77 54 S.LGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  3139.47 83.4 V.SVHPDYRQDESYNFEGDIALLELENSV.T Complement C1r subcomponent  
1842.91 66.9 T.FMGVVSLGSPSGEVSHPR.K Alpha-2-HS-glycoprotein  1174.70 61.8 I.RLEKGFQVVV.T Complement C1s subcomponent  
2072.06 142.4 T.FMGVVSLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  1619.77 77.4 V.IFKSDFSNEERFT.G Complement C1s subcomponent  
1932.96 105.2 V.AIDYINQNLPWGYKHT.L Alpha-2-HS-glycoprotein  1894.89 60 V.IFKSDFSNEERFTGFA.A Complement C1s subcomponent  
1909.00 78.9 V.LLAAPPGHQLHRAHYDL.R Alpha-2-HS-glycoprotein  2612.29 62.5 A.KDKNRWEDPGKQLYNVEATSYA.L Complement C3  
2303.24 83 V.LLAAPPGHQLHRAHYDLRHT.F Alpha-2-HS-glycoprotein  1388.66 55.1 A.NYMNLQRSYTV.A Complement C3  
1309.65 51.8 V.SLGSPSGEVSHPR.K Alpha-2-HS-glycoprotein  2559.41 75.4 A.VDKGVFVLNKKNKLTQSKIWDV.V Complement C3  
1538.80 98.6 V.SLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  1098.58 70.7 I.HWESASLLR.S Complement C3  
1408.72 77.7 V.VSLGSPSGEVSHPR.K Alpha-2-HS-glycoprotein  1751.77 58.7 L.NEQRYYGGGYGSTQAT.F Complement C3  
1637.86 97.1 V.VSLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  2168.06 63.7 Q.ALAQYQKDAPDHQELNLDV.S Complement C3  
864.46 49 M.HGPEGLRV.G Alpha-2-macroglobulin  1493.72 64.5 Q.KDAPDHQELNLDV.S Complement C3  
1447.72 67 M.HGPEGLRVGFYES.D Alpha-2-macroglobulin  3576.84 93 R.EGVQKEDIPPADLSDQVPDTESETRILLQGTPV.A Complement C3  
1661.80 83.9 M.HGPEGLRVGFYESDV.M Alpha-2-macroglobulin  1551.81 50.8 R.SSKITHRIHWESA.S Complement C3  
2639.38 74.7 M.HGPEGLRVGFYESDVMGRGHARLV.H Alpha-2-macroglobulin  1208.65 65.6 T.KLMNIFLKDS.I Complement C3  
1210.66 56.5 S.DVMGRGHARLV.H Alpha-2-macroglobulin  1860.09 50.6 T.YLIMNKGRLLKAGRQV.R Complement C3  
1793.84 89.8 V.GFYESDVMGRGHARLV.H Alpha-2-macroglobulin  3879.07 52.6 V.HYLDETEQWEKFGLEKRQGALELIKKGYTQQL.A Complement C3  
1568.88 50.9 A.ARLEALKENGGARLA.E Apolipoprotein A-I  2334.15 102.1 V.IVEPTEKFYYIYNEKGLEV.T Complement C3  
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1550.82 79.8 A.ELQEGARQKLHEL.Q Apolipoprotein A-I  3147.57 111.1 V.KSGQSEDRQPVPGQQMTLKIEGDHGARVV.L Complement C3  
2792.38 131.8 A.ELQEGARQKLHELQEKLSPLGEEM.R Apolipoprotein A-I  1472.71 71.4 V.NFLLRMDRAHEA.K Complement C3  
1285.62 65.3 A.EYHAKATEHLS.T Apolipoprotein A-I  1737.95 85.7 V.REPGQDLVVLPLSITT.D Complement C3  
2211.15 161 A.EYHAKATEHLSTLSEKAKPA.L Apolipoprotein A-I  2333.26 86.2 V.SLQLPSRSSKITHRIHWESA.S Complement C3  
2681.33 176.6 A.EYHAKATEHLSTLSEKAKPALEDL.R Apolipoprotein A-I  2829.42 46.1 A.SRYLDKTEQWSTLPPETKDHAVDL.I Complement C4-A  
3444.86 215.6 A.EYHAKATEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1896.03 95.5 R.NGFKSHALQLNNRQIR.G Complement C4-A  
1710.92 108.7 A.KATEHLSTLSEKAKPA.L Apolipoprotein A-I  3185.67 55.3 R.NGFKSHALQLNNRQIRGLEEELQFSLGS.K Complement C4-A  
2944.66 182.5 A.KATEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2751.31 145.3 R.TLEIPGNSDPNMIPDGDFNSYVRVT.A Complement C4-A  
1252.70 54.6 A.LEDLRQGLLPV.L Apolipoprotein A-I  2388.42 60.9 S.KINVKVGGNSKGTLKVLRTYNV.L Complement C4-A  
1581.86 61.1 A.LEDLRQGLLPVLES.F Apolipoprotein A-I  1934.09 78.4 V.KVGGNSKGTLKVLRTYNV.L Complement C4-A  
1956.11 75.7 A.LEDLRQGLLPVLESFKV.S Apolipoprotein A-I  2932.51 73.4 V.SYKHKGALHNYKMTDKNFLGRPVEV.L Complement C5  
2043.15 60.6 A.LEDLRQGLLPVLESFKVS.F Apolipoprotein A-I  2467.33 44.3 A.SSINDAPVLISQKLSPIYNLVPV.K Complement component C9  
1366.71 73.5 A.LEEYTKKLNTQ.- Apolipoprotein A-I  1155.65 56.3 V.KGEIHLGRFV.M Complement component C9  
3220.69 55.1 A.LKENGGARLAEYHAKATEHLSTLSEKAKPA.L Apolipoprotein A-I  1756.96 57.8 V.QELQKRLDRLEETV.Q Coronin-1A  
2736.30 46.4 A.RHFWQQDEPPQSPWDRVKDLAT.V Apolipoprotein A-I  1465.65 57.7 A.DSGEGDFLAEGGGVR.G Fibrinogen alpha chain  
1625.81 51.6 A.RLAEYHAKATEHLS.T Apolipoprotein A-I  1973.94 56.1 A.DSGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
2551.34 124.5 A.RLAEYHAKATEHLSTLSEKAKPA.L Apolipoprotein A-I  1954.92 42.4 A.EYHFRVGSEAEGYALQV.S Fibrinogen alpha chain  
3785.10 117.6 A.RLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  3076.43 43 A.MDLGTLSGIGTLDGFRHRHPDEAAFFDT.A Fibrinogen alpha chain  
1497.85 93.5 A.RLEALKENGGARLA.E Apolipoprotein A-I  1948.96 89.4 A.STGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
1998.06 135.7 A.RLEALKENGGARLAEYHA.K Apolipoprotein A-I  1622.74 54.8 L.RVELEDWAGNEAYA.E Fibrinogen alpha chain  
2677.38 110.5 A.RLEALKENGGARLAEYHAKATEHL.S Apolipoprotein A-I  2622.27 68.1 S.SSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
2764.42 69.2 A.RLEALKENGGARLAEYHAKATEHLS.T Apolipoprotein A-I  2897.35 40.5 S.SSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
3689.96 122.7 A.RLEALKENGGARLAEYHAKATEHLSTLSEKAKPA.L Apolipoprotein A-I  2045.00 44.1 T.ADSGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
2165.15 147.8 A.RQKLHELQEKLSPLGEEM.R Apolipoprotein A-I  1474.68 41.4 T.ASTGKTFPGFFSPM.L Fibrinogen alpha chain  
3126.63 63.8 A.RQKLHELQEKLSPLGEEMRDRARAHV.D Apolipoprotein A-I  1920.91 92.1 T.ASTGKTFPGFFSPMLGEF.V Fibrinogen alpha chain  
2745.47 89.2 A.TEHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2020.00 109.8 T.ASTGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
2537.28 89.3 G.SALGKQLNLKLLDNWDSVTSTFS.K Apolipoprotein A-I  2125.00 51.8 T.KESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
1483.66 56.4 L.DDFQKKWQEEM.E Apolipoprotein A-I  2966.43 121.5 T.KESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
1612.77 119.8 L.KLLDNWDSVTSTFS.K Apolipoprotein A-I  3241.52 66 T.KESSSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
2734.40 102.3 L.KLLDNWDSVTSTFSKLREQLGPVT.Q Apolipoprotein A-I  2030.96 52.4 T.LDGFRHRHPDEAAFFDT.A Fibrinogen alpha chain  
1308.68 46 L.QEGARQKLHEL.Q Apolipoprotein A-I  1294.65 53.6 T.NIMEILRGDFS.S Fibrinogen alpha chain  
2550.33 125.9 L.QEGARQKLHELQEKLSPLGEEM.R Apolipoprotein A-I  3181.51 110.6 T.NTKESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
1260.60 99 L.QEKLSPLGEEM.R Apolipoprotein A-I  3456.62 48.4 T.NTKESSSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
2222.16 105.6 L.QEKLSPLGEEMRDRARAHV.D Apolipoprotein A-I  2810.17 72.8 T.SESSVSGSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  
1777.95 83.3 L.RAELQEGARQKLHEL.Q Apolipoprotein A-I  1573.82 43 T.SLGGWLLIQQRMDG.S Fibrinogen alpha chain  
3019.54 58.9 L.RAELQEGARQKLHELQEKLSPLGEEM.R Apolipoprotein A-I  2174.94 83.3 T.SSTSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
1524.79 91.8 L.SALEEYTKKLNTQ.- Apolipoprotein A-I  2246.01 89.2 T.SSTSYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
1964.09 108.8 L.SEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1899.84 68.3 T.SYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
2265.25 141 L.STLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1970.89 90.6 T.SYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
2968.68 48.2 L.STLSEKAKPALEDLRQGLLPVLESFKV.S Apolipoprotein A-I  1395.70 41 T.TNIMEILRGDFS.S Fibrinogen alpha chain  
2129.11 50.8 M.ELYRQKVEPLRAELQEGA.R Apolipoprotein A-I  1408.75 49.8 V.IGPDGHKEVTKEV.V Fibrinogen alpha chain  
2205.14 69.5 M.RDRARAHVDALRTHLAPYS.D Apolipoprotein A-I  1608.84 57.9 V.IGPDGHKEVTKEVVT.S Fibrinogen alpha chain  
2151.07 40.3 N.WDSVTSTFSKLREQLGPVT.Q Apolipoprotein A-I  1486.66 45.3 V.SETESRGSESGIFT.N Fibrinogen alpha chain  
1853.87 53.5 Q.DEPPQSPWDRVKDLAT.V Apolipoprotein A-I  1701.76 75.7 V.SETESRGSESGIFTNT.K Fibrinogen alpha chain  
2215.11 64.7 Q.DEPPQSPWDRVKDLATVYV.D Apolipoprotein A-I  2045.93 135.5 V.SETESRGSESGIFTNTKES.S Fibrinogen alpha chain  
1437.77 72.6 S.ALEEYTKKLNTQ.- Apolipoprotein A-I  3633.75 95.1 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  
1540.86 54.2 S.DELRQRLAARLEA.L Apolipoprotein A-I  3807.81 153.6 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
2210.17 99.6 S.DELRQRLAARLEALKENGGA.R Apolipoprotein A-I  4144.98 81.2 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  
2550.40 110.7 S.DELRQRLAARLEALKENGGARLA.E Apolipoprotein A-I  1341.69 46.1 V.SFRGADYSLRAV.R Fibrinogen alpha chain  
3050.60 119.2 S.DELRQRLAARLEALKENGGARLAEYHA.K Apolipoprotein A-I  2030.05 63.5 V.SGNVSPGTRREYHTEKLV.T Fibrinogen alpha chain  
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1656.87 73.9 S.FLSALEEYTKKLNT.Q Apolipoprotein A-I  2131.10 46.4 V.SGNVSPGTRREYHTEKLVT.S Fibrinogen alpha chain  
1784.94 105.1 S.FLSALEEYTKKLNTQ.- Apolipoprotein A-I  3788.04 61.6 V.SGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVT.S Fibrinogen alpha chain  
1140.68 65.1 S.KLREQLGPVT.Q Apolipoprotein A-I  1837.98 44.6 V.TKTVIGPDGHKEVTKEV.V Fibrinogen alpha chain  
2560.28 156.8 S.KLREQLGPVTQEFWDNLEKET.E Apolipoprotein A-I  1456.82 44.4 L.KDLWQKRQKQV.K Fibrinogen beta chain  
3403.72 56.6 S.KLREQLGPVTQEFWDNLEKETEGLRQEM.S Apolipoprotein A-I  1936.95 79.2 M.EDWKGDKVKAHYGGFTV.Q Fibrinogen beta chain  
2178.23 112.2 S.TLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1160.63 50.1 M.KIRPFFPQQ.- Fibrinogen beta chain  
1662.81 74.4 T.EGLRQEMSKDLEEV.K Apolipoprotein A-I  1289.66 51.5 T.RMGPTELLIEM.E Fibrinogen beta chain  
2644.47 165.2 T.EHLSTLSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1747.75 112.2 T.WDMAKHGTDDGVVWM.N Fibrinogen beta chain  
1739.93 82.2 T.HLAPYSDELRQRLAA.R Apolipoprotein A-I  1856.76 106.5 A.FDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  
2077.20 64.7 T.LSEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  2846.14 57 A.FDGFDFGDDPSDKFFTSHNGMQFST.W Fibrinogen gamma chain  
1438.63 100.3 T.QEFWDNLEKET.E Apolipoprotein A-I  2399.96 137.5 A.GGDAGDAFDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  
3082.48 50.9 T.QEFWDNLEKETEGLRQEMSKDLEEV.K Apolipoprotein A-I  2486.95 90.1 A.GGDAGDAFDGFDFGDDPSDKFFTS.H Fibrinogen gamma chain  
2982.48 58.6 T.STFSKLREQLGPVTQEFWDNLEKET.E Apolipoprotein A-I  3288.30 135.3 A.GGDAGDAFDGFDFGDDPSDKFFTSHNGMQFS.T Fibrinogen gamma chain  
1243.65 61.9 V.DALRTHLAPYS.D Apolipoprotein A-I  3389.38 135.2 A.GGDAGDAFDGFDFGDDPSDKFFTSHNGMQFST.W Fibrinogen gamma chain  
2296.22 103 V.DALRTHLAPYSDELRQRLAA.R Apolipoprotein A-I  1515.69 113.8 A.GHLNGVYYQGGTYS.K Fibrinogen gamma chain  
1266.62 60.1 V.DVLKDSGRDYV.S Apolipoprotein A-I  1654.86 73.7 A.MFKVGPEADKYRLT.Y Fibrinogen gamma chain  
1901.88 64.3 V.DVLKDSGRDYVSQFEGS.A Apolipoprotein A-I  1888.97 70.1 A.MFKVGPEADKYRLTYA.Y Fibrinogen gamma chain  
2512.25 73.6 V.DVLKDSGRDYVSQFEGSALGKQL.N Apolipoprotein A-I  2270.14 50.7 A.MFKVGPEADKYRLTYAYFA.G Fibrinogen gamma chain  
2739.36 129.6 V.DVLKDSGRDYVSQFEGSALGKQLNL.K Apolipoprotein A-I  2781.08 175.3 A.YFAGGDAGDAFDGFDFGDDPSDKFFT.S Fibrinogen gamma chain  
2411.18 151.4 V.KAKVQPYLDDFQKKWQEEM.E Apolipoprotein A-I  1458.68 97.8 G.HLNGVYYQGGTYS.K Fibrinogen gamma chain  
3666.91 135.8 V.KAKVQPYLDDFQKKWQEEMELYRQKVEPL.R Apolipoprotein A-I  1922.85 46.6 I.QLTYNPDESSKPNMIDA.A Fibrinogen gamma chain  
3894.11 62 V.KAKVQPYLDDFQKKWQEEMELYRQKVEPLRA.E Apolipoprotein A-I  1606.79 102.8 S.KASTPNGYDNGIIWA.T Fibrinogen gamma chain  
722.40 42.6 V.LESFKV.S Apolipoprotein A-I  2309.13 91.7 T.ADYAMFKVGPEADKYRLTYA.Y Fibrinogen gamma chain  
1069.58 66.4 V.LESFKVSFL.S Apolipoprotein A-I  2690.30 41.4 T.ADYAMFKVGPEADKYRLTYAYFA.G Fibrinogen gamma chain  
1156.62 83.3 V.LESFKVSFLS.A Apolipoprotein A-I  2406.17 73.2 T.QSAIPYALRVELEDWNGRTST.A Fibrinogen gamma chain  
1227.66 89.3 V.LESFKVSFLSA.L Apolipoprotein A-I  2826.34 63.4 T.QSAIPYALRVELEDWNGRTSTADYA.M Fibrinogen gamma chain  
1862.94 129.6 V.LESFKVSFLSALEEYT.K Apolipoprotein A-I  907.36 54.3 T.SHNGMQFS.T Fibrinogen gamma chain  
2447.31 130.8 V.LESFKVSFLSALEEYTKKLNT.Q Apolipoprotein A-I  1008.43 66.7 T.SHNGMQFST.W Fibrinogen gamma chain  
2575.36 166.9 V.LESFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  1599.85 59.8 T.TEFWLGNEKIHLI.S Fibrinogen gamma chain  
2525.29 79.9 V.LKDSGRDYVSQFEGSALGKQLNL.K Apolipoprotein A-I  2453.19 68.2 V.DFKKNWIQYKEGFGHLSPTGT.T Fibrinogen gamma chain  
1743.91 76.5 V.SFLSALEEYTKKLNT.Q Apolipoprotein A-I  1727.76 46.7 V.ELEDWNGRTSTADYA.M Fibrinogen gamma chain  
1871.95 112.9 V.SFLSALEEYTKKLNTQ.- Apolipoprotein A-I  1932.84 48.8 V.RPEHPAETEYDSLYPE.D Fibrinogen gamma chain  
1264.64 76.5 V.SQFEGSALGKQL.N Apolipoprotein A-I  2276.02 102 V.RPEHPAETEYDSLYPEDDL.- Fibrinogen gamma chain  
1491.76 99.4 V.SQFEGSALGKQLNL.K Apolipoprotein A-I  938.40 47 V.YYQGGTYS.K Fibrinogen gamma chain  
2463.22 143.4 V.SQFEGSALGKQLNLKLLDNWDS.V Apolipoprotein A-I  2696.20 117.8 S.SYRAGFGNQESEFWLGNENLHQL.T Ficolin-3  
2663.38 101.5 V.SQFEGSALGKQLNLKLLDNWDSVT.S Apolipoprotein A-I  1278.62 84.5 V.DHYQLALGKFS.E Ficolin-3  
3085.56 182.9 V.SQFEGSALGKQLNLKLLDNWDSVTSTFS.K Apolipoprotein A-I  1411.75 57.6 A.NFKFTDHLKYV.M Haptoglobin  
1539.67 75.5 V.TQEFWDNLEKET.E Apolipoprotein A-I  1388.74 72.7 A.AFRQGHNSVFLI.K Hemopexin  
2738.48 81 A.EAKSYFEKSKEQLTPLIKKAGTEL.V Apolipoprotein A-II  1916.07 64.8 A.AFRQGHNSVFLIKGDKV.W Hemopexin  
2538.40 180.4 A.KSYFEKSKEQLTPLIKKAGTEL.V Apolipoprotein A-II  3869.12 103.7 I.KGDKVWVYPPEKKEKGYPKLLQDEFPGIPSPLDA.A Hemopexin  
2637.47 129.6 A.KSYFEKSKEQLTPLIKKAGTELV.N Apolipoprotein A-II  1532.74 49.6 I.SERWKNFPSPVDA.A Hemopexin  
3979.21 157.7 L.MEKVKSPELQAEAKSYFEKSKEQLTPLIKKAGTEL.V Apolipoprotein A-II  1440.78 49.6 V.RGEVPPRYPRDV.R Hemopexin  
3590.97 62 V.KSPELQAEAKSYFEKSKEQLTPLIKKAGTELV.N Apolipoprotein A-II  3341.76 51.4 V.WVYPPEKKEKGYPKLLQDEFPGIPSPLDA.A Hemopexin  
2052.03 106.1 V.TDYGKDLMEKVKSPELQA.E Apolipoprotein A-II  1194.61 61.6 V.KDYFPEPVTV.S Ig gamma-2 chain C region  
2252.10 123.7 V.TDYGKDLMEKVKSPELQAEA.K Apolipoprotein A-II  1240.68 43.1 V.RQAPGKGLEWV.G Ig heavy chain V-III region TIL  
2607.37 123.7 A.DEFKVKIDQTVEELRRSLAPYA.Q Apolipoprotein A-IV  1866.97 77.1 S.TLTLSKADYEKHKVYA.C Ig kappa chain C region  
2066.07 135.5 A.KEAVEHLQKSELTQQLNA.L Apolipoprotein A-IV  1545.80 55.7 V.AWKADSSPVKAGVET.T Ig lambda chain C regions  
3310.72 66.7 A.KEAVEHLQKSELTQQLNALFQDKLGEVNT.Y Apolipoprotein A-IV  2844.56 56.8 A.KRYIEKIQPSGGTNINEALLRAIFI.L Inter-alpha-trypsin inhibitor heavy chain H2  
1915.99 45.4 A.QRMERVLRENADSLQA.S Apolipoprotein A-IV  1803.00 46 A.YLTINQLLAERSLAPT.A Inter-alpha-trypsin inhibitor heavy chain H2  
3191.70 100.8 A.SLRPHADELKAKIDQNVEELKGRLTPYA.D Apolipoprotein A-IV  1159.68 40.2 I.NEALLRAIFI.L Inter-alpha-trypsin inhibitor heavy chain H2  
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1737.89 122.3 A.VEHLQKSELTQQLNA.L Apolipoprotein A-IV  3558.04 80.2 T.KTQVADAKRYIEKIQPSGGTNINEALLRAIFI.L Inter-alpha-trypsin inhibitor heavy chain H2  
2767.45 142.3 A.VEHLQKSELTQQLNALFQDKLGEV.N Apolipoprotein A-IV  3204.56 108.1 T.LAQMDDLQDFLSKDKHADPDFTRKLWA.Y Inter-alpha-trypsin inhibitor heavy chain H2  
1287.65 46.6 V.EGHLSFLEKDL.R Apolipoprotein A-IV  1341.69 61.9 T.SSQLKKFYNQV.S Inter-alpha-trypsin inhibitor heavy chain H2  
2368.21 74.6 V.EGHLSFLEKDLRDKVNSFFS.T Apolipoprotein A-IV  2222.24 52.7 T.SSQLKKFYNQVSTPLLRNV.Q Inter-alpha-trypsin inhibitor heavy chain H2  
1788.91 58.9 V.NTQAEQLRRQLTPYA.Q Apolipoprotein A-IV  3101.67 117.3 V.ADAKRYIEKIQPSGGTNINEALLRAIFI.L Inter-alpha-trypsin inhibitor heavy chain H2  
2258.17 41.4 V.SQKIGDNLRELQQRLEPYA.D Apolipoprotein A-IV  2377.18 170 V.AGKFDPAKLDQIESVITATSANT.Q Inter-alpha-trypsin inhibitor heavy chain H2  
3098.64 71.3 V.SQKIGDNLRELQQRLEPYADQLRTQV.N Apolipoprotein A-IV  2967.46 78.9 V.DYDFLKRLSNENHGIAQRIYGNQDT.S Inter-alpha-trypsin inhibitor heavy chain H2  
2199.40 98 A.HVALKAGKLKFIIPSPKRPV.K Apolipoprotein B-100  1737.91 96.4 V.HFFAPDNLDPIPKNI.L Inter-alpha-trypsin inhibitor heavy chain H2  
1810.00 77.9 A.LNLPTLPEVKFPEVDV.L Apolipoprotein B-100  2097.10 109.1 V.HFFAPDNLDPIPKNILFV.I Inter-alpha-trypsin inhibitor heavy chain H2  
2071.12 48.7 A.LRKMEPKDKDQEVLLQT.F Apolipoprotein B-100  2076.07 41.5 V.IDFNQNIRTWRNDLISA.T Inter-alpha-trypsin inhibitor heavy chain H2  
1684.77 84 A.NDYLNSFNWERQV.S Apolipoprotein B-100  2177.08 92.3 V.IDFNQNIRTWRNDLISAT.K Inter-alpha-trypsin inhibitor heavy chain H2  
1386.69 64.8 A.SQELQQIHQYI.M Apolipoprotein B-100  2127.04 123.6 V.KENIQDNISLFSLGMGFDV.D Inter-alpha-trypsin inhibitor heavy chain H2  
1951.16 67.2 C.KLDFREIQIYKKLRT.S Apolipoprotein B-100  2805.44 62.6 V.KMKQTVEAMKTILDDLRAEDHFSV.I Inter-alpha-trypsin inhibitor heavy chain H2  
2038.20 47.2 C.KLDFREIQIYKKLRTS.S Apolipoprotein B-100  3214.47 56.2 V.QFNYPHTSVTDVTQNNFHNYFGGSEIVV.A Inter-alpha-trypsin inhibitor heavy chain H2  
1277.64 54 I.DDIDVRFQKAA.S Apolipoprotein B-100  2028.09 122.4 V.SDGDPTVGELKLSKIQKNV.K Inter-alpha-trypsin inhibitor heavy chain H2  
1167.73 70.8 M.KLAPGELTIIL.- Apolipoprotein B-100  2288.17 44.1 V.STPLLRNVQFNYPHTSVTDV.T Inter-alpha-trypsin inhibitor heavy chain H2  
1848.98 42 M.RDAVEKPQEFTIVAFV.K Apolipoprotein B-100  1825.85 93 V.TQNNFHNYFGGSEIVV.A Inter-alpha-trypsin inhibitor heavy chain H2  
1185.63 76.2 M.SAFGYVFPKAV.S Apolipoprotein B-100  1456.68 72.9 T.YQHFYDGSEIVV.A Inter-alpha-trypsin inhibitor heavy chain H3  
1558.80 41.3 T.IEMSAFGYVFPKAV.S Apolipoprotein B-100  1952.99 80.4 T.YQHFYDGSEIVVAGRLV.D Inter-alpha-trypsin inhibitor heavy chain H3  
2081.19 82.2 T.IIVPEQTIEIPSIKFSVPA.G Apolipoprotein B-100  1649.91 78.1 V.HFFAPQGLPVVPKNV.A Inter-alpha-trypsin inhibitor heavy chain H3  
3434.88 97 T.KIKFDKYKAEKSHDELPRTFQIPGYTVPV.V Apolipoprotein B-100  3089.47 65.8 A.LDNGGLARRIHEDSDSALQLQDFYQEV.A Inter-alpha-trypsin inhibitor heavy chain H4  
2824.44 70.3 T.LNLNDFQVPDLHIPEFQLPHISHT.I Apolipoprotein B-100  2589.26 70.8 A.SAENVNKARSFAAGIQALGGTNINDA.M Inter-alpha-trypsin inhibitor heavy chain H4  
2977.47 177 T.SLKDNVPKATGVLYDYVNKYHWEHT.G Apolipoprotein B-100  2680.45 91.3 S.RQLGLPGPPDVPDHAAYHPFRRLA.I Inter-alpha-trypsin inhibitor heavy chain H4  
1254.71 41.4 T.VRTPALHFKSV.G Apolipoprotein B-100  1640.88 93.9 V.AGKLQDRGPDVLTATV.S Inter-alpha-trypsin inhibitor heavy chain H4  
2027.12 81.3 V.ALNANTKNQKIRWKNEV.R Apolipoprotein B-100  1704.84 103.9 V.HYFAPEGLTTMPKNV.V Inter-alpha-trypsin inhibitor heavy chain H4  
1380.73 48.7 V.ISMYRELLKDL.S Apolipoprotein B-100  2050.04 45 V.HYFAPEGLTTMPKNVVFV.I Inter-alpha-trypsin inhibitor heavy chain H4  
1767.82 80.7 V.LYDYVNKYHWEHT.G Apolipoprotein B-100  1783.91 46.7 V.TQNNFRLLFKGSEMV.V Inter-alpha-trypsin inhibitor heavy chain H4  
2032.05 69.8 V.NGQVPDGVSKVLVDHFGYT.K Apolipoprotein B-100  1882.99 100.7 V.TQNNFRLLFKGSEMVV.A Inter-alpha-trypsin inhibitor heavy chain H4  
2225.02 65 V.QVHASQPSSFHDFPDLGQEV.A Apolipoprotein B-100  1330.66 68.9 T.AVDRTAGWNIPM.G Lactotransferrin  
1797.05 100.4 V.RVPSYTLILPSLELPV.L Apolipoprotein B-100  1259.63 66.5 T.YEKYLGPQYV.A Lactotransferrin  
2358.20 102.3 V.SDGIAALDLNAVANKIADFELPT.I Apolipoprotein B-100  1496.81 85.5 A.AFKGLKSLEYLDL.S Lumican  
1006.56 40.5 V.SQFTLPKSV.S Apolipoprotein B-100  2185.03 84.9 L.DNNKISNIPDEYFKRFNA.L Lumican  
1861.98 86.8 V.SQFTLPKSVSDGIAALDL.N Apolipoprotein B-100  2702.39 52.2 L.DNNKISNIPDEYFKRFNALQYL.R Lumican  
1814.96 45.8 V.SSKLRRNLQNNAEWV.Y Apolipoprotein B-100  1498.84 70.7 L.SFNQIARLPSGLPV.S Lumican  
2744.47 117.3 V.SSKLRRNLQNNAEWVYQGAIRQI.D Apolipoprotein B-100  2988.55 46.1 V.SLLTLYLDNNKISNIPDEYFKRFNA.L Lumican  
1641.85 81 V.YDKSLWDFLKLDV.T Apolipoprotein B-100  2025.88 56 I.TFRSDFSNEERFTGFDA.H Mannan-binding lectin serine protease 1  
1213.57 44.8 A.KMREWFSET.F Apolipoprotein C-I  2670.37 51.9 A.TPLGPKWPEPVFGRLASPGFPGEYA.N Mannan-binding lectin serine protease 2  
1715.83 41.1 A.KMREWFSETFQKV.K Apolipoprotein C-I  1547.78 59.3 E.IVGGHEAQPHSRPY.M Myeloblastin  
1462.86 72.9 T.FQKVKEKLKIDS.- Apolipoprotein C-I  1749.86 95.9 E.IVGGHEAQPHSRPYMA.S Myeloblastin  
2945.56 68.2 A.AQNLYEKTYLPAVDEKLRDLYSKST.A Apolipoprotein C-II  1457.69 40.2 V.RTQEPTQQHFSV.A Myeloblastin  
1553.81 69.2 A.VDEKLRDLYSKST.A Apolipoprotein C-II  1755.87 84.5 V.RTQEPTQQHFSVAQV.F Myeloblastin  
2279.11 77.1 A.VDEKLRDLYSKSTAAMSTYT.G Apolipoprotein C-II  1606.83 75.4 A.ILREDKDPQKMYA.T Neutrophil gelatinase-associated lipocalin  
2074.94 94.6 G.TQQPQQDEMPSPTFLTQV.K Apolipoprotein C-II  1707.90 62 G.RTKELTSELKENFI.R Neutrophil gelatinase-associated lipocalin  
2419.19 90 G.TQQPQQDEMPSPTFLTQVKES.L Apolipoprotein C-II  2098.12 72.4 G.RTKELTSELKENFIRFS.K Neutrophil gelatinase-associated lipocalin  
2519.30 89.4 L.YEKTYLPAVDEKLRDLYSKST.A Apolipoprotein C-II  1431.79 47.6 L.GLPENHIVFPVPI.D Neutrophil gelatinase-associated lipocalin  
1634.84 106.8 T.GIFTDQVLSVLKGEE.- Apolipoprotein C-II  3141.63 125.6 L.IPAPPLSKVPLQQNFQDNQFQGKWYVV.G Neutrophil gelatinase-associated lipocalin  
1586.76 85.7 V.KESLSSYWESAKTA.A Apolipoprotein C-II  1511.76 76.9 N.YNQHAMVFFKKV.S Neutrophil gelatinase-associated lipocalin  
2012.97 137.4 V.KESLSSYWESAKTAAQNL.Y Apolipoprotein C-II  1624.87 114.1 T.LGNIKSYPGLTSYLV.R Neutrophil gelatinase-associated lipocalin  
2534.23 59.3 V.KESLSSYWESAKTAAQNLYEKT.Y Apolipoprotein C-II  3456.73 44.8 T.SDLIPAPPLSKVPLQQNFQDNQFQGKWYVV.G Neutrophil gelatinase-associated lipocalin  
2978.48 156.5 V.KESLSSYWESAKTAAQNLYEKTYLPA.V Apolipoprotein C-II  1285.66 44.4 V.SQNREYFKIT.L Neutrophil gelatinase-associated lipocalin  
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2187.11 127.9 A.KDALSSVQESQVAQQARGWV.T Apolipoprotein C-III  2017.04 46 I.RENYPLPWEKDTEKLV.A Phosphatidylinositol-glycan-specific phospholipase D  
2288.16 86.3 A.KDALSSVQESQVAQQARGWVT.D Apolipoprotein C-III  1763.94 41.7 V.LISPEASSRFGSSLITV.R Phosphatidylinositol-glycan-specific phospholipase D  
2694.27 109.4 A.KDALSSVQESQVAQQARGWVTDGFS.S Apolipoprotein C-III  2115.04 98.1 V.TSGLIGGEDGRVYVYNGKET.T Phosphatidylinositol-glycan-specific phospholipase D  
1872.95 63.9 A.LSSVQESQVAQQARGWV.T Apolipoprotein C-III  2071.15 106.5 V.RKGHFDTLSKGELKQLLT.K Protein S100-A12  
1974.01 51.5 A.LSSVQESQVAQQARGWVT.D Apolipoprotein C-III  1869.04 76.5 N.FLKKENKNEKVIEHI.M Protein S100-A9  
2380.11 71.5 A.LSSVQESQVAQQARGWVTDGFS.S Apolipoprotein C-III  2357.24 78.2 N.FLKKENKNEKVIEHIMEDL.D Protein S100-A9  
3459.74 73.3 A.LSSVQESQVAQQARGWVTDGFSSLKDYWSTV.K Apolipoprotein C-III  2573.31 77.7 N.FLKKENKNEKVIEHIMEDLDT.N Protein S100-A9  
2104.02 89.5 A.RGWVTDGFSSLKDYWSTV.K Apolipoprotein C-III  1825.93 98.2 V.KLGHPDTLNQGEFKEL.V Protein S100-A9  
2114.95 171 A.SEAEDASLLSFMQGYMKHA.T Apolipoprotein C-III  1925.02 127.5 V.KLGHPDTLNQGEFKELV.R Protein S100-A9  
2445.14 111.6 A.SEAEDASLLSFMQGYMKHATKT.A Apolipoprotein C-III  2437.28 53.6 V.KLGHPDTLNQGEFKELVRKDL.Q Protein S100-A9  
2516.17 160 A.SEAEDASLLSFMQGYMKHATKTA.K Apolipoprotein C-III  1677.91 68.5 A.RLSQRFPKAEFAEV.S Serum albumin  
2830.35 91.1 A.SEAEDASLLSFMQGYMKHATKTAKDA.L Apolipoprotein C-III  1473.71 69.3 L.FEQLGEYKFQNA.L Serum albumin  
1512.71 104.5 A.SLLSFMQGYMKHA.T Apolipoprotein C-III  2541.25 109.8 R.DAHKSEVAHRFKDLGEENFKAL.V Serum albumin  
1613.78 83.2 A.SLLSFMQGYMKHAT.K Apolipoprotein C-III  2640.36 144.1 R.DAHKSEVAHRFKDLGEENFKALV.L Serum albumin  
1842.92 102.8 A.SLLSFMQGYMKHATKT.A Apolipoprotein C-III  2753.46 61.2 R.DAHKSEVAHRFKDLGEENFKALVL.I Serum albumin  
1913.94 89.1 A.SLLSFMQGYMKHATKTA.K Apolipoprotein C-III  2866.53 94.5 R.DAHKSEVAHRFKDLGEENFKALVLI.A Serum albumin  
2228.13 85.3 A.SLLSFMQGYMKHATKTAKDA.L Apolipoprotein C-III  2937.56 125.8 R.DAHKSEVAHRFKDLGEENFKALVLIA.F Serum albumin  
2090.04 158.5 A.TKTAKDALSSVQESQVAQQA.R Apolipoprotein C-III  3155.67 109.4 R.DAHKSEVAHRFKDLGEENFKALVLIAFA.Q Serum albumin  
2588.34 157.5 A.TKTAKDALSSVQESQVAQQARGWV.T Apolipoprotein C-III  1524.87 47.9 T.KKVPQVSTPTLVEV.S Serum albumin  
2689.40 127.3 A.TKTAKDALSSVQESQVAQQARGWVT.D Apolipoprotein C-III  1873.99 81.6 V.AHRFKDLGEENFKALV.L Serum albumin  
1425.69 69.3 S.LLSFMQGYMKHA.T Apolipoprotein C-III  2100.16 48.1 V.AHRFKDLGEENFKALVLI.A Serum albumin  
1098.55 66.1 S.SLKDYWSTV.K Apolipoprotein C-III  2171.19 56.4 V.AHRFKDLGEENFKALVLIA.F Serum albumin  
1504.68 80.8 T.DGFSSLKDYWSTV.K Apolipoprotein C-III  1945.08 83.3 V.RYTKKVPQVSTPTLVEV.S Serum albumin  
2109.03 113.4 V.KDKFSEFWDLDPEVRPT.S Apolipoprotein C-III  1314.61 62.1 A.NYIGSDKYFHA.R Serum amyloid A protein  
2508.23 100 V.KDKFSEFWDLDPEVRPTSAVAA.- Apolipoprotein C-III  1580.75 57.6 A.LQGVGDMGRAYWDI.M Serum amyloid A-4 protein  
1486.72 43.1 V.QESQVAQQARGWV.T Apolipoprotein C-III  1710.81 88.2 I.MISNHQNSNRYLYA.R Serum amyloid A-4 protein  
1993.90 44.4 V.QESQVAQQARGWVTDGFS.S Apolipoprotein C-III  1466.68 46.2 I.SNHQNSNRYLYA.R Serum amyloid A-4 protein  
3073.47 74.6 V.QESQVAQQARGWVTDGFSSLKDYWSTV.K Apolipoprotein C-III  1286.60 50.3 S.ESWRSFFKEA.L Serum amyloid A-4 protein  
1605.72 95 V.TDGFSSLKDYWSTV.K Apolipoprotein C-III  1683.85 70.8 S.ESWRSFFKEALQGV.G Serum amyloid A-4 protein  
2147.09 66.8 A.GLVEKVQAAVGTSAAPVPSDNH.- Apolipoprotein E  3290.70 58.3 S.KSNEKAEEWGRSGKDPDRFRPDGLPKKY.- Serum amyloid A-4 protein  
3410.63 66.8 A.KVEQAVETEPEPELRQQTEWQSGQRWEL.A Apolipoprotein E  2875.32 93.3 V.GDMGRAYWDIMISNHQNSNRYLYA.R Serum amyloid A-4 protein  
1762.09 48.7 A.SHLRKLRKRLLRDA.D Apolipoprotein E  3443.74 49.4 V.LEDSKSNEKAEEWGRSGKDPDRFRPDGLPK.K Serum amyloid A-4 protein  
2328.23 83.1 V.RAKLEEQAQQIRLQAEAFQA.R Apolipoprotein E  3734.91 73.8 V.LEDSKSNEKAEEWGRSGKDPDRFRPDGLPKKY.- Serum amyloid A-4 protein  
2633.36 117.4 A.ALKPALRSGVQQLIQYYQDQKDA.N Apolipoprotein F  2490.31 104.2 I.RHKLLPNLNDIVAVGPEHFYGT.N Serum paraoxonase/arylesterase 1  
2335.15 43.6 V.LEFSDHPGIHEPLEPEVKYV.G 
Carboxypeptidase N catalytic 
chain  1518.73 86.1 L.NDIVAVGPEHFYGT.N Serum paraoxonase/arylesterase 1  
1493.81 84.8 A.KEKHYYIGIIET.T Ceruloplasmin  1657.85 46.9 L.TLLGMGLALFRNHQS.S Serum paraoxonase/arylesterase 1  
2646.18 123.7 C.SEPEKVDKDNEDFQESNRMYSV.N Ceruloplasmin  2137.09 49.6 L.TLLGMGLALFRNHQSSYQT.R Serum paraoxonase/arylesterase 1  
2418.20 78.1 V.DVHAAFFHGQALTNKNYRIDT.I Ceruloplasmin  2291.13 68.1 M.DLNEEDPTVLELGITGSKFDV.S Serum paraoxonase/arylesterase 1  
2204.10 112.8 V.HAAFFHGQALTNKNYRIDT.I Ceruloplasmin  2274.25 94.6 S.GLKYPGIKSFNPNSPGKILLM.D Serum paraoxonase/arylesterase 1  
1986.95 75 V.HFHGHSFQYKHRGVYS.S Ceruloplasmin  2589.39 52.4 S.SGLKYPGIKSFNPNSPGKILLMDL.N Serum paraoxonase/arylesterase 1  
1670.88 42.3 V.HLKNLASRPYTFHS.H Ceruloplasmin  1556.81 52.6 T.LLGMGLALFRNHQS.S Serum paraoxonase/arylesterase 1  
1444.81 60.5 V.WLGFLGPIIKAET.G Ceruloplasmin  1957.81 99.2 T.NDHYFLDPYLQSWEM.Y Serum paraoxonase/arylesterase 1  
2151.00 107.1 A.MDIHFHSPAFQHPPTEFI.R Clusterin  2013.92 138.7 V.AEGFDFANGINISPDGKYV.Y Serum paraoxonase/arylesterase 1  
1492.68 73.8 A.MFQPFLEMIHEA.Q Clusterin  1653.93 49.6 V.LRIQNILTEEPKVT.Q Serum paraoxonase/arylesterase 1  
2478.15 126.5 A.QQAMDIHFHSPAFQHPPTEFI.R Clusterin  2368.20 156.8 V.RVVAEGFDFANGINISPDGKYV.Y Serum paraoxonase/arylesterase 1  
2272.00 87.9 G.DQTVSDNELQEMSNQGSKYV.N Clusterin  2458.09 176.2 V.SSFNPHGISTFTDEDNAMYLLV.V Serum paraoxonase/arylesterase 1  
1791.83 106.1 I.HFHSPAFQHPPTEFI.R Clusterin  2557.15 162.5 V.SSFNPHGISTFTDEDNAMYLLVV.N Serum paraoxonase/arylesterase 1  
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Endogenous Protein/Peptides Identified from Plasma 
m/z  Scores Sequence Protein m/z  Scores Sequence Protein 
1110.5730 40.2 D.IFTSCKDVVV.Q 
26S proteasome non-ATPase 
regulatory subunit 2  1160.6756 39.2 M.KIRPFFPQQ.- Fibrinogen beta chain  
1853.9313 75.2 D.TQNIFFMSKVTNPKQA.- Alpha-1-antichymotrypsin  1791.7288 68.9 F.FSTYDRDNDGWLTSD.P Fibrinogen beta chain  
2259.2120 101.3 M.IEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  2047.0116 65.8 W.YSMRKMSMKIRPFFPQ.Q Fibrinogen beta chain  
2375.2026 76.8 F.LMIEQNTKSPLFMGKVVNPTQ.K Alpha-1-antitrypsin  2175.0758 78.2 W.YSMRKMSMKIRPFFPQQ.- Fibrinogen beta chain  
2390.2274 142 L.MIEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  1088.5715 70.8 D.WVQKTIAEN.- Haptoglobin  
2503.3005 163.3 F.LMIEQNTKSPLFMGKVVNPTQK.- Alpha-1-antitrypsin  1959.0198 133.6 Y.VKVTSIQDWVQKTIAEN.- Haptoglobin  
1752.7861 43.7 S.APHGPGLIYRQPNCDD.P Alpha-2-HS-glycoprotein  2122.0923 124.8 V.YVKVTSIQDWVQKTIAEN.- Haptoglobin  
2579.3122 81 D.LRHTFMGVVSLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  2278.1951 161.6 Y.GVYVKVTSIQDWVQKTIAEN.- Haptoglobin  
1524.7987 75.7 L.SALEEYTKKLNTQ.- Apolipoprotein A-I  2441.2306 48.8 E.YGVYVKVTSIQDWVQKTIAEN.- Haptoglobin  
1568.7060 48.2 Q.DEPPQSPWDRVKD.L Apolipoprotein A-I  1699.9602 47.8 D.KFLASVSTVLTSKYR.- Hemoglobin subunit alpha  
1637.8607 96.8 F.LSALEEYTKKLNTQ.- Apolipoprotein A-I  2910.4764 97.8 M.VLSPADKTNVKAAWGKVGAHAGEYGAEAL.E Hemoglobin subunit alpha  
1971.0246 95.9 K.VSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  3326.6948 114 M.VLSPADKTNVKAAWGKVGAHAGEYGAEALERM.F Hemoglobin subunit alpha  
2099.1040 53.2 F.KVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  3356.7831 65.2 A.AHLPAEFTPAVHASLDKFLASVSTVLTSKYR.- Hemoglobin subunit alpha  
2115.9996 36.1 Q.DEPPQSPWDRVKDLATVY.V Apolipoprotein A-I  3427.7758 216.8 L.AAHLPAEFTPAVHASLDKFLASVSTVLTSKYR.- Hemoglobin subunit alpha  
2118.1183 163.8 S.FKVSFLSALEEYTKKLNT.Q Apolipoprotein A-I  3473.7329 216.5 M.VLSPADKTNVKAAWGKVGAHAGEYGAEALERMF.L Hemoglobin subunit alpha  
2246.1816 133.7 S.FKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  3540.8930 67.4 T.LAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR.- Hemoglobin subunit alpha  
2330.1041 31.3 Q.DEPPQSPWDRVKDLATVYVD.V Apolipoprotein A-I  3740.9833 256.8 L.VTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR.- Hemoglobin subunit alpha  
2333.2437 94.7 E.SFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  3820.9689 172.4 M.VLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSF.P Hemoglobin subunit alpha  
2334.2046 38.2 L.ESFKVSFLSALEEYTKKLNT.Q Apolipoprotein A-I  3854.0775 100.5 L.LVTLAAHLPAEFTPAVHASLDKFLASVSTVLTSKYR.- Hemoglobin subunit alpha  
2462.2888 142.9 L.ESFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  1271.6976 39 D.PENFRLLGNVL.V Hemoglobin subunit beta  
2771.4213 131.4 L.PVLESFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  1494.8184 74.2 M.VHLTPEEKSAVTAL.W Hemoglobin subunit beta 
2785.3662 58.8 Q.DEPPQSPWDRVKDLATVYVDVLKD.S Apolipoprotein A-I  1737.9038 77.4 M.VHLTPEEKSAVTALWG.K Hemoglobin subunit beta 
3200.5571 67.1 Q.DEPPQSPWDRVKDLATVYVDVLKDSGRD.Y Apolipoprotein A-I  2293.1856 86.8 M.VHLTPEEKSAVTALWGKVNVD.E Hemoglobin subunit beta  
1462.8553 73.8 T.FQKVKEKLKIDS.- Apolipoprotein C-I  3274.7342 233.3 M.VHLTPEEKSAVTALWGKVNVDEVGGEALGRL.L Hemoglobin subunit beta  
1606.8271 85.2 G.TPDVSSALDKLKEFG.N Apolipoprotein C-I  3387.7989 84.4 M.VHLTPEEKSAVTALWGKVNVDEVGGEALGRLL.V Hemoglobin subunit beta  
1980.9585 106.6 P.DVSSALDKLKEFGNTLED.K Apolipoprotein C-I  1987.9460 134.6 G.GSKGPLDQLEKGGETAQSAD.P Heparin cofactor 2  
2179.0531 171.4 G.TPDVSSALDKLKEFGNTLED.K Apolipoprotein C-I  1296.6239 72 D.PEVQFNWYVD.G Ig gamma-2 chain C region  
1626.7848 41.9 F.WDLDPEVRPTSAVAA.- Apolipoprotein C-III  2336.1187 57.5 C.SVMHEALHNHYTQKSLSLSPG.K Ig gamma-2 chain C region  
2271.0692 32.6 D.GFSSLKDYWSTVKDKFSEF.W Apolipoprotein C-III  1421.7780 74.8 V.KLSLDIEIATYR.K Keratin, type II cytoskeletal 73  
2759.2609 118.9 A.SEAEDASLLSFMQGYMKHATKTAKD.A Apolipoprotein C-III  2866.5176 41.2 E.RPPTGPALPSPYSKVTAPRRPQRYSS.G Kinesin-like protein KIF26A  
1930.8610 36.9 A.EEAGARVQQNVPSGTDTGD.P Apolipoprotein L1  904.4656 40.8 K.RPPGFSPF.R Kininogen-1  
1389.8262 30.4 N.PRRKLEFALLF.L Ceruloplasmin  1060.5543 47.4 K.RPPGFSPFR.S Kininogen-1  
1750.0006 41.4 K.VFNPRRKLEFALLF.L Ceruloplasmin  1295.6089 32.6 L.SHVQSQTNGGPSP.T Leucine-rich repeat and fibronectin type-III  
1088.5535 42.7 A.GVAGAAGGGGSIGAS.K Chromobox protein homolog 6  1083.5541 34.6 K.HWNGSGSLLL.N Leucine-rich repeat-containing protein 36  
2682.3054 163.2 D.PKKGHIYQGSEADSVFSGFLIFPSA.- 
Complement C1q subcomponent 
subunit A  1458.7066 40.3 I.ATALNTSGAGGSRPAQ.A Misshapen-like kinase 1  
942.4601 75.6 I.HWESASLL.R Complement C3  1690.8775 54.6 L.FVLWDQQHKFPVF.M Plasma protease C1 inhibitor  
961.4913 66.1 H.WESASLLR.S Complement C3  2736.3733 43.9 L.FVLWDQQHKFPVFMGRVYDPRA.- Plasma protease C1 inhibitor  
1098.5728 76.4 I.HWESASLLR.S Complement C3  1525.7972 42.8 D.PNHFRPAGLPEKY.- Putative serum amyloid A-3 protein  
1211.6388 66.7 R.IHWESASLLR.S Complement C3  1628.8530 100.5 D.PQTFYYAVAVVKKD.S Serotransferrin precursor  
1367.7617 31.4 H.RIHWESASLLR.S Complement C3  1157.6633 38.7 L.VEVSRNLGKVG.S Serum albumin precursor  
1504.8270 53.5 G.SPMYSIITPNILR.L Complement C3  1232.6647 73.6 D.LGEENFKALVL.I Serum albumin precursor) 
1605.8524 48.4 I.THRIHWESASLLR.S Complement C3  1416.8042 70.2 D.LGEENFKALVLIA.F Serum albumin precursor  
1617.8841 65 G.SPMYSIITPNILRL.E Complement C3  1424.7592 37.4 R.DAHKSEVAHRFK.D Serum albumin precursor  
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1746.9586 43.3 G.SPMYSIITPNILRLE.S Complement C3  1539.7601 85.9 R.DAHKSEVAHRFKD.L Serum albumin precursor  
1865.0066 65 R.SSKITHRIHWESASLL.R Complement C3  1652.8449 75.6 R.DAHKSEVAHRFKDL.G Serum albumin precursor  
1934.0474 44.2 S.SKITHRIHWESASLLR.S Complement C3  1709.8671 87.7 R.DAHKSEVAHRFKDLG.E Serum albumin precursor  
2021.0874 91.2 R.SSKITHRIHWESASLLR.S Complement C3  1830.0820 33.4 L.LVRYTKKVPQVSTPTL.V Serum albumin precursor  
2032.0160 95 D.APDHQELNLDVSLQLPSR.S Complement C3  1838.9086 53.1 R.DAHKSEVAHRFKDLGE.E Serum albumin precursor  
2092.0336 84 G.SPMYSIITPNILRLESEE.T Complement C3  1967.9467 33.9 R.DAHKSEVAHRFKDLGEE.N Serum albumin precursor) 
2193.0926 96.4 G.SPMYSIITPNILRLESEET.M Complement C3  2081.9884 87.3 R.DAHKSEVAHRFKDLGEEN.F Serum albumin precursor  
2324.1341 92.2 G.SPMYSIITPNILRLESEETM.V Complement C3  2229.0487 99.1 R.DAHKSEVAHRFKDLGEENF.K Serum albumin precursor  
2536.2580 85.2 G.SPMYSIITPNILRLESEETMVL.E Complement C3  2242.1180 68.2 A.HKSEVAHRFKDLGEENFKA.L Serum albumin precursor  
2988.4284 116.8 G.SPMYSIITPNILRLESEETMVLEAHD.A Complement C3  2302.1907 43.2 K.SEVAHRFKDLGEENFKALVL.I Serum albumin precursor  
3359.6068 70.3 G.SPMYSIITPNILRLESEETMVLEAHDAQGD.V Complement C3  2313.1534 44.1 D.AHKSEVAHRFKDLGEENFKA.L Serum albumin precursor  
1449.7797 38.6 K.SHALQLNNRQIR.G Complement C4-B  2357.1283 80.4 R.DAHKSEVAHRFKDLGEENFK.A Serum albumin precursor  
1498.7919 34.6 R.NGFKSHALQLNNR.Q Complement C4-B  2428.1987 133.7 R.DAHKSEVAHRFKDLGEENFKA.L Serum albumin precursor  
1739.9334 87.8 R.NGFKSHALQLNNRQI.R Complement C4-B  2430.2686 43.8 H.KSEVAHRFKDLGEENFKALVL.I Serum albumin precursor  
1781.9911 39.9 N.GFKSHALQLNNRQIR.G Complement C4-B  2541.2748 117.5 R.DAHKSEVAHRFKDLGEENFKAL.V Serum albumin precursor  
1891.0332 71.4 R.GLEEELQFSLGSKINVK.V Complement C4-B  2567.3374 140.4 A.HKSEVAHRFKDLGEENFKALVL.I Serum albumin precursor  
1896.0234 102.2 R.NGFKSHALQLNNRQIR.G Complement C4-B  2638.3699 142.4 D.AHKSEVAHRFKDLGEENFKALVL.I Serum albumin precursor  
2378.2221 40.9 K.DDPDAPLQPVTPLQLFEGRRN.R Complement C4-B  2753.4069 162.8 R.DAHKSEVAHRFKDLGEENFKALVL.I Serum albumin precursor  
1830.9485 112 L.PWLKEKLQDEDLGFL.- Complement factor B  2822.4883 111.8 D.AHKSEVAHRFKDLGEENFKALVLIA.F Serum albumin precursor  
2318.2055 126.4 L.FQVLPWLKEKLQDEDLGFL.- Complement factor B  2866.4612 80.2 R.DAHKSEVAHRFKDLGEENFKALVLI.A Serum albumin precursor  
1959.0691 46.2 E.KKVGEKLSEGDLLAEIET.D 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial  2898.5628 129 A.HKSEVAHRFKDLGEENFKALVLIAF.A Serum albumin precursor 
905.4795 41 D.FLAEGGGVR.G Fibrinogen alpha chain  2937.5528 164.9 R.DAHKSEVAHRFKDLGEENFKALVLIA.F Serum albumin precursor  
1020.5121 58.6 G.DFLAEGGGVR.G Fibrinogen alpha chain  2969.5945 78.5 D.AHKSEVAHRFKDLGEENFKALVLIAF.A Serum albumin precursor  
1206.5678 93.5 G.EGDFLAEGGGVR.G Fibrinogen alpha chain  3084.6029 145.8 R.DAHKSEVAHRFKDLGEENFKALVLIAF.A Serum albumin precursor 
1263.5850 104.4 S.GEGDFLAEGGGVR.G Fibrinogen alpha chain  3283.7031 113.3 R.DAHKSEVAHRFKDLGEENFKALVLIAFAQ.Y Serum albumin precursor 
1350.6167 87.4 D.SGEGDFLAEGGGVR.G Fibrinogen alpha chain  3446.7408 156 R.DAHKSEVAHRFKDLGEENFKALVLIAFAQY.L Serum albumin precursor  
1465.6812 149.4 A.DSGEGDFLAEGGGVR.G Fibrinogen alpha chain  3559.8010 46.3 R.DAHKSEVAHRFKDLGEENFKALVLIAFAQYL.Q Serum albumin precursor  
1536.6770 147.6 T.ADSGEGDFLAEGGGVR.G Fibrinogen alpha chain  1588.8558 58.7 D.PDRFRPDGLPKKY.- Serum amyloid A-4 protein  
2284.0347 64.6 F.FDTASTGKTFPGFFSPMLGEF.V Fibrinogen alpha chain  1437.7793 43.2 E.TPSAAALAAARVELP.G Solute carrier family 12 member 2  
2931.3294 56.2 K.SSSYSKQFTSSTSYNRGDSTFESKSY.K Fibrinogen alpha chain  1856.9203 120.6 L.LSPYSYSTTAVVTNPKE.- Transthyretin  
3239.5287 35.4 K.SYKMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  1969.9945 93.2 A.LLSPYSYSTTAVVTNPKE.- Transthyretin  
    2041.0344 167 A.ALLSPYSYSTTAVVTNPKE.- Transthyretin  
    2697.3925 50 A.GPTGTGESKCPLMVKVLDAVRGSPAIN.V Transthyretin  
    3042.5575 90 D.SGPRRYTIAALLSPYSYSTTAVVTNPKE.- Transthyretin  
    3443.8026 61.4 F.TANDSGPRRYTIAALLSPYSYSTTAVVTNPKE.- Transthyretin  
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Peptide/Protein Identifications from Ionophore Experiments 
m/z Scores Sequence Protein m/z Scores Sequence Protein 
1286.63 36.6 G.DDAPRAVFPSIV.G Actin, cytoplasmic 1  1765.83 31.7 T.KESSSHHPGIAEFPSR.G Fibrinogen alpha chain  
2215.01 58.1 K.DLYANTVLSGGTTMYPGIADR.M Actin, cytoplasmic 1  1822.86 31.7 T.KESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  
1686.83 36.2 P.EEHPVLLTEAPLNPK.A Actin, cytoplasmic 1  1822.88 101.3 T.KESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  
1198.68 38.5 R.AVFPSIVGRPR.H Actin, cytoplasmic 1  1950.95 47 T.KESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  
1912.85 32.6 V.GMGQKDSYVGDEAQSKRG.I Actin, cytoplasmic 1  1950.97 123.9 T.KESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  
2240.07 55.8 V.GMGQKDSYVGDEAQSKRGILT.L Actin, cytoplasmic 1  2212.04 47.7 T.KESSSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  
1675.84 35.6 A.GFAGDDAPRAVFPSIVG.R Actin, cytoplasmic 1  2125.01 61.8 T.KESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
1275.67 47.7 N.ELRVAPEEHPV.L Actin, cytoplasmic 1  2125.06 136.3 T.KESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
1954.07 114.1 R.VAPEEHPVLLTEAPLNPK.A Actin, cytoplasmic 1  1728.82 31.7 T.ESRGSESGIFTNTKES.S Fibrinogen alpha chain  
1309.65 41.4 V.SLGSPSGEVSHPR.K Alpha-2-HS-glycoprotein  1474.72 104.8 T.FPGFFSPMLGEFV.S Fibrinogen alpha chain  
1538.78 34.8 V.SLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  1760.79 35.7 T.GKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
1538.82 81.6 V.SLGSPSGEVSHPRKT.R Alpha-2-HS-glycoprotein  2585.11 100.4 S.YKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
2110.02 52.4 K.LHTEAQIQEEGTVVELTGR.Q Alpha-2-macroglobulin  2585.15 57.2 S.YKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
1661.80 54 M.HGPEGLRVGFYESDV.M Alpha-2-macroglobulin  3152.44 50.5 S.YKMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  
1047.47 33.2 E.AGDNGMEQIL.W Alpha-actinin-4  1553.69 68.7 S.YNRGDSTFESKSY.K Fibrinogen alpha chain  
2032.96 53.9 K.FTASAGIQVVGDDLTVTNPK.R Alpha-enolase -  1812.81 71.7 S.YNRGDSTFESKSYKM.A Fibrinogen alpha chain  
1964.12 53.5 L.SEKAKPALEDLRQGLLPV.L Apolipoprotein A-I  1883.87 133.3 S.YNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
1853.89 39.3 Q.DEPPQSPWDRVKDLAT.V Apolipoprotein A-I  2292.00 53.3 S.YSKQFTSSTSYNRGDSTFES.K Fibrinogen alpha chain  
1555.79 35.4 S.FLSALEEYTKKLN.T Apolipoprotein A-I  2507.12 48.6 S.YSKQFTSSTSYNRGDSTFESKS.Y Fibrinogen alpha chain  
1784.88 32.8 S.FLSALEEYTKKLNTQ.- Apolipoprotein A-I  1536.65 62.9 T.ADSGEGDFLAEGGGVR.G Fibrinogen alpha chain  
2575.25 127.1 V.LESFKVSFLSALEEYTKKLNTQ.- Apolipoprotein A-I  1536.69 75.4 T.ADSGEGDFLAEGGGVR.G Fibrinogen alpha chain  
1642.80 25.8 V.SFLSALEEYTKKLN.T Apolipoprotein A-I  2158.97 92.7 S.STSYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
1743.86 50.2 V.SFLSALEEYTKKLNT.Q Apolipoprotein A-I  2507.05 56.6 S.SVSGSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  
1871.92 47.3 V.SFLSALEEYTKKLNTQ.- Apolipoprotein A-I  2379.03 48.5 S.SYSKQFTSSTSYNRGDSTFES.K Fibrinogen alpha chain  
1871.96 80.6 V.SFLSALEEYTKKLNTQ.- Apolipoprotein A-I  2594.18 31.2 S.SYSKQFTSSTSYNRGDSTFESKS.Y Fibrinogen alpha chain  
2048.01 51.7 V.LKPEEEAPAPEVGASKPEGI.D Vitronectin  3016.31 55.4 S.SYSKQFTSSTSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
2048.02 115.4 V.LKPEEEAPAPEVGASKPEGI.D Vitronectin  3087.36 55 S.SYSKQFTSSTSYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
1672.83 48.8 A.NTQPRGPPASSPAPAPK.F Zyxin  1001.52 58.1 S.TGKTFPGFF.S Fibrinogen alpha chain  
3340.64 95.5 E.EEIFPSPPPPPEEEGGPEAPIPPPPQPREKV.S Zyxin  1316.64 36.6 S.TGKTFPGFFSPM.L Fibrinogen alpha chain  
1760.95 39.1 F.HVQPQPQPKPQVQLH.V Zyxin  1861.91 105.2 S.TGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
2203.16 61.2 F.HVQPQPQPKPQVQLHVQSQ.T Zyxin  2045.01 123.7 T.ADSGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
2304.18 98 F.HVQPQPQPKPQVQLHVQSQT.Q Zyxin  2019.98 109.5 T.ASTGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
2809.36 37.9 I.DLEIDSLSSLLDDMTKNDPFKARVS.S Zyxin  2466.02 97.4 S.SSYSKQFTSSTSYNRGDSTFES.K Fibrinogen alpha chain  
2120.01 34.3 K.FSPGAPGGSGSQPNQKLGHPEA.L Zyxin  2681.20 51.9 S.SSYSKQFTSSTSYNRGDSTFESKS.Y Fibrinogen alpha chain  
1704.80 30.9 K.VNPFRPGDSEPPPAPGA.Q Zyxin  3103.41 49.4 S.SSYSKQFTSSTSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
1832.87 36.7 K.VNPFRPGDSEPPPAPGAQ.R Zyxin  3174.40 47.8 S.SSYSKQFTSSTSYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  
2060.00 54.1 K.VNPFRPGDSEPPPAPGAQRA.Q Zyxin  1665.74 39.6 S.STSYNRGDSTFESKS.Y Fibrinogen alpha chain  
1743.87 32.7 L.ANTQPRGPPASSPAPAPK.F Zyxin  1828.80 68.5 S.STSYNRGDSTFESKSY.K Fibrinogen alpha chain  
2174.09 59.4 L.ANTQPRGPPASSPAPAPKFSPV.T Zyxin  2087.96 73.7 S.STSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
1989.01 45.1 N.TQPRGPPASSPAPAPKFSPV.T Zyxin  2897.35 99.2 S.SSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
2361.18 41.4 S.KFSPGAPGGSGSQPNQKLGHPEAL.S Zyxin  2622.17 102.5 S.SSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
2287.21 66.6 S.LANTQPRGPPASSPAPAPKFSPV.T Zyxin  2622.23 85 S.SSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
1921.99 32.1 V.RSPGAPGPLTLKEVEELE.Q Zyxin  1780.86 33 S.SSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
2211.01 50.2 V.GGPSLTSDLQAQSKGNPEQTPV.L Vitronectin  1780.90 97.2 S.SSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
2211.05 82.2 V.GGPSLTSDLQAQSKGNPEQTPV.L Vitronectin  1867.85 36.5 S.SSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  
1611.75 31.9 S.DLQAQSKGNPEQTPV.L Vitronectin  2117.96 71 S.SSHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  
1843.93 49.6 V.IIEGDLERTEERAELA.E Tropomyosin alpha-3 chain  2117.98 56.2 S.SSHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  
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2380.23 60.4 E.KTIDDLEEKLAQAKEENVGLH.Q Tropomyosin alpha-4 chain  1265.58 62.8 S.SSHHPGIAEFPS.R Fibrinogen alpha chain  
2072.02 33.5 V.ILEGELERAEERAEVSEL.K Tropomyosin alpha-4 chain  1265.61 40.9 S.SSHHPGIAEFPS.R Fibrinogen alpha chain  
2714.20 124.4 D.AKAVLEEDEEVTEEAEMEPEDKGH.- Tubulin beta-1 chain  1421.70 35.1 S.SSHHPGIAEFPSR.G Fibrinogen alpha chain  
2515.06 90.3 K.AVLEEDEEVTEEAEMEPEDKGH.- Tubulin beta-1 chain  1478.68 75.5 S.SSHHPGIAEFPSRG.K Fibrinogen alpha chain  
2231.83 78.8 L.EEDEEVTEEAEMEPEDKGH.- Tubulin beta-1 chain  1478.71 83.3 S.SSHHPGIAEFPSRG.K Fibrinogen alpha chain  
2231.88 126.1 L.EEDEEVTEEAEMEPEDKGH.- Tubulin beta-1 chain  1693.86 63.6 S.SSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  
3739.62 79.2 V.SEYQQFQDAKAVLEEDEEVTEEAEMEPEDKGH.- Tubulin beta-1 chain  2535.20 59.2 S.SHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
2040.01 86 R.EANLQALIATGGDINAAIER.L Ubiquilin-1  2535.20 114.1 S.SHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
2353.10 58.9 G.EKTPKDESANQEEPEARVPAQ.S Vasodilator-stimulated phosphoprotein  1304.65 62.7 S.HHPGIAEFPSRG.K Fibrinogen alpha chain  
2353.11 54 G.EKTPKDESANQEEPEARVPAQ.S Vasodilator-stimulated phosphoprotein  1943.91 47.2 S.HHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  
2497.18 63.1 R.LLQDSVDFSLADAINTEFKNTR.T Vimentin  1178.54 55.4 S.SHHPGIAEFPS.R Fibrinogen alpha chain  
1134.54 32 I.IESPSTSLSVD.L Stromal interaction molecule 2  1178.57 51.5 S.SHHPGIAEFPS.R Fibrinogen alpha chain  
1398.70 31.3 A.QISPEGRAAMEPI.V Talin-1  1391.66 52.3 S.SHHPGIAEFPSRG.K Fibrinogen alpha chain  
2846.35 32.2 E.AVDNLSAFASNPEFSSIPAQISPEGRAA.M Talin-1  1391.68 80.5 S.SHHPGIAEFPSRG.K Fibrinogen alpha chain  
2113.04 42.8 E.KNPLPSKETIEQEKQAGES.- Thymosin beta-4  1519.78 63.8 S.SHHPGIAEFPSRGK.S Fibrinogen alpha chain  
2701.23 54.3 K.TETQEKNPLPSKETIEQEKQAGES.- Thymosin beta-4  2030.94 72.7 S.SHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  
2113.07 107.8 E.KNPLPSKETIEQEKQAGES.- Thymosin beta-4-like protein 6  2810.31 73.7 S.SHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
2946.65 172.5 I.EKFDKSKLKKTETQEKNPLPSKETI.E Thymosin beta-4-like protein 6  1606.82 58.9 S.SHHPGIAEFPSRGKS.S Fibrinogen alpha chain  
3933.12 175.2 I.EKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES.- Thymosin beta-4-like protein 6  933.47 43.4 P.GIAEFPSRG.K Fibrinogen alpha chain  
2829.37 136.4 K.KTETQEKNPLPSKETIEQEKQAGES.- Thymosin beta-4-like protein 6  1572.74 30.1 P.GIAEFPSRGKSSSYS.K Fibrinogen alpha chain  
2701.28 126 K.TETQEKNPLPSKETIEQEKQAGES.- Thymosin beta-4-like protein 6  2076.98 55 P.GIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
3198.63 132.3 S.KLKKTETQEKNPLPSKETIEQEKQAGES.- Thymosin beta-4-like protein 6  2077.03 62.2 P.GIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
1613.82 66.7 T.ETQEKNPLPSKETI.E Thymosin beta-4-like protein 6  1450.65 30.1 R.GDSTFESKSYKMA.D Fibrinogen alpha chain  
2600.24 119 T.ETQEKNPLPSKETIEQEKQAGES.- Thymosin beta-4-like protein 6  1870.78 86.6 R.GGSTSYGTGSETESPRNPS.S Fibrinogen alpha chain  
2098.02 93.3 K.TLFELAAESDVSTAIDLFR.Q Transforming growth factor-beta-induced protein ig-h3  2603.11 100.6 R.GSESGIFTNTKESSSHHPGIAEFPS.R Fibrinogen alpha chain  
2121.92 59.7 G.SYALTSEEAERSDGDPVQPA.V Serum deprivation-response protein  2816.30 37.9 R.GSESGIFTNTKESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  
2121.94 42.2 G.SYALTSEEAERSDGDPVQPA.V Serum deprivation-response protein  2944.39 42.7 R.GSESGIFTNTKESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  
2471.08 79.7 R.YEGSYALTSEEAERSDGDPVQPA.V Serum deprivation-response protein  1220.48 33.7 R.HPDEAAFFDTA.S Fibrinogen alpha chain  
3363.55 65 R.YEGSYALTSEEAERSDGDPVQPAVLQVHQTS.- Serum deprivation-response protein  1442.61 36.1 R.HRHPDEAAFFDT.A Fibrinogen alpha chain  
2524.24 76.4 S.GAVEGKEELPDENKSLEETLHTV.D Serum deprivation-response protein  1442.64 36.4 R.HRHPDEAAFFDT.A Fibrinogen alpha chain  
1871.83 54.4 Y.ALTSEEAERSDGDPVQPA.V Serum deprivation-response protein  1399.62 48.4 S.ETESRGSESGIFT.N Fibrinogen alpha chain  
1871.85 40 Y.ALTSEEAERSDGDPVQPA.V Serum deprivation-response protein  1399.63 64.7 S.ETESRGSESGIFT.N Fibrinogen alpha chain  
1623.75 61.6 K.DVFLGMFLYEYAR.R Serum albumin precursor  1614.70 34.2 S.ETESRGSESGIFTNT.K Fibrinogen alpha chain  
1639.88 39.3 K.KVPQVSTPTLVEVSR.N Serum albumin precursor 1614.73 34.1 S.ETESRGSESGIFTNT.K Fibrinogen alpha chain  
2753.38 62.5 R.DAHKSEVAHRFKDLGEENFKALVL.I Serum albumin  1958.87 30.9 S.ETESRGSESGIFTNTKES.S Fibrinogen alpha chain  
1184.68 32.2 I.LPNVATLGRMI.L Rab GDP dissociation inhibitor beta  2646.14 47.1 S.FRPDSPGSGNARPNNPDWGTFEEV.S Fibrinogen alpha chain  
2603.11 101.4 R.SLDRNLPSDSQDLGQHGLEEDFM.L Serglycin  1263.56 76 S.GEGDFLAEGGGVR.G Fibrinogen alpha chain  
2716.18 45 R.SLDRNLPSDSQDLGQHGLEEDFML.- Serglycin  2233.89 78.5 S.GSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  
1359.66 31.9 E.EGIGCAARGGATPLS.Y Serine/threonine-protein phosphatase 6 regulatory subunit 1  1091.53 44.3 S.HHPGIAEFPS.R Fibrinogen alpha chain  
1152.61 43.9 K.DDNPNLPRLV.R Serum albumin  1304.62 66.4 S.HHPGIAEFPSRG.K Fibrinogen alpha chain  
1681.82 109.6 R.NLAKGKEESLDSDLY.A Platelet basic protein  2031.92 57.4 M.LGEFVSETESRGSESGIFT.N Fibrinogen alpha chain  
2177.10 55.9 R.QVTITGSAASISLAQYLINAR.L Poly(rC)-binding protein 1  2247.00 56.2 M.LGEFVSETESRGSESGIFTNT.K Fibrinogen alpha chain  
1675.84 35.6 A.GFAGDDAPRAVFPSIVG.R P 2591.18 37.3 M.LGEFVSETESRGSESGIFTNTKES.S Fibrinogen alpha chain  
1275.67 47.7 N.ELRVAPEEHPV.L P 2591.18 81.2 M.LGEFVSETESRGSESGIFTNTKES.S Fibrinogen alpha chain  
3611.67 42.6 T.MDDDTAVLVIDNGSGMCKAGFAGDDAPRAVFPSIVG.R P 1193.45 32 N.NPDWGTFEEV.S Fibrinogen alpha chain  
3723.13 99.7 K.LAADEDDDDDDEEDDDEDDDDDDFDDEEAEEK.A Nucleophosmin  2945.39 34.7 M.DLGTLSGIGTLDGFRHRHPDEAAFFDT.A Fibrinogen alpha chain  
1441.76 30.3 I.DLQGPGPWGFRLV.G PDZ and LIM domain protein 1  1370.67 30 M.ELERPGGNEITR.G Fibrinogen alpha chain  
2346.14 38.1 L.QEILESEEKGDPNKPSGFRSV.K PDZ and LIM domain protein 1  1554.73 47.1 L.DGFRHRHPDEAAF.F Fibrinogen alpha chain  
2218.07 93.8 Q.EILESEEKGDPNKPSGFRSV.K PDZ and LIM domain protein 1  1917.84 56.8 L.DGFRHRHPDEAAFFDT.A Fibrinogen alpha chain  
2719.35 108.1 T.SFLVLQEILESEEKGDPNKPSGFR.S PDZ and LIM domain protein 1  1918.87 45.7 L.GEFVSETESRGSESGIFT.N Fibrinogen alpha chain  
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2905.45 38.9 T.SFLVLQEILESEEKGDPNKPSGFRSV.K PDZ and LIM domain protein 1  2162.91 94 M.ADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
2631.26 67.3 G.TEFMQDPDEEHLKKSSQVPRTE.A PDZ and LIM domain protein 7  2730.20 84.6 M.ADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  
3045.48 54 Q.AEKKKMQQNIQELEEQLEEEESARQ.K Myosin-9  2127.91 40.8 I.TRGGSTSYGTGSETESPRNPS.S Fibrinogen alpha chain  
3414.71 59.6 Q.AEKKKMQQNIQELEEQLEEEESARQKLQ.L Myosin-9  1481.65 39.1 K.ESSSHHPGIAEFPS.R Fibrinogen alpha chain  
1842.90 31.5 E.KSQEDQENPLRSLNAN.E Mitotic spindle assembly checkpoint protein MAD1  1481.68 62.8 K.ESSSHHPGIAEFPS.R Fibrinogen alpha chain  
1230.61 33.8 S.EVTWNITVPDG.F Mannan-binding lectin serine protease 1  1637.73 41 K.ESSSHHPGIAEFPSR.G Fibrinogen alpha chain  
2212.12 70.9 V.SRIDGPTGQKTKEAQPGQSQV.S Latent-transforming growth factor beta-binding protein 1  1637.76 48.3 K.ESSSHHPGIAEFPSR.G Fibrinogen alpha chain  
2054.04 52.9 K.ILTATVDNANVLLQIDNAR.L Keratin, type I cytoskeletal 14  1694.79 116.5 K.ESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  
2068.09 61.2 K.ILTATVDNANILLQIDNAR.L Keratin, type I cytoskeletal 17  1909.93 68.1 K.ESSSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  
2392.11 71.9 R.GLGVGFGSGGGSSSSVKFVSTTSSSR.K Keratin, type II cytoskeletal 5  1996.92 42.7 K.ESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
2520.22 110 R.GLGVGFGSGGGSSSSVKFVSTTSSSRK.S Keratin, type II cytoskeletal 5  1996.98 64.2 K.ESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  
2646.26 95.7 R.QSSVSFRSGGSRSFSTASAITPSVSR.T Keratin, type II cytoskeletal 5  2083.94 54.2 K.ESSSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  
2359.11 51.4 R.AEAESWYQTKYEELQVTAGR.H Keratin, type II cytoskeletal 6C  2083.95 32.2 K.ESSSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  
2418.21 69.7 R.AIGGGLSSVGGGSSTIKYTTTSSSSR.K Keratin, type II cytoskeletal 6C  1359.75 49.8 K.GDKELRTGKEKV.T Fibrinogen alpha chain  
2546.26 126.5 R.AIGGGLSSVGGGSSTIKYTTTSSSSRK.S Keratin, type II cytoskeletal 6C  1460.79 57.6 K.GDKELRTGKEKVT.S Fibrinogen alpha chain  
1705.74 30.4 G.HGHEQQHGLGHGHKF.K Kininogen-1  2028.85 49.1 K.MADEAGSEADHEGTHSTKR.G Fibrinogen alpha chain  
2069.94 47.7 G.HGLGHGHEQQHGLGHGHKF.K Kininogen-1  2293.95 78.5 K.MADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
1943.83 45.4 H.NLGHGHKHERDQGHGHQ.R Kininogen-1  2861.30 105.7 K.MADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  
904.45 44.8 K.RPPGFSPF.R Kininogen-1  1913.82 58.3 K.QFTSSTSYNRGDSTFES.K Fibrinogen alpha chain  
1655.81 45 S.SRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2553.05 128.7 K.SSSYSKQFTSSTSYNRGDSTFES.K Fibrinogen alpha chain  
1655.84 49.6 S.SRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2553.10 55.1 K.SSSYSKQFTSSTSYNRGDSTFES.K Fibrinogen alpha chain  
1726.84 43.1 S.SRQLGLPGPPDVPDHAA.Y Inter-alpha-trypsin inhibitor heavy chain H4  3190.46 36.7 K.SSSYSKQFTSSTSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  
2271.07 51.4 S.SRQLGLPGPPDVPDHAAYHPF.R Inter-alpha-trypsin inhibitor heavy chain H4  2122.83 101.4 K.SYKMADEAGSEADHEGTHST.K Fibrinogen alpha chain  
1568.78 41.4 S.RQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2122.86 145.2 K.SYKMADEAGSEADHEGTHST.K Fibrinogen alpha chain  
1639.79 34 S.RQLGLPGPPDVPDHAA.Y Inter-alpha-trypsin inhibitor heavy chain H4  2250.92 50.2 K.SYKMADEAGSEADHEGTHSTK.R Fibrinogen alpha chain  
2184.03 37.9 S.RQLGLPGPPDVPDHAAYHPF.R Inter-alpha-trypsin inhibitor heavy chain H4  2250.94 68.3 K.SYKMADEAGSEADHEGTHSTK.R Fibrinogen alpha chain  
2526.27 39.4 M.NFRPGVLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2464.03 70.4 K.SYKMADEAGSEADHEGTHSTKRG.H Fibrinogen alpha chain  
2012.00 40.4 P.GVLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2464.05 47.1 K.SYKMADEAGSEADHEGTHSTKRG.H Fibrinogen alpha chain  
2083.02 30.6 P.GVLSSRQLGLPGPPDVPDHAA.Y Inter-alpha-trypsin inhibitor heavy chain H4  2601.11 80.2 K.SYKMADEAGSEADHEGTHSTKRGH.A Fibrinogen alpha chain  
2627.25 37.9 P.GVLSSRQLGLPGPPDVPDHAAYHPF.R Inter-alpha-trypsin inhibitor heavy chain H4  2672.08 132.4 K.SYKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
2657.26 79.2 R.MNFRPGVLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2672.13 134 K.SYKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
2582.22 63.1 R.NVHSGSTFFKYYLQGAKIPKPEA.S Inter-alpha-trypsin inhibitor heavy chain H4  1707.93 77.2 K.TVIGPDGHKEVTKEVV.T Fibrinogen alpha chain  
2109.04 40.7 R.PGVLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  1336.60 38.5 L.DGFRHRHPDEA.A Fibrinogen alpha chain  
2724.30 83.7 R.PGVLSSRQLGLPGPPDVPDHAAYHPF.R Inter-alpha-trypsin inhibitor heavy chain H4  1336.61 39.8 L.DGFRHRHPDEA.A Fibrinogen alpha chain  
1412.67 54 R.QLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  1550.76 35.7 G.TLDGFRHRHPDEA.A Fibrinogen alpha chain  
1483.70 31.6 R.QLGLPGPPDVPDHAA.Y Inter-alpha-trypsin inhibitor heavy chain H4  954.45 36.2 H.HPGIAEFPS.R Fibrinogen alpha chain  
2027.92 33.1 R.QLGLPGPPDVPDHAAYHPF.R Inter-alpha-trypsin inhibitor heavy chain H4  1110.55 33.2 H.HPGIAEFPSR.G Fibrinogen alpha chain  
1742.88 59.4 L.SSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  1167.58 52.2 H.HPGIAEFPSRG.K Fibrinogen alpha chain  
1100.51 52.1 L.GLPGPPDVPDH.A Inter-alpha-trypsin inhibitor heavy chain H4  1480.64 33.1 H.SESGSFRPDSPGSGN.A Fibrinogen alpha chain  
1171.56 79 L.GLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  2736.13 54.1 H.SESGSFRPDSPGSGNARPNNPDWGTF.E Fibrinogen alpha chain  
1242.59 39.2 L.GLPGPPDVPDHAA.Y Inter-alpha-trypsin inhibitor heavy chain H4  2736.17 66.1 H.SESGSFRPDSPGSGNARPNNPDWGTF.E Fibrinogen alpha chain  
1954.99 32.8 G.VLSSRQLGLPGPPDVPDHA.A Inter-alpha-trypsin inhibitor heavy chain H4  3093.32 57.7 H.SESGSFRPDSPGSGNARPNNPDWGTFEEV.S Fibrinogen alpha chain  
2570.23 39.1 G.VLSSRQLGLPGPPDVPDHAAYHPF.R Inter-alpha-trypsin inhibitor heavy chain H4  1906.92 86.4 I.AEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  
3836.77 33 Q.PPVEEEDEHFDDTVVCLDTYNCDLHFKISRDR.L Heterogeneous nuclear ribonucleoprotein U  2182.02 30.8 I.AEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  
3877.28 169.4 K.KKEEEEDEEDEEDEEEEEDEEDEDEEEDDDD.E High mobility group protein B1  1077.52 49.7 E.GDFLAEGGGVR.G Fibrinogen alpha chain  
4005.35 196 K.KKKEEEEDEEDEEDEEEEEDEEDEDEEEDDDD.E High mobility group protein B1  1352.61 45.2 E.SSSHHPGIAEFPS.R Fibrinogen alpha chain  
1946.01 81.3 A.VLEYLTAEILELAGNAAR.D Histone H2A type 1-H  1690.80 45.7 F.DTASTGKTFPGFFSPM.L Fibrinogen alpha chain  
2431.28 30.8 A.VLEYLTAEILELAGNAARDNKK.T Histone H2A type 1-H  1816.82 47.7 F.EEVSGNVSPGTRREYH.T Fibrinogen alpha chain  
1359.67 36.6 W.EPNKVSSNSGMLP.N Histone-lysine N-methyltransferase MLL  2046.92 40.1 F.EEVSGNVSPGTRREYHTE.K Fibrinogen alpha chain  
1917.87 39.6 A.GEYGAEALERMFLSFPT.T Haemoglobin subunit alpha  2488.24 39.7 F.EEVSGNVSPGTRREYHTEKLVT.S Fibrinogen alpha chain  
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2125.92 43.3 A.HAGEYGAEALERMFLSFPT.T Haemoglobin subunit alpha  2467.04 85.4 F.ESKSYKMADEAGSEADHEGTHST.K Fibrinogen alpha chain  
2015.05 60.4 A.SLDKFLASVSTVLTSKYR.- Haemoglobin subunit alpha  3016.30 136.4 F.ESKSYKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
1502.68 31.9 A.WGKVGAHAGEYGAEA.L Haemoglobin subunit alpha  3583.65 103.7 F.ESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  
1833.86 48.2 K.TYFPHFDLSHGSAQVK.G Haemoglobin subunit alpha  1228.59 32.9 F.FDTASTGKTFPG.F Fibrinogen alpha chain  
1399.76 30.5 S.DLHAHKLRVDPV.N Haemoglobin subunit alpha  2383.11 68.1 F.FDTASTGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
1947.91 51.5 V.DDMPNALSALSDLHAHKL.R Haemoglobin subunit alpha  2691.16 30 F.TNTKESSSHHPGIAEFPSRGKSSSY.S Fibrinogen alpha chain  
2514.23 35.3 V.DDMPNALSALSDLHAHKLRVDPV.N Haemoglobin subunit alpha  1020.50 67.5 G.DFLAEGGGVR.G Fibrinogen alpha chain  
1437.73 41.2 V.TLAAHLPAEFTPAV.H Haemoglobin subunit alpha  1206.55 93.9 G.EGDFLAEGGGVR.G Fibrinogen alpha chain  
1645.82 34.3 V.TLAAHLPAEFTPAVHA.S Haemoglobin subunit alpha  1206.56 62.5 G.EGDFLAEGGGVR.G Fibrinogen alpha chain  
2606.27 52.8 V.TLAAHLPAEFTPAVHASLDKFLASV.S Haemoglobin subunit alpha  1516.73 37.9 G.EGDFLAEGGGVRGPR.V Fibrinogen alpha chain  
1441.64 41 Y.FPHFDLSHGSAQV.K Haemoglobin subunit alpha  1350.59 69.3 D.SGEGDFLAEGGGVR.G Fibrinogen alpha chain  
1705.78 38.8 A.FSDGLAHLDNLKGTFA.T Haemoglobin subunit beta  1350.63 37.1 D.SGEGDFLAEGGGVR.G Fibrinogen alpha chain  
1423.69 42.7 A.HHFGKEFTPPVQ.A Haemoglobin subunit beta  1403.67 57.4 A.STGKTFPGFFSPM.L Fibrinogen alpha chain  
1212.66 38.3 D.EVGGEALGRLLV.V Haemoglobin subunit beta 1948.94 114.6 A.STGKTFPGFFSPMLGEFV.S Fibrinogen alpha chain  
1286.63 63.2 H.HFGKEFTPPVQ.A Haemoglobin subunit beta  1560.67 30 A.RPNNPDWGTFEEV.S Fibrinogen alpha chain  
2178.12 38.3 M.VHLTPEEKSAVTALWGKVNV.D Haemoglobin subunit beta 1088.54 51.6 A.STGKTFPGFF.S Fibrinogen alpha chain  
2521.24 75.8 M.VHLTPEEKSAVTALWGKVNVDEV.G Haemoglobin subunit beta  1272.63 60.9 A.STGKTFPGFFSP.M Fibrinogen alpha chain  
1327.68 51.5 V.DEVGGEALGRLLV.V Haemoglobin subunit beta  1883.76 46.2 A.DEAGSEADHEGTHSTKRG.H Fibrinogen alpha chain  
1328.66 42.1 V.NVDEVGGEALGRL.L Haemoglobin subunit beta 2091.88 95.8 A.DEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  
1441.72 45.5 V.NVDEVGGEALGRLL.V Haemoglobin subunit beta 2659.16 132 A.DEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  
1540.78 64.1 V.NVDEVGGEALGRLLV.V Haemoglobin subunit beta  1465.62 76.2 A.DSGEGDFLAEGGGVR.G Fibrinogen alpha chain  
2296.21 42.7 V.TALWGKVNVDEVGGEALGRLLV.V Haemoglobin subunit beta  1465.63 133.2 A.DSGEGDFLAEGGGVR.G Fibrinogen alpha chain  
1350.70 67.4 V.VAGVANALAHKYH.- Haemoglobin subunit beta 1619.74 61 A.DSGEGDFLAEGGGVRGP.R Fibrinogen alpha chain  
1327.73 31.4 V.DEVGGEALGRLLV.V Haemoglobin subunit beta  1775.78 66 A.DSGEGDFLAEGGGVRGPR.V Fibrinogen alpha chain  
1540.84 59.5 V.NVDEVGGEALGRLLV.V Haemoglobin subunit beta  1775.80 72.1 A.DSGEGDFLAEGGGVRGPR.V Fibrinogen alpha chain  
2276.96 68.2 K.WGDAGAEYVVESTGVFTTMEK.A Glyceraldehyde-3-phosphate dehydrogenase 1973.96 122.6 A.DSGEGDFLAEGGGVRGPRVV.E Fibrinogen alpha chain  
1299.56 30.5 Y.DNEFGYSNRVV.D Glyceraldehyde-3-phosphate dehydrogenase 1566.70 30.1 K.DQKAEGDANPVPYY.Y Cyclin-dependent kinase-like 4  
1368.67 54.4 R.DSSRLPSEGPRPA.H Flavin reductase  2551.12 153.5 R.TLEIPGNSDPNMIPDGDFNSYVR.V Complement C4-A  
1826.70 66.2 T.DEYDGHSTYPSHQYQ.- Flavin reductase  1896.01 81.8 R.NGFKSHALQLNNRQIR.G Complement C4-A  
1696.76 31.5 V.MPPHIGDQPLTGAYTV.T Flavin reductase  1896.03 45.4 R.NGFKSHALQLNNRQIR.G Complement C4-A  
2079.04 33.9 K.KREEAPSLRPAPPPISGGGY.R Fibrinogen beta chain  1739.89 71.5 R.NGFKSHALQLNNRQI.R Complement C4-A  
1950.95 45.4 K.REEAPSLRPAPPPISGGGY.R Fibrinogen beta chain  2378.18 81.7 K.DDPDAPLQPVTPLQLFEGRRN.R Complement C4-A  
1951.00 40.1 K.REEAPSLRPAPPPISGGGY.R Fibrinogen beta chain  1626.82 48.7 R.NGFKSHALQLNNRQ.I Complement C4-A  
2502.29 35.7 K.REEAPSLRPAPPPISGGGYRARPA.K Fibrinogen beta chain  1865.00 44.3 R.SSKITHRIHWESASLL.R Complement C3  
1071.54 39.6 P.APPPISGGGYR.A Fibrinogen beta chain  2021.11 42.2 R.SSKITHRIHWESASLLR.S Complement C3  
1425.77 44.2 H.RPLDKKREEAPS.L Fibrinogen beta chain  1671.80 51 R.SYTVAIAGYALAQMGR.L Complement C3  
1776.96 48.1 V.TSKGDKELRTGKEKVT.S Fibrinogen alpha chain  1219.65 32.2 S.KITHRIHWE.S Complement C3  
1872.71 81.5 Y.KMADEAGSEADHEGTHST.K Fibrinogen alpha chain  1377.74 49.4 S.KITHRIHWESA.S Complement C3  
2422.04 139 Y.KMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  1464.75 39.6 S.SKITHRIHWESA.S Complement C3  
2989.40 84 Y.KMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  1464.77 51.1 S.SKITHRIHWESA.S Complement C3  
1390.60 68.2 Y.NRGDSTFESKSY.K Fibrinogen alpha chain  1855.82 32.3 R.SEETKENEGFTVTAEGK.G Complement C3  
1390.63 73.2 Y.NRGDSTFESKSY.K Fibrinogen alpha chain  1551.80 62 R.SSKITHRIHWESA.S Complement C3  
1649.73 94.9 Y.NRGDSTFESKSYKM.A Fibrinogen alpha chain  942.44 54.3 I.HWESASLL.R Complement C3  
1720.77 110.4 Y.NRGDSTFESKSYKMA.D Fibrinogen alpha chain  1098.55 72.7 I.HWESASLLR.S Complement C3  
1720.78 59.2 Y.NRGDSTFESKSYKMA.D Fibrinogen alpha chain  1098.56 57.3 I.HWESASLLR.S Complement C3  
1775.93 35 A.RGHRPLDKKREEAPS.L Fibrinogen beta chain  1504.75 57 G.SPMYSIITPNILR.L Complement C3  
2320.93 65.4 V.SGSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  1136.56 56.6 I.THRIHWESA.S Complement C3  
2320.98 89.3 V.SGSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  2868.37 92.3 R.EGVQKEDIPPADLSDQVPDTESETRI.L Complement C3  
2391.99 32.4 V.SGSTGQWHSESGSFRPDSPGSGNA.R Fibrinogen alpha chain  1914.96 39.2 V.AEKALQEYRKKHREE.- Clusterin  
3933.73 36.5 V.SGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTFEEV.S Fibrinogen alpha chain  1914.99 66.8 V.AEKALQEYRKKHREE.- Clusterin  
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2218.14 46.6 V.SGNVSPGTRREYHTEKLVTS.K Fibrinogen alpha chain  1075.54 32.8 R.RPHFFFPK.S Clusterin  
2131.10 53.4 V.SGNVSPGTRREYHTEKLVT.S Fibrinogen alpha chain  1069.47 35.8 I.DELFQDRF.F Clusterin  
4924.15 44.2 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  1069.50 36.6 I.DELFQDRF.F Clusterin  
3894.77 42.6 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  1317.58 32.2 I.DELFQDRFFT.R Clusterin  
4057.80 66 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSY.S Fibrinogen alpha chain  1317.62 63.7 I.DELFQDRFFT.R Clusterin  
3807.78 184.1 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  1791.84 82.5 I.HFHSPAFQHPPTEFI.R Clusterin  
3720.70 208.5 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  2271.94 54.4 G.DQTVSDNELQEMSNQGSKYV.N Clusterin  
2132.94 75 V.SETESRGSESGIFTNTKESS.S Fibrinogen alpha chain  1043.59 51.6 G.VPPEVFTRV.S Cathepsin G  
2132.97 131.5 V.SETESRGSESGIFTNTKESS.S Fibrinogen alpha chain  932.51 30.7 S.FLPWIRT.T Cathepsin G  
2761.18 39.9 V.SETESRGSESGIFTNTKESSSHHPGI.A Fibrinogen alpha chain  1033.56 34.7 S.FLPWIRTT.M Cathepsin G  
2761.25 104.2 V.SETESRGSESGIFTNTKESSSHHPGI.A Fibrinogen alpha chain  1033.58 35.3 S.FLPWIRTT.M Cathepsin G  
2832.34 71.4 V.SETESRGSESGIFTNTKESSSHHPGIA.E Fibrinogen alpha chain  2189.12 31.6 A.SEPGEAKKMEDKEKDNKLI.S Bridging integrator 2  
3505.65 187.4 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  2170.11 99 V.DTKEAEGAPQVEAGKRLEEL.R Caldesmon  
3633.64 153.8 V.SETESRGSESGIFTNTKESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  2610.16 37.8 N.TEEVPGSLCLRKFSCMFFGAVSSD.Q 
Cell cycle checkpoint control          protein 
RAD9B  
1486.65 38.5 V.SETESRGSESGIFT.N Fibrinogen alpha chain  1426.75 33.1 A.TVGSLAGQPLQERA.Q Apolipoprotein E  
1486.67 96.9 V.SETESRGSESGIFT.N Fibrinogen alpha chain  2009.99 37.8 G.SLAGQPLQERAQAWGERL.R Apolipoprotein E  
1701.74 35.8 V.SETESRGSESGIFTNT.K Fibrinogen alpha chain  2547.17 44.7 K.SWFEPLVEDMQRQWAGLVEKV.Q Apolipoprotein E  
1701.75 93.3 V.SETESRGSESGIFTNT.K Fibrinogen alpha chain  2111.03 52.1 A.KVEQAVETEPEPELRQQT.E Apolipoprotein E  
2045.90 48.3 V.SETESRGSESGIFTNTKES.S Fibrinogen alpha chain  2108.97 49.9 V.KDKFSEFWDLDPEVRPT.S Apolipoprotein C-III  
2045.93 135.2 V.SETESRGSESGIFTNTKES.S Fibrinogen alpha chain  2109.00 112 V.KDKFSEFWDLDPEVRPT.S Apolipoprotein C-III  
1507.82 62.8 V.IGPDGHKEVTKEVV.T Fibrinogen alpha chain  1504.70 81.3 T.DGFSSLKDYWSTV.K Apolipoprotein C-III  
3169.31 45.4 T.SYNRGDSTFESKSYKMADEAGSEADHEGT.H Fibrinogen alpha chain  1947.85 34.1 R.GWVTDGFSSLKDYWSTV.K Apolipoprotein C-III  
3494.41 122.7 T.SYNRGDSTFESKSYKMADEAGSEADHEGTHST.K Fibrinogen alpha chain  1374.63 40 E.FWDLDPEVRPT.S Apolipoprotein C-III  
4043.66 33.2 T.SYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHA.K Fibrinogen alpha chain  1590.71 40 F.SEFWDLDPEVRPT.S Apolipoprotein C-III  
2286.01 143.9 T.SYNRGDSTFESKSYKMADEA.G Fibrinogen alpha chain  1590.75 32.6 F.SEFWDLDPEVRPT.S Apolipoprotein C-III  
2561.09 67.5 T.SSTSYNRGDSTFESKSYKMADEA.G Fibrinogen alpha chain  1227.58 39.5 F.WDLDPEVRPT.S Apolipoprotein C-III  
3769.54 67.5 T.SSTSYNRGDSTFESKSYKMADEAGSEADHEGTHST.K Fibrinogen alpha chain  2058.96 35.3 K.DALSSVQESQVAQQARGWV.T Apolipoprotein C-III  
4886.25 33.4 T.SSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen alpha chain  1980.89 44.3 K.DKFSEFWDLDPEVRPT.S Apolipoprotein C-III  
1477.67 77.9 T.SYNRGDSTFESKS.Y Fibrinogen alpha chain  1980.92 64.6 K.DKFSEFWDLDPEVRPT.S Apolipoprotein C-III  
1640.70 76.9 T.SYNRGDSTFESKSY.K Fibrinogen alpha chain  2689.35 74.1 A.TKTAKDALSSVQESQVAQQARGWVT.D Apolipoprotein C-III  
1262.51 65.4 T.SYNRGDSTFES.K Fibrinogen alpha chain  2588.25 137.9 A.TKTAKDALSSVQESQVAQQARGWV.T Apolipoprotein C-III  
1899.86 94 T.SYNRGDSTFESKSYKM.A Fibrinogen alpha chain  2614.23 35 A.SLLSFMQGYMKHATKTAKDALSSV.Q Apolipoprotein C-III  
1970.87 121.4 T.SYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  1913.94 41.7 A.SLLSFMQGYMKHATKTA.K Apolipoprotein C-III  
1537.63 48.2 T.SSTSYNRGDSTFES.K Fibrinogen alpha chain  1842.87 35.9 A.SLLSFMQGYMKHATKT.A Apolipoprotein C-III  
1752.76 76.9 T.SSTSYNRGDSTFESKS.Y Fibrinogen alpha chain  1512.69 35.9 A.SLLSFMQGYMKHA.T Apolipoprotein C-III  
1915.83 83.5 T.SSTSYNRGDSTFESKSY.K Fibrinogen alpha chain  1464.71 34.5 I.FTDQVLSVLKGEE.- Apolipoprotein C-II  
2246.00 93.1 T.SSTSYNRGDSTFESKSYKMA.D Fibrinogen alpha chain  1577.78 31.4 G.IFTDQVLSVLKGEE.- Apolipoprotein C-II  
2174.98 72.4 T.SSTSYNRGDSTFESKSYKM.A Fibrinogen alpha chain  2691.33 107.9 P.DVSSALDKLKEFGNTLEDKARELI.S Apolipoprotein C-I  
1574.87 40.3 T.SKGDKELRTGKEKV.T Fibrinogen alpha chain  1634.87 86.4 T.GIFTDQVLSVLKGEE.- Apolipoprotein C-II  
1675.91 36.8 T.SKGDKELRTGKEKVT.S Fibrinogen alpha chain  2187.05 47.3 A.KDALSSVQESQVAQQARGWV.T Apolipoprotein C-III  
2810.11 34.8 T.SESSVSGSTGQWHSESGSFRPDSPGSGN.A Fibrinogen alpha chain  2516.12 58.6 A.SEAEDASLLSFMQGYMKHATKTA.K Apolipoprotein C-III  
2340.10 38.2 T.NTKESSSHHPGIAEFPSRGKSS.S Fibrinogen alpha chain  2114.88 62.5 A.SEAEDASLLSFMQGYMKHA.T Apolipoprotein C-III  
2427.18 37.9 T.NTKESSSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  1919.94 66 Y.ADEFKVKIDQTVEELR.R Apolipoprotein A-IV  
2590.19 107.6 T.NTKESSSHHPGIAEFPSRGKSSSY.S Fibrinogen alpha chain  2614.23 44.4 V.SQKIGDNLRELQQRLEPYADQL.R Apolipoprotein A-IV  
2590.21 81.6 T.NTKESSSHHPGIAEFPSRGKSSSY.S Fibrinogen alpha chain  1838.86 44.7 R.GNTEGLQKSLAELGGHLD.Q Apolipoprotein A-IV  
2677.16 125.5 T.NTKESSSHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  2599.21 144.9 R.GNTEGLQKSLAELGGHLDQQVEEF.R Apolipoprotein A-IV  
2677.24 129.4 T.NTKESSSHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain  2755.31 42.1 R.GNTEGLQKSLAELGGHLDQQVEEFR.R Apolipoprotein A-IV  
2253.07 64.6 T.NTKESSSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  2394.20 40.8 R.LTPYADEFKVKIDQTVEELR.R Apolipoprotein A-IV  
2253.12 105.5 T.NTKESSSHHPGIAEFPSRGKS.S Fibrinogen alpha chain  2573.32 46.1 L.KEEIGKELEELRARLLPHANEV.S Apolipoprotein A-IV  
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3181.53 135.2 T.NTKESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain  1954.96 41.4 I.SASAEELRQRLAPLAEDV.R Apolipoprotein A-IV  
3456.66 92.3 T.NTKESSSHHPGIAEFPSRGKSSSYSKQFTSST.S Fibrinogen alpha chain  1927.89 52.7 K.SLAELGGHLDQQVEEFR.R Apolipoprotein A-IV  
1824.82 47.6 T.NTKESSSHHPGIAEFPS.R Fibrinogen alpha chain  1319.64 26.3 L.EPYADQLRTQV.N Apolipoprotein A-IV  
1824.84 55.2 T.NTKESSSHHPGIAEFPS.R Fibrinogen alpha chain  1258.53 43.6 L.GGHLDQQVEEF.R Apolipoprotein A-IV  
1980.92 54.9 T.NTKESSSHHPGIAEFPSR.G Fibrinogen alpha chain  1414.66 48.3 L.GGHLDQQVEEFR.R Apolipoprotein A-IV  
2037.94 48.6 T.NTKESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  1848.91 66.7 A.DEFKVKIDQTVEELR.R Apolipoprotein A-IV  
2037.95 54 T.NTKESSSHHPGIAEFPSRG.K Fibrinogen alpha chain  2607.28 73.2 A.DEFKVKIDQTVEELRRSLAPYA.Q Apolipoprotein A-IV  
2166.05 60.6 T.NTKESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  1796.88 30 A.SAEELRQRLAPLAEDV.R Apolipoprotein A-IV  
2166.09 117.3 T.NTKESSSHHPGIAEFPSRGK.S Fibrinogen alpha chain  1144.48 45.9 G.HLDQQVEEF.R Apolipoprotein A-IV  
2212.11 116.1 T.KESSSHHPGIAEFPSRGKSSS.Y Fibrinogen alpha chain  1661.83 38.5 I.DQNVEELKGRLTPY.A Apolipoprotein A-IV  
2375.13 50.4 T.KESSSHHPGIAEFPSRGKSSSY.S Fibrinogen alpha chain      
2462.16 101 T.KESSSHHPGIAEFPSRGKSSSYS.K Fibrinogen alpha chain      
2718.23 77.6 T.KESSSHHPGIAEFPSRGKSSSYSKQ.F Fibrinogen alpha chain      
2966.43 146 T.KESSSHHPGIAEFPSRGKSSSYSKQFT.S Fibrinogen alpha chain      
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Proteins Identified and Quantitated in the ECLIPSE A1ATD Shotgun Experiments 
Protein Scores Peptide 114_116 #114_116 114_115 #114_115 114_117 #114_117 
Complement component C9  107.2 1 0.29 1 0.38 1 0.57 1 
Plasma serine protease inhibitor  47.6 1 0.47 1 0.38 1 0.29 1 
Alpha-1-antitrypsin  472 7 0.49 6 0.41 7 0.47 7 
Apolipoprotein(a)  52.5 1 0.52 1 0.57 1 1.04 1 
Afamin  135.2 2 0.94 2 0.6 2 1.1 2 
Complement C1r subcomponent-like protein  141.1 2 0.52 2 0.61 2 0.56 2 
Vitamin K-dependent protein S  70.2 1 1.22 1 0.61 1 1.31 1 
Plasma kallikrein  50.6 1 0.61 1 0.63 1 0.84 1 
Carboxypeptidase N catalytic chain  30.3 1 0.67 1 0.66 1 0.84 1 
Apolipoprotein A-I  303.5 4 1.18 4 0.69 4 0.75 4 
Apolipoprotein A-IV  108.7 2 0.8 2 0.7 2 0.61 2 
Voltage-dependent calcium channel subunit alpha-2/delta-1  36.8 1 1.02 1 0.71 1 0.98 1 
Follistatin-related protein 1  47.8 1 0.82 1 0.73 1 0.79 1 
CD5 antigen-like  572.7 7 0.58 6 0.78 7 0.79 6 
Extracellular matrix protein 1  56.1 1 1.08 1 0.78 1 1.12 1 
C-Myc-binding protein  34.9 1 1.09 1 0.79 1 0.85 1 
Carboxypeptidase N subunit 2  215 3 0.82 3 0.81 3 1 3 
Vascular cell adhesion protein 1  74.9 1 2.29 1 0.82 1 1.28 1 
Lumican  152.6 3 0.93 3 0.84 3 1.16 3 
Serotransferrin  4802.5 58 0.77 48 0.85 50 0.93 49 
Coagulation factor XIII B chain  95.2 1 0.84 1 0.88 1 0.91 1 
Alpha-2-macroglobulin  2153.9 28 1.37 22 0.9 22 1.91 22 
ATP-binding cassette sub-family G member 2  33.6 1 0.73 1 0.9 1 0.98 1 
Leucine-rich alpha-2-glycoprotein  136.3 2 1.55 2 0.9 2 2.01 2 
Carboxypeptidase B2  210.7 2 1.4 2 0.91 2 1.44 2 
CD44 antigen  46.4 1 0.59 1 0.93 1 1.05 1 
Target of Nesh-SH3  31 1 1.79 1 0.96 1 1.55 1 
Insulin-like growth factor-binding protein 3  162.6 2 1.57 2 0.99 2 1.62 2 
Complement factor D  38.3 1 0.59 1 1.03 1 0.67 1 
Hyaluronan-binding protein 2  57.3 1 1.6 1 1.04 1 1.84 1 
Alpha-1-acid glycoprotein 2  382.5 7 0.77 6 1.05 7 0.83 6 
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Tetraspanin-14  31.1 1 2.46 1 1.05 1 1.56 1 
Vitamin D-binding protein  119.9 2 1.41 2 1.06 2 1.26 2 
Fibrinogen gamma chain  47.2 1 1.08 1 1.09 1 0.71 1 
Fibulin-1  59.3 1 2.57 1 1.12 1 1.77 1 
Clusterin  130 2 1.27 1 1.13 1 1.42 1 
Attractin  102.1 2 3.02 2 1.14 2 2.49 2 
Protein Z-dependent protease inhibitor  57.7 1 1.83 1 1.14 1 1.59 1 
Protein AMBP  489.7 7 1.75 6 1.15 6 1.79 6 
Neuronal growth regulator 1  75.7 1 1.85 1 1.16 1 1.96 1 
Inter-alpha-trypsin inhibitor heavy chain H4  283.5 5 2.08 4 1.18 4 1.83 4 
Syntaxin-12  37.8 1 1.39 1 1.19 1 1.78 1 
Plastin-2  44.2 1 3.45 1 1.21 1 1.41 1 
Apolipoprotein E  49 1 1.68 1 1.22 1 1.52 1 
Lymphatic vessel endothelial hyaluronic acid receptor 1  73.6 1 1.88 1 1.22 1 1.43 1 
Apolipoprotein B-100  345.7 5 2.36 4 1.23 4 2.26 4 
Complement C3  92.4 1 1.45 1 1.24 1 1.42 1 
Hepatocyte growth factor activator  231 4 2.16 4 1.26 4 2.23 4 
Interleukin-1 receptor accessory protein  42 1 1.71 1 1.26 1 1.69 1 
Sex hormone-binding globulin  77.9 1 2.29 1 1.27 1 2.27 1 
Angiotensinogen  218.2 3 0.64 2 1.28 3 0.66 2 
Dopamine beta-hydroxylase  31 1 0.89 1 1.3 1 2.22 1 
Selenoprotein P  135.8 2 1.85 2 1.3 2 2.14 2 
Kallistatin  105.1 2 4.11 2 1.31 2 4.21 2 
Thyroxine-binding globulin  360.1 4 2.04 3 1.34 4 2.19 3 
Vascular non-inflammatory molecule 3  42.2 1 1.31 1 1.35 1 1.28 1 
Complement C1r subcomponent  90.6 1 2.36 1 1.39 1 1.96 1 
L-selectin  54.9 1 3.85 1 1.4 1 3.29 1 
Phosphatidylinositol-glycan-specific phospholipase D  84.4 1 1.38 1 1.44 1 1.22 1 
Hepatocyte growth factor-like protein  188.5 3 2.26 3 1.47 3 2.31 3 
Cell surface glycoprotein MUC18  78.2 1 1.17 1 1.5 1 2.2 1 
Zinc-alpha-2-glycoprotein  173.8 3 1.85 3 1.55 3 1.48 3 
Serum paraoxonase/arylesterase 2  36.6 1 0.79 1 1.58 1 0.52 1 
Thrombospondin-4  68.2 1 1.44 1 1.58 1 1.62 1 
Bone marrow proteoglycan  47.7 1 1.58 1 1.6 1 1.44 1 
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Tetranectin  237.4 2 2.33 2 1.6 2 2.08 2 
Fibrinogen alpha chain  142.3 1 2.91 1 1.69 1 4.37 1 
Alpha-1-acid glycoprotein 1  277.3 5 1.37 5 1.77 5 0.78 4 
Complement C1s subcomponent  111.4 1 2.93 1 1.92 1 3.34 1 
Galectin-3-binding protein  59.5 1 1.83 1 2.03 1 3.87 1 
Complement C2  277.1 4 2.9 4 2.22 4 4.43 4 
Coagulation factor V  55.6 1 3.64 1 2.34 1 3.33 1 
Laminin subunit alpha-2  54.1 1 1.98 1 2.35 1 2.18 1 
Corticosteroid-binding globulin  218.5 3 6.27 3 2.43 3 5.54 3 
Pigment epithelium-derived factor  106.2 1 8.62 1 3.38 1 9.29 1 
Serum albumin  9759.6 120 0.59 100 0.78 109 0.59 102 
Haptoglobin  755 11 0.66 11 1.05 11 0.82 11 
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Proteins Identified and Quantitated in the EXACTLE Shotgun Experiments 
Protein Scores Peptides 114_116 #114_116 114_115 #114_115 114_117 #114_117 
Complement C2  185.8 3 1.07 3 1.51 3 2.55 3 
Pigment epithelium-derived factor  197 4 1.23 4 1.12 4 2.45 4 
Insulin-like growth factor-binding protein complex   81.3 2 1.13 2 1.14 2 2.03 2 
Cystatin-A  55.2 1 1.31 1 4.22 1 2.28 1 
Zinc-alpha-2-glycoprotein  595.8 10 1.95 8 1.63 8 2.98 8 
Clusterin  206.6 3 1.31 2 1.34 2 1.85 2 
Neural cell adhesion molecule L1  42.4 1 1.22 1 1.32 1 1.72 1 
Insulin-like growth factor-binding protein 2  108.4 2 1.2 2 1.45 2 1.63 2 
Receptor-type tyrosine-protein phosphatase eta  103.3 1 1.32 1 1.03 1 1.79 1 
Neurogenic locus notch homolog protein 2  89.8 1 1.16 1 0.97 1 1.5 1 
Glutathione peroxidase 3  34.8 1 1.44 1 1.67 1 1.79 1 
Biotinidase  84.6 1 0.97 1 1.24 1 1.2 1 
Fibrinogen gamma chain  35.2 1 1.08 1 1.49 1 1.31 1 
Di-N-acetylchitobiase  43.5 1 0.99 1 1.04 1 1.2 1 
Tetranectin  147.2 2 1.33 1 0.55 1 1.53 1 
Insulin-like growth factor-binding protein 3  36.3 1 1.41 1 1.59 1 1.58 1 
Angiotensinogen  257.5 3 0.87 3 0.5 3 0.97 3 
Aminopeptidase N  32.6 1 1.31 1 1.38 1 1.44 1 
Protein S100-A14  79.7 1 1.47 1 1.32 1 1.61 1 
Apolipoprotein B-100  40.2 1 0.93 1 1.26 1 1 1 
Insulin-like growth factor II  61.4 1 1.34 1 1.13 1 1.42 1 
Platelet basic protein  197.2 3 1.13 3 1.35 3 1.19 3 
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Hepatocyte growth factor activator  268.4 4 1.58 4 1.62 4 1.65 4 
Inositol polyphosphate 5-phosphatase CRL-1 67.8 2 1.54 1 1.93 1 1.59 1 
Interleukin-1 receptor accessory protein  39.4 1 1.38 1 1.18 1 1.4 1 
Vasorin  38.1 1 1.12 1 1.51 1 1.13 1 
Leucine-rich alpha-2-glycoprotein  355 8 1.27 8 1.27 7 1.28 7 
L-selectin  280 4 1.32 4 1.97 4 1.33 4 
Alpha-2-macroglobulin  323.4 5 1.08 5 0.95 5 1.07 5 
Alpha-1-acid glycoprotein 1  120.9 3 1.07 2 1.51 2 1.05 2 
Actin, cytoplasmic 1  38.1 1 1.14 1 1.15 1 1.1 1 
Pregnancy zone protein  116.1 2 1.63 2 1.18 2 1.57 2 
Protein EMSY  35.4 1 1.4 1 1.76 1 1.32 1 
Protein AMBP  509.9 7 1.47 5 1.25 5 1.37 5 
Cholinesterase  90.8 2 1.28 2 1.71 2 1.18 2 
Vascular cell adhesion protein 1  41.9 1 1.52 1 1.12 1 1.39 1 
Pantetheinase  122.6 3 1.66 2 1.73 2 1.51 2 
Tigger transposable element-derived protein 6  32.4 1 3.42 1 3.07 1 3.1 1 
Ig delta chain C region  105.6 2 0.8 2 1.09 2 0.7 2 
Immunoglobulin J chain  173.4 2 0.99 1 1.02 1 0.86 1 
Lactotransferrin  37.3 1 1.49 1 1.18 1 1.28 1 
Thyroxine-binding globulin  578.1 8 1.08 7 0.93 7 1.09 7 
Dynein heavy chain 12, axonemal  32.1 1 1.75 1 1.23 1 1.44 1 
Ig alpha-2 chain C region  72.5 2 1.06 2 1.45 2 0.85 2 
DnaJ homolog subfamily C member 7  30.6 1 1.61 1 1.3 1 1.28 1 
Serum albumin  1643.2 23 1.11 13 1.23 14 1.14 15 
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Extracellular matrix protein 1  116.8 3 1.97 3 1.41 3 1.51 3 
Complement C1r subcomponent-like protein  69.4 2 1.4 2 1.42 2 1.02 2 
Catalase  112.6 2 1.25 1 1.83 1 0.91 1 
C-Myc-binding protein  34.3 1 5.08 1 3.59 1 3.65 1 
Ig mu chain C region  227.2 4 0.85 4 1.06 4 0.61 4 
Peptidase inhibitor 16  109.8 2 2.05 2 2.1 2 1.42 2 
Attractin  127.5 2 1.16 2 1.4 2 0.79 2 
Putative macrophage-stimulating protein MSTP9  32.8 1 1.38 1 1.41 1 0.93 1 
Corticosteroid-binding globulin  132 2 1.56 2 1.1 2 1.04 2 
Serotransferrin  609.2 9 1.11 9 1.03 9 0.74 9 
Alpha-1-antitrypsin  121.8 2 1.6 2 1.95 2 0.46 2 
 
 
 
 
 
 
 
 
 
 
 
